<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/html/xsl/rss2html.xsl"?>
<rss version="2.0"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:admin="http://webns.net/mvcb/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:content="http://purl.org/rss/1.0/modules/content/">
<channel><title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20130831&amp;edate=20130501&amp;rs=</link>
<description>DKPHybrids Dashboard</description><dc:language>en-us</dc:language><copyright>Copyright &amp;copy; 2016  All rights reserved.</copyright><category>News</category><docs>http://backend.userland.com/rss</docs><ttl>20</ttl><rating>A1</rating><image>
<title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20130831&amp;edate=20130501&amp;rs=</link>
<url>http://ci.beaufour-ipsen.com/share/tsi/logos/ipsenbaseline07.jpg</url>
<width>108</width>
<height>31</height>
</image><admin:generatorAgent rdf:resource="http://tractionsoftware.com" /><item>
<title>Yale U. Evaluating Xeomin for Focal Pain and Restless Leg Syndrome [comp:Merz, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7121</link>
<description>Yale U. Evaluating Xeomin for Focal Pain and Restless Leg Syndrome [comp:Merz, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Merz</category><category>prod:Xeomin</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7121</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7121">Yale U.<wbr> Evaluating Xeomin for Focal Pain and Restless Leg Syndrome</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7121">Neurology7121</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 August 2013 | 19:10</font><br><br><div style="margin-bottom: 10px;">Comment: The two POC trials started last year, but have just been listed in clinicaltrials.<wbr>gov.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01931865?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=07%2F30%2F2013&amp;rank=219"><STRONG><FONT size="3">NCT01931865</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Indication: focal pain after surgery and/<wbr>or radiation </div><div style="margin-bottom: 10px;">Hypothesis: injection of incobotulinum toxin A into an area of local pain, at or around the area of a post-surgical/<wbr>post radiation scar, relieves the focal cancer pain </div><div style="margin-bottom: 10px;">n= 22 </div><div style="margin-bottom: 10px;">Completion date: Dec 2014 /<wbr> Dec 2015 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01931878?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=07%2F30%2F2013&amp;rank=223"><STRONG><FONT size="3">NCT01931878</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Indication: Relieving Symptoms of Restless Leg Syndrome </div><div style="margin-bottom: 10px;">n= 20 </div><div>Completion date: Aug 2014 /<wbr> Dec 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7121">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-30T19:10:06+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Pioneers New Indication with BOTOX® [comp:Allergan, prod:Botox, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7120</link>
<description>Allergan Pioneers New Indication with BOTOX® [comp:Allergan, prod:Botox, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Allergan</category><category>prod:Botox</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7120</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7120">Allergan Pioneers New Indication with BOTOX®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7120">Neurology7120</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 August 2013 | 18:46</font><br><br><div style="margin-bottom: 10px;">Comment: A POC trial started this month in the US in approx.<wbr> 60 participants with premature ejaculation.<wbr> PE will evaluate change from baseline in geometric mean Intravaginal Ejaculatory Latency Time (IELT).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01917006?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=07%2F30%2F2013&amp;rank=42"><STRONG><FONT size="3">NCT01917006</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Completion date: July 2015 </div><div style="margin-bottom: 10px;">Sites: USA; UK (London- not yet recruiting) </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7120">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-30T18:46:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: FDA Approves the Lowest Volume Preparation for Colonoscopy</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1908</link>
<description>re: FDA Approves the Lowest Volume Preparation for Colonoscopy</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1908</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1908">re: FDA Approves the Lowest Volume Preparation for Colonoscopy</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1908">GastroEnterology1908</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 August 2013 | 18:36</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Comment: The FDA approval of Ferring's Prepopik (sodium picosulfate, magnesium oxide, and anhydrous citric acid powder) marks the company's first entry into the gastrointestinal market in the U.<wbr>S.<wbr>.<wbr> The company now must conduct studies to determine if the drug can be used safely and effectively in children.<wbr></span>&nbsp;<br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1848" class="commentpermalink">GastroEnterology1848</a> / <span class="date">18 July 2012</span> /
<span class="time">10:06:24 o'clock CEST</span>
</font></div><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Ferring is to start Ph1/<wbr>Ph2 study in the US to evaluate the efficacy and safety of Prepopik™ in children aged 9 to 16 years for overall colon cleansing in preparation of colonoscopy.<wbr> PE will assess the number of subjects defined by "excellent" or "good" in the Aronchick Scale.<wbr></P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><a href="http://clinicaltrials.gov/ct2/show/NCT01928862?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=07%2F30%2F2013&amp;rank=13&amp;submit_fld_opt=" class="defaultlink">NCT01928862</a></P>
<DIV class="identifier">n= 75</DIV>
<DIV class="identifier">Start date: Oct 2013 - Completion: May 2015 /<wbr> June 2015</DIV></DIV> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1908" class="commentpermalink">GastroEnterology1908</a> / <span class="date">30 August 2013</span> /
<span class="time">18:36:51 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1908">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1848">View thread  GastroEnterology1848: FDA Approves the Lowest Volume Preparation for Colonoscopy</a>]]></content:encoded><dc:date>2013-08-30T18:36:51+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Positive Opinion for BioPartners' Once-Weekly Somatropin Granted by EMA for Growth Hormone Deficiciency</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7442</link>
<description>re: Positive Opinion for BioPartners' Once-Weekly Somatropin Granted by EMA for Growth Hormone Deficiciency</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7442</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7442">re: Positive Opinion for BioPartners' Once-Weekly Somatropin Granted by EMA for Growth Hormone Deficiciency</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7442">Endocrinology7442</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 August 2013 | 15:41</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Comment: The CHMP's recommendation is now referred to the European Commission (EC), which grants approval for the EU, Norway and Iceland.<wbr> The EC decision is anticipated in the middle of the third quarter of 2013.<wbr> The drug is in joint development with LG Life Sciences.<wbr></span>&nbsp;<br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7358" class="commentpermalink">Endocrinology7358</a> / <span class="date">31 May 2013</span> /
<span class="time">19:52:00 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">On August 8th, the European Commission granted a marketing authorisation to Somatropin Biopartners in the EU, Norway and Iceland.<wbr> </div><div style="margin-bottom: 10px;">Somatropin Biopartners allows for a once-weekly injection instead of the currently available therapies that require once-daily injections of growth hormone.<wbr> Poor adherence and noncompliance have been identified as a major cause of suboptimal efficacy of current growth hormone replacement therapy in children as well as adults.<wbr> </div><div>Source: Biopartners </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7442" class="commentpermalink">Endocrinology7442</a> / <span class="date">30 August 2013</span> /
<span class="time">15:41:49 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7442">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7358">View thread  Endocrinology7358: Positive Opinion for BioPartners' Once-Weekly Somatropin Granted by EMA for Growth Hormone Deficiciency</a>]]></content:encoded><dc:date>2013-08-30T15:41:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J Reorganises Reporting in China [mkt:China, mkt:Intercontinental, :Oncology:comp:JnJ]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10592</link>
<description>J&amp;J Reorganises Reporting in China [mkt:China, mkt:Intercontinental, :Oncology:comp:JnJ]</description><category>mkt:China</category><category>mkt:Intercontinental</category><category>comp:JnJ</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10592</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10592">J&J Reorganises Reporting in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10592">PharmaWorld10592</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 August 2013 | 15:03</font><br><br><div style="margin-bottom: 10px;">Comment: J&amp;J's three businesses in the country will start reporting to a single chairman in an effort to boost sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Organization</FONT></STRONG> </div><div style="margin-bottom: 10px;">Jesse Wu is to become the chairman of J&amp;J China and reports directly to Alex Gorsky (CEO).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">The reorgaisation will also increase oversight at the Chinese unit.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10592">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-30T15:03:55+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Abbvie Initiates 2nd PhIII Trial With GnRH Antagonist Elagolix [dis:Gynea, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9133</link>
<description>Abbvie Initiates 2nd PhIII Trial With GnRH Antagonist Elagolix [dis:Gynea, headline]</description><category>dis:Gynea</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9133</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9133">Abbvie Initiates 2nd PhIII Trial With GnRH Antagonist Elagolix</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9133">Oncology9133</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 August 2013 | 12:31</font><br><br><div style="margin-bottom: 10px;">Comment: Neurocrine Bioscience has announced today the initiation of a 2nd phIII study in endometriosis by its partner Abbvie.<wbr> It will be similar in design to the first study, which is scheduled to provide top-line data in Q32014.<wbr> Based on completion of both trials an NDA filing is on track for 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design Of New PhIII</STRONG> </div><div style="margin-bottom: 10px;">The second Phase III trial is a 24-week multinational, randomized double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 788 women, age 18-49, with moderate-to-severe endometriosis-associated pain.<wbr> It will be conducted at more than 200 sites globally.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Elagolix's Profile<BR></STRONG><BR>Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in development by AbbVie for the treatment of uterine fibroids and endometriosis.<wbr> Neurocrine and AbbVie entered into a collaboration and license agreement for elagolix during 2010.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Uterine Fibroid Development Programme</STRONG> </div><div style="margin-bottom: 10px;">Running behind the endometriosis development programme, Neurocrine Biosciences is expecting phIIb data in 2014 and for a phIII programme to commence the same year.<wbr> </div><div>Source: <A href="http://www.neurocrinebioscience.com/">www.<wbr>neurocrine.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9133">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-30T12:31:21+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Corcept Initiates New PhIII Trial With Korlym [dis:Cushing, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7440</link>
<description>Corcept Initiates New PhIII Trial With Korlym [dis:Cushing, news]</description><category>dis:Cushing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7440</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7440">Corcept Initiates New PhIII Trial With Korlym</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7440">Endocrinology7440</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 August 2013 | 17:57</font><br><br><div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing a new phIII pediatric trial being 
undertaken by Corcept Pharmaceuticals with Korlym in patients with 
refractory Cushing's disease.<wbr> </div><div style="margin-bottom: 10px;">The phIII study is designed to evaluate the safety, PK and PD effects of 
mifepristone on glucose metabolism, body weight and GH/<wbr>IGF-1.<wbr> </div><div style="margin-bottom: 10px;">The open label trial in 20 patients is scheduled to start this August 
and conclude in December 2016.<wbr> It is being undertaken at the NICHD in 
Bethseda.<wbr> The PI is  Charalampos Lysikatos-Lyssikatos.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex"><TBODY><TR valign="top"><TD>ClinicalTrials.<wbr>gov Identifier:</TD>
<TD style="PADDING-LEFT: 1em"><A class="study-link" href="http://clinicaltrials.gov/show/NCT01925092" title="Current version of study NCT01925092 on ClinicalTrials.gov">NCT01925092</A></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7440">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-29T17:57:49+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Innovators On Verge Of Winning California Battle Over Biosimilar Switches</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10589</link>
<description>Innovators On Verge Of Winning California Battle Over Biosimilar Switches</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10589</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10589">Innovators On Verge Of Winning California Battle Over Biosimilar Switches</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10589">PharmaWorld10589</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 29 August 2013 | 14:50</font><br><br><div style="margin-bottom: 10px;">Comment: California is on the verge of adopting a law that would authorise pharmacists (within California) to substitute an FDA-approved biosimilar medicine for an innovator biologic, but they must notify a prescriber within five days.<wbr> </div><div style="margin-bottom: 10px;">Pharmacists would be prohibited from substituting a biosimilar if the prescriber indicates "Do not substitute" on the prescription.<wbr> </div><div style="margin-bottom: 10px;">Although no biosimilars are available in the USA to date, companies such as Amgen and Genentech (alongside the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA)) are behind the legislation and are trying to convince other States to take action before the markets see biosimilar entry.<wbr> </div><div style="margin-bottom: 10px;">On the other hand,  the Generic Pharmaceutical Association (GPhA) has asserted bills that attempt to impose physician notification, like California's, would create access barriers to biosimilar medicines, preempt the FDA's guidance and reduce potential savings for consumers, the government and the private sector.<wbr> </div><div style="margin-bottom: 10px;">The bill has also been opposed by major health plans in the state, most notably, CalPERS, which provides retirement and health benefits to more than 1.<wbr>6 million public employees and retirees and their families and more than 3,000 employers.<wbr> </div><div style="margin-bottom: 10px;">According to GPhA, 10 states have "killed" biosimilar bills: </div><div><UL><LI>Oregon, Utah and Virginia have adopted bills permitting pharmacies to dispense FDA-approved biosimilars, but imposed sunset timelines on the physician notifications.<wbr> </LI>
<LI>Florida also passed a biosimilar bill, but did not include the notification provision.<wbr> </LI>
<LI>North Dakota stands alone as the only state so far that has adopted a biosimilar bill with a prescriber notification measure that does not sunset.<wbr> </LI>
<LI>Majority of US states have yet to take up biosimilar bills.<wbr> </LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10589">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-29T14:50:03+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Analyst Speculate On Who Could Be The Focus Of The Next Big M&amp;A Activity</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10586</link>
<description>Analyst Speculate On Who Could Be The Focus Of The Next Big M&amp;A Activity</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10586</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10586">Analyst Speculate On Who Could Be The Focus Of The Next Big M&A Activity</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10586">PharmaWorld10586</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 28 August 2013 | 17:28</font><br><br><div style="margin-bottom: 10px;">Comment: Analysts are lining up Medivation, Seattle Generics and BioMarin as probable M&amp;A targets for big pharma in the future.<wbr> </div><div style="margin-bottom: 10px;">Now that we are at the final stages of Amgen's $10.<wbr>4 billion buyout of Onyx,  analsyts have started to speculate who is next.<wbr> </div><div style="margin-bottom: 10px;">The rumour mill has been buzzing over stories that Roche has been working towards the buyout of Alexion and we are never far away from the next Shire take over story - and now, analysts have cited three companies they believe could whet the appetites of Big Pharma: </div><div style="margin-bottom: 10px;"><UL><LI>Medivation - with Xtandi, the new prostate cancer drug that is helping to shake up that fast-changing market.<wbr> Analysts stated "If the prostate cancer data that comes out in the next couple of months is positive, one could easily imagine Medivation catching a bid, a big one that could come at a major premium to where it's now trading"</LI>
<LI>Seattle Genetics -  In addition to Adcetris (Hodgkin lymphoma) the biotech has become one of the leading go-to outfits of targeted cancer technology</LI>
<LI>BioMarin -  with its portfolio of  rare diseases and is currently valued at a bit more than $9 billion </LI>
</UL> </div><div>Analysts did not state which companies may be interested but we will have to watch this space to see if any of their forecasts are correct.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10586">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-28T17:28:54+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Summit's Position Strengthened By New DMD Patent [dis:MuscularDystrophy, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7119</link>
<description>Summit's Position Strengthened By New DMD Patent [dis:MuscularDystrophy, news]</description><category>dis:MuscularDystrophy</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7119</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7119">Summit's Position Strengthened By New DMD Patent</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMuscularDystrophy"><font color="#e95e0b">:Neurology:dis:MuscularDystrophy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7119">Neurology7119</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 August 2013 | 17:02</font><br><br><div style="margin-bottom: 10px;">Comment: Summit, a drug discovery and development company focusing on 
therapies for Duchenne Muscular Dystrophy ('DMD') and C.<wbr> difficile infection, 
has announced that the USPTO has issued a composition of matter patent that 
protects SMT C1100 and its use in the treatment of DMD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How does SMT C1100 Fit Alongside Other DMD Therapie?<BR></STRONG> </div><div style="margin-bottom: 10px;">Utrophin modulation has the potential to slow down or even stop the 
progression of DMD regardless of the dystrophin mutation.<wbr> </div><div style="margin-bottom: 10px;">Importantly it is also expected to be complementary to other DMD therapeutic 
approaches in development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current Status</STRONG> </div><div style="margin-bottom: 10px;">SMT C1100, an orally administered small molecule, is Summit's most advanced 
utrophin modulator and it is expected to start clinical trials in DMD patients 
during the second half of 2013.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><STRONG>Details of The Patent Estate<BR></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body">United States Patent number 8,518,980 is entitled 
"Treatment of Duchenne Muscular Dystrophy" and will provide a period of 
exclusivity for the small molecule utrophin modulator SMT C1100 through at least 
November 2028.<wbr> <BR><BR>Commenting on this patent Glyn Edwards CEO stated "The 
grant of this cornerstone patent for SMT C1100 in a key commercial market 
represents a critical component in our strategy for advancing this promising 
utrophin modulator in the treatment of DMD.<wbr> Together with the recently issued US 
patent covering the use of SMT C1100 in combination with steroids, the 
intellectual property estate protecting this potential life-changing drug has 
been significantly strengthened as we prepare to start patient clinical trials 
during the second half of this year.<wbr>" <BR><BR>The patent "Drug Combinations for 
the Treatment of Duchenne Muscular Dystrophy" was recently issued by the US 
Patent and Trademark Officer and covers the use of SMT C1100 in combination with 
steroids such as prednisolone and deflazacort (US Patent number 8,501,713).<wbr> 
<BR><BR></DIV> </div><div><DIV class="article_body">Source; <A href="http://www.summit.com">www.<wbr>summit.<wbr>com</A><BR></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7119">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-28T17:02:41+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7118</link>
<description>re: Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7118</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7118">re: Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7118">Neurology7118</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 August 2013 | 16:54</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Auxillium reported Q2 revenues of $100m +29%, with growth 
underpinned by sales of Xiaflex and products from the newly acquired company 
Actient which has expanded the testosterone portfolio and added a new erectile 
dysfunction buisiness.<wbr> Meanwhile, the group has recently initiated a 
collaboration with SOBI covering the European distribution of Xiaflex in 71 
countries for Dupuytren's contracture and Peyronie's disease.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7102">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7102" class="commentpermalink">Neurology7102</a> / <span class="date">12 August 2013</span> /
<span class="time">12:41:02 o'clock CEST</span>
</font></div><div>The FDA has notified Auxillium that it is extending the PDUFA goal date for the Company's sBLA for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease ("PD") from September 6, 2013 to December 6, 2013.<wbr> <BR><BR>During the course of recent product label discussions, Auxilium submitted revisions regarding the Company's proposed REMS program and other aspects related to the proposed label.<wbr> The FDA determined that this submission qualified as a major amendment filed during the final three months of the review and extended the PDUFA goal date to December 6, 2013.<wbr> The FDA has not requested that any additional clinical studies be performed prior to the revised PDUFA action date.<wbr> <BR><BR>Whilst the company is disappointed with the delay of approval, it remains confident in the XIAFLEX Peyronie's program and committed to working with the FDA while they complete their review.<wbr>" </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7118" class="commentpermalink">Neurology7118</a> / <span class="date">28 August 2013</span> /
<span class="time">16:54:36 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7118">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7102">View thread  Neurology7102: Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease</a>]]></content:encoded><dc:date>2013-08-28T16:54:36+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>China's Simcere To Be Taken Private [sub:Finance, mkt:China, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10585</link>
<description>China's Simcere To Be Taken Private [sub:Finance, mkt:China, mkt:Intercontinental]</description><category>sub:Finance</category><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10585</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10585">China's Simcere To Be Taken Private</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10585">PharmaWorld10585</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 August 2013 | 16:46</font><br><br><div style="margin-bottom: 10px;">Comment: According to Reuters, China's Simcere Pharmaceuticals has agreed to 
be taken private for about $495m by a consortium led by its founder Jinsheng 
Ren.<wbr> It joins a growing list of Chinese firms opting out of the US stock market 
to avoid regulatory scrutiny.<wbr> Simcere continues to be hard hit by China's 
pricing policy and restrictions on the use of antibiotics.<wbr> </div><div style="margin-bottom: 10px;">This month the company reported that its quarterly net income from continuing 
operations fell by &gt;50% and warned that the second half of the year would 
remain under pressure due to Chinese regulatory challenges.<wbr> </div><div>The consortium which already owns about 78% of Simcere has slightly increased 
its offer to that made in March.<wbr> The deal is at a premium of 20% to the stock's 
close on March 8th before the initial offer was made.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10585">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-28T16:46:21+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>How Alpharadin Fits Into The CRPC Treatment Paradigm [dis:Prostate, comp:BayerSchering, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9129</link>
<description>How Alpharadin Fits Into The CRPC Treatment Paradigm [dis:Prostate, comp:BayerSchering, headline]</description><category>dis:Prostate</category><category>comp:BayerSchering</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9129</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9129">How Alpharadin Fits Into The CRPC Treatment Paradigm</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9129">Oncology9129</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 August 2013 | 16:36</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its first half results, Algeta the "world-leader in alpha radiopharmaceuticals" provided a detailed update on the further development and commercialisation of its CRPC drug Alpharadin, launched in the US in May.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">It is important to note that Alpharadin's label indication is focused on a stage of the disease i.<wbr>e.<wbr> patients with symptomatic bone diseasse and not on usage in either the pre or post chemotherapy setting.<wbr> Thus said its positioning is indicated below in a diagramtic representation of the evolving CRPC treatment landscape.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Development Programme</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation Plans</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Details Of The Bayer Partnership &amp; Next Events</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/6/ScreenCapture6.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/7/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9129attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(124,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(108,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(107,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(100,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(106,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(101,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(101,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9129">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-28T16:36:03+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/1/ScreenCapture1.jpg" length="127188" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/2/ScreenCapture2.jpg" length="110856" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/3/ScreenCapture3.jpg" length="109737" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/4/ScreenCapture4.jpg" length="103340" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/5/ScreenCapture5.jpg" length="108902" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/6/ScreenCapture6.jpg" length="104089" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9129/7/ScreenCapture7.jpg" length="103931" type="image/jpeg"/></item><item>
<title>.</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10584</link>
<description>.</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10584</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10584">.<wbr></a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10584">PharmaWorld10584</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 28 August 2013 | 16:21</font><br><br><div>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10584">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-28T16:21:46+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>re: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9128</link>
<description>re: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9128</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9128">re: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9128">Oncology9128</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/396">Roger BELUSA</a> | 28 August 2013 | 15:53</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font><br><span style="font-size: 12px;">Comment: As interest in the immunotherapy oncology expands and 
excitement in the PD-1 pathway grows, AstraZeneca has announced today the 
acquisition of Amplimmune for a total consideration of $500m ($225m 
upfront).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9126">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126" class="commentpermalink">Oncology9126</a> / <span class="date">27 August 2013</span> /
<span class="time">17:05:21 o'clock CEST</span>
</font></div><div>There is much more info in the database I can dig into.<wbr> </div><!-- Comment details --><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9128" class="commentpermalink">Oncology9128</a> / <span class="date">28 August 2013</span> /
<span class="time">15:53:36 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9128">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126">View thread  Oncology9126: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</a>]]></content:encoded><dc:date>2013-08-28T15:53:36+02:00</dc:date><dc:creator>ROB61416</dc:creator></item><item>
<title>re: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9127</link>
<description>re: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9127</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9127">re: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9127">Oncology9127</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/396">Roger BELUSA</a> | 28 August 2013 | 15:52</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font><br><span style="font-size: 12px;">Comment: As interest in the immunotherapy oncology expands and 
excitement in the PD-1 pathway grows, AstraZeneca has announced today the 
acquisition of Amplimmune for a total consideration of $500m ($225m 
upfront).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9126">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126" class="commentpermalink">Oncology9126</a> / <span class="date">27 August 2013</span> /
<span class="time">17:05:21 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Some info on PD-1 </div><div>See PDF </div><!-- Comment details --><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9127" class="commentpermalink">Oncology9127</a> / <span class="date">28 August 2013</span> /
<span class="time">15:52:15 o'clock CEST</span>
</font><br><a name="oncology9127attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9127/1/PD%2d1%20%20CI%20landscape.pdf">PD-1 CI landscape.pdf</a>&nbsp;&nbsp;(139,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9127">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126">View thread  Oncology9126: Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</a>]]></content:encoded><dc:date>2013-08-28T15:52:15+02:00</dc:date><dc:creator>ROB61416</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9127/1/PD%2d1%20%20CI%20landscape.pdf" length="142534" type="application/pdf"/></item><item>
<title>re: The Acromegaly Therapy Area Landscape (2) [:Endocrinology:dis:Acromegaly]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10583</link>
<description>re: The Acromegaly Therapy Area Landscape (2) [:Endocrinology:dis:Acromegaly]</description><category>dis:Acromegaly</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10583</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10583">re: The Acromegaly Therapy Area Landscape (2)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10583">PharmaWorld10583</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/396">Roger BELUSA</a> | 28 August 2013 | 15:11</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The Acromegaly Therapy Area Landscape (2)</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=TAL%3aAcromegaly"><font color="#e95e0b">:Endocrinology:TAL:Acromegaly</font></a>]</font></font><br><span style="font-size: 12px;">Comment: You will find attached an update version of the competitive landscape in acromegaly.<wbr> We encourage you to contribute to our internal knowledge by evaluating some of the "Key Intelligence Questions" included in the document.<wbr><WBR></WBR></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10508">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10508" class="commentpermalink">PharmaWorld10508</a> / <span class="date">12 July 2013</span> /
<span class="time">17:13:47 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><DIV class="cit">Please see below from <A href="http://www.ncbi.nlm.nih.gov/pubmed/23969184?dopt=Abstract" title="The Journal of clinical endocrinology and metabolism.">J Clin Endocrinol Metab.<wbr></A> 2013 Aug 22.<wbr> [Epub ahead of print] Findings show that the octreotide implant maintained reduced blood levels of GH and IGF-1 with continuous octreotide release over 6 months, which was well tolerated.<wbr></DIV> </div><div style="margin-bottom: 10px;"><H1>Efficacy and Safety of an Octreotide Implant in the Treatment of Patients with Acromegaly.<wbr></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Chieffo%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Chieffo C</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cook%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Cook D</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Xiang%20Q%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Xiang Q</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Frohman%20LA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Frohman LA</A>.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff">
<H3 class="label">Source</H3>
<P>1 Endo Health Solutions, Inc.<wbr>, Clinical Research &amp; Development, Malvern PA, USA;</P></DIV> </div><div><DIV class="abstr">
<H3>Abstract</H3>
<DIV>
<P>Context:Acromegaly is caused by excessive GH secretion and IGF-1 overproduction.<wbr> The goals of treatment are to reduce GH and IGF-1 values to normal and relieve associated symptoms.<wbr>Objective:To demonstrate that octreotide implant (84 mg) is safe and efficacious in patients with acromegaly who were responsive to prior monthly octreotide LAR injections.<wbr>Design:Phase 3, open-label study.<wbr> Before treatment, subjects received a stable monthly dose of octreotide LAR injections (10 to 40 mg) for ≥3 months.<wbr> Randomization was in a 3:1 ratio to either 6-month octreotide implant or monthly octreotide LAR injections.<wbr>Setting:This was a multicenter, international study conducted in private or institutional practices.<wbr>Subjects:Enrollment included 163 subjects (aged ≥18 years) with acromegaly.<wbr>Main Outcome Measure:To evaluate the efficacy, safety, and tolerability of the octreotide implant during 24 weeks of treatment.<wbr>Results:After 24 weeks, the success rate of the implant for maintenance of IGF-1 and GH levels was 86% (95% CI: 80.<wbr>3%) compared to 84% (95% CI: 73.<wbr>8%) for octreotide LAR.<wbr> Serum octreotide concentrations after implant insertion increased within 8 days and peaked between day 14 and 28.<wbr> Overall safety of the octreotide implant and octreotide LAR were similar.<wbr> Diarrhea and headache were more frequent with the implant, while cholecystitis and hypertension were more frequent with octreotide LAR.<wbr>Conclusions:In this pivotal phase 3 study, the octreotide implant maintained reduced blood levels of GH and IGF-1 with continuous octreotide release over 6 months, which was well tolerated.<wbr></P></DIV></DIV> </div><!-- Comment details --><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10583" class="commentpermalink">PharmaWorld10583</a> / <span class="date">28 August 2013</span> /
<span class="time">15:11:35 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10583">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10508">View thread  PharmaWorld10508: The Acromegaly Therapy Area Landscape (2)</a>]]></content:encoded><dc:date>2013-08-28T15:11:35+02:00</dc:date><dc:creator>ROB61416</dc:creator></item><item>
<title>Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune [headline, dis:Prostate, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126</link>
<description>Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune [headline, dis:Prostate, :PharmaWorld:sub:Acquisition]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126</comments><category>headline</category><category>dis:Prostate</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9126">Interest In Immuno-Oncology Undperinned By AZ' s Acquisition of Amplimmune</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9126">Oncology9126</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 August 2013 | 17:05</font><br><br><div style="margin-bottom: 10px;">Comment: As interest in the immunotherapy oncology expands and 
excitement in the PD-1 pathway grows, AstraZeneca has announced today the 
acquisition of Amplimmune for a total consideration of $500m ($225m 
upfront).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Medimmune will acquire 100% of Amplimmune's 
shares for the initial consideration of $225m.<wbr> Whilst a deferred consderation of 
up to $275m will become payable on reaching certain pre-determined development 
milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Development Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/1/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">AZ is interested in both the company's technology platform and AMP-514.<wbr> 
currently Amplimmune's only unpartnered asset.<wbr> </div><div style="margin-bottom: 10px;">AMP-514 is an anti-PD1 mAb which Amplimmune positions as being 
unique and mechanistically differentiated and potentially best-in-class.<wbr> An IND 
filing for the first candidate is expected in 2013.<wbr> It will be of interest to 
note where AZ chooses to focus its development activity as its 
develompent tracks behind that of BMS &amp; Roche (prostate cancer 
maybe).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/4/ScreenCapture5.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/5/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9127c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Some info on PD-1 </div><div>See PDF </div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9127" class="commentpermalink">Oncology9127</a> / <span class="date">28 August 2013</span> /
<span class="time">15:52:15 o'clock CEST</span>
</font></div><a name="Oncology9128c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>There is much more info in the database I can dig into.<wbr> </div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9128" class="commentpermalink">Oncology9128</a> / <span class="date">28 August 2013</span> /
<span class="time">15:53:36 o'clock CEST</span>
</font></div><a name="oncology9126attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(52,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(120 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(144,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(83,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(87,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9126">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-27T17:05:21+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/1/ScreenCapture2.jpg" length="53747" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/2/ScreenCapture3.jpg" length="122883" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/3/ScreenCapture4.jpg" length="147824" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/4/ScreenCapture5.jpg" length="85568" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9126/5/ScreenCapture6.jpg" length="89682" type="image/jpeg"/></item><item>
<title>Cost Benefit Of Eligard 6M Utilisiation Evaluated Across Europe [headline, dis:Prostate, comp:Astellas, prod:Eligard]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9125</link>
<description>Cost Benefit Of Eligard 6M Utilisiation Evaluated Across Europe [headline, dis:Prostate, comp:Astellas, prod:Eligard]</description><category>headline</category><category>dis:Prostate</category><category>comp:Astellas</category><category>prod:Eligard</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9125</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9125">Cost Benefit Of Eligard 6M Utilisiation Evaluated Across Europe</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aEligard"><font color="#e95e0b">:Oncology:prod:Eligard</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9125">Oncology9125</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 August 2013 | 16:24</font><br><br><div style="margin-bottom: 10px;">Comment: The latest issue of Clincoecon Outcomes Research includes an 
evidence based review and economic evaluation of Eligard usage based on the 1-3 
and 6-monthly depot formulations, concluding that the 5M formulation offers the 
greatest cost savings and should be considered the treatment of choice in 
eligible patients in Europe.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(9,29,66); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT color="#000000" face="Verdana" size="2">The study evaluated the efficacy, safety and 
cost of the three different formulations in nine European countries, Austrai, 
Belgium, Czech republic, Hungary, Italy, Latvia, Netherlands, Poland and 
Portuga.<wbr> 13 clinical trials were evaluated as part of the 
process.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(9,29,66); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT color="#000000" face="Verdana" size="2"><STRONG>Key 
Findings</STRONG></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(9,29,66); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT color="#000000" face="Verdana" size="2">No sigficant differences were observed in the 
percentage of intention-to-treat patients achieving testosterone levels 
&lt;50ng/<wbr>dl following treatment with Eligard 1M, 3M and 6M and adverse event 
profiles of the three formulations were comparable.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(9,29,66); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT color="#000000" face="Verdana" size="2">Overall, 6M was the least expensive with 
average total annual costs from Euro788 (Belgium) to Euro 1830 (Portugal).<wbr> The 
3M option was between 2.<wbr>5% (Hungary) and 37.<wbr>6% (Belgium) more expensive than the 
6M whilst the 1M was the most expensive formulation.<wbr> Total costs were associated 
with frequency of visits and monitoring.<wbr></FONT></SPAN> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(9,29,66); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">Source; <SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(9,29,66); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Clinicoecon Outcomes Res.<wbr> 2013 Jun 
24;5:257-69.<wbr> </SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9125">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-27T16:24:45+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Bayer Receives Priority Designation For Its US Thyroid Cancer Submission [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7438</link>
<description>Bayer Receives Priority Designation For Its US Thyroid Cancer Submission [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7438</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7438">Bayer Receives Priority Designation For Its US Thyroid Cancer Submission</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7438">Endocrinology7438</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 August 2013 | 16:08</font><br><br><div style="margin-bottom: 10px;">Comment: The FDA has granted priority review designation (six-month) review process to Bayer's sNDA for Nexavar (sorafenib) for the treatment of locally advanced or metastatic radioactive iodine refractory differentiated thyroid cancer.<wbr> </div><div style="margin-bottom: 10px;">The regulatory submission is based on data from the PhIII Decision study, an international multi-centre placebo-controlled trial in which sorafenib significantly extended PFS compared to placebo (HR=0.<wbr>587, p&lt;0.<wbr>0001), representing a 41% reduction in the risk of progression or death.<wbr> The median PFS was 10.<wbr>8 months in patients treated with sorafenibb compared to 5.<wbr>8 months in patients receiving placebo.<wbr> </div><div style="margin-bottom: 10px;">According to Bayer thyroid cancer has become the fastest-increasing cancer in the work in recent years and is the sixth most common in women.<wbr> Papillary, follucular, Hurthle cell and poorly differentiated types of thryoid cancer are classified as differentiated thyroid cancer and account for approx.<wbr> 94% of all thyroid cancers.<wbr> Whilst most are treatable with resection and or radioactive iodine, RIA-refracotry differentiated thyroid cancer is more difficult to treat and is associated with a lower patient survival rate.<wbr> </div><div>source: <A href="http://www.bayer.com/">www.<wbr>bayer.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7438">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-27T16:08:19+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9124</link>
<description>re: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9124</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9124">re: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9124">Oncology9124</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/14">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD</a> | 27 August 2013 | 14:17</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;"><STRONG>The reimbursement is for the post-chemo setting only.<wbr> Zytiga is not yet approved for pre-chemo in Australia.<wbr> Abiraterone is still not listed (no price yet).<wbr> This will usually take place 2 to 4 months afterwards</STRONG></span>&nbsp;<br><font size="-1">Monica DE ABADAL / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9039" class="commentpermalink">Oncology9039</a> / <span class="date">25 June 2013</span> /
<span class="time">07:13:11 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Commen : Zytiga Listed on Australia's PBS August Additions </div><div style="margin-bottom: 10px;">Australia's Pharmaceutical Benefits Scheme (PBS) has released the latest round of price reductions under the Expanded and Accelerated Price Disclosure (EAPD) scheme, which took effect from 1 August 2013.<wbr> According to its Minister of Health, the price cuts are described as meaning that patients would pay around AUD20 million (USD17.<wbr>9 million) less per year.<wbr> <SPAN style="line-height: 1.5em;">The 492 drugs face 25% price cuts on average (with for instance Sanofi's Plavix &ndash; facing the greatest loss of market value with 43.<wbr>7% cut or Simvastatin dealing with the second-largest reduction of 44.<wbr>66%.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The PBS has also released the list of august additions, most prominently including US Johnson &amp; Johnson's prostate cancer drug Zytiga (abiraterone) under following restrictions :</SPAN> </div><div style="margin-bottom: 10px;">Indication : Castration resistant metastatic carcinoma of the prostate </div><div><DIV>
<DIV label="Restriction">
<P>The required clinical criteria are :</P>
<P>1/<wbr> <SPAN style="line-height: 1.5em;">The treatment must be in combination with prednisone or prednisolone</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>2/<wbr> <SPAN style="line-height: 1.5em;">The treatment must not be used in combination with chemotherapy</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>3/<wbr> <SPAN style="line-height: 1.5em;">Patient must have failed treatment with docetaxel due to resistance or intolerance</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>4/<wbr> <SPAN style="line-height: 1.5em;">Patient must have a WHO performance status of 2 or less,</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>5/<wbr> <SPAN style="line-height: 1.5em;">Patient must not receive PBS-subsidised abiraterone if progressive disease develops while on abiraterone.<wbr></SPAN></P>
<P><SPAN style="line-height: 1.5em;">Source : Global Insight - Aug 1st</SPAN></P>

</DIV>
</DIV> </div><!-- Comment details --><font size="-1">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9124" class="commentpermalink">Oncology9124</a> / <span class="date">27 August 2013</span> /
<span class="time">14:17:37 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9124">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9034">View thread  Oncology9034: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</a>]]></content:encoded><dc:date>2013-08-27T14:17:37+02:00</dc:date><dc:creator>len82156</dc:creator></item><item>
<title>Cytokinetics Reports Positive Results From Its Neuromuscular Program With Tirasemtiv In ALS [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7116</link>
<description>Cytokinetics Reports Positive Results From Its Neuromuscular Program With Tirasemtiv In ALS [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7116</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7116">Cytokinetics Reports Positive Results From Its Neuromuscular Program With Tirasemtiv In ALS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7116">Neurology7116</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 23 August 2013 | 15:49</font><br><br><div style="margin-bottom: 10px;">Comment: Cytokinetics has announced the publication of two manuscripts 
reporting positive data from two clinical trials of <I>tirasemtiv</I>, a 
first-in-class fast skeletal muscle troponin activator in patients with 
amyotrophic lateral sclerosis (ALS).<wbr> The trials were designed to 
evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of two 
different dosing regimens of <I>tirasemtiv</I>.<wbr> </div><div style="margin-bottom: 10px;">The lead author of the 
manuscripts Jeremy M.<wbr> Shefner, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, Professor and Chair, Department of 
Neurology at the Upstate Medical University, State University of New York, 
states “These manuscripts highlight encouraging results from two prior 
Phase II clinical trials of <I>tirasemtiv</I> in patients with ALS.<wbr> Activation 
of skeletal muscle with <I>tirasemtiv</I>, as assessed under different dosing 
regimens in these studies, appears to be generally well-tolerated and to impact 
positively tests of strength, endurance and respiratory function that may be 
relevant to preserving the functional status of patients with 
ALS.<wbr>” </div><div style="margin-bottom: 10px;">Statistically significant relationships between increases in 
these functional measures and increasing plasma concentration of 
<I>tirasemtiv</I> were observed for all measures except for vital 
capacity.<wbr> Shefner concludes that all findings support the ongoing 
development of this drug candidate for the potential treatment of 
ALS.<wbr> </div><div style="margin-bottom: 10px;">Results from these trials seemingly informed the design of 
the large phIIb BENEFIT-ALS trial (n=680) which is currently 
ongoing and looking to demonstrate longer term safety and potential durability 
of clinically meaningful effects of  the drug.<wbr> Results are expected by 
end-of-year 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Scope Of The Drug Development Program</STRONG> </div><div style="margin-bottom: 10px;">The slides below illustrate the scope of the <EM>tirasemtiv</EM> programme 
and the value proposition the company believes it can address in the 
neuromuscular disease setting.<wbr> Whilst, the company's lead drug development 
programme with <STRONG><EM>omecamtiv mecarbil</EM> in heart failure is partnered 
with Amgen,</STRONG> the <EM>tirasemtive</EM> program is currently 
unpartnered.<wbr> <img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/6/ScreenCapture6.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/7/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7116attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(125,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(141 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(132,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(108,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(121,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(114,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(85,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7116">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-23T15:49:40+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/1/ScreenCapture1.jpg" length="128828" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/2/ScreenCapture2.jpg" length="144333" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/3/ScreenCapture3.jpg" length="135435" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/4/ScreenCapture4.jpg" length="111199" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/5/ScreenCapture5.jpg" length="124352" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/6/ScreenCapture6.jpg" length="116833" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7116/7/ScreenCapture7.jpg" length="87900" type="image/jpeg"/></item><item>
<title>J&amp;J Finalises Acquisition of Aragon As The Dynamics Of The CRPC Market Start To Play Out [headline, prod:MDV3100, prod:Zytiga, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9123</link>
<description>J&amp;J Finalises Acquisition of Aragon As The Dynamics Of The CRPC Market Start To Play Out [headline, prod:MDV3100, prod:Zytiga, dis:Prostate]</description><category>headline</category><category>prod:MDV3100</category><category>prod:Zytiga</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9123</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9123">J&J Finalises Acquisition of Aragon As The Dynamics Of The CRPC Market Start To Play Out</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9123">Oncology9123</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 23 August 2013 | 15:05</font><br><br><div style="margin-bottom: 10px;">Comment: With J&amp;J announcing yesterday that its acquisition of 
Aragon and its 2nd generation androgen-antagonist program is now complete, 
the company is poised to move forward with the development of ARN-509.<wbr> It 
believes ARN-509 "will allow J&amp;J to meet the needs of an even broader 
range of prostate cancer patients.<wbr>" Recent evidence of how this class of 
drug is performing relative to Zytiga (exemplified by XTANDI) relative 
to Zytiga is shown as are the highlights of a recent discussion on this topic 
between Barclays analysts and Dr Mary Taplin from the Dana-Farber Cancer 
Institute.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Barclay's Report (August 13th)</STRONG> </div><div style="margin-bottom: 10px;">Barclays analysts discussion with Dr Taplin focused 
on the upcomoing interim analysis of the PREVAIL trial and how she can 
envisage XTANDI &amp; Zytiga being used in the pre-chemo CRPC segment of the 
market.<wbr> </div><div style="margin-bottom: 10px;">Dr Taplin appears to view the two drugs similarly and has expectations 
that the results of PREVAIL will be similar in terms of Hazard ratio and 
survival benefit (&lt;0.<wbr>8 and ~6-7 months respectively).<wbr> She believes the 
results will be unblinded within the next 3 months.<wbr> </div><div style="margin-bottom: 10px;">Regarding whether the entry of XTANDI into the pre-chemo segement will change 
prescribing,  she suggests that its lack of requirement for steroid use 
could be a deciding factor.<wbr> For example in a patient with concomitant diabetes 
you would look to avoid steroids, whilst in a patient with existing 
bone-metastases use of Zytiga may be favoured since steroids may help.<wbr> </div><div style="margin-bottom: 10px;">Currently Dr Taplin almost exclusively prescribes Zytiga in the 
pre-chemotherapy setting and then switches to XTANDI post-Zytiga failure, with 
chemotherapy reserved as last-line.<wbr> </div><div style="margin-bottom: 10px;">She believes the real game-changer will depend on adoption of XTANDI in the 
urology community, The big question is whether urologists will hold onto their 
prostate cancer patients longer before referring them to an oncologist.<wbr> 
Urologists may be willing to prescribe XTANDI given their comfort with Casodex, 
but have largely stayed away from Zytiga because of its monitoring requirements.<wbr> 
However, urologists will still need to order bone scans every 3-4 months to 
check for radiographic progression, rather than relying as they do now on 
PSA tests.<wbr> This, she claims.<wbr> will require phyician education.<wbr> She also noted 
that it will be critical which drug CRPC patients receive first, because 
resistance mechanism develop and only a minority of patients will respond well 
to the second drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>US Market Performance</STRONG> </div><div style="margin-bottom: 10px;">Looking at how XTANDI and Zytiga sales are tracking relative to one another, 
Lerrink and Swan analysts recent report (August 9th) presents a chart 
showing the relative uptake of the two drugs in the US market (see below).<wbr> 
Sales reflect initial usage in the post-chemo CRPC segment where both drugs 
are currently approved.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9123/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9123attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9123/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9123">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-23T15:05:25+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9123/1/ScreenCapture1.jpg" length="114408" type="image/jpeg"/></item><item>
<title>Bavarian Nordic Q2 Earnings - Update On Prostvac [dis:Prostate, class:Vaccines]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9122</link>
<description>Bavarian Nordic Q2 Earnings - Update On Prostvac [dis:Prostate, class:Vaccines]</description><category>dis:Prostate</category><category>class:Vaccines</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9122</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9122">Bavarian Nordic Q2 Earnings - Update On Prostvac</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9122">Oncology9122</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 August 2013 | 15:47</font><br><br><div style="margin-bottom: 10px;">Comment: Management noted that there are now 13 countries and 144 sites participating in the Ph3 PROSPECT trial with its cancer immunotherapy for CRPC Prostvac.<wbr> Enrolment is now scheduled to complete in 1H14 and an early data read-out is planned based on a pre-agreed interim analysis with the FDA.<wbr> </div><div style="margin-bottom: 10px;">Trying to gain ground on Dendreon's PROVENGE in terms of potential combination usage, Bavarian Nordic has already initiated two Ph2 studies combining Prostvac with XTANDI (enzalutamide) in May this year, one in metastatic patients (n=70) and the other in non-metatatic patients (n=38).<wbr> Both studies are scheduled to complete in June 2016.<wbr> </div><div style="margin-bottom: 10px;">Dendreon is progressing with a Ph2 abiraterone combination study but has yet to initiate a study in combination with XTANDI.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9122/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9122attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9122/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(251,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9122">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-22T15:47:28+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9122/1/ScreenCapture1.jpg" length="257493" type="image/jpeg"/></item><item>
<title>MedyTox Q213 earnings - Key Takeaways [comp:MediTox, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7115</link>
<description>MedyTox Q213 earnings - Key Takeaways [comp:MediTox, news]</description><category>comp:MediTox</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7115</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7115">MedyTox Q213 earnings - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7115">Neurology7115</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 August 2013 | 14:28</font><br><br><div style="margin-bottom: 10px;">Comment: Medytox recently reported strong top-line growth (+17.<wbr>3% 
y-y) due to bouyant domestic sales of Meditoxin but downward pressure on 
operating profit (-6% y-y) and net income (-10.<wbr>1% y-y).<wbr> Little information is 
forthcoming from the company, with only a handful of analysts able to report on 
ongoing progress.<wbr> </div><div style="margin-bottom: 10px;">Domestic sales benefited from from a new sales contract with Pacific 
Pharma  and grew by 30.<wbr>9% to reach W5.<wbr>6bn </div><div style="margin-bottom: 10px;">Elsewhere, Asian sales dipped 7.<wbr>4% Y-Y to W3.<wbr>6bn due to delayed orders 
(stemming from contracts lapsing and new supply volume negotiations ongoing).<wbr> 
Sales in Latin America, by contrast, surged surged 43% yo W1.<wbr>4bn , lifting 
Meytox's overall export sales 5.<wbr>8% to W5.<wbr>4bn.<wbr> </div><div style="margin-bottom: 10px;">Whilst the companies COGS ratio rose by 3.<wbr>5 p.<wbr>p.<wbr> to 11.<wbr>5% pressure on 
operating margins arose from an escalating SG&amp;A ratio up by 8.<wbr>6 p.<wbr>p to 
39.<wbr>4%, leaving the overall operating margin at 49.<wbr>1%.<wbr> Profitability should 
recover in Q3 due to lower payments to Pacific Pharma.<wbr> </div><div>Source: Woori Investment Report August 14th </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7115">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-22T14:28:26+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Poland Health Fund Reimburses Only One-Quarter of Cost of Treatment With Zytiga [comp:JnJ, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9120</link>
<description>Poland Health Fund Reimburses Only One-Quarter of Cost of Treatment With Zytiga [comp:JnJ, prod:Zytiga]</description><category>comp:JnJ</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9120</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9120">Poland Health Fund Reimburses Only One-Quarter of Cost of Treatment With Zytiga</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9120">Oncology9120</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/14">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD</a> | 22 August 2013 | 11:08</font><br><br><div style="margin-bottom: 10px;">Comment : The NFZ -Polish National Health Fund- has ceased paying the full cost of treatment with Janssen-Cilag's (the EU branch of US Johnson &amp; Johnson) Zytiga.<wbr> </div><div style="margin-bottom: 10px;">The <EM>Gazeta Wyborcza </EM>reports that until recently the regional NFZ was paying the full cost of treatment with Zytiga, but it is now paying a proportion of the cost, ie.<wbr> only PLN3,700 (USD1,174) of the PLN17,000, within the context of its non-standard chemotherapy programme<EM>.<wbr> </EM> </div><div style="margin-bottom: 10px;">The source quotes that the NFZ's reasoning for reducing the funding is the recommendation of the Agency for Heath Technology Assessment in Poland (AOTM) from April, recommending Zytiga's reimbursement on condition that its cost be reduced to within the cost-effectiveness thresholds recognised by the Agency.<wbr> It also reports that the Reimbursement Act (introduced at the beginning of 2012) allows for such a drastic cut in reimbursement.<wbr> The <EM>Gazeta</EM> <EM>Wyborcza </EM>however points out that the decision goes contrary to this Act, stating that medicines funded under non-standard chemotherapy should continue to be funded under the same conditions until the beginning of 2014, when the division between standard and non-standard chemotherapy is to be annulled.<wbr> </div><div>Source : Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9120">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-22T11:08:47+02:00</dc:date><dc:creator>len82156</dc:creator></item><item>
<title>Patients and Support Organisations Urging To Be Heard During HTAs</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10561</link>
<description>Patients and Support Organisations Urging To Be Heard During HTAs</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10561</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10561">Patients and Support Organisations Urging To Be Heard During HTAs</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10561">PharmaWorld10561</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 21 August 2013 | 16:06</font><br><br><div style="margin-bottom: 10px;">Comment: Is there a change on the horizon, will end users have a say in how cancer drugs are priced? </div><div style="margin-bottom: 10px;">Within the last 6 months, we have seen prescribers protesting at high cost of cancer drugs, forcing a pricing U-turn in one case and now we have support groups/<wbr>patient advocates voicing their concerns over access.<wbr> </div><div style="margin-bottom: 10px;">Another new cancer drug, Pfizer's Xalkori (crizotinib) looks set to be rejected by the HTA and as a result, patient groups are calling for a ‘louder voice’ during NICEs’  Health Technology Appraisals </div><div style="margin-bottom: 10px;">Lorraine Dallas, director of information &amp; support at the Roy Castle Lung Cancer Foundation is urging Pfizer and NICE to work together to further discuss pricing and make the drug available to patients.<wbr> </div><div style="margin-bottom: 10px;">She says of her organisation (who was a part of the appraisal) -"<EM>We look at it from a patient's perspective.<wbr> There is a lack of treatments available for late-stage lung cancer patients, and Xalkori is something that has good clinical evidence behind it…From a patient perspective, it's about ensuring that people have access to the most appropriate clinical care, including medicines, and recognizing that although decisions have a cost issue and that the community that benefits may be small, they can have a major impact on individuals,".<wbr></EM> </div><div style="margin-bottom: 10px;">Whereas NICE believed that the drug would not be a cost-effective use of NHS resources and had doubts about its overall survival benefits.<wbr> </div><div style="margin-bottom: 10px;">Not only are prescribers and groups moving for a call to action, patients are becoming more active and adding their voices to the pricing/<wbr>access debates as they are better educated and are asking more questions of their clinicians about why certain treatments might not be available and what is the justification for this.<wbr> </div><div style="margin-bottom: 10px;">Patients are also increasingly taking to national and international online forums swapping stories on access to medicines.<wbr> </div><div>These moves on part of the end users are forcing the decision makers to be accountable for their actions and it will be interesting to see if agencies will start bowing from the pressure or making further allowances in certain cases.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10561">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-21T16:06:59+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Hikma Comes Out On Top With Strong First Half Results</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10560</link>
<description>Hikma Comes Out On Top With Strong First Half Results</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10560</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10560">Hikma Comes Out On Top With Strong First Half Results</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10560">PharmaWorld10560</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 21 August 2013 | 15:23</font><br><br><div style="margin-bottom: 10px;">Comment: Hikma delivers exceptionally strong first half results with 20% revenue growth </div><div style="margin-bottom: 10px;"><STRONG>Injectables Division Highlights </STRONG><STRONG>(Hikma sells GP Pharm’s Lutrate 1M in over 23 countries - MENA/<wbr>EU regions)</STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Global Injectables revenue grew 9.<wbr>5%, with adjusted operating margin of 28.<wbr>6%, driven by strong performances in the US and Europe </LI>
<LI>The Injectables business remains on track to deliver low double-digit revenue growth for the full year </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Generics Division Highlights</STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Generics revenue increased by 136.<wbr>6% to $132.<wbr>0 million and full year Generics revenue guidance raised to $230 million, reflecting exceptionally strong doxycycline sales </LI>
<LI>Generics operating profit of $49.<wbr>4 million, after non-recurring costs of $32.<wbr>8 million </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Group financial highlights</STRONG> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" width="“,”100%“,”"><TBODY><TR><TD valign="top" width="331">
<P><STRONG>Summary P&amp;L</STRONG><BR>$ million</P></TD>
<TD valign="top" width="117">
<P><STRONG>H1 2013</STRONG></P></TD>
<TD valign="top" width="117">
<P><STRONG>H1 2012</STRONG></P></TD>
<TD valign="top" width="117">
<P><STRONG>Change </STRONG></P></TD>
</TR>
<TR><TD valign="top" width="331">
<P>Revenue</P></TD>
<TD valign="top" width="117">
<P><STRONG>638.<wbr>3</STRONG></P></TD>
<TD valign="top" width="117">
<P>532.<wbr>3</P></TD>
<TD valign="top" width="117">
<P>+19.<wbr>9%</P></TD>
</TR>
<TR><TD valign="top" width="331">
<P>Gross profit</P></TD>
<TD valign="top" width="117">
<P><STRONG>353.<wbr>3</STRONG></P></TD>
<TD valign="top" width="117">
<P>234.<wbr>1</P></TD>
<TD valign="top" width="117">
<P>+50.<wbr>9%</P></TD>
</TR>
<TR><TD valign="top" width="331">
<P><EM>Gross margin</EM></P></TD>
<TD valign="top" width="117">
<P><STRONG><I>55.<wbr>3%</I></STRONG></P></TD>
<TD valign="top" width="117">
<P><EM>44.<wbr>0%</EM></P></TD>
<TD valign="top" width="117">
<P><EM>+11.<wbr>3pp</EM></P></TD>
</TR>
<TR><TD valign="top" width="331">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
</TR>
<TR><TD valign="top" width="331">
<P>Operating profit</P></TD>
<TD valign="top" width="117">
<P><STRONG>144.<wbr>0</STRONG></P></TD>
<TD valign="top" width="117">
<P>75.<wbr>1</P></TD>
<TD valign="top" width="117">
<P>+91.<wbr>8%</P></TD>
</TR>
<TR><TD valign="top" width="331">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
</TR>
<TR><TD valign="top" width="331">
<P>Adjusted operating profit<SUP>1,2</SUP></P></TD>
<TD valign="top" width="117">
<P><STRONG>189.<wbr>1</STRONG></P></TD>
<TD valign="top" width="117">
<P>83.<wbr>7</P></TD>
<TD valign="top" width="117">
<P>+125.<wbr>8%</P></TD>
</TR>
<TR><TD valign="top" width="331">
<P><EM>Adjusted operating margin</EM></P></TD>
<TD valign="top" width="117">
<P><STRONG><I>29.<wbr>6%</I></STRONG></P></TD>
<TD valign="top" width="117">
<P><EM>15.<wbr>7%</EM></P></TD>
<TD valign="top" width="117">
<P><EM>+13.<wbr>9pp</EM></P></TD>
</TR>
<TR><TD valign="top" width="331">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
<TD valign="top" width="117">&nbsp;</TD>
</TR>
<TR><TD valign="top" width="331">
<P>EBITDA<SUP>3</SUP></P></TD>
<TD valign="top" width="117">
<P><STRONG>182.<wbr>6</STRONG></P></TD>
<TD valign="top" width="117">
<P>103.<wbr>7</P></TD>
<TD valign="top" width="117">
<P>+76.<wbr>1%</P></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><a name="pharmaworld10560attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10560/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(149,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10560/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(39,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10560">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-21T15:23:32+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10560/1/ScreenCapture1.jpg" length="152939" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10560/2/ScreenCapture2.jpg" length="40097" type="image/jpeg"/></item><item>
<title>Shire Fears A Potential Takeover [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10558</link>
<description>Shire Fears A Potential Takeover [sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10558</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10558">Shire Fears A Potential Takeover</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10558">PharmaWorld10558</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2013 | 16:14</font><br><br><div style="margin-bottom: 10px;">Comment: The UK Sunday Times suggests that Shire has hired investment 
bank Lazard to advise the company regarding concerns of a potential takeover 
attempt by a major US drugmaker.<wbr> It apparently rebuffed an informal approach by 
BMS earlier this year.<wbr> </div><div>Shire is also benig rumoured as a potential takeover target for AstraZeneca, 
whose decision to suspend a share repurchase programme last October has given it 
more financial flexibility to consider a large acquisition.<wbr> One of the 
attractions of Shire is it is now domiciled in Ireland and hence benefits from 
lower tax rates.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10558">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-20T16:14:54+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Quarterly US MEDACorp Cosmetic Survey Findings [Alert, comp:Allergan, comp:Merz, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7114</link>
<description>Quarterly US MEDACorp Cosmetic Survey Findings [Alert, comp:Allergan, comp:Merz, sub:Aesthetics]</description><category>Alert</category><category>comp:Allergan</category><category>comp:Merz</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7114</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7114">Quarterly US MEDACorp Cosmetic Survey Findings</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7114">Neurology7114</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2013 | 15:43</font><br><br><div style="margin-bottom: 10px;">Comment: Leerink &amp; Swann's recent review of the US aesthetic market 
highlights stable market trends but evidence of growing interest in Merz's 
Xeomin and topical botulinum toxin, the former projected to cause 
escalating share losses for Botox.<wbr> However, US approval for Crows's feet 
(expected late 2013) coupled with HHS's Botox pricing decision which may give 
Allergan greater pricing flexibility on cosmetic indications 
could help to impede Xeomin's growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Scope of The Survey </STRONG> </div><div style="margin-bottom: 10px;">The analysts latest report on the cosmetic market highlights the findings of 
the Q213 MEDACorp surbey of 31 US-based dermatologists and 30 plastic 
surgesons.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Market Outlook</STRONG> </div><div style="margin-bottom: 10px;">Procedure volume and consultations were stable but not as bullish as 
witnessed in the Q113 survey.<wbr> Y/<wbr>Y growth forecasts for toxins and fillers 
declined to +3.<wbr>5% om the 2Q survey vs.<wbr> 6% &amp; 5.<wbr>3% in Q1 respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Usage/<wbr>Interest Findings</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7114attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(173,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(190,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(185,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(149,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7114">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-20T15:43:41+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/1/ScreenCapture1.jpg" length="177436" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/2/ScreenCapture2.jpg" length="195152" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/3/ScreenCapture3.jpg" length="189646" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7114/4/ScreenCapture4.jpg" length="153370" type="image/jpeg"/></item><item>
<title>First Clinical Accurin Targets Prostate Cancer [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9118</link>
<description>First Clinical Accurin Targets Prostate Cancer [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9118</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9118">First Clinical Accurin Targets Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9118">Oncology9118</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2013 | 14:36</font><br><br><div style="margin-bottom: 10px;">Comment: BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, has dosed the first chemotherapy naive CRPC patient in a phII study with its PSMA-targeted Accurin containing docetaxel.<wbr> </div><div><TABLE style="width: 100%;"><TBODY><TR align="left"><TD>
<DIV class="article_body">&ldquo;Prostate-specific membrane antigen (PSMA) is an attractive target in patients with advanced prostate cancer.<wbr> By delivering an established cytotoxic to this target, there is the potential to significantly improve the therapeutic index and patient outcomes,&rdquo; commented Howard Scher, MD, the Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center and principal investigator of the study.<wbr> </DIV>
<DIV class="article_body"><STRONG>Study Design<BR></STRONG>This 40 patient, open label, single arm multi-center study is designed to determine the efficacy of BIND-014 as measured by progression-free survival in patients with chemotherapy-na&iuml;ve metastatic castrate-resistant prostate cancer clinicaltrials.<wbr>gov (NCT01812746).<wbr> </DIV>
<DIV class="article_body"><STRONG>Lead Program To Emerge From This New Platform Technology<BR></STRONG>BIND-014 represents the first Accurin nanomedicine to reach the clinic from BIND&rsquo;s Medicinal Nanoengineering&reg; platform.<wbr></DIV>
<DIV class="article_body">Source: <A href="http://www.bind.com">www.<wbr>bind.<wbr>com</A></DIV>
</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9118">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-20T14:36:54+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Temira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7437</link>
<description>re: Temira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7437</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7437">re: Temira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7437">Endocrinology7437</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/396">Roger BELUSA</a> | 19 August 2013 | 16:21</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7434/1/Tekmira.jpg?user-agent=rss"></span>&nbsp;<br><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434" class="commentpermalink">Endocrinology7434</a> / <span class="date">19 August 2013</span> /
<span class="time">09:18:21 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Some more info I found: </div><div style="margin-bottom: 10px;"><STRONG>Two drugs with similar approach: </STRONG>TKM-080301 (Nucleic Acid Therapies) - Tekmira Pharmaceuticals and <SPAN style="line-height: 1.5em;">MDRNA-1 (Nucleic Acid Therapies) - Marina Biotech</SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Other drugs in development with the same target (PLK=Serine/<wbr>Threonine protein  kinase PLK1)</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7437/1/PLK%20inhibitors.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;">Highest stage of development Phase:II </div><div><STRONG>Other indications:</STRONG> Hodkin&rsquo;s Lymphoma (Ph I), non- Hodkin&rsquo;s Lymphoma (Ph I), Solid tumors (Ph I), Liver cancer (preclin) </div><!-- Comment details --><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7437" class="commentpermalink">Endocrinology7437</a> / <span class="date">19 August 2013</span> /
<span class="time">16:21:00 o'clock CEST</span>
</font><br><a name="endocrinology7437attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7437/1/PLK%20inhibitors.jpg">PLK inhibitors.jpg</a>&nbsp;&nbsp;(22,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7437">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428">View thread  Endocrinology7428: Tekmira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</a>]]></content:encoded><dc:date>2013-08-19T16:21:00+02:00</dc:date><dc:creator>ROB61416</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7437/1/PLK%20inhibitors.jpg" length="23129" type="image/jpeg"/></item><item>
<title>Auxilium Releases Preliminary PhIIa Data On Frozen Shoulder Treatment With Xiaflex [sub:Aesthetics, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7111</link>
<description>Auxilium Releases Preliminary PhIIa Data On Frozen Shoulder Treatment With Xiaflex [sub:Aesthetics, news]</description><category>sub:Aesthetics</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7111</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7111">Auxilium Releases Preliminary PhIIa Data On Frozen Shoulder Treatment With Xiaflex</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7111">Neurology7111</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 August 2013 | 16:03</font><br><br><div style="margin-bottom: 10px;">Comment: At the Cannacrod Genuity conference last week, Auxilium expanded on some of its recent pipeline developments with Xiaflex, highlighting both some phI cellulitis data and phII frozen-should results.<wbr> </div><div style="margin-bottom: 10px;">Commenting on these programs Adrian Adams.<wbr> President &amp; CEO noted.<wbr> "We are very pleased to have the phI cellultis results, which pointed to us moving into Phase II.<wbr> Below is pictorial evidence of some of the early findings that we saw in terms of overall improvement in dimple size and obviously dimension, and it was this type of data which gave us confidence and move it into Phase II in the second half of this year.<wbr>" </div><div style="margin-bottom: 10px;">"Similarly on frozen shoulder syndrome we were very pleased with the results of our Phase IIa study in this area.<wbr> I think not only getting statistical significant in terms of the mobility aspects of frozen shoulder but also on the pain involved in frozen shoulder.<wbr> Again, based on these very good results, we anticipate initiating later stage studies in the second half of this year as well.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7111/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7111/2/ScreenCapture2.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.auxillium.com">www.<wbr>auxillium.<wbr>com</A> </div><!-- Comment details --><a name="neurology7111attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7111/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(275,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7111/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(182,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7111">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-19T16:03:33+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7111/1/ScreenCapture1.jpg" length="282366" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7111/2/ScreenCapture2.jpg" length="186646" type="image/jpeg"/></item><item>
<title>Sophiris NASDAQ Debut [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9117</link>
<description>Sophiris NASDAQ Debut [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9117</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9117">Sophiris NASDAQ Debut</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9117">Oncology9117</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 August 2013 | 15:40</font><br><br><div style="margin-bottom: 10px;">Comment: Canadian pharmaceutical company Sophiris Bio Inc, previouly known as 
Protalix raised $65m last week through the sale of 13 million shares, more than 
double what it had expected earlier in the month.<wbr> The fund-raising is designed 
to support the phIII development of its lead product PRX302 for the treatment of 
BPH.<wbr> </div><div style="margin-bottom: 10px;">This half-year Sophiris plans to start the first of two phIII trials of 
PRX302 to treat benign prostatic hypertrophy (BPH).<wbr> The product is a 
pore-forming prodrug activated by PSA that is deisgned to be administered in the 
urologists office.<wbr> </div><div style="margin-bottom: 10px;"><P class="bottom">A multi-center, double blinded, placebo controlled Phase IIb 
study (TRIUMPH) of PRX302 in men with moderate to severe BPH met its primary 
endpoint demonstrating a statistically significant improvement in IPSS from 
baseline when compared to placebo at 3 months post-treatment.<wbr> In the study, 
patients treated with PRX302 showed an improvement of 9.<wbr>1 points from baseline 
versus an improvement in IPSS of 5.<wbr>8 points from baseline in patients receiving 
placebo (p&lt;0.<wbr>05).<wbr></P> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9117/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9117attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9117/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9117">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-19T15:40:05+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9117/1/ScreenCapture1.jpg" length="45920" type="image/jpeg"/></item><item>
<title>Novo's New LAGH To Complete PhI Development This Year For AGHD [class:GrowthHormone, comp:NovoNordisk, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7436</link>
<description>Novo's New LAGH To Complete PhI Development This Year For AGHD [class:GrowthHormone, comp:NovoNordisk, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>comp:NovoNordisk</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7436</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7436">Novo's New LAGH To Complete PhI Development This Year For AGHD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7436">Endocrinology7436</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 August 2013 | 14:43</font><br><br><div style="margin-bottom: 10px;">Comment: Novo Nordisk disclosed in its Q213 earnings positive top-line results from a phI healthy volunteert study with its new long-acting growth hormone.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01514500?term=NN8640&amp;rank=1&amp;submit_fld_opt=">NCT01514500</A> - The European double-blind placebo-controlled dose escalation study in 105 healthy volunteers reportedly showed that single and multiple ascending doses of subcutaneous <STRONG>NN8640 </STRONG>were well tolerated.<wbr> </div><div style="margin-bottom: 10px;">A phI trial evaluating multiple doses of <STRONG>NN8640 in adults with GHD</STRONG> is expected to complete during this half year.<wbr> </div><div>Source.<wbr> <a href="http://www.novo-nordisk.com" class="defaultlink" title="http://www.novo-nordisk.com">novo-nordisk.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7436">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-19T14:43:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Nanoparticle Formulation of 177Lu-DOTATATE  For NET Therapy [dis:MidGutNET, news, dis:pNET]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7435</link>
<description>New Nanoparticle Formulation of 177Lu-DOTATATE  For NET Therapy [dis:MidGutNET, news, dis:pNET]</description><category>dis:MidGutNET</category><category>news</category><category>dis:pNET</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7435</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7435">New Nanoparticle Formulation of 177Lu-DOTATATE  For NET Therapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7435">Endocrinology7435</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 August 2013 | 11:37</font><br><br><div style="margin-bottom: 10px;">Comment: At the forthcoming EANM conference in October, one of the 
presentations will focus on a new nanoparticle formulation 
of 177Lu-DOTATATE being developed by the All India Institute Of Medical 
Sciences in Dehli.<wbr> Preclinical data suggests this formulation has the potential 
to enhance the efficacy of PRRT by reducing the associated renal radiation 
dose.<wbr> </div><div style="margin-bottom: 10px;">The abstract references the application of nanoparticles in drug 
delivery and the promising results this has yielded with 
chemotherapy both in terms of enhanced efficacy while simultaneously reducing 
the associated side effects.<wbr> Based on these facts, G Arora and 
colleagues have developed biopolymeric nanoparticles containing 
177Lu-DOTATATE for NET therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Methodology</STRONG> </div><div style="margin-bottom: 10px;">Nanoparticles (NPs) of PLGA, alginate and alginate/<wbr>chitosan were prepared 
followed by 177Lu-DOTATATE encapsulation and PEG-coating.<wbr> They were compared 
in-vitro with respect to various parameters such as ease of formulation, 
particle size, stability at physiological pH (7.<wbr>4), drug-loading efficiency and 
release kinetics over 21 days.<wbr> The most suitable NPs were evaluated in vivo in 
tumor-induced wistar albino rats (C6 glioma cell) by imaging followed by blood 
and organ counting upto 24 h.<wbr> Uptake ratio of tumor (T) to kidney (K), liver (L) 
and bone (B) were calculated and compared to that of control group injected with 
177Lu-DOTATATE.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">All NPs were spherical in shape as seen on electron microscope with size 
range between 200-300 nm.<wbr> PLGA NPs, however, had smoother surface.<wbr> Optimum size 
(303.<wbr>8 ± 67.<wbr>2 nm), better stability, drug-loading capacity (65.<wbr>385 ± 5.<wbr>67%) and 
minimum release till 6 h (27.<wbr>89 ± 4.<wbr>60%) favored the use of PLGA NPs over 
alginate and alginate/<wbr>chitosan NPs.<wbr> T:K, T:L and T:B values were 8.<wbr>58, 5.<wbr>68 and 
8.<wbr>00 in the group injected with 177Lu-DOTATATE-NPs at 24 h post-injection 
compared to 2.<wbr>17 (p&lt;0.<wbr>001), 6.<wbr>82 (p=0.<wbr>2) and 8.<wbr>71 (p=0.<wbr>3) for the control 
group, respectively.<wbr> </div><div style="margin-bottom: 10px;">Moreover, the uptake in tumor with 177Lu-DOTATATE-NPs (43%) was significantly 
higher than the control group (33%; p&lt;0.<wbr>05).<wbr> </div><div style="margin-bottom: 10px;"><B>Key Conclusions</B> </div><div style="margin-bottom: 10px;">A 4-fold increase in tumor-to-kidney ratio and higher tumor uptake of 
177Lu-DOTATATE indicates the high potential of these nanoprobes in enhancing the 
efficacy of PRRT by reducing the associated renal radiation dose.<wbr> NPs can play a 
significant role for delivery of radiopharmaceuticals, particularly in patients 
who otherwise remain undertreated owing to increased side effects at high doses.<wbr> </div><div style="margin-bottom: 10px;">The researchers note that Radiolabeled nanoparticles have yet not found a 
widespread clinical application in nuclear medicine therapy.<wbr> This study 
findings, they believe, will serve as a foundation for further trials in 
human subjects, so that NPs can be applied in routine PRRT and also encourage 
nano-biotechnology-based research in nuclear medicine and molecular imaging.<wbr> </div><div style="margin-bottom: 10px;">Source: Abstact </div><div><TABLE border="0" cellpadding="4" cellspacing="0" width="100%"><TBODY><TR><TD class="tdbg2" valign="top" width="13%"><STRONG>OP035</STRONG></TD>
<TD class="tdbg2" colspan="2" valign="top" width="87%">
      <P>Sunday October 20, 2013  12:36h – 12:47h </P>
      <P><STRONG>G.<wbr> Arora</STRONG><SUP>1</SUP>, J.<wbr> Shukla<SUP>2</SUP>, S.<wbr> 
      Ghosh<SUP>3</SUP>, S.<wbr> Ballal<SUP>1</SUP>, G.<wbr> Bandopadhyaya<SUP>1</SUP> 
      <BR></P></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7435">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-19T11:37:56+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Temira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434</link>
<description>re: Temira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7434">re: Temira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434">Endocrinology7434</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/396">Roger BELUSA</a> | 19 August 2013 | 09:18</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">This looks very interesting.<wbr> I think we should consider taking a look</span>&nbsp;<br><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7432" class="commentpermalink">Endocrinology7432</a> / <span class="date">14 August 2013</span> /
<span class="time">08:40:22 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Some info I have on the pipeline </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7434/1/Tekmira.jpg?user-agent=rss"> <a name="Endocrinology7437c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Some more info I found: </div><div style="margin-bottom: 10px;"><STRONG>Two drugs with similar approach: </STRONG>TKM-080301 (Nucleic Acid Therapies) - Tekmira Pharmaceuticals and <SPAN style="line-height: 1.5em;">MDRNA-1 (Nucleic Acid Therapies) - Marina Biotech</SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Other drugs in development with the same target (PLK=Serine/<wbr>Threonine protein  kinase PLK1)</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7437/1/PLK%20inhibitors.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;">Highest stage of development Phase:II </div><div><STRONG>Other indications:</STRONG> Hodkin&rsquo;s Lymphoma (Ph I), non- Hodkin&rsquo;s Lymphoma (Ph I), Solid tumors (Ph I), Liver cancer (preclin) </div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7437" class="commentpermalink">Endocrinology7437</a> / <span class="date">19 August 2013</span> /
<span class="time">16:21:00 o'clock CEST</span>
</font></div></div><!-- Comment details --><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434" class="commentpermalink">Endocrinology7434</a> / <span class="date">19 August 2013</span> /
<span class="time">09:18:21 o'clock CEST</span>
</font><br><a name="endocrinology7434attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7434/1/Tekmira.jpg">Tekmira.jpg</a>&nbsp;&nbsp;(149,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7434">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428">View thread  Endocrinology7428: Tekmira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</a>]]></content:encoded><dc:date>2013-08-19T09:18:21+02:00</dc:date><dc:creator>ROB61416</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7434/1/Tekmira.jpg" length="153328" type="image/jpeg"/></item><item>
<title>Novartis Dragged Into China Bribery Scandal [mkt:China, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10555</link>
<description>Novartis Dragged Into China Bribery Scandal [mkt:China, mkt:Intercontinental]</description><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10555</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10555">Novartis Dragged Into China Bribery Scandal</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10555">PharmaWorld10555</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 16 August 2013 | 16:27</font><br><br><div style="margin-bottom: 10px;"><FONT face="Verdana"><SPAN lang="EN-US" style="FONT-FAMILY: Arial; COLOR: rgb(23,23,23)">Comment: Novartis and the Chinese government is currently investigating claims that a Sales Rep</SPAN><SPAN lang="EN-US" style="FONT-FAMILY: Arial"> bribed doctors 50,000 Yuan ($8,000) to prescribe at least five doses of Sandostatin LAR.<wbr></SPAN></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial"><FONT face="Verdana">The whistleblower in question claims her line manager forced her to act in this way and has now filed a five million Yuan ($817,000) compensation claim against the company.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Verdana"><SPAN style="FONT-FAMILY: Arial">As a result, Novartis is conducting its own investigations to the allegations while the Chinese government has vowed to continue to pursue fraud, bribery and corrupt practices within theHealthcare industry.<wbr> Officials have also ordered </SPAN><SPAN style="FONT-FAMILY: Arial">Chinese hospitals to search for corruption in regards to the pricing and purchasing of drugs and in clinical trials.<wbr></SPAN></FONT> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Other multinational companies caught up in the bribery allegations include AstraZeneca, GSK, Lilly, Lundbeck, Novo Nordisk, Sanofi and UCB.<wbr></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10555">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-16T16:27:05+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>New Australian Biosimilar Guidance</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10554</link>
<description>New Australian Biosimilar Guidance</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10554</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10554">New Australian Biosimilar Guidance</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10554">PharmaWorld10554</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 16 August 2013 | 16:12</font><br><br><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">Comment: Companies planning to market biosimilar medicines in Australia will have to apply to the WHO for a unique INN identifying code, and all biosimilars will have to have a clearly distinguishable trade name.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">This is the first time that advice (in Australia) on biosimilars has been issued in the form of a guideline and highlights another geography moving closer to providing solid regulatory guidelines for approval.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">For some time now, the TGA has adopted the guidelines drawn up by the EMA on the requirements for demonstrating comparability between a biosimilar and the reference drug.<wbr>  </SPAN><SPAN lang="EN-US" style="FONT-FAMILY: Arial">Where the Australian guidance now departs from current practice in the EU is in the naming of biosimilars.<wbr> It explains that, under the Therapeutic Goods Regulations (1990), all medicines must use the Australian Approved Name (AAN), which in the case of biosimilars will be drawn from the Australian Biological Names (ABN) list.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><I><SPAN lang="EN-US" style="FONT-FAMILY: Arial">"However, special provisions are needed forbiosimilars, because they are not identical to the reference product, and "must be assumed to be different to any other biosimilar as no direct comparability study has been conducted,"</SPAN></I><SPAN lang="EN-US" style="FONT-FAMILY: Arial"> says the TGA.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">The ABN for a biosimilar must be composed of the reference product ABN (in order to identify the reference product to which it has been shown comparable) together with a biosimilar identifier consisting of the prefix <I>sim</I> and a three-letter code issued by the WHO's INN Committee.<wbr> The ABN for a biosimilar infliximab, for example, could be "infliximab simfam".<wbr> The ABN must be used in full in all labeling and in each reference to the product.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">To obtain a biosimilar ABN, the company will first need to apply to the WHO INN Committee for the three-letter code, and then to the Australian ABN Committee to use that code in the biosimilar identifier; finally it must apply for the identifier to be added to the list of Australian Approved Names.<wbr></SPAN> </div><div><I><SPAN lang="EN-US" style="FONT-FAMILY: Arial">“This naming convention will allow prescribers to identify the reference product and to distinguish clearly between biosimilars, </SPAN></I><SPAN lang="EN-US" style="FONT-FAMILY: Arial">says the TGA, <I>noting that such distinctions are also important for pharmacovigilance purposes.<wbr> It stresses that the addition of a biosimilar identifier to the AAN list "does not in any way imply endorsement of acceptance by the TGA of the substance as a biosimilar, but only that the sponsor's application for the use of a biosimilar identifier has been approved.<wbr>"</I></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10554">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-16T16:12:01+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Quintiles To Acquire Novella Clinical</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10553</link>
<description>Quintiles To Acquire Novella Clinical</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10553</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10553">Quintiles To Acquire Novella Clinical</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10553">PharmaWorld10553</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 16 August 2013 | 13:07</font><br><br><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">Comment: Quintiles expands it expertise in Oncology capabilities through the acquisition of Novella Clinical</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">Quintiles has agreed to acquire Novella Clinical, a full-service clinical research organisation (CRO) focused mainly on emerging oncology, medical devices and diagnostics customers.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">No financial terms were disclosed for the deal</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">Quintiles said it was acquiring Novella Clinical, <EM>“to stay ahead of the diverse and evolving needs of its global customer base”.<wbr></EM></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial">Novella operates out of Research Triangle Park, North Carolina, through more than 800 professionals located across North America and Europe.<wbr> </SPAN> </div><div><SPAN lang="EN-US" style="FONT-FAMILY: Arial">Once the acquisition is wrapped up, the company will function as a Quintiles unit to be known as ‘Novella Clinical, a Quintiles company’.<wbr></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10553">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-16T13:07:40+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>MerrimacK Pharmaceuticals Pursues Development of MM-111 for Gastric &amp; Esophageal Cancers [class:MonoclonalAntibody, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9114</link>
<description>MerrimacK Pharmaceuticals Pursues Development of MM-111 for Gastric &amp; Esophageal Cancers [class:MonoclonalAntibody, news]</description><category>class:MonoclonalAntibody</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9114</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9114">MerrimacK Pharmaceuticals Pursues Development of MM-111 for Gastric & Esophageal Cancers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9114">Oncology9114</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2013 | 16:49</font><br><br><div style="margin-bottom: 10px;">Comment; MM-111 has been granted two seperate orphan drug designations for its bispecific antibody MM-111 for the treatment of esophageal cancer and for the treatment of gastric as well as gastroesophageal junction cancers.<wbr> </div><div style="margin-bottom: 10px;">This product is designed to address HER-2 expressing tumours.<wbr> <SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/18px Arial; white-space: normal; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-stroke-width: 0px;">MM-111 is designed to inhibit ErbB3 (HER3) receptor signaling in cancers that overexpress ErbB2 (HER2).<wbr> Overexpression of the ErbB2 cell surface receptor has been reported in 7-34 percent of gastric cancers according to various scientific articles.<wbr> Research has shown that ErbB3 expression is associated with poor prognosis in gastric cancer and may contribute to resistance to some current standard treatments.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/18px Arial; white-space: normal; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Currently, MM-111 is being tested in a Phase 2 study in these gastric cancer settings</SPAN> </div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/18px Arial; white-space: normal; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Source: <A href="http://www.merrimack.com">www.<wbr>merrimack.<wbr>com</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9114">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-15T16:49:01+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Astellas Rumoured To Be Expanding Its Commercial Team To Support XTANDI [class:Antihormonals, comp:Astellas, prod:MDV3100, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9113</link>
<description>Astellas Rumoured To Be Expanding Its Commercial Team To Support XTANDI [class:Antihormonals, comp:Astellas, prod:MDV3100, headline]</description><category>class:Antihormonals</category><category>comp:Astellas</category><category>prod:MDV3100</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9113</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9113">Astellas Rumoured To Be Expanding Its Commercial Team To Support XTANDI</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9113">Oncology9113</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2013 | 12:21</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to soft intelligence from the field forwarded to us by David Brown (UK Business Unit Director Uro-Oncology), we have learnt that Astellas appear to be recruiting a team of 8 account managers in the UK plus 6 market access mamagers to support the launch and promotion of XTANDI (enzalutamide).<wbr> </div><div style="margin-bottom: 10px;">Whilst sales and marketing investment behind XTANDI is not altogether surprising given the recent European approval of the drug in June.<wbr> Approval was for the treatment of post chemotherapy CRPC patients.<wbr> the size of the build-out is of interest to note.<wbr> If this information is available in other countries please could you forward the information to the franchise or CI Dept.<wbr> </div><div>Whether there could be further commercial expansion within any given market in due course remains to be seen and doubtless will depend on the outcome of the PhIII PREVAIL trial conducted in earlier chemonaive patients.<wbr> Interim data from this trial is expected before the year-end.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9113">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-15T12:21:52+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Prosensa's RNAi Modulation Platform Is Focused On DMD, Myotonic Dystrophy &amp; Huntington's Disease [news, dis:MuscularDystrophy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7109</link>
<description>Prosensa's RNAi Modulation Platform Is Focused On DMD, Myotonic Dystrophy &amp; Huntington's Disease [news, dis:MuscularDystrophy]</description><category>news</category><category>dis:MuscularDystrophy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7109</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7109">Prosensa's RNAi Modulation Platform Is Focused On DMD, Myotonic Dystrophy & Huntington's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMuscularDystrophy"><font color="#e95e0b">:Neurology:dis:MuscularDystrophy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7109">Neurology7109</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2013 | 11:58</font><br><br><div style="margin-bottom: 10px;">Comment: Prosensa, a rare disease company partnered with its lead 
compound Drisparersen (phIII) focused on Duchenne Muscular 
Dystrophy.<wbr> The company was launched on NASDAQ in June 2013 
and its Drisapersen phIII data is expected Q413.<wbr> Data Presented This Week 
At the 2013 Wedbush Life Science Conference has highlighted the up-to-date 
status of Prosensa's DMD program and what are its retained assets vs.<wbr> those 
partnered with GSK.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/10/ScreenCapture10.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/11/ScreenCapture11.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7109attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(146,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(113,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(140,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(107,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(99,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(92,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(104,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(90,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(103,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(95,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(106,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(122,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7109">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-15T11:58:41+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/1/ScreenCapture1.jpg" length="149823" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/2/ScreenCapture2.jpg" length="116617" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/3/ScreenCapture3.jpg" length="144000" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/4/ScreenCapture4.jpg" length="109641" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/5/ScreenCapture5.jpg" length="102289" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/6/ScreenCapture6.jpg" length="95037" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/7/ScreenCapture7.jpg" length="106897" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/8/ScreenCapture8.jpg" length="93039" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/9/ScreenCapture9.jpg" length="105755" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/10/ScreenCapture10.jpg" length="98218" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/11/ScreenCapture11.jpg" length="109051" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7109/12/ScreenCapture12.jpg" length="124981" type="image/jpeg"/></item><item>
<title>Soft Toxin Intelligence From Korea [headline, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7107</link>
<description>Soft Toxin Intelligence From Korea [headline, sub:Aesthetics]</description><category>headline</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7107</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7107">Soft Toxin Intelligence From Korea</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7107">Neurology7107</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2013 | 11:21</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Youn-eun Lee (Dysport Product Manager Korea), we have learnt that Daewoong's new toxin will be called "Nabota" and it is expected to be launched this October.<wbr> Additionally, Lanzhou's Chinese Toxin has been withdrawn from the market due to commercial considerations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Daewoong's Nabota</STRONG> </div><div style="margin-bottom: 10px;">The launch time-line is in line with time projections gathererd from external intelligence undertaken by the CI department earlier this year.<wbr> Preliminary pricing discussions at that time suggested a targeted price of 75-80% of that of Botox.<wbr> </div><div style="margin-bottom: 10px;">The regulatory submission to the KDFA was based on the phIII results from a trial undertaken with DPW450 in moderate to severe glabellar lines (n=268).<wbr> At the time of our research a therapeutic trial in chronic migraine was planned to start in Q213 (phI/<wbr>II) </div><div style="margin-bottom: 10px;">It is not yet know what unit size formulation Daewoong will market but since the company has been trying to position the drug as a Biosimilar Botox, we believe the dosing should be similar to Botox.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7107/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>BTXA</STRONG> </div><div>Additionally, Korean pharmaceuticals company Hanall has stopped selling BTXA from this June due to low sales performance and severe price competition.<wbr> BTXA is Chinese Lanzhou's botulinum toxin product.<wbr> </div><!-- Comment details --><a name="neurology7107attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7107/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(178,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7107">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-15T11:21:40+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7107/1/ScreenCapture1.jpg" length="182336" type="image/jpeg"/></item><item>
<title>Xeomin Given PIP Nod For Treatment Of Sialorrhoea [:Neurology:comp:Merz, :Neurology:prod:Xeomin, sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10550</link>
<description>Xeomin Given PIP Nod For Treatment Of Sialorrhoea [:Neurology:comp:Merz, :Neurology:prod:Xeomin, sub:Regulatory]</description><category>comp:Merz</category><category>prod:Xeomin</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10550</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10550">Xeomin Given PIP Nod For Treatment Of Sialorrhoea</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10550">PharmaWorld10550</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 14 August 2013 | 17:52</font><br><br><div style="margin-bottom: 10px;">Comment: The European Medicines Agency has agreed to Merz' application for a Paediatric Investigation Plan for the treatment Of Sialorrhoea with Xeomin.<wbr> </div><div style="margin-bottom: 10px;">See below: </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10550/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10550attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10550/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10550">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-14T17:52:52+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10550/1/ScreenCapture1.jpg" length="78709" type="image/jpeg"/></item><item>
<title>Sandoz Confims It's A Major Player In The Biosimilar Arena With Launch Of Dedicated Website</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10549</link>
<description>Sandoz Confims It's A Major Player In The Biosimilar Arena With Launch Of Dedicated Website</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10549</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10549">Sandoz Confims It's A Major Player In The Biosimilar Arena With Launch Of Dedicated Website</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10549">PharmaWorld10549</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 14 August 2013 | 17:23</font><br><br><div style="margin-bottom: 10px;">Comment: Sandoz continues to define itself as a major biosimilars player with the re-launch of its biosimilars website.<wbr>  Sandoz now has seven Phase III clinical trials across five molecules – more than any other company in the industry.<wbr> </div><div style="margin-bottom: 10px;">Sandoz has re-launched its website which provides a comprehensive educational resource, designed for visitors with varying levels of knowledge.<wbr> </div><div style="margin-bottom: 10px;">The site itself explains: </div><div style="margin-bottom: 10px;"><UL><LI>What biosimilars are</LI>
<LI>Their importance</LI>
<LI>How they are developed </LI>
<LI>How they are approved</LI>
</UL> </div><div style="margin-bottom: 10px;">Highlights include multimedia tools, company presentations, relevant publications, and tailored information for healthcare professionals and payers.<wbr> </div><div style="margin-bottom: 10px;">List of the Phase III trials on-going is captured below </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10549/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Listed on their website highlighting their top position is the Biosimilar Pipeline Comparison Chart below </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10549/2/ScreenCapture2.jpg?user-agent=rss"> </div><div>The site can be viewed via this link <A href="http:///“,”http://sandoz-biosimilars.com/“,”">Sandoz-Biosimilars.<wbr>com</A> </div><!-- Comment details --><a name="pharmaworld10549attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10549/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(115,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10549/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(43,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10549">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-14T17:23:19+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10549/1/ScreenCapture1.jpg" length="118149" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10549/2/ScreenCapture2.jpg" length="44209" type="image/jpeg"/></item><item>
<title>GW Pharma Opens Phase 3 IND Application In U.S. With Sativex For MS Spasticity</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10548</link>
<description>GW Pharma Opens Phase 3 IND Application In U.S. With Sativex For MS Spasticity</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10548</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10548">GW Pharma Opens Phase 3 IND Application In U.<wbr>S.<wbr> With Sativex For MS Spasticity</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10548">PharmaWorld10548</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 14 August 2013 | 17:04</font><br><br><div style="margin-bottom: 10px;">Comment:  GW Pharmaceuticals moves forward with its aim to launch Sativex® for the treatment of spasticity due to Multiple Sclerosis (MS) in the US.<wbr>  Sativex is currently approved in 22 countries outside the U.<wbr>S for this indication.<wbr> </div><div style="margin-bottom: 10px;">The company announced today that it has opened a Phase 3 IND application with FDA to conduct a pivotal efficacy and safety clinical program to evaluate Sativex® for the treatment of spasticity due to MS.<wbr> </div><div style="margin-bottom: 10px;">As part of its MS spasticity IND application, GW requested feedback from the FDA on key features of the protocol and will work closely with the FDA to finalise the protocol design (which may include a request for Special Protocol Assessment ).<wbr>  The trial is expected to commence in 2014.<wbr> </div><div style="margin-bottom: 10px;">The US based programme will be fully funded by GW’s licensing partner, Otsuka Pharmaceutical Co.<wbr> Ltd.<wbr> </div><div>Cancer pain remains the initial target indication for Sativex in the US and it is intended that MS spasticity would represent a future second indication.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10548">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-14T17:04:44+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>re: Temira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7432</link>
<description>re: Temira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7432</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7432</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7432">re: Temira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7432">Endocrinology7432</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/359">Philip HARRIS</a> | 14 August 2013 | 08:40</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Tekmira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Tekmira a leading developer of RNA interfernece (RNAi) therapeutics has today announced that it has initiated a phI/<wbr>II trial with TK-PLK-1 its RNAi oncology therapeutic for the treatment of advanced GI neuroendocrine tumours and adrenalcortical carcinoma.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7428">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428" class="commentpermalink">Endocrinology7428</a> / <span class="date">13 August 2013</span> /
<span class="time">16:47:42 o'clock CEST</span>
</font></div><div>This looks very interesting.<wbr> I think we should consider taking a look <a name="Endocrinology7434c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Some info I have on the pipeline </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7434/1/Tekmira.jpg?user-agent=rss"> <a name="Endocrinology7437c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Some more info I found: </div><div style="margin-bottom: 10px;"><STRONG>Two drugs with similar approach: </STRONG>TKM-080301 (Nucleic Acid Therapies) - Tekmira Pharmaceuticals and <SPAN style="line-height: 1.5em;">MDRNA-1 (Nucleic Acid Therapies) - Marina Biotech</SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Other drugs in development with the same target (PLK=Serine/<wbr>Threonine protein  kinase PLK1)</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7437/1/PLK%20inhibitors.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;">Highest stage of development Phase:II </div><div><STRONG>Other indications:</STRONG> Hodkin&rsquo;s Lymphoma (Ph I), non- Hodkin&rsquo;s Lymphoma (Ph I), Solid tumors (Ph I), Liver cancer (preclin) </div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7437" class="commentpermalink">Endocrinology7437</a> / <span class="date">19 August 2013</span> /
<span class="time">16:21:00 o'clock CEST</span>
</font></div></div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434" class="commentpermalink">Endocrinology7434</a> / <span class="date">19 August 2013</span> /
<span class="time">09:18:21 o'clock CEST</span>
</font></div></div><!-- Comment details --><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7432" class="commentpermalink">Endocrinology7432</a> / <span class="date">14 August 2013</span> /
<span class="time">08:40:22 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7432">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428">View thread  Endocrinology7428: Tekmira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</a>]]></content:encoded><dc:date>2013-08-14T08:40:22+02:00</dc:date><dc:creator>phh74924</dc:creator></item><item>
<title>Tekmira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma [dis:MidGutNET, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428</link>
<description>Tekmira Initiates PhI/II Study In NET &amp; Adrenocortical Carciinoma [dis:MidGutNET, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428</comments><category>dis:MidGutNET</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7428">Tekmira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7428">Endocrinology7428</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 August 2013 | 16:47</font><br><br><div style="margin-bottom: 10px;">Comment: Tekmira a leading developer of RNA interfernece (RNAi) therapeutics has today announced that it has initiated a phI/<wbr>II trial with TK-PLK-1 its RNAi oncology therapeutic for the treatment of advanced GI neuroendocrine tumours and adrenalcortical carcinoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Activity Profile of TKM-PLK1 </STRONG> </div><div style="margin-bottom: 10px;">TKM-PLK1, targets polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target.<wbr> Inhibition of PLK1 expression prevents the tumor cell from completing cell division, resulting in cell cycle arrest and death of the cancer cell.<wbr> PLK1 has been a target of interest for years, and evidence that patients with elevated levels of PLK1 in their tumors exhibit poorer prognosis and survival rates has been documented in the medical literature.<wbr> By using an RNAi approach and exploiting its naturally occurring mechanism of action, Tekmira can potentially overcome the limitations of other approaches and effectively silence PLK1 </div><div style="margin-bottom: 10px;"><STRONG>Basis For NET &amp; Adrenocortical Carcinoma Trials</STRONG> </div><div style="margin-bottom: 10px;">Based on the encouraging results from our Phase I clinical trial, we are initiating a Phase I/<wbr>II clinical trial with TKM-PLK1, which will enroll patients with either advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) or Adrenocortical Carcinoma (ACC).<wbr> By focusing on these indications, where we observed drug activity in the Phase I trial, we aim to collect additional data on the efficacy of TKM-PLK1 to guide our future development and regulatory strategy for this promising agent.<wbr> Tekmira expects to have results from this completed trial by mid-2014, and if supported by the data, commence a pivotal trial in GI-NET in 2014.<wbr> </div><div style="margin-bottom: 10px;">In addition, it anticipates initiating a separate Phase I/<wbr>II clinical trial with TKM-PLK1, which will enroll patients with Hepatocellular Carcinoma (HCC) in the first half of 2014 </div><div style="margin-bottom: 10px;"><STRONG>NET Study Design</STRONG> </div><div style="margin-bottom: 10px;">The GI-NET and ACC Phase I/<wbr>II clinical trial will be a multi-center, single arm, open label study designed to measure efficacy using RECIST and tumor biomarkers for GI-NET patients, as well as to evaluate the safety, tolerability and pharmacokinetics of TKM-PLK1.<wbr> TKM-PLK1 will be administered weekly with each four-week cycle consisting of three once-weekly doses followed by a rest week.<wbr> It is expected that approximately 20 patients with advanced GI-NET or ACC tumors will be enrolled in this trial, with a minimum of 10 GI-NET patients to be enrolled.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Partnerships</STRONG> </div><div style="margin-bottom: 10px;">Interestingly, Alnylam has a license to use Tekmira&rsquo;s LNP technology to advance RNAi therapeutic products, and Tekmira is eligible to receive milestones and royalties as Alnylam&rsquo;s LNP enabled products are developed and commercialized (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10547" class="defaultlink">PharmaWorld10547: Game Changing Results For Alnylam's RNAi Platform</a>).<wbr> </div><div>Source: <A href="http://www.tekmirapharm.com">www.<wbr>tekmirapharm.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7432c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Temira Initiates PhI/<wbr>II Study In NET & Adrenocortical Carciinoma</span> </div><div>This looks very interesting.<wbr> I think we should consider taking a look <a name="Endocrinology7434c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Some info I have on the pipeline </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7434/1/Tekmira.jpg?user-agent=rss"> <a name="Endocrinology7437c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Some more info I found: </div><div style="margin-bottom: 10px;"><STRONG>Two drugs with similar approach: </STRONG>TKM-080301 (Nucleic Acid Therapies) - Tekmira Pharmaceuticals and <SPAN style="line-height: 1.5em;">MDRNA-1 (Nucleic Acid Therapies) - Marina Biotech</SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Other drugs in development with the same target (PLK=Serine/<wbr>Threonine protein  kinase PLK1)</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7437/1/PLK%20inhibitors.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;">Highest stage of development Phase:II </div><div><STRONG>Other indications:</STRONG> Hodkin&rsquo;s Lymphoma (Ph I), non- Hodkin&rsquo;s Lymphoma (Ph I), Solid tumors (Ph I), Liver cancer (preclin) </div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7437" class="commentpermalink">Endocrinology7437</a> / <span class="date">19 August 2013</span> /
<span class="time">16:21:00 o'clock CEST</span>
</font></div></div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7434" class="commentpermalink">Endocrinology7434</a> / <span class="date">19 August 2013</span> /
<span class="time">09:18:21 o'clock CEST</span>
</font></div></div><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7432" class="commentpermalink">Endocrinology7432</a> / <span class="date">14 August 2013</span> /
<span class="time">08:40:22 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7428">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-13T16:47:42+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>PTC Therapeutics - Poised For Success In The Duchenne Muscular Dystrophy Market [dis:MuscularDystrophy, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7104</link>
<description>PTC Therapeutics - Poised For Success In The Duchenne Muscular Dystrophy Market [dis:MuscularDystrophy, headline]</description><category>dis:MuscularDystrophy</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7104</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7104">PTC Therapeutics - Poised For Success In The Duchenne Muscular Dystrophy Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMuscularDystrophy"><font color="#e95e0b">:Neurology:dis:MuscularDystrophy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7104">Neurology7104</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 August 2013 | 15:53</font><br><br><div style="margin-bottom: 10px;">Comment: Having successfully completed an IPO in June raising more than $144m, the group is now well positioned to move forwards with the phIII development of its lead drug candidate for Duchenne muscular dystrophy Ataluren.<wbr> It even faces the possibility of a conditional European approval for this indication by the year-end.<wbr> At a share price of $15.<wbr>46 the group is currently capatilised at $366m.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Confirmatory phIII study</STRONG> </div><div style="margin-bottom: 10px;">In April 2013, PTC initiated a confirmatory Phase 3 clinical trial evaluating ataluren as a potential treatment for patients with Duchenne muscular dystrophy due to a nonsense mutation (nmDMD).<wbr> The study is on-track to complete enrollment by mid-2014 with country approvals for the trial and clinical trial site initiation proceeding according to plan.<wbr> The Phase 3 study is expected to be conducted at 53 clinical sites across 18 countries and to complete by mid 2015.<wbr> </div><div style="margin-bottom: 10px;">In planning the design of the phIII trial, the company has looked to de-risk the program as shown below:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7104/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>European Regulatory Situation</STRONG> </div><div style="margin-bottom: 10px;">Following the October 2012 submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for conditional approval of ataluren in nmDMD, the EMA provided a list of questions to PTC regarding its application, known as the Day 120 Questions.<wbr> In July 2013, PTC submitted responses to the Day 120 Questions to the EMA.<wbr> The company anticipates a response from the Committee for Medicinal Products for Human Use, or CHMP, on the MAA submission for conditional approval of ataluren for the treatment of nmDMD by the end of 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New SMA Collaboration With Roche</STRONG> </div><div style="margin-bottom: 10px;">On August 8, 2013, in collaboration with its partners, the SMA Foundation and Roche, PTC declared a lead development candidate in the spinal muscular atrophy (SMA) program.<wbr> Selection of the development candidate triggered a $10 million milestone payment by Roche to PTC, which will be recognized as revenue in the third quarter of 2013.<wbr> This milestone is important for moving this program forward and evidences the value of PTC's splicing platform technology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Situation In Duchenne Muscular Dystropy</STRONG> </div><div style="margin-bottom: 10px;">There are several treatments in development for DMD, however ataluren is uniques as an oral drug targeting patients with a nonsense mutation.<wbr> No other therapy currenlly marketed or in development addresses the same genetic mutation of the patient population targeted by ataluren (13% of those with DMD due to a nonsense mutation).<wbr> Sarepta and Prosensa are also clinical-stage companies currently testing exon-skipping but there is no overlap in ataluren's target population and the pipelines of Sarepta or Prosensa.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7104/2/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7104attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7104/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(101,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7104/2/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(116,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7104">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-13T15:53:42+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7104/1/ScreenCapture1.jpg" length="103487" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7104/2/ScreenCapture4.jpg" length="119281" type="image/jpeg"/></item><item>
<title>Medivation Q2 Earnings - Meaningful European Revenues Should Start In The 2H [class:Antihormonals, comp:Astellas, prod:MDV3100]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9112</link>
<description>Medivation Q2 Earnings - Meaningful European Revenues Should Start In The 2H [class:Antihormonals, comp:Astellas, prod:MDV3100]</description><category>class:Antihormonals</category><category>comp:Astellas</category><category>prod:MDV3100</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9112</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9112">Medivation Q2 Earnings - Meaningful European Revenues Should Start In The 2H</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9112">Oncology9112</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 August 2013 | 17:11</font><br><br><div style="margin-bottom: 10px;">Comment: XTANDI generated US sales of $82.<wbr>4m in the second quarter and $230m 
cumulatively snce its launch in September 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>XTANDI's Commercial Progress</STRONG> </div><div style="margin-bottom: 10px;">XTANDI bottles 
dispensed by our distribution partners in the second quarter increased by approximately 19% compared to the first quarter.<wbr>  For the full year 2013, Medivation expects net sales of XTANDI in the U.<wbr>S.<wbr> to be in the range of $345 million to $365 million </div><div style="margin-bottom: 10px;"><P class="pwrapper">Medivation noted that onene of the highlights of the quarter was 
the European Union's authorization 
of the XTANDI marketing application for metastatic CRPC patients post-docetaxel which came 
in June.<wbr> During the quarter XTANDI was also proved in Canada and South Korea.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Collaborative Revenue</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">For the second quarter, Medivation's collaboration revenue 
attributable to 
upfront and milestone payments was $28.<wbr>5 million.<wbr> This included milestone payments of $15 million for XTANDI's marketing approval in the EU and $5 million for the submission of XTANDI's marketing application in Japan.<wbr> It remains eligible to earn an additional $257 million in development milestone payments and up to $320 million in sales milestone payments 
under the Astellas collaboration</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Additional Filings/<wbr>Reviews</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In May, Astellas filed for marketing approval with the 
Ministry of Health, Labor and Welfare in Japan, and received priority review in July, which reduces the agency's review time to approximately nine months.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In addition to Japan, XTANDI marketing applications 
are currently under review in Argentina, Australia, Brazil, South Africa and Switzerland.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Development Progress</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Furthest along is the <STRONG>PREVAIL</STRONG> trial, 
Medivation's Phase 3 trial in metastatic pre-chemo patients.<wbr> Enrollment of approximately 1,700 
patients was completed in May 2012 and  those patients are currently 
benig followed.<wbr> The co-primary endpoints in this trial are overall survival and radiographic PFS.<wbr> Medivation stated "We 
and Astellas look forward to the results of the interim analysis for PREVAIL this year.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Medivations has intentions to initiate a new Phase 3 trial upstream of the PREVAIL population in patients with non-metastatic, (M0), castration-resistant prostate cancer.<wbr></P> </div><div><P class="pwrapper">Two 
other ongoing clinical trials, 
<STRONG>TERRAIN and 
</STRONG><STRONG>STRIVE</STRONG>, that are comparing the effect of enzalutamide head-to-head 
versus bicalutamide, 
the most commonly used antiandrogen.<wbr> Astellas has recently completed targeted patient enrollment in the TERRAIN trial, which enrolled approximately 370 men with metastatic disease primarily in Europe.<wbr> Meanwhile, enrollment is continuing in the STRIVE trial, which is targeting approximately 400 men with either metastatic or non-metastatic disease 
primarily in the U.<wbr>S.<wbr> 
</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9112">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-12T17:11:51+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Analysts See Meaningful Commercial Opportunities For Both Gattex &amp; Natpara [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7422</link>
<description>Analysts See Meaningful Commercial Opportunities For Both Gattex &amp; Natpara [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7422</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7422">Analysts See Meaningful Commercial Opportunities For Both Gattex & Natpara</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7422">Endocrinology7422</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 August 2013 | 15:04</font><br><br><div style="margin-bottom: 10px;">Comment: Better than expected Gattex numbers underpinned a strong jump in NPS 
Pharmaceuticals share price on Friday.<wbr> NPS recorded sales of $4.<wbr>8m vs.<wbr> analysts 
estimates of $2.<wbr>5m.<wbr> For the first time it provided revenue guidence of $25-30m 
for 2013 sales.<wbr> Morgan Stanley analysts have increased their W/<wbr>W peak sales 
estimates to $985m vs.<wbr> prior of $550m.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Utility In Short Bowel Syndrome Is Revised Upwards</STRONG> </div><div style="margin-bottom: 10px;">As of August, 318 prescriptions had been recieved and 141 patients were 
reciving the drug vs.<wbr> comparable figures of 160 and 42 in 
early May.<wbr> NPS now expects to have 275-325 patients on the GLP-2 
analogue by year end.<wbr> This is up from its previous guidance of 200-325.<wbr> </div><div style="margin-bottom: 10px;">Gattex was launched in the US in February with a US list price of $295,000 
annually.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Following a fruitful meeting with FDA along with correspondents from the European regulators, NPS's clinical team is initiating a global Phase 3 study of Gattex in pediatric Short Bowel Syndrome.<wbr> This study is expected to include approximately 50 patients who are between the ages of 1 and 18 and enrollment is expected to begin before the end of this year.<wbr> Commercially, the pediatric indication would extend NPS 
market exclusivity 
period for Gattex in the U.<wbr>S.<wbr> by six months to October 2020 and for Revestive in the EU by two years to August 2024.<wbr> </P> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation prospects ex-US</STRONG> </div><div style="margin-bottom: 10px;"><P class="pwrapper">NPS claims to have made 
tremendous progress 
executing on a deliberate and systematic global expansion in the short period of time since signing the termination agreement with Takeda.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">It has completed an extensive market assessment of Revestive.<wbr> As a result of this analysis and with the benefit of learnings from sizing the U.<wbr>S.<wbr> market, it estimates 
that there are between 6,000 and 12,000 Short Bowel Syndrome patients, who are Revestive eligible in the 30 ex-U.<wbr>S.<wbr> countries NPS 
intends to target.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">It also expects international 
peak sales for Revestive to exceed those of Gattex in the U.<wbr>S and 
sees international markets will drive the growth of this product significantly beyond the loss of U.<wbr>S.<wbr> exclusivity in 2020.<wbr> Its international 
commercial strategy 
is now fully developed and it has started the build-out, 
which will be 
gated based on key milestones.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The international HQ has been established in Dublin, along with a regional presence in London, for our European operations.<wbr> The development of a 
European reimbursement dossier 
is underway and it will soon be initiating targeted named-patient programs.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>NPS's Next Key Product</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Switching to <STRONG>Natpara.<wbr></STRONG> Having successfully addressed 
the fill-finish issue, NPS confirmed that it plans to submit a US BLA 
for Natpara in the fourth quarter of this year, leaving the company 
well-positioned to 
have a second orphan product approved in the U.<wbr>S.<wbr> before the end of 2014.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Natpara could be the first treatment approved for the underlying cause of hypoparathyroidism</STRONG> and serve the unmet medical needs of these patients.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Based on extensive market research, NPS's 
experience in launching Gattex and in orphan drug pricing, it believes 
that the global commercial potential of Natpara could exceed that of Gattex and Revestive at peak.<wbr></P> </div><div><P class="pwrapper">Source: <A href="http://www.npsp.com">www.<wbr>npsp.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7422">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-12T15:04:01+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease [headline, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7102</link>
<description>Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease [headline, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:xLicensing]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7102</comments><category>headline</category><category>mkt:Europe</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7102</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7102">Auxillium Reports Strong Revenue Growth As It Waits For The Potential Approval of Xiaflex For Peyronie's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7102">Neurology7102</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 August 2013 | 12:41</font><br><br><div style="margin-bottom: 10px;">Comment: Auxillium reported Q2 revenues of $100m +29%, with growth 
underpinned by sales of Xiaflex and products from the newly acquired company 
Actient which has expanded the testosterone portfolio and added a new erectile 
dysfunction buisiness.<wbr> Meanwhile, the group has recently initiated a 
collaboration with SOBI covering the European distribution of Xiaflex in 71 
countries for Dupuytren's contracture and Peyronie's disease.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7102/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7102/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Development Progress</STRONG> </div><div>On the research and development front, Auxilium is continuing to make progress on the clinical trial design for placebo-controlled 
double-blind studies 
of CCH in frozen shoulder 
and cellulite.<wbr> 
It expects to begin enrolling patients in both indications in the second half of this year.<wbr> In the second quarter, it 
also completed enrollment in our Dupuytren's contracture multi-cord 
trial ahead of schedule and now expect top line data by the end of this year.<wbr> Finally it is 
preparing for a successful launch of Xialflex in Peyronie's disease if approved 
by the FDA this September.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7118c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The FDA has notified Auxillium that it is extending the PDUFA goal date for the Company's sBLA for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease ("PD") from September 6, 2013 to December 6, 2013.<wbr> <BR><BR>During the course of recent product label discussions, Auxilium submitted revisions regarding the Company's proposed REMS program and other aspects related to the proposed label.<wbr> The FDA determined that this submission qualified as a major amendment filed during the final three months of the review and extended the PDUFA goal date to December 6, 2013.<wbr> The FDA has not requested that any additional clinical studies be performed prior to the revised PDUFA action date.<wbr> <BR><BR>Whilst the company is disappointed with the delay of approval, it remains confident in the XIAFLEX Peyronie's program and committed to working with the FDA while they complete their review.<wbr>" </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7118" class="commentpermalink">Neurology7118</a> / <span class="date">28 August 2013</span> /
<span class="time">16:54:36 o'clock CEST</span>
</font></div><a name="neurology7102attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7102/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(164 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7102/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(170,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7102">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-12T12:41:02+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7102/1/ScreenCapture1.jpg" length="167963" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7102/2/ScreenCapture2.jpg" length="174920" type="image/jpeg"/></item><item>
<title>OncoGenex Provides Clinical Program Overview Alongside Q2 Figures [dis:Prostate, dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9111</link>
<description>OncoGenex Provides Clinical Program Overview Alongside Q2 Figures [dis:Prostate, dis:Bladder]</description><category>dis:Prostate</category><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9111</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9111">OncoGenex Provides Clinical Program Overview Alongside Q2 Figures</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9111">Oncology9111</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 August 2013 | 12:09</font><br><br><div style="margin-bottom: 10px;">Comment: OncoGenex continues to make progress with both its CRPC Custirsen 
programs and its bladder cancer programs with OGX-427 (Apatorsen).<wbr> The former 
will now read-out in Q214 due to death events occuring more slowly than 
anticipated whilst data from the Borealis-1™ OGX-427 trial in metastatic bladder 
cancer is expected 2H14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status of the Custirsen CRPC &amp; NSCLC Trials</STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The primary registration Phase 3 <STRONG>SYNERGY</STRONG> trial, designed 
  to evaluate a survival benefit for custirsen in combination with first-line 
  docetaxel chemotherapy in men with metastatic castrate-resistant prostate 
  cancer (CRPC), completed enrollment in 2012.<wbr> As a result of death events 
  occurring more slowly than previously expected, the anticipated timing of the 
  pre-specified number of events is currently projected to occur late in the 
  first quarter or early in the second quarter of 2014.<wbr> These survival results 
  are expected to be announced in mid-2014.<wbr></LI>
<LI>Patient enrollment continues in the additional Phase 3 custirsen trials, 
  <STRONG>AFFINITY</STRONG> and <STRONG>ENSPIRIT</STRONG>.<wbr> The 
  <STRONG>AFFINITY</STRONG> trial will evaluate the potential survival benefit 
  of custirsen in combination with Jevtana® (cabazitaxel) as second-line 
  chemotherapy in men with metastatic CRPC, and <STRONG>ENSPIRIT</STRONG> will 
  evaluate the potential survival benefit of combining custirsen with docetaxel 
  as second-line chemotherapy in patients with advanced or metastatic non-small 
  cell lung cancer (NSCLC).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><B>Apatorsen (OGX-427)Program Update</B> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The Company announced that the <ORG>United States Adopted Names 
  Council</ORG> has approved the use of the nonproprietary generic name 
  "apatorsen" for OGX-427.<wbr><BR></LI>
<LI>In <CHRON>July 2013</CHRON>, the Company 
  announced that enrollment has been completed in <STRONG>Borealis-1™,</STRONG> 
  a company-sponsored, randomized, placebo-controlled Phase 2 trial of apatorsen 
  in <STRONG>combination with first-line gemcitabine and cisplatin in patients 
  with</STRONG> <STRONG>metastatic bladder cancer</STRONG>.<wbr> Approximately 180 
  patients have been randomized into Borealis-1 at 55 clinical sites throughout 
  <LOCATION value="LB/nam">North 
  America</LOCATION> and <LOCATION value="LR/eur">Europe</LOCATION>.<wbr> The primary endpoint of the trial 
  is overall survival and data are expected to be available in the the 
  second-half of 2014.<wbr><BR><BR></LI>
<LI>In <CHRON>August 2013</CHRON>, the Company 
  announced initiation of patient enrollment in the Spruce™ clinical trial.<wbr> 
  Spruce is an investigator-sponsored, randomized, double-blind, 
  placebo-controlled Phase 2 trial evaluating apatorsen in patients with 
  previously untreated advanced non-squamous NSCLC.<wbr> <BR><BR></LI>
<LI>In addition to Borealis-1 and Spruce, as part of the ORCA™ (<B>O</B>ngoing 
  Studies Evaluating Treatment <B>R</B>esistance in <B>CA</B>ncer) program, 
  apatorsen is currently being evaluated in the following 
  investigator-sponsored, randomized Phase 2 trials across four tumor types.<wbr> 
  Recent updates to additional ORCA trials are as follows: 
  <UL type="disc"><LI>The<STRONG> Borealis-2™</STRONG> Trial was initiated in <CHRON>April 2013</CHRON> and is currently enrolling 
    patients.<wbr> This investigator-sponsored, randomized, open-label Phase 2 trial 
    is evaluating <STRONG>apatorsen in combination with docetaxel in patients 
    with advanced or metastatic bladder cancer who have disease progression 
    following first-line platinum-based chemotherapy.<wbr></STRONG> Borealis-2 aims 
    to enroll approximately 200 patients.<wbr> </LI>
<LI>The Cedar™ Trial is an investigator-sponsored, randomized, open-label 
    Phase 2 trial evaluating apatorsen in previously untreated patients with 
    advanced squamous cell lung cancer.<wbr> Plans to initiate Cedar were announced 
    in <CHRON>May 2013</CHRON>.<wbr> The trial aims to 
    enroll approximately 140 patients and is being conducted in the <LOCATION value="LC/gb">UK</LOCATION>.<wbr> </LI>
<LI>The Rainier™ Trial is an investigator-sponsored, randomized, 
    placebo-controlled Phase 2 trial evaluating apatorsen in combination with 
    ABRAXANE® (paclitaxel protein-bound particles for injectable 
    suspension)(albumin-bound) and gemcitabine in approximately 130 patients 
    with previously untreated metastatic pancreatic cancer.<wbr> Plans for Rainier 
    were announced in <CHRON>May 2013</CHRON> and 
    patient enrollment is expected to begin in mid-2013.<wbr> </LI>
<LI>The <STRONG>Pacific™</STRONG> Trial is an investigator-sponsored, 
    randomized, open-label Phase 2 trial evaluating apatorsen in approximately 
    <STRONG>80 men with metastatic CRPC who are experiencing rising 
    prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone 
    acetate).<wbr></STRONG> The trial was initiated in <CHRON>December 2012</CHRON> and is currently 
    enrolling at sites in <LOCATION value="LC/us">the United States</LOCATION> and <LOCATION value="LC/ca">Canada.<wbr></LOCATION></LI>
</UL></LI>
</UL> </div><div style="margin-bottom: 10px;">The Company had <MONEY>$57.<wbr>0 million</MONEY> in 
cash, cash equivalents and short-term investments as of <CHRON>June 30, 2013</CHRON>, compared to <MONEY>$75.<wbr>4 million</MONEY> as of <CHRON>December 31, 2012</CHRON>.<wbr> </div><div style="margin-bottom: 10px;">In terms of its 2013 cash guidance it is suggesting that net cash 
requirements are expected to be in the range of <MONEY>$40</MONEY> - <MONEY>$50 million and y</MONEY>ear-end cash, 
cash equivalents and short-term investments are expected to be in the range of 
<MONEY>$25</MONEY> - <MONEY>$35 million</MONEY>.<wbr> 
<BR> </div><div>Source: <a href="http://www.oncogenex.com" class="defaultlink" title="www.oncogenex.com">oncogenex.com</a><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9111">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-12T12:09:09+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Bioniche Prepares For Canadian Equity Offering To Finance Registration &amp; Development of Urocidin [dis:Bladder, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9109</link>
<description>Bioniche Prepares For Canadian Equity Offering To Finance Registration &amp; Development of Urocidin [dis:Bladder, news]</description><category>dis:Bladder</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9109</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9109">Bioniche Prepares For Canadian Equity Offering To Finance Registration & Development of Urocidin</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9109">Oncology9109</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 August 2013 | 15:18</font><br><br><div style="margin-bottom: 10px;">Comment: Bioniche has this week confirmed the price of its forthcoming 
Canadian equity offering which is aimed at raising between $5 and $7.<wbr>5m to 
support the  further development of its bladder cancer drug Urocidin, 
Canadian registration for which may be made before the 2013 
year-end.<wbr> Recent commercialisation partnership with Palladin labs 
also points towards a brighter outlook for this late-stage bladder 
cancer product.<wbr> </div><div style="margin-bottom: 10px;"><EM>Urocidin™ </EM>is a formulation of MCC, a sterile mycobacterial cell 
wall-DNA complex composition that has a dual mode of action: immune stimulation 
and direct anticancer activity.<wbr> <I>Urocidin<SUP>TM</SUP> </I>is formulated for 
the treatment of bladder cancer, where it is administered by trans-urethral 
catheter directly into the bladder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Canadian Health Authorities Potentially Support Registration of 
Urocidin</STRONG> </div><div style="margin-bottom: 10px;">Recently Bionich announced the outcome of a meeting in late June with Health 
Canada, at which time the Company discussed the filing of a regulatory 
submission for Urocidin™ - under Health Canada's Notice of Compliance with 
Conditions (NOC/<wbr>c) policy.<wbr> </div><div style="margin-bottom: 10px;">Health Canada advised the Company that the 
data from the first Phase III clinical trial with Urocidin™ may be sufficient to 
qualify for filing under the NOC/<wbr>c policy.<wbr> </div><div style="margin-bottom: 10px;">The regulator asked the Company to submit a clinical assessment package 
addressing some clinical questions as part of the request to file a New Drug 
Submission (NDS).<wbr> It is anticipated that all materials may be submitted to 
Health Canada before the end of calendar 2013.<wbr> Approximately one year of review 
would follow and, if Health Canada is satisfied with the submission, an approval 
under NOC/<wbr>c could follow before the end of 2014.<wbr> </div><div style="margin-bottom: 10px;">An early registration 
in Canada would generate revenues from commercial sales to offset the cost of 
additional clinical trial work that may be required for the U.<wbr>S.<wbr> and other 
jurisdictions.<wbr> </div><div style="margin-bottom: 10px;">The Company will also be seeking a meeting with the U.<wbr>S.<wbr> 
Food and Drug Administration (FDA) to discuss a clinical development plan to 
achieve U.<wbr>S.<wbr> registration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of New Commercialisation Partnership</STRONG> </div><div style="margin-bottom: 10px;">The Company recently announced its first new licensing deal for Urocidin™ - 
with Paladin Labs Inc following the return of licensing rights from Endo 
Pharmaceuticals in January.<wbr> </div><div style="margin-bottom: 10px;">The Company has granted Paladin an exclusive license to market and distribute 
Urocidin™ for bladder cancer in Canada, South Africa and Mexico.<wbr> The companies 
have agreed to a net revenue sharing arrangement.<wbr> Bioniche will be responsible 
for all product development and manufacturing costs and Paladin will be 
responsible for all sales and marketing costs in the said territories.<wbr> The 
agreement provides that Paladin will pay a series of potential sales performance 
milestones that can total up to $16 million during the term of the 
agreement.<wbr> </div><div style="margin-bottom: 10px;">Additionally, Bioniche has granted Palladin warrants to acquire 750,000 
common shares and Paladin has agreed to invest $500,000 in Bioniche should it 
complete and equity raising by September 30th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Size of The Candian NMIBC Market &amp; Potential Urocidin 
Label</STRONG> </div><div>Treatment of non-muscle-invasive bladder cancer in patients who failed BCG 
therapy is the first target indication for Urocidin™.<wbr> The Company estimates 
that, in Canada alone, a minimum of 3,100 patients per year will qualify for 
treatment with Urocidin™ according to this label claim.<wbr> At up to 21 doses per 
patient and at a pricing per dose that is competitive relative to other 
treatments, the Company believes that the market for UrocidinTM could be 
considerable.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9109">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-09T15:18:41+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Game Changing Results For Alnylam's RNAi Platform [sub:DrugDelivery, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10547</link>
<description>Game Changing Results For Alnylam's RNAi Platform [sub:DrugDelivery, Alert]</description><category>sub:DrugDelivery</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10547</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10547">Game Changing Results For Alnylam's RNAi Platform</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:PharmaWorld:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10547">PharmaWorld10547</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 August 2013 | 13:27</font><br><br><div style="margin-bottom: 10px;">Comment: Alnylam has reported positive phI results with its subcutaneously 
administered RNAi therapeutic targeting TTR for the treatment of ATTR.<wbr> It 
witnessed 80% knockdown of serum TTR and an encouraging safety profile and 
believes that its platform now represent the best-in-class approach for 
knockdown of liver-expressed disease genes across the industry.<wbr> </div><div style="margin-bottom: 10px;">The company talks about Q2 being a very data rich period with the company 
having reported positive clinical results for two out of its 5 X15 
programms and positive pre-clinical data for three other 5 X15 
programs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Progress With Lead Product ALN-TTR02</STRONG> </div><div style="margin-bottom: 10px;">ALN-TTR02 is aimed at the treatment of TTR-mediated amyloidosis (ATTR), a 
devastating often fatal heriditary orphan disease caused by mutations in the TTR 
gene afflicting approx.<wbr> 50,000 people worldwide.<wbr> </div><div style="margin-bottom: 10px;">In the second quarter Alnylam reported positive phII data showing that 
multiple doses of ALN-TTR)" lead to a robust knockdown of serum TTR protein 
levels of up to 93%, a highly statistically significant finding (see data 
below).<wbr> </div><div style="margin-bottom: 10px;">Enrollment in this study of about 30 ATTR patients is almost complete with 
final data due to be presented in Brazil in November.<wbr> In the coming weeks the 
company plans to initiate an open-label extension study for patients treated in 
the phII study.<wbr> Meanwhile, it remains on track to start a phIII pivotal trial 
for ALN-TTR02 in FAP patients by the end of 2013 (see nature of trial 
below).<wbr> </div><div style="margin-bottom: 10px;">Alongside, Alnylam has been advancing a subcutaneous version of the drug with 
which it recently announced positive top-line results as indicated above.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/9/ScreenCapture9.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.alnylam.com">www.<wbr>alnylam.<wbr>com</A> </div><!-- Comment details --><a name="pharmaworld10547attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(66,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(62,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(56,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(63,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(56,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(75,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(69,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10547">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-09T13:27:50+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/1/ScreenCapture1.jpg" length="49645" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/2/ScreenCapture2.jpg" length="67841" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/3/ScreenCapture3.jpg" length="64171" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/4/ScreenCapture4.jpg" length="57401" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/5/ScreenCapture5.jpg" length="65214" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/6/ScreenCapture6.jpg" length="58270" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/7/ScreenCapture7.jpg" length="58117" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/8/ScreenCapture8.jpg" length="77571" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10547/9/ScreenCapture9.jpg" length="71451" type="image/jpeg"/></item><item>
<title>Strong Demand For Raptor's New Orphan Therapy [sub:CompanyProfile, :Neurology:dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10546</link>
<description>Strong Demand For Raptor's New Orphan Therapy [sub:CompanyProfile, :Neurology:dis:Huntington]</description><category>sub:CompanyProfile</category><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10546</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10546">Strong Demand For Raptor's New Orphan Therapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aCompanyProfile"><font color="#e95e0b">:PharmaWorld:sub:CompanyProfile</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10546">PharmaWorld10546</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 August 2013 | 12:46</font><br><br><div style="margin-bottom: 10px;">Comment: Raptor has confirmed in its Q2 earnings statement it is on track to meet initial guidance of having 125 patients on treatment with its newly approved drug Procysbi for nephropathic cystinosis by year-end.<wbr> Meanwhile, the company is expecting interim results from a phII/<wbr>III Huntington's disease study in Q114.<wbr> </div><div style="margin-bottom: 10px;">Procysbi a delayed-release formulation of a degradation product of the amino acid cystein was launched in the US June 17th at an annual average treatment cost per patient of $250,000.<wbr> </div><div style="margin-bottom: 10px;">To date, 154 prescriptions have been submitted, of which 75 have received payer approval and 49 shipped to patients </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/5/ScreenCapture5.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10546attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(92,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(105,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(147,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(122,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(85 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10546">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-09T12:46:38+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/1/ScreenCapture1.jpg" length="101516" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/2/ScreenCapture2.jpg" length="95154" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/3/ScreenCapture3.jpg" length="107798" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/4/ScreenCapture4.jpg" length="150906" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/5/ScreenCapture5.jpg" length="125574" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10546/6/ScreenCapture6.jpg" length="87000" type="image/jpeg"/></item><item>
<title>Competitive Pressures Point Towards Flat Year-on-year Sales For Dendreon's PROVENGE [headline, class:Vaccines, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9108</link>
<description>Competitive Pressures Point Towards Flat Year-on-year Sales For Dendreon's PROVENGE [headline, class:Vaccines, dis:Prostate]</description><category>headline</category><category>class:Vaccines</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9108</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9108">Competitive Pressures Point Towards Flat Year-on-year Sales For Dendreon's PROVENGE</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9108">Oncology9108</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 August 2013 | 11:57</font><br><br><div style="margin-bottom: 10px;">Comment: An important quarter for Dendreon as it continues to navigate many 
challenges including an increasingly competitive envrionment.<wbr> That said net 
revenues were $73.<wbr>3m up 8% versus first quarters $67.<wbr>6m with urology sales 
at their highest level post launch.<wbr> However, given recent enrollment 
trends, Dendreon indicated that the second half uplift is not going to be 
sufficient for the company to meet its goal of growing PROVENGE 
year-on-year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Revenue Trends</STRONG> </div><div style="margin-bottom: 10px;">The dynamics are complex, with the number of accounts being added 
(42) higher in Q2 than Q1 and a good response being seen to DTC advertising 
offset by higher disease burden patients tending to be put on Zytiga or Xtandi 
in place of PROVENGE.<wbr> Before when PROVENGE was the only product approved these 
patients would have been put on PROVENGE first.<wbr> </div><div style="margin-bottom: 10px;">Looking at the Q2 revenue split where community clinics accounted for 71% of 
sales:- </div><div style="margin-bottom: 10px;"><UL><LI>Oncology clinics 38% of revenues sales down 10% vs.<wbr> 17% in Q1</LI>
<LI>Urology clinics 33% of revenue sales up 37%</LI>
<LI>Academic centres 18% of revenue sales up 10%</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Immuno-oncology Therapy Is An Emergent Field Requiring 
Educational Support</STRONG> </div><div style="margin-bottom: 10px;">Dendreon continues to believe that PROVENGE is best positioned early in the 
treatment progression paradigm.<wbr> Raising awareness about the importance of early 
screening and detection will continue to be a top priority for Dendreon as 
is convincing clinicians that immunotherapy is an important class of treatment 
for cancer patients.<wbr> The latter is something that is gaining ground with the 
success of other immune therapies in other cancer fields such as melanoma and 
NSCLC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Operational Issues</STRONG> </div><div style="margin-bottom: 10px;">Lower than expected revenue levels has delayed the realisation of some of the 
operational efficiencies that were expected in Q3.<wbr> As such COGS are not expected 
to decline below 50% in the third quarter.<wbr> Initiatives focused on automating the 
manufacturing process are underway with a vendor having been selected.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>European Launch Plans</STRONG> </div><div style="margin-bottom: 10px;">With regard to Europe, Dendreon noted that one of the postiive milestones of 
the quarter was receiving a positive opinion from the CHMP which it anticipated 
will lead to final regulatory approval in the second half of the year.<wbr> It stated 
that it is in discussions with potential partners and prioritizing plans 
for a launch there but would not say more for competitive reasons.<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.dendreon.com">www.<wbr>dendreon.<wbr>com</A> </div><div><FONT face="Arial">.<wbr></FONT> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9108">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-09T11:57:03+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Clinical Data Confirms Sativex's Safety Profile [dis:Spasticity, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7100</link>
<description>New Clinical Data Confirms Sativex's Safety Profile [dis:Spasticity, news]</description><category>dis:Spasticity</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7100</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7100">New Clinical Data Confirms Sativex's Safety Profile</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7100">Neurology7100</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 August 2013 | 15:29</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its Q3 earnings, GW Pharma announced the results of a long-term safety study with Sativex, which demonstrates that the drug has no impact on cognition in patients being treated for MS spasticity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design &amp; Top-Line Findings</STRONG> </div><div style="margin-bottom: 10px;">The study was a 12 month multicentre, double-blind, randomised parallel group, placebo-controlled study in 121 patients with MS spasticity.<wbr> The study was required as a post-approval commitment by the UK regulatory authority, with the primary objective of evaluating whether Sativex may have long term adverse effects on cognitive function or mood.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint was the change in cognitive function as assessed by the total Paced Auditory Serial Addition Test (PASAT) score from baseline to end of treatment.<wbr> Mood was assessed by the Beck Depression Inventory-II.<wbr> </div><div style="margin-bottom: 10px;">There was a slight improvement in the PASAT score from the beginning to the end of the study in both the Sativex and placebo groups, thus confirming that there is no evidence of long-term cognitive impairment in patients taking Sativex compared with those taking placebo.<wbr> </div><div style="margin-bottom: 10px;">Similarly, the change in mood over the 12 month period was more or less identical in the Sativex and the placebo group, confirming no untoward effect on mood.<wbr> </div><div style="margin-bottom: 10px;">The key efficacy secondary endpoints were the global impression of change scores as assessed by the patient, physician and carer.<wbr> Each of these endpoints was highly significantly in favour of Sativex (p&lt;0.<wbr>0001, p=0.<wbr>001 and p=0.<wbr>004 respectively).<wbr> </div><div style="margin-bottom: 10px;">Detailed data from this study is due to be presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on 2-5 October in Copenhagen, Denmark.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Q3 Commercial Update</STRONG> </div><div style="margin-bottom: 10px;">GW announced the recent launch of Savitex for MS in Italy by its partner Almirall.<wbr> Almirall has also made Sativexx available in the private non-reimbursed markets of Poland, Austria and Sweden, bringing the total number of countries in which the drug is marketed to 11.<wbr> There are a further 11 countries in which launch is now pending.<wbr> </div><div style="margin-bottom: 10px;">Following a change in the law in France, allowing for the approval of cannabis medicines GW has recently submitted a regulatory application.<wbr> Whilst in Germany, Almirall is challenging a decision taken in March 2013 to imporse a price discount on the product.<wbr> </div><div style="margin-bottom: 10px;">Sativex in-market sales volumes sold by GW's commercial partners for the 3 months ended 30th June 2013 were 21% higher than the three months ended June 2012 and 24% higher for the nine-month period.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/4/ScreenCapture4.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7100attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(124,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(170,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(144,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(195,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7100">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-08T15:29:22+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/1/ScreenCapture1.jpg" length="127373" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/2/ScreenCapture2.jpg" length="174547" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/3/ScreenCapture3.jpg" length="148325" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7100/4/ScreenCapture4.jpg" length="200398" type="image/jpeg"/></item><item>
<title>Exelixis Q2 Earnings- Key Takeaways [class:KinaseInhibitors, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9107</link>
<description>Exelixis Q2 Earnings- Key Takeaways [class:KinaseInhibitors, dis:Prostate]</description><category>class:KinaseInhibitors</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9107</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9107">Exelixis Q2 Earnings- Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9107">Oncology9107</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 August 2013 | 12:52</font><br><br><div style="margin-bottom: 10px;">Comment: Exelixis's top organisational priority continues to be the 
COMET trials with cabozantinib for CRPC.<wbr> Good progress continues to be 
made, with expected top-line data in 2014.<wbr> Meanwhile,  the commercialized 
form of this drug for medullary thyroid cancer (COMTRIQ) registered sales of $4m 
in the quarter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>COMTRIQ Progress Update</STRONG> </div><div style="margin-bottom: 10px;">Exelixis calims to be continuing to see gains and improved market penetration 
of the MTC market and reiterated its assumptions about the size of the market in 
the US (500-700 drug eligible fist and second-line metatstatic patients 
diagnosed each year with MTC.<wbr> </div><div style="margin-bottom: 10px;">Exelixis has expanded the size of its sales force from 5 to 15  due to a 
realisztion that the market is less concentrated than previously anticipated.<wbr>The 
sales force continues to be outsourced through a contract sales 
organisation.<wbr> </div><div style="margin-bottom: 10px;">In Europe.<wbr> Exelixis partner SOBI is waiting for a final oprinion from the 
CHMP.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>COMET Trials In Post Chemo CRPC</STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Arial">If both trials are successful, the combined data package would 
demonstrate a survival benefit and improvement of pain associated with bone 
metastasis.<wbr> This Exelixis  believes would differentiate 
cabozantinib from other agents used in the treatment of CRPC and support the 
product activity profile in this indication.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">A detailed analysis of overall survival in our non-randomized 
expansion Phase II study in 144 CRPC patients treated with cabozantinib was 
presented at ASCO in June demonstrated a 10.<wbr>8 month median overall survival in 
this heavily pre-treated patient population.<wbr> All of the patients had received 
prior docetaxel and about half of patients had received prior abiraterone and/<wbr>or 
enzalutamide and 25% of patients had also received 
cabazitaxel.<wbr></FONT> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><STRONG>Earlier 
CRPC Treatment Studies</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt">Exelixis is also 
actively working on advancing cabozantinib in the earlier line of treatment of 
CRPC patients prior to chemotherapy.<wbr> It is on track to 
initiate two earlier line Phase I/<wbr>II studies, one evaluating the combination of 
cabozantinib with enzalutamide and one evaluating the combination of 
cabozantinib with abiraterone towards the end of 2013 or early 2014.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><STRONG>Other 
PhIII Indications</STRONG></P> </div><div style="margin-bottom: 10px;">Exelixis claims 
to be working very actively on the initiation and execution of two new 
Phase III pivotal trials in <STRONG>metastatic renal cell cancer and 
hepatocellular cancer</STRONG>.<wbr>The Phase III study in 
<STRONG>RCC was initiated in May 2013</STRONG> and is now screening patients.<wbr> It 
is a 650-patient randomized open label study that is comparing cabozantinib with 
everolimus in patients who have received and progressed on or following at least 
one prior VEGFR tyrosine kinase inhibitor.<wbr> </div><div><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><STRONG>The HCC trial will be initiated shortly</STRONG>.<wbr> It is a 760 
patient study in patients who have received prior sorafenib and will compare 
overall survival between patients treated with cabozantinib and those receiving 
placebo</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9107">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-08T12:52:34+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>TPG Is Exploring The Sale of Specialty Drugmaker Aptalis [headline, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1906</link>
<description>TPG Is Exploring The Sale of Specialty Drugmaker Aptalis [headline, :PharmaWorld:sub:Acquisition]</description><category>headline</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1906</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1906">TPG Is Exploring The Sale of Specialty Drugmaker Aptalis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1906">GastroEnterology1906</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 August 2013 | 11:24</font><br><br><div style="margin-bottom: 10px;">Comment: A Reuters exclusive is suggesting that Aptalis is up for sale with a 
price-tag of $3bn.<wbr> </div><div style="margin-bottom: 10px;">Venture capital company TPG Capital LP has owned Aptalis since 2008 and is 
apparently working with JP Morgan Chase and Evercore Partners on the sale 
of the business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature of Buyer Interest</STRONG> </div><div style="margin-bottom: 10px;">The report suggests that a number of potential buyers have reviewed the 
business and consider the asking price of more than $3bn yoo high.<wbr> These include 
Sun Pharmaceuticals and Salix.<wbr> Both are reported to be no longer pursuing the 
deal.<wbr> Elan and Forest seemingly also reviewed the business earlier in the year 
and bowed out for different reasons.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Alternatives To A Sale</STRONG> </div><div style="margin-bottom: 10px;">It is suggested that TPG may yet consider other options such as an IPO or a 
dividend recapitalisation should a deal fail to materialise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company History</STRONG> </div><div style="margin-bottom: 10px;">TPG Bought the drugmaker formerly known as Axcan Pharma for $1.<wbr>3bn in 2008 
and  merged it with Eurand Pharmaceuticals in 2011.<wbr> The combined company 
was renamed Aptalis.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology1906attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(242,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(199 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(236,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1906">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-08T11:24:42+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/1/ScreenCapture1.jpg" length="248647" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/2/ScreenCapture2.jpg" length="203760" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1906/3/ScreenCapture3.jpg" length="242317" type="image/jpeg"/></item><item>
<title>EU Regulatory Changes On The Horizon For Generic Products</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10544</link>
<description>EU Regulatory Changes On The Horizon For Generic Products</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10544</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10544">EU Regulatory Changes On The Horizon For Generic Products</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10544">PharmaWorld10544</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 07 August 2013 | 17:24</font><br><br><div style="margin-bottom: 10px;">Comment: Companies planning generic product submissions in the EU are to have new guidance on how to demonstrate the bioequivalence of specific active substances by the end of this year </div><div style="margin-bottom: 10px;">The EMA already has a general bioequivalence (BE) guideline in place that explains the requirements for demonstrating bioequivalence for generic products but the new guidance will make the assessment more transparent and predictable.<wbr> </div><div style="margin-bottom: 10px;">The EMA  also said that a more consistent approach to assessing applications based on bioequivalence data is now needed across all submission routes — centralised, decentralised, mutual recognition and national.<wbr> </div><div style="margin-bottom: 10px;">The first set of guidance (on oral immediate-release forms) is expected to be released for public consultation following the October CHMP meeting.<wbr>  Individual products will then be selected by the network of regulatory agencies based on the need for guidance.<wbr> </div><div style="margin-bottom: 10px;">The guidance will be based on the previous regulations and will further cover: </div><div style="margin-bottom: 10px;"><UL><LI>BE study design elements</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>ie, the main pharmacokinetic variables and width of confidence intervals.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Whether <I>in vivo </I>BE studies can be waived for that substance under the Biopharmaceutics Classification System-based biowaiver approach</LI>
</UL> </div><div><UL><LI>ie, where an assumption of <I>in vivo </I>equivalence can be made based on <I>in vitro </I>data</LI>
</UL> </div><!-- Comment details --><a name="pharmaworld10544attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(61,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(64,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(21,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10544">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-07T17:24:23+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/1/ScreenCapture1.jpg" length="49998" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/2/ScreenCapture2.jpg" length="63425" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/3/ScreenCapture3.jpg" length="66400" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10544/4/ScreenCapture4.jpg" length="21928" type="image/jpeg"/></item><item>
<title>Small Molecule Progress For OncoTherapy As MELK Inhibitor Moves Into Clinic</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9106</link>
<description>Small Molecule Progress For OncoTherapy As MELK Inhibitor Moves Into Clinic</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9106</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9106">Small Molecule Progress For OncoTherapy As MELK Inhibitor Moves Into Clinic</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9106">Oncology9106</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 07 August 2013 | 11:33</font><br><br><div style="margin-bottom: 10px;">Comment: OncoTherapy Science has initiated a clinical program for its first small molecule drug candidate, OTS167.<wbr>  Its' use is being investigated in patients with refractory locally advanced or metastatic solid tumors unresponsive to standard therapies.<wbr>  Enrolment in the US Phase I trial has begun.<wbr> </div><div style="margin-bottom: 10px;">The intravenously infused MELK (maternal embryonic leucine zipper kinase) inhibitor is part of the Snf1/<wbr>AMPK kinase family and is not expressed in normal cells, rather it is up-regulated in various cancer types and involved in cancer cell cycle, growth and apoptosis processes.<wbr> </div><div style="margin-bottom: 10px;">Preclinical studies with OTS167 have shown potent activity in models of lung, breast, prostate and pancreatic cancers.<wbr>  The company however is not alone in the field - the Canadian firm Lorus Therapeutics, MELK inhibitor program (LOR-500) is in the preclinical stage with breast cancer and malignant glioma as potential indications.<wbr> </div><div style="margin-bottom: 10px;">In addition, OTS has recently decided to pursue the clinical development of other small molecule candidates against another unidentified novel kinase target, isolated through genomic expression profiling techniques.<wbr> The lead molecule in the series, OTS964, has potential against lung and bladder cancer.<wbr> </div><div>In the peptide vaccines area, OTS has licensing deals for various pipeline projects with Otsuka and Shionogi.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9106">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-07T11:33:17+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Afinitor in Advanced HCC Did Not Meet Primary Endpoint of OS</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9103</link>
<description>Afinitor in Advanced HCC Did Not Meet Primary Endpoint of OS</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9103</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9103">Afinitor in Advanced HCC Did Not Meet Primary Endpoint of OS</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9103">Oncology9103</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 07 August 2013 | 11:11</font><br><br><div style="margin-bottom: 10px;">Comment: Another one bites the dust in the ever-increasing line of set of backs within the HCC field.<wbr> Novartis has stated that they will no longer proceed with regulatory filings of Afinitor in this indication.<wbr> </div><div style="margin-bottom: 10px;">Novartis announced that results of a global Phase III study showed that Afinitor® did not extend OS compared to placebo in patients with locally advanced or metastatic HCC after progression on or intolerance to sorafenib.<wbr> </div><div style="margin-bottom: 10px;">Alessandro Riva, Global Head, Oncology Development &amp; Medical Affairs, Novartis Oncology stated "While we are disappointed with these results, Novartis remains committed to studying everolimus through a robust research and development program to address unmet needs in different types of cancer.<wbr> To date, Afinitor has proven efficacy in a number of tumor types, including hormone receptor positive advanced breast cancer, advanced pancreatic neuroendocrine tumors and advanced renal cell carcinoma.<wbr>" </div><div style="margin-bottom: 10px;">Afinitor development will continue in other diseases with high unmet needs including GI and lung NET, HER2 positive breast cancer, lymphoma and TSC </div><div style="margin-bottom: 10px;"><B>Study details</B><BR>The Phase III study, EVOLVE-1 (EVerOlimus for LiVer cancer Evaluation-1), is a randomized, double-blind, placebo-controlled trial examining the efficacy and safety of everolimus versus placebo, plus best supportive care (BSC), in adult patients with advanced HCC whose disease progressed after treatment with or who were intolerant to sorafenib, a targeted therapy.<wbr> The study results continue to be evaluated and will be presented at an upcoming medical conference.<wbr> </div><div style="margin-bottom: 10px;">EVOLVE-1 involved 546 patients and was conducted at 156 sites worldwide.<wbr> Patients in the trial were randomized (2:1) to receive therapy with everolimus 7.<wbr>5 mg/<wbr>day orally plus BSC or placebo plus BSC.<wbr> The primary endpoint was overall survival.<wbr> Secondary endpoints included time to tumor progression, disease control rate,time to deterioration of performance status, safety and quality of life </div><div>From <A href="http://www.novartis.com/">http:/<wbr>/<wbr>www.<wbr>novartis.<wbr>com</A>, see <A href="http://www.novartis.com/newsroom/media-releases/en/2013/1721562.shtml">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9103">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-07T11:11:38+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>HuGel Initiates New Korean Comparative Study With Botulax In Post-Stroke Upper Limb Spasticity [class:BotulinumToxins, dis:Spasticity, headline, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7099</link>
<description>HuGel Initiates New Korean Comparative Study With Botulax In Post-Stroke Upper Limb Spasticity [class:BotulinumToxins, dis:Spasticity, headline, prod:Botox]</description><category>class:BotulinumToxins</category><category>dis:Spasticity</category><category>headline</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7099</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7099">HuGel Initiates New Korean Comparative Study With Botulax In Post-Stroke Upper Limb Spasticity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7099">Neurology7099</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2013 | 15:37</font><br><br><div style="margin-bottom: 10px;">Comment: HuGel has started a randomised multicentre comparative PhIII trial 
evaluating the safety and efficacy of Botulax vs.<wbr> Botox in 186 patients with 
ULS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Endpoints</STRONG> </div><div style="margin-bottom: 10px;">Primary is the change in MAS from baseline to week 4 and for writs 
flexor muscle tone specifically.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Secondary</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Change in MAS for elbow, finger and thumb flexor from baseline to week 4.<wbr> 
  week 8 and week 12</LI>
<LI>Change in DAS from baseline to week 4,8 and 12</LI>
<LI>Global assessment investigator evaluated and patient evaluated at week 4, 
  8 &amp; 12</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Trial Timeline &amp; Location</STRONG> </div><div style="margin-bottom: 10px;">Study start date August 2013, Estimated completion November 2013 (primary 
outcome).<wbr> Six centres in Korea are mentioned as participants.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); MARGIN-TOP: 1ex; TEXT-INDENT: 0px; FONT: 14px/19px arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><TBODY><TR style="FONT: 14px/1.4em arial, 'Nimbus Sans L', sans-serif" valign="top"><TD style="FONT: 14px/1.4em arial, 'Nimbus Sans L', sans-serif"><STRONG>ClinicalTrials.<wbr>gov Identifier:</STRONG></TD>
<TD style="PADDING-LEFT: 1em; FONT: 14px/1.4em arial, 'Nimbus Sans L', sans-serif"><A class="study-link" href="http://clinicaltrials.gov/show/NCT01915459" style="BORDER-BOTTOM: 1px dotted; COLOR: rgb(26,61,133); TEXT-DECORATION: none" title="Current version of study NCT01915459 on ClinicalTrials.gov">NCT01915459</A> </TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: ClinicalTrial.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7099">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-06T15:37:47+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Merck Serono Q2- Key Takeaways [:PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9102</link>
<description>Merck Serono Q2- Key Takeaways [:PharmaWorld:sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9102</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9102">Merck Serono Q2- Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9102">Oncology9102</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2013 | 15:08</font><br><br><div style="margin-bottom: 10px;">Comment: During yesterday's conference call, Merck's Finance Cheif mentioned 
that the company would hold off on larger takeover deals but would now focus 
more actively on seeking acquisitions over the 2014-16 period.<wbr>  Having 
made good progress with strengthening its balance sheet and focusing its 
business it now feels better positioned to strengthen its portfolio.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Performance Indicators</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>R&amp;D Development Progress</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/5/ScreenCapture5.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.merckgroup.com">www.<wbr>merckgroup.<wbr>com</A> </div><!-- Comment details --><a name="oncology9102attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(161,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(122,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(175,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(150,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(110,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9102">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-06T15:08:43+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/1/ScreenCapture1.jpg" length="165175" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/2/ScreenCapture2.jpg" length="125349" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/3/ScreenCapture3.jpg" length="179967" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/4/ScreenCapture4.jpg" length="153753" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9102/5/ScreenCapture5.jpg" length="113095" type="image/jpeg"/></item><item>
<title>Bayer Enters Into $540m Cancer Immunotherapy Agreement With Compugen [class:MonoclonalAntibody, news, comp:BayerSchering]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9101</link>
<description>Bayer Enters Into $540m Cancer Immunotherapy Agreement With Compugen [class:MonoclonalAntibody, news, comp:BayerSchering]</description><category>class:MonoclonalAntibody</category><category>news</category><category>comp:BayerSchering</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9101</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9101">Bayer Enters Into $540m Cancer Immunotherapy Agreement With Compugen</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9101">Oncology9101</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2013 | 14:44</font><br><br><div style="margin-bottom: 10px;">Comment: Bayer yesterday announced a new oncology collaboration and license 
agreement with Compugen covering the research, development and commercialisation 
of antibody based therapeutics targeting two novel immune checkpoint regulators 
discovered by Compugen.<wbr> </div><div style="margin-bottom: 10px;">Together the companies will pursue a preclinical research program, whilst 
subsequently Bayer will take over full control of further development.<wbr> </div><div style="margin-bottom: 10px;">Bayer makes the point that the latest immunotherapies have demonstrated 
impressive durable clinical benefits, even for end-stage patients with 
difficult-to -treat tumours such as metastatic melanoma and NSCLC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Upfront payment of $10m plus milestone payments for both programmes of up to 
$500m.<wbr> Additional milestone payment sof $30m are associated with preclinical 
activities.<wbr> </div><div style="margin-bottom: 10px;">Compugen is also eligible to receieve mid to high single digit royalties on 
worldwide commercial sales.<wbr> </div><div>Source: <a href="http://www." class="defaultlink" title="www."></a> Bayer.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9101">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-06T14:44:07+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Drug To Treat Polycystic Kidney Disease May Not Gain US Approval [dis:PolycysticLiver]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7421</link>
<description>New Drug To Treat Polycystic Kidney Disease May Not Gain US Approval [dis:PolycysticLiver]</description><category>dis:PolycysticLiver</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7421</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7421">New Drug To Treat Polycystic Kidney Disease May Not Gain US Approval</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aPolycysticLiver"><font color="#e95e0b">:Endocrinology:dis:PolycysticLiver</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7421">Endocrinology7421</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2013 | 14:18</font><br><br><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">Comment: 
FDA's Cardiovasucular and Renal Drugs Advisory Committee voted 9-6 yesterday 
that the overall risk/<wbr>benefit profile of Otsuka Pharmaceutical's tolvaptan does 
not support is apporval to slow kidney disease in adults with polycystic kidney 
diseaxe (ADPKD).<wbr> The PDUFA date is Sept 1st.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">Tolvaptan 
a vasopressin V2 receptor antagonist is already approved in the US under the 
trade name Samsca for the treatment of hypervolemic and euvolemic hyponatraemia.<wbr> 
However, in May the FDA issued a safety alert regarding potential liver 
toxicity, based on data emerging from an ADPKD trial.<wbr> It stipulated that the 
drug should be used for no longer than 30 days and should not be used in 
patients with underlying liver disease because of the risk of liver injury 
potentially leading to liver transplant or death.<wbr></SPAN> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">Source: 
Biocentury 5th August</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7421">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-06T14:18:27+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>SIMPONI Recommended for EU Approval in Adult Patients with Moderately to Severely Active Ulcerative Colitis</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1905</link>
<description>SIMPONI Recommended for EU Approval in Adult Patients with Moderately to Severely Active Ulcerative Colitis</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1905</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1905">SIMPONI Recommended for EU Approval in Adult Patients with Moderately to Severely Active Ulcerative Colitis</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1905">GastroEnterology1905</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 05 August 2013 | 14:29</font><br><br><div style="margin-bottom: 10px;">Comment: Based on the CHMP's positive opinion, a final decision from the European Commission is expected during the third quarter of 2013.<wbr> </div><div style="margin-bottom: 10px;">Janssen Biologics announced that the CHMP adopted a positive opinion recommending the use of SIMPONI® (golimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies.<wbr> </div><div style="margin-bottom: 10px;">If approved, SIMPONI will be the only biologic therapy available for this patient population that is administered subcutaneously every four weeks following an induction regimen.<wbr> </div><div>The CHMP adopted the opinion based on a review of data from two pivotal studies in the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment (PURSUIT) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1905">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-05T14:29:40+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>AstraZeneca Feeling More Positive - Q2 Highlights</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10541</link>
<description>AstraZeneca Feeling More Positive - Q2 Highlights</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10541</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10541">AstraZeneca Feeling More Positive - Q2 Highlights</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10541">PharmaWorld10541</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 05 August 2013 | 14:01</font><br><br><div style="margin-bottom: 10px;">Comment: AstraZeneca highlighted that despite a number of setbacks, real progress has been made in the second quarter against their strategic priorities </div><div style="margin-bottom: 10px;"><B>AstraZeneca Q2 2013 highlights</B> </div><div style="margin-bottom: 10px;"><UL><LI>2Q revenue down 4% CER: ~ $500m decline from loss of exclusivity</LI>
<LI>Good progression of growth platforms: $400m (double-digit growth @ CER)</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="circle"><LI>5 key growth platforms include: Brilinta, Diabetes (<I>Byetta/<wbr>Bydureon, Forxiga and Onglyza)</I>, Emerging Markets, Japan and Respiratory </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Growing late-stage pipeline:</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>2 NDA submissions</LI>
<LI>1 Phase 3 start</LI>
<LI>3 late-stage projects added via business development</LI>
</UL> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/1/ScreenCapture1.jpg?user-agent=rss"></EM> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/2/ScreenCapture2.jpg?user-agent=rss"></EM> </div><div style="margin-bottom: 10px;"><B>Pipeline Chart — no movement seen with their AKT inhibitor in P1.<wbr> </B> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/3/ScreenCapture3.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><B>Recent pipeline news includes: </B> </div><div style="margin-bottom: 10px;"><UL type="square"><LI><I>Forxiga </I>(dapagliflozin) NDA resubmitted in US; 11 January 2014 PDUFA</LI>
<LI>Moxetumomab (unresponsive or relapsed hairy cell leukaemia patients) Phase III start</LI>
<LI>Headline results for SAVOR study</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="circle"><LI><I>Onglyza </I>met its primary safety objective of non-inferiority and did not meet the primary efficacy objective of superiority for a composite endpoint(CV death, non-fatal MI, non-fatal ischaemic stroke)</LI>
<LI>Presentation at ESC in Septembe</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><FONT size="2">Metreleptin ( an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystroph) US NDA accepted; designated for priority review (PDUFA 27 Feb 2014)</FONT></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Fostamatinib (<STRONG>rheumatoid arthritis</STRONG>) will not progress to regulatory filings</LI>
</UL> </div><div><UL><LI>Growing portfolio of late stage assets; Omthera and Pearl acquisitions,FibroGen collaboration</LI>
</UL> </div><!-- Comment details --><a name="pharmaworld10541attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(119,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(155,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(304,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10541">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-05T14:01:30+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/1/ScreenCapture1.jpg" length="122576" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/2/ScreenCapture2.jpg" length="158947" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10541/3/ScreenCapture3.jpg" length="311780" type="image/jpeg"/></item><item>
<title>re: Pasireotide PAOLA Study Has Completed &amp; Met Endpoint</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7420</link>
<description>re: Pasireotide PAOLA Study Has Completed &amp; Met Endpoint</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7420</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7420">re: Pasireotide PAOLA Study Has Completed & Met Endpoint</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7420">Endocrinology7420</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/852">Christine MASSIEN</a> | 05 August 2013 | 11:28</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pasireotide PAOLA Study Has Completed & Met Endpoint</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Alongside its Q2 earnings, Novartis made a preliminary announcement 
about the Pasireotide (Signifor) PAOLA study, the second phIII study with 
pasireotide LAR in inadequate responders to octreotide LAR or lanreotide.<wbr>  
It noted that the study had met its primary endpoint and that regulatory 
discussions with authorities are now underway.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7416">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416" class="commentpermalink">Endocrinology7416</a> / <span class="date">02 August 2013</span> /
<span class="time">10:58:22 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">These announced timelines for the Phase 3 were expected and positive results for the primary endpoint of PAOLA study  were expected as well.<wbr> They are the assumptions taken into consideration in the 4 year Somatuline forecast model </div><div style="margin-bottom: 10px;">This study confirms what has been observed in the other pivotal phase 3 study (C2305) where pasireotide 40 had a better efficacy than Oct LAR 20 on GH and IGF1 (proportion of patients with a reduction of mean GH level to &lt;2.<wbr>5 &micro;g/<wbr>L and the normalization of IGF-1 to within normal limits (age and sex related) at 12 months) in medically na&iuml;ve patients with active acromegaly .<wbr> The results were elegantly presented in May 2012 by Novartis claiming that pasireotide LAR patients were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care (but absolute values [pasireotide LAR(31%) vs Sandostatin LAR (19%)] were less impressive !!).<wbr> </div><div style="margin-bottom: 10px;">This PAOLA study is in a different study population, patients have active acromegaly but inadequately controlled on SSA ( not na&iuml;ve); the control arm for this study keeping the uncontrolled patients as they are on LAR 30 or ATG 120.<wbr> The primary endpoint is GH and IGF-1 levels at 24 weeks for pasireotide LAR 40 and 60 mg versus octreotide LAR 30 or lanreotide ATG 120.<wbr> Based on Novartis announcement, it means pasireotide could control part of these inadequately controlled patients when they switch to pasireotide 40 or 60mg ( active arm).<wbr> This is on line with what we are expecting from pasireotide, a slightly better efficacy than SSA 1st generation.<wbr> No absolute numbers and thresholds for defining controlled acromegaly  are disclosed so far.<wbr> </div><div style="margin-bottom: 10px;">Pasireotide was granted an orphan drug status in October 2009, for both Cushing&rsquo;s disease(CD) and acromegaly.<wbr> Our current approval assumption for acromegaly was  April 2014 with  pasireotide as a 2nd line after SSA 1st generation, assuming there is no delay due to the  hyperglycemic deleterious effects that pasireotide has.<wbr> A special warning for hyperglycemia will probably be &ldquo;granted&rdquo; to pasireotide.<wbr> Most KOL remain reserved due to hyperglycemia-related side effects and tend to position pasireotide anyway as a second-line treatment, to be used after failure of existing SSA.<wbr> </div><div style="margin-bottom: 10px;">For Cushing disease, after priority review and fast-track and orphan drug designations, FDA has approved pasireotide for Cushing's disease patients for whom surgery has been unsuccessful or who are not surgical candidates but requested 3 postmarketing studies including a clinical trial to assess hyperglycemia management, a long-term prospective observational cohort study of patients with Cushing's disease treated with pasireotide, and focused safety monitoring for reports of serious hyperglycemia, acute liver injury, and adrenal insufficiency.<wbr> </div><div style="margin-bottom: 10px;">When we know that the unmet medical need for Cushing disease is more important than for acromegaly and that Cushing disease is generally a more severe condition than Acromegaly, it will be interesting to see how FDA will assess the benefit /<wbr>risk ratio of pasireotide in acromegaly </div><div>At franchise level and as a follow up of the pasireotide war gaming (multidisciplinary session organized last October by the Endo Franchise and then shared with regions and  countries for sensitization and implementation of the counteracting plan at country level) , the franchise will monitor closely the NOVARTIS strategic approach re- pasireotide in acromegaly and will adapt and fine tune the counteraction plan accordingly.<wbr> </div><!-- Comment details --><font size="-1">Christine MASSIEN / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7420" class="commentpermalink">Endocrinology7420</a> / <span class="date">05 August 2013</span> /
<span class="time">11:28:43 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7420">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416">View thread  Endocrinology7416: Pasireotide PAOLA Study Has Completed & Met Endpoint</a>]]></content:encoded><dc:date>2013-08-05T11:28:43+02:00</dc:date><dc:creator>chm23683</dc:creator></item><item>
<title>New Formulation of Enzalutamide Tested in Ph1 [comp:Astellas, dis:Prostate, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9099</link>
<description>New Formulation of Enzalutamide Tested in Ph1 [comp:Astellas, dis:Prostate, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9099</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9099">New Formulation of Enzalutamide Tested in Ph1</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9099">Oncology9099</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 August 2013 | 17:27</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas in collaboration with Medivation have started a multiple dose relative bioavailability study in patients with prostate cancer comparing a capsule and a tablet formulation of enzalutamide.<wbr> PE will measure PK profile of the drug under fasted conditions measured by Cmax.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details <a href="http://clinicaltrials.gov/ct2/show/NCT01902251?recr=Open&no_unk=Y&phase=012&rcv_s=07%2F02%2F2013&rank=253" class="defaultlink">NCT01902251</a></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: Approx 26 </div><div style="margin-bottom: 10px;">Completion date: Sept 2013 </div><div>Location: USA (4 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9099">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-02T17:27:26+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Nycomed Obtains Exclusive Rights to Commercialise MOVIPREP(R) in Russia/CIS</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1904</link>
<description>re: Nycomed Obtains Exclusive Rights to Commercialise MOVIPREP(R) in Russia/CIS</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1904</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1904">re: Nycomed Obtains Exclusive Rights to Commercialise MOVIPREP(R) in Russia/<wbr>CIS</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1904">GastroEnterology1904</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/14">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD</a> | 02 August 2013 | 14:00</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Nycomed Obtains Exclusive Rights to Commercialise MOVIPREP(R) in Russia/<wbr>CIS</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=comp%3aNorgine"><font color="#e95e0b">:GastroEnterology:comp:Norgine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font><br><span style="font-size: 12px;">Comment: MOVIPREP(R) will be subject to regulatory review/<wbr>approval and Nycomed will conduct the necessary steps for approval.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1820">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1820" class="commentpermalink">GastroEnterology1820</a> / <span class="date">22 August 2011</span> /
<span class="time">14:33:02 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><FONT face="arial, helvetica, sans-serif">Takeda/<wbr>Nycomed's <STRONG>Moviprep</STRONG> study in Russian Federation has just terminated, 9 months after the first patient was included in October 2012.<wbr></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><FONT face="arial, helvetica, sans-serif">Study purpose : </FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="arial, helvetica, sans-serif">Multicenter Endoscopist-blinded randomized parallel-group comparative study to assess Efficacy, Safety and Tolerance of<STRONG> morning-only dosing</STRONG> <STRONG>compared to control split-dosing</STRONG> with nocturnal pause in MOVIPREP&reg; bowel preparation prior to colonoscopy.<wbr></FONT> </div><div style="margin-bottom: 10px;"><U style="font-family: arial, helvetica, sans-serif; line-height: 1.5em;">Locations </U><SPAN style="font-family: arial, helvetica, sans-serif; line-height: 1.5em;">:</SPAN> </div><div style="margin-bottom: 10px;"><FONT face="arial, helvetica, sans-serif">- Kazakhstan (Alma Ata)</FONT> </div><div style="margin-bottom: 10px;"><FONT face="arial, helvetica, sans-serif">- Russian Federation (Moscow, Saint-Petersburg).<wbr></FONT> </div><div><FONT face="arial, helvetica, sans-serif">Study has been completed last July 31st and according to field intelligence, results are in the process of being interpretated.<wbr><BR><BR></FONT> </div><!-- Comment details --><font size="-1">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1904" class="commentpermalink">GastroEnterology1904</a> / <span class="date">02 August 2013</span> /
<span class="time">14:00:29 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1904">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1820">View thread  GastroEnterology1820: Nycomed Obtains Exclusive Rights to Commercialise MOVIPREP(R) in Russia/<wbr>CIS</a>]]></content:encoded><dc:date>2013-08-02T14:00:29+02:00</dc:date><dc:creator>len82156</dc:creator></item><item>
<title>Takeda and Sanofi Expand Diabetes Business in China [dis:Diabetes, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7418</link>
<description>Takeda and Sanofi Expand Diabetes Business in China [dis:Diabetes, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Diabetes</category><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7418</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7418">Takeda and Sanofi Expand Diabetes Business in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7418">Endocrinology7418</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 August 2013 | 12:49</font><br><br><div style="margin-bottom: 10px;">Comment: Last quarter, both companies agreed to co-promote Nesina (alogliptin), which just got clearance from the China FDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Drug MOA</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
<SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">orally-administered dipeptidyl peptidase-4 inhibitor (DPP-4i)</SPAN>

</LI>
<LI>
<SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">designed to slow the inactivation of incretin hormones GLP-1 </SPAN>(Glucagon<SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">-like peptide-1) and GIP (glucose-dependent </SPAN>Insulin<SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">otropic peptide).<wbr></SPAN>

</LI>
</UL> </div><div><EM><SPAN style="text-align: justify; line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 12px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Source: GBI</SPAN></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7418">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-02T12:49:23+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Pasireotide PAOLA Study Has Completed &amp; Met Endpoint</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7417</link>
<description>re: Pasireotide PAOLA Study Has Completed &amp; Met Endpoint</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7417</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7417">re: Pasireotide PAOLA Study Has Completed & Met Endpoint</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7417">Endocrinology7417</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/803">Emilie CHARLOT</a> | 02 August 2013 | 11:48</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Comment: Alongside its Q2 earnings, Novartis made a preliminary announcement 
about the Pasireotide (Signifor) PAOLA study, the second phIII study with 
pasireotide LAR in inadequate responders to octreotide LAR or lanreotide.<wbr>  
It noted that the study had met its primary endpoint and that regulatory 
discussions with authorities are now underway.<wbr></span>&nbsp;<br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416" class="commentpermalink">Endocrinology7416</a> / <span class="date">02 August 2013</span> /
<span class="time">10:58:22 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">This announcement could be a reason of the silence around PAOLA during last Novartis communications in international congresses (ECE, Endocrine).<wbr> </div><div style="margin-bottom: 10px;">They might have launched the filing process very early, and since Health Authorities usually do not appreciate massive communication while data are being reviewed, Novartis adopted a low-profile attitude.<wbr> </div><div>Their next congress communication or presence might be different.<wbr> </div><!-- Comment details --><font size="-1">Emilie CHARLOT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7417" class="commentpermalink">Endocrinology7417</a> / <span class="date">02 August 2013</span> /
<span class="time">11:48:14 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7417">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416">View thread  Endocrinology7416: Pasireotide PAOLA Study Has Completed & Met Endpoint</a>]]></content:encoded><dc:date>2013-08-02T11:48:14+02:00</dc:date><dc:creator>emc06915</dc:creator></item><item>
<title>Pasireotide PAOLA Study Has Completed &amp; Met Endpoint [Alert, comp:Novartis, dis:Acromegaly, prod:Pasireotide, prod:Octreotide]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416</link>
<description>Pasireotide PAOLA Study Has Completed &amp; Met Endpoint [Alert, comp:Novartis, dis:Acromegaly, prod:Pasireotide, prod:Octreotide]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416</comments><category>Alert</category><category>comp:Novartis</category><category>dis:Acromegaly</category><category>prod:Pasireotide</category><category>prod:Octreotide</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7416">Pasireotide PAOLA Study Has Completed & Met Endpoint</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7416">Endocrinology7416</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 August 2013 | 10:58</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its Q2 earnings, Novartis made a preliminary announcement 
about the Pasireotide (Signifor) PAOLA study, the second phIII study with 
pasireotide LAR in inadequate responders to octreotide LAR or lanreotide.<wbr>  
It noted that the study had met its primary endpoint and that regulatory 
discussions with authorities are now underway.<wbr> <a name="Endocrinology7417c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">This announcement could be a reason of the silence around PAOLA during last Novartis communications in international congresses (ECE, Endocrine).<wbr> </div><div style="margin-bottom: 10px;">They might have launched the filing process very early, and since Health Authorities usually do not appreciate massive communication while data are being reviewed, Novartis adopted a low-profile attitude.<wbr> </div><div>Their next congress communication or presence might be different.<wbr> </div><font size="-1">Emilie CHARLOT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7417" class="commentpermalink">Endocrinology7417</a> / <span class="date">02 August 2013</span> /
<span class="time">11:48:14 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><STRONG>PAOLA study design</STRONG> </div><div style="margin-bottom: 10px;">SOM230C2402 is a multicenter, randomized study of double-blind pasireotide 
LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR 30 mg or 
lanreotide ATG 120 mg, in patients with inadequately controlled acromegaly.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7416/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>The Q2 earnings release notes that:-</STRONG> </div><div style="margin-bottom: 10px;">"First results from the Phase III study SOM230C2402 showed that a 
statistically significant greater proportion of acromegaly patients treated with 
pasireotide LAR saw a reduction of mean GH levels to &lt; 2.<wbr>5 µg/<wbr>L and 
normalization of sex- and age-adjusted IGF-1 at 24 weeks versus continued 
treatment with octreotide or lanreotide, meeting the primary objective of the 
study.<wbr>" </div><div style="margin-bottom: 10px;">Full results of the study will apparently be submitted for 
presentation at an upcoming congress.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regulatory Status</STRONG> </div><div style="margin-bottom: 10px;">Novartis mentions its plans to include these results in regulatory 
<BR>submissions for pasireotide LAR in acromegaly and claims to 
have initiated discussions with health authorities worldwide.<wbr> </div><div style="margin-bottom: 10px;">Below is a reminder of Joe Jiminez's statement regarding launch expectations 
over the next 2 years delivered at the JP Morgan Conference in January 
7th 2013.<wbr> His slide stated an expected US approval for Signifor 
in acromegaly within 12 months and an EU approval within 13-24 
months.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7416/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7420c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">These announced timelines for the Phase 3 were expected and positive results for the primary endpoint of PAOLA study  were expected as well.<wbr> They are the assumptions taken into consideration in the 4 year Somatuline forecast model </div><div style="margin-bottom: 10px;">This study confirms what has been observed in the other pivotal phase 3 study (C2305) where pasireotide 40 had a better efficacy than Oct LAR 20 on GH and IGF1 (proportion of patients with a reduction of mean GH level to &lt;2.<wbr>5 &micro;g/<wbr>L and the normalization of IGF-1 to within normal limits (age and sex related) at 12 months) in medically na&iuml;ve patients with active acromegaly .<wbr> The results were elegantly presented in May 2012 by Novartis claiming that pasireotide LAR patients were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care (but absolute values [pasireotide LAR(31%) vs Sandostatin LAR (19%)] were less impressive !!).<wbr> </div><div style="margin-bottom: 10px;">This PAOLA study is in a different study population, patients have active acromegaly but inadequately controlled on SSA ( not na&iuml;ve); the control arm for this study keeping the uncontrolled patients as they are on LAR 30 or ATG 120.<wbr> The primary endpoint is GH and IGF-1 levels at 24 weeks for pasireotide LAR 40 and 60 mg versus octreotide LAR 30 or lanreotide ATG 120.<wbr> Based on Novartis announcement, it means pasireotide could control part of these inadequately controlled patients when they switch to pasireotide 40 or 60mg ( active arm).<wbr> This is on line with what we are expecting from pasireotide, a slightly better efficacy than SSA 1st generation.<wbr> No absolute numbers and thresholds for defining controlled acromegaly  are disclosed so far.<wbr> </div><div style="margin-bottom: 10px;">Pasireotide was granted an orphan drug status in October 2009, for both Cushing&rsquo;s disease(CD) and acromegaly.<wbr> Our current approval assumption for acromegaly was  April 2014 with  pasireotide as a 2nd line after SSA 1st generation, assuming there is no delay due to the  hyperglycemic deleterious effects that pasireotide has.<wbr> A special warning for hyperglycemia will probably be &ldquo;granted&rdquo; to pasireotide.<wbr> Most KOL remain reserved due to hyperglycemia-related side effects and tend to position pasireotide anyway as a second-line treatment, to be used after failure of existing SSA.<wbr> </div><div style="margin-bottom: 10px;">For Cushing disease, after priority review and fast-track and orphan drug designations, FDA has approved pasireotide for Cushing's disease patients for whom surgery has been unsuccessful or who are not surgical candidates but requested 3 postmarketing studies including a clinical trial to assess hyperglycemia management, a long-term prospective observational cohort study of patients with Cushing's disease treated with pasireotide, and focused safety monitoring for reports of serious hyperglycemia, acute liver injury, and adrenal insufficiency.<wbr> </div><div style="margin-bottom: 10px;">When we know that the unmet medical need for Cushing disease is more important than for acromegaly and that Cushing disease is generally a more severe condition than Acromegaly, it will be interesting to see how FDA will assess the benefit /<wbr>risk ratio of pasireotide in acromegaly </div><div>At franchise level and as a follow up of the pasireotide war gaming (multidisciplinary session organized last October by the Endo Franchise and then shared with regions and  countries for sensitization and implementation of the counteracting plan at country level) , the franchise will monitor closely the NOVARTIS strategic approach re- pasireotide in acromegaly and will adapt and fine tune the counteraction plan accordingly.<wbr> </div><font size="-1">Christine MASSIEN / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7420" class="commentpermalink">Endocrinology7420</a> / <span class="date">05 August 2013</span> /
<span class="time">11:28:43 o'clock CEST</span>
</font></div><a name="endocrinology7416attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7416/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(130,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7416/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(79,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7416">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-02T10:58:22+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7416/1/ScreenCapture1.jpg" length="133285" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7416/2/ScreenCapture2.jpg" length="81720" type="image/jpeg"/></item><item>
<title>Takeda Q2 Earnings- Key Takeaways [dis:IBD, news, :Endocrinology:dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1902</link>
<description>Takeda Q2 Earnings- Key Takeaways [dis:IBD, news, :Endocrinology:dis:Diabetes]</description><category>dis:IBD</category><category>news</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1902</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1902">Takeda Q2 Earnings- Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1902">GastroEnterology1902</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 August 2013 | 15:31</font><br><br><div style="margin-bottom: 10px;">Comment::- Having already flagged the recent disappointing news with orteronel (TAK-700), Takeda's earnings webcast focused on some of its more promising developments with its new first-in-class diabetes drug TAK-875, a GPR40 agonist and its mAb vedoluzimab for ulverative colitis and Crohn's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Q1 2013/<wbr>14 Financials</STRONG> </div><div style="margin-bottom: 10px;">Net sales were up &yen;12 billion or 3.<wbr>0% from the same period last year to &yen;410.<wbr>3 billion.<wbr> Operating income went down &yen;14.<wbr>9 billion or 23.<wbr>8% to &yen;47.<wbr>7 billion and net income went down &yen;58.<wbr>5 billion or 66.<wbr>8% to &yen;29.<wbr>1 billion.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In order to have a competitive operating model as a global company, Takeda has initiated cost cutting project named Summit.<wbr> It was  announced in May and the company is  now in the process of discussing specific initiatives by cost category.<wbr> The project it is claimed is advancing very smoothly.<wbr> By the second quarter earnings report, management  hope to be able to expand on the whole picture of the project and specific measures.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Vedoluzimab (UC &amp; Crohn's)</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Following on from the filing in Europe, a BLA was recently filed in the U.<wbr>S.<wbr> for MLN0002 vedolizumab as a treatment for ulcerative colitis and Crohn's disease.<wbr> The product is a first-in-class novel gut-selective monoclonal antibody that targets &alpha;4&beta;7 integrin on leukocytes involved in ulcerative colitis and Crohn's disease.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Findings from <STRONG>GEMINI I trial for ulcerative colitis</STRONG> showed that vedolizumab met primary endpoints of improvement in clinical response at week six and clinical remission at week 52.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
The six-week clinical response in vedolizumab arm was 47.<wbr>1% compared to 25.<wbr>5% in the placebo arm.<wbr>

</LI>
<LI>
Remission rates at 52 weeks were 44.<wbr>8% of patients receiving vedolizumab every four weeks and 41.<wbr>8% of vedolizumab every eight weeks, it compared to 15.<wbr>9% of patients who received placebo.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In <STRONG>GEMINI II for Crohn's disease</STRONG>, vedolizumab demonstrated a statistically significant improvement in the primary endpoint of clinical remission at week six and week 52.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
Clinical remission at week six was seen in 14.<wbr>5% of vedolizumab patients versus 6.<wbr>8% of placebo;

</LI>
<LI>
Remission at week 52 was seen in 36.<wbr>4% and 39% of patients on vedolizumab every four weeks and every eight weeks, respectively versus 21.<wbr>6% of patients receiving placebo.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>TAK-875, fasiglifam (diabetes).<wbr> </STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Has displayed its new mechanism of action of stimulating insulin secretion dependent on glucose level.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Because it is glucose dependent, the risk of hypoglycemia is much lower than existing sulfonylurea drugs.<wbr> And in Phase II clinical trials, the incidence of hypoglycemia for TAK-875 was 2% versus 19% for the sulfonylurea glimepiride.<wbr> TAK-875 is currently in global Phase III trials.<wbr> In addition to trials in comparison to placebo and glimepiride,  head-to-head trials and concomitant use trials with DPP-4 inhibitor sitagliptin are also being undertaken.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In order to satisfy the U.<wbr>S.<wbr> FDA's requirements, a cardiovascular outcomes study is also underway.<wbr> Projected timeline of the approval in Japan is fiscal 2015 and in the U.<wbr>S.<wbr> and the Europe, fiscal 2016.<wbr></P> </div><div><P class="pwrapper">Source: Takeda Q1 Earnings Release</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1902">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-01T15:31:51+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Botox Therapeutic Sales Benefit From New Indications [comp:Allergan, dis:Migraine, dis:iOAB, dis:nOAB, prod:Botox, sub:Aesthetics, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7096</link>
<description>Botox Therapeutic Sales Benefit From New Indications [comp:Allergan, dis:Migraine, dis:iOAB, dis:nOAB, prod:Botox, sub:Aesthetics, headline]</description><category>comp:Allergan</category><category>dis:Migraine</category><category>dis:iOAB</category><category>dis:nOAB</category><category>prod:Botox</category><category>sub:Aesthetics</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7096</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7096">Botox Therapeutic Sales Benefit From New Indications</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7096">Neurology7096</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 August 2013 | 15:03</font><br><br><div style="margin-bottom: 10px;">Comment:<STRONG> </STRONG>Allergan reported second quarter, double digit sales and earnings growth is in line with its long term growth aspirations and slightly above market consensus.<wbr> Botox sales sales grew 11.<wbr>8% year-to-date, 13.<wbr>5% year-over-year in local currencies, with double-digit year-to-date growth seen in both the therapeutic and aesthetic categories.<wbr> </div><div style="margin-bottom: 10px;">Allergan claims to be gaining share in therapeutics as it builds out the chronic migraine and bladder indications, by contrast, in aesthetics it is experiencing some loss of share.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>New Approvals</STRONG></FONT> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Since its last earnings call, Allergan has received several new approvals:-</P> </div><div style="margin-bottom: 10px;"><UL><LI>Neurogenic overactive bladder - Singapore and Morocco plus public reimbursement in Australia </LI>
<LI>Overactive bladder - Hungary, Poland, New Zealand, India, Oman, and Chile.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Geographic Developments</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>U.<wbr>S - </STRONG>the therapeutic business continues to grow strongly, driven by chronic migraine, the two bladder indications, and upper limb spasticity.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>Chronic migraine has achieved a high level of reimbursement coverage, with 92% of commercial lives covered and 100% of Medicare lives.<wbr> </LI>
<LI>The company is continuiuing to invest in deepening injector experience by local live programs and preceptorships in order to increase rates of adoption and productivity.<wbr> </LI>
<LI>Additionally, it has created a dedicated practice management group to assist physicians with the organization ofa Botox clinic and improved patient flow.<wbr> </LI>
<LI>Beyond working on increased physician capacity to handle patients, it claims to have also stepped up its efforts to educate patients about the availability of Botox by launching the first branded television campaign for Botox for chronic migraine.<wbr> This started at the end of June.<wbr> Since that date, a major increase in the number of website visits and views of what is called "Find a Headache Specialist".<wbr>has occurred.<wbr> </LI>
<LI>Since approval of neurogenic overactive bladder, over half of the universe of urologists and urogynecologists have been trained and Allergian is claiming that.<wbr> user and patient satisfaction is high.<wbr> </LI>
<LI>During 2013, sales in the urology channel, have almost doubled albeit off a small base in 2012.<wbr> Reimbursement for overactive bladder is still a barrier.<wbr>.<wbr> As of June, 82% coverage of Medicare lives has been achieved and 42% of commercial lives.<wbr> Denial rates for prior authorizations are falling steadily.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In the movement disorders area, Allergan claims to be both growing the market as well as maintaining high market share.<wbr> With Ipsen's recent announcement to restructure its U.<wbr>S.<wbr> operations, Allergan expects to face less competitive pressure</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Europe - </STRONG>Allergan noted that the market seems to be growing above mid-single-digits and that Botox is gaining share based on initial uptake in chronic migraine and in urology.<wbr>.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG><FONT size="3">Aesthetics</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Allergan claims to have witnessed strong growth in Q2 in most of the principal markets of the world with the exception of Canada and Australia, </P> </div><div style="margin-bottom: 10px;"><UL><LI>In Canada it has been drawing down inventory in the doctor's office after a combined promotion with JUVÉDERM in Q1.<wbr> This has bee strategically timed to be just ahead of the launches of Xeomin and Dysport; </LI>
<LI>In Australia, Galderma's heavy price discounting of Azzalure has impacted Botox's sales growth.<wbr>.<wbr> </LI>
<LI>Eslewhere, such as in Russia, Japan, China and most countries in East and South Asia Allergan claims to be enjoying strong growth.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Allergan claims that Xeomin's aesthetic share has stagnated at 5% for several months now with a significant part of the share stemming from free goods and samples.<wbr> In Western Europe, Allergan believes that it has now been able to contain its market share loss to Azzalure and Bocouture.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>When questioned about how he expected the international/<wbr>US revenue mix to shake out, Pyott responded:-</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Clearly in the short swing, the biggest opportunity for migraine and bladder is the U.<wbr>S.<wbr> And part of that is just because of what you hear from all companies is the delay effects elsewhere in the world.<wbr> So, even once you've got an approval in some country in the European Union, the time required to then get full access to patients across the European continent probably is about two to two and a half years.<wbr> And when you look to Southern Europe, basically the Spanish Government has been saving money by just not getting around to issuing answers on what is the reimbursement price.<wbr> So we're pleased that we've cracked those codes in Spain and Italy.<wbr> But the point I'm making is it's a long swing effect in many of those markets.<wbr>.<wbr> So, net-net, what does that all mean? Assume that new Botox indications are just longer swing.<wbr> They take time to come through.<wbr> But they will come through".<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG><FONT size="3">Full-year Guidance</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Allergan estimates that revenues for the full-year will be between $6.<wbr>05 &amp; $6.<wbr>2bn and that Botox sales will reach $1.<wbr>94-$2bn.<wbr></P> </div><div><P class="pwrapper">Source: Allergan Q2 Earnings Release</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7096">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-01T15:03:14+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Highlights of Sanofi Q2:13 Results [dis:Prostate, :PharmaWorld:sub:Finance, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9095</link>
<description>Highlights of Sanofi Q2:13 Results [dis:Prostate, :PharmaWorld:sub:Finance, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Prostate</category><category>sub:Finance</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9095</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9095">Highlights of Sanofi Q2:13 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9095">Oncology9095</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 August 2013 | 12:15</font><br><br><div style="margin-bottom: 10px;">Comment: Management reported a difficult quarter due to the residual impact of the patent cliff, charge related to Brazil, currency and commercial underperformance in certain business areas.<wbr> Pharma sales were €6,714 million, a decrease of 7.<wbr>1%, which reflected generic competition, and EU austerity measures.<wbr> Sales in Emerging Markets totaled €2,669 million, a decrease of 2.<wbr>3%.<wbr> Sanofi expects to return to growth in H2:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Q2 Sales Impacted by Patent Losses, Brazil and Currency</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth Platforms</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Jevtana® Sales</FONT></STRONG> </div><div style="margin-bottom: 10px;">Jevtana® sales were €54 million in the second quarter, reflecting lower sales in the U.<wbr>S.<wbr> due to a more competitive environment.<wbr> </div><div style="margin-bottom: 10px;">In Western Europe sales of the product were stable at €25 million.<wbr> First-half sales of Jevtana® were €106 million (down 10.<wbr>1%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Net Sales by Region</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9095attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(47,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(30,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9095">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-01T12:15:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/1/ScreenCapture1.jpg" length="75425" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/2/ScreenCapture2.jpg" length="56689" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/3/ScreenCapture3.jpg" length="48647" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9095/4/ScreenCapture4.jpg" length="31383" type="image/jpeg"/></item><item>
<title>Astellas Reports 1Q/FY13 Results [comp:Astellas, :PharmaWorld:mkt:Intercontinental, prod:MDV3100, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9093</link>
<description>Astellas Reports 1Q/FY13 Results [comp:Astellas, :PharmaWorld:mkt:Intercontinental, prod:MDV3100, :PharmaWorld:sub:Finance]</description><category>comp:Astellas</category><category>mkt:Intercontinental</category><category>prod:MDV3100</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9093</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9093">Astellas Reports 1Q/<wbr>FY13 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9093">Oncology9093</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 August 2013 | 10:22</font><br><br><div style="margin-bottom: 10px;">Comment: Major growth drivers include Vesicare (+5%), Mirabegron (+4%), and XTANDI which delivered $82M in Q2 US sales.<wbr> Gonax (degarelix 3M) is listed to be in Ph3/<wbr>Japan meaning no change in its status.<wbr> To be noted the slow sales progression of Eligard (+1%).<wbr> Sales decreased in Japan and steadily expanded in Americas, EU and Asia.<wbr> A selection of key strategic slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results of 1Q/<wbr>FY13 in Sales (vs Previous Year)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Status of R&amp;D Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Focus on Late Phase Drugs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Overactive Bladder Franchise in Urology</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Oncology Franchise</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Focus on Enzalutamide Development Progress</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales by Region</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Affiliate in Singapore</FONT></STRONG> </div><div style="margin-bottom: 10px;">Astellas reported it will start business in Singapore from Oct 1st, 2013.<wbr> In addition to sales affiliates throughout EU/<wbr>The Middle and near East/<wbr>Africa and the Americas, Astellas now owns 10 sales affiliates in the Asia/<wbr>Oceania region.<wbr> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><a name="oncology9093attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(80,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(65,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(79,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(70,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(62,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(167,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(82,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(96,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(36,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9093">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-08-01T10:22:09+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/1/ScreenCapture1.jpg" length="38355" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/2/ScreenCapture2.jpg" length="82384" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/3/ScreenCapture3.jpg" length="67087" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/4/ScreenCapture4.jpg" length="81698" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/5/ScreenCapture5.jpg" length="72039" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/6/ScreenCapture6.jpg" length="64264" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/7/ScreenCapture7.jpg" length="171273" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/8/ScreenCapture8.jpg" length="84500" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/9/ScreenCapture9.jpg" length="98522" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9093/10/ScreenCapture10.jpg" length="36954" type="image/jpeg"/></item><item>
<title>Merz Acquires Swiss Dermatology Company [comp:Merz, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Acquisition, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7090</link>
<description>Merz Acquires Swiss Dermatology Company [comp:Merz, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Acquisition, sub:Aesthetics]</description><category>comp:Merz</category><category>mkt:NorthAmerica</category><category>sub:Acquisition</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7090</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7090">Merz Acquires Swiss Dermatology Company</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7090">Neurology7090</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 July 2013 | 16:54</font><br><br><div style="margin-bottom: 10px;">Comment: The acquisition of Neocutis' cosmeceutical skin care products will consolidate Merz' market position in the field of aesthetic dermatology, and expand its business in the U.<wbr>S.<wbr>.<wbr> Financial terms are not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Merz</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Neocutis' products used as pre- and post-treatments to aesthetic procedures.<wbr> </div><div style="margin-bottom: 10px;">- In the U.<wbr>S Merz offers a well-balanced range of products for minimally invasive treatments, including the dermal fillers Radiesse® and Belotero®, the neurotoxin Xeomin®, a product for the treatment of varicose veins, as well as products for the treatment of scars and fungal skin diseases.<wbr> The U.<wbr>S.<wbr> is the main market for Neocutis.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><A href="http://www.neocutis.com/"><STRONG>Neocutis</STRONG></A><STRONG> Mini Profile</STRONG></FONT> </div><div style="margin-bottom: 10px;">- founded in February 2003 as a spin-off of the medical faculty of the Lausanne University Clinic, Switzerland.<wbr> </div><div style="margin-bottom: 10px;">- privately owned company with HQs in Pully (Switzerland) </div><div style="margin-bottom: 10px;">- develops and distributes innovative products for aesthetic dermatology (anti-aging, pigmentation problems, sun protection).<wbr> </div><div style="margin-bottom: 10px;">Since the company entered the market in 2009, it has recorded strong annual growth.<wbr> The anti-aging line is one of the products with the highest recorded turnover.<wbr> </div><div>Source: Merz </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7090">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-31T16:54:26+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Astellas Japan  Appoints New Senior VP of Global Oncology [comp:Astellas, :PharmaWorld:sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9092</link>
<description>Astellas Japan  Appoints New Senior VP of Global Oncology [comp:Astellas, :PharmaWorld:sub:People]</description><category>comp:Astellas</category><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9092</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9092">Astellas Japan  Appoints New Senior VP of Global Oncology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9092">Oncology9092</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 July 2013 | 16:40</font><br><br><div style="margin-bottom: 10px;">Comment: Claire Thom, Pharm.<wbr>D.<wbr>, will replace Dr Wayne Klohs who recently retired.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">Most recently Claire served as Senior VP Portfolio Management, Drug Development Management and Strategic Business Operations at Millennium, where she was responsible for the oncology portfolio management process.<wbr> </div><div style="margin-bottom: 10px;">Previously, she was responsible for the oversight and implementation of the global therapeutic area strategies for oncology, urology and gynecology franchises of Takeda Pharmaceutical Company in Japan.<wbr> </div><div style="margin-bottom: 10px;">She is a graduate of the University of Illinois at Chicago where she earned a bachelor's degree and Doctorate of Pharmacy.<wbr> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9092">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-31T16:40:57+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Botulinum Toxin Type A2 Has Entered Ph2/3 for Stroke Patients with Lower Limb Spasticity [class:BotulinumToxins, dis:Spasticity, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7089</link>
<description>Botulinum Toxin Type A2 Has Entered Ph2/3 for Stroke Patients with Lower Limb Spasticity [class:BotulinumToxins, dis:Spasticity, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial, headline]</description><category>class:BotulinumToxins</category><category>dis:Spasticity</category><category>mkt:Japan</category><category>sub:ClinicalTrial</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7089</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7089">Botulinum Toxin Type A2 Has Entered Ph2/<wbr>3 for Stroke Patients with Lower Limb Spasticity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7089">Neurology7089</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 July 2013 | 16:10</font><br><br><div style="margin-bottom: 10px;">Comment: The randomized, double-blind study will compare clinical efficacy of single IM injection of 300U of A2NTX and 300U of BOTOX&reg;.<wbr> PE will assess the change in modified Ashworth Scale of the ankle joint.<wbr> More details on the Japanese toxin are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">A2NTX Characteristics</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV>
 </div><div style="margin-bottom: 10px;"><P>Feedback from the Neurology Franchise (S.<wbr> Guillebaud and S.<wbr> Om) has outlined the following:</P>
<P>As presented during a plenary session that took place in Hannover at the International Congress of Dystonia on the 11th of May 2013, this botulinum type A derived from a subtype A2 strain of <EM>Clostridium botulinum</EM> seems to have some advantages vs other toxins.<wbr></P>
</DIV> </div><div style="margin-bottom: 10px;"><UL><LI>Stay at local site (<SPAN lang="EN-US" style="line-height: 14px; font-family: Arial, sans-serif; font-size: 10pt;">Less spread to un-injected muscles than A1 (showed by grip power test /<wbr> shown in animal studies that A2NTX is less diffusible than BOTOX<SUP>&reg;</SUP> or other BoNT)</SPAN>
</LI>
<LI><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Less antigenicity </SPAN>
</LI>
<LI>2-fold efficacy (<SPAN lang="EN-US" style="line-height: 14px; font-family: Arial, sans-serif; font-size: 10pt;">A2 requires less dose (50%) than botox to have same effect)</SPAN>
</LI>
<LI>Safe
</LI>
<LI>Less axonal transport to CNS
</LI>
<LI>Storage at room temperature.<wbr>(<SPAN style="line-height: 14px; font-family: Arial, sans-serif; font-size: 10pt;">Still stable at 45&deg;C for several month)</SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Manufactured by Kaketsuken (Japan) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">A2NTX Ph2/<wbr>3 New Trial - <A href="http://clinicaltrials.gov/ct2/show/NCT01910363?term=kaji&amp;rank=1">NCT01910363</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Location/<wbr>Contact: U.<wbr> of Tokushima /<wbr> <SPAN style="text-decoration: underline;">Ryuji Kaji</SPAN>, Professor and Chairman, Department of Neurology, University of Tokushima </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 30 patients </div><div style="margin-bottom: 10px;">Completion Date: November 2013 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Presentation at Future Congresses</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U><STRONG>At WCN</STRONG> (September-Vienna)</U>, Ryuji Kaji will be a speaker for "The challenge of botulinum toxin for spasticity" </div><div style="margin-bottom: 10px;">Ryuji Kaji is cited in the poster below (to be noted the association with Allergan).<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7089/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7089attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7089/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(54 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7089/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7089/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7089">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-31T16:10:32+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7089/1/ScreenCapture1.jpg" length="55314" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7089/2/ScreenCapture2.jpg" length="67388" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7089/3/ScreenCapture3.jpg" length="53888" type="image/jpeg"/></item><item>
<title>Pfizer Q2 12 Results Provides Additional Perspectives [:Endocrinology:comp:Pfizer, sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10539</link>
<description>Pfizer Q2 12 Results Provides Additional Perspectives [:Endocrinology:comp:Pfizer, sub:Finance]</description><category>comp:Pfizer</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10539</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10539">Pfizer Q2 12 Results Provides Additional Perspectives</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10539">PharmaWorld10539</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 July 2013 | 19:10</font><br><br><div style="margin-bottom: 10px;">Comment: Foreign exchange negatively impacted BRIC-Mexico and Turkey revenue by 1% vs Q2:12.<wbr> However CEO expects H2:13 to be stronger than H1:13 in emerging markets.<wbr> He outlined that the new commercial structure will better position Pfizer, and provide greater financial transparency.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Innovative and Value Business Segments</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10539/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets Performance</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10539/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10539attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10539/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(175,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10539/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(95,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10539">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-30T19:10:36+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10539/1/ScreenCapture1.jpg" length="179892" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10539/2/ScreenCapture2.jpg" length="97732" type="image/jpeg"/></item><item>
<title>Key Messages from Lexicon Q2:13 Earnings [dis:Diabetes, :GastroEnterology:dis:IBS, :GastroEnterology:dis:Diarrhoea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7413</link>
<description>Key Messages from Lexicon Q2:13 Earnings [dis:Diabetes, :GastroEnterology:dis:IBS, :GastroEnterology:dis:Diarrhoea]</description><category>dis:Diabetes</category><category>dis:IBS</category><category>dis:Diarrhoea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7413</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7413">Key Messages from Lexicon Q2:13 Earnings</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7413">Endocrinology7413</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 July 2013 | 18:13</font><br><br><div style="margin-bottom: 10px;">Comment: Top-line results from Ph2 of telotristat etiprate for UC and LX1033 for IBS-d are expected around end of Q3:13 and Q4:13 respectively.<wbr> Management reported that safety data from the Ph2 trial of LX4211 in T1DM allowed the study to advance into its expansion phase.<wbr> </div><div style="margin-bottom: 10px;"><FONT style="BACKGROUND-COLOR: #ffffff"><STRONG>Financial Figures</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2"><FONT style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><U>Revenues</U> for the 2013 second quarter of $0.<wbr>2 million consist went the prior year period.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">For the first half of 2013 our revenues increased to $0.<wbr>6 million </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">from $0.<wbr>5 million in the prior year period.<wbr> </SPAN></FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><FONT size="2"><FONT style="BACKGROUND-COLOR: #ffffff"><U>R&amp;D expenses</U> for the 2013 second quarter increased 22% to $23.<wbr>7 million from $19.<wbr>4 million in the prior year period.<wbr></FONT></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT size="2"><FONT style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><U>G&amp;A expenses</U> for the 2013 second quarter were $4.<wbr>7 million an increase of 12 about percent from $4.<wbr>2 million inthe </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">prior year period.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">The increase was primarily attributable to increases in personnel costs and legal and patent fees</SPAN>.<wbr> As of June 30, 2013 Lexicon had $175.<wbr>4 million in cash and investments as compared to $197.<wbr>2 million <SPAN style="BACKGROUND-COLOR: #ffffff">as of of March 31, 2013 and $223.<wbr>2 million </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">as of December 31, 2012.<wbr></SPAN></FONT></FONT> </div><div style="margin-bottom: 10px;"><STRONG>Presenters</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Agenda</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recruitment Update</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><STRONG><FONT size="3">Pipeline Update</FONT></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/8/ScreenCapture8.jpg?user-agent=rss"></SPAN>
 </div><div style="margin-bottom: 10px;"><FONT style="BACKGROUND-COLOR: #ffffff"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/7/ScreenCapture7.jpg?user-agent=rss"></STRONG></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/6/ScreenCapture6.jpg?user-agent=rss"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #fdfd00">Q&amp;A Sessions</FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">Lexicon is "continuing to make progress on the partnership discussions and its objective remains to move into Ph3 with a partner this year for <STRONG>LX4211</STRONG> (in T2DM)".<wbr> .<wbr>.<wbr>.<wbr> "<SPAN style="BACKGROUND-COLOR: #ffffff">it is important to have someone with experience in the diabetes space and that is really our focus and our </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">discussions".<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff">Recruitment of <STRONG>LX1032 /<wbr> Telotristat etiprate</STRONG> for carcinoid syndrome - Management reported that "<SPAN style="BACKGROUND-COLOR: #ffffff">We had a wave of sites come up</SPAN>.<wbr> In Europe a little longer than in the US and we are very satisfied with the European participation that that has come onboard in the past quarter and so we are consistent right now in randomization with our projections to complete randomization in 2014".<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff">Endpoints for <STRONG>LX1032</STRONG> for UC - "<SPAN style="BACKGROUND-COLOR: #ffffff">The most important is the Mayo score which integrates patients symptoms, physician observation and colonoscopy results", endoscopy scores and bowel movement frequency (BMF).<wbr></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff">Timelines for <STRONG>LX2761</STRONG> - " .<wbr>.<wbr>.<wbr> currently in IND enabling studies and we anticipate filing an IND near mid year of next year".<wbr></SPAN></SPAN></SPAN> </div><div><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><EM>Source: Lexicon Webcast</EM></SPAN></SPAN></SPAN> </div><!-- Comment details --><a name="endocrinology7413attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(22,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(76,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(49,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(54,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(59,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(77,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7413">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-30T18:13:22+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/1/ScreenCapture1.jpg" length="79726" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/2/ScreenCapture2.jpg" length="23372" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/3/ScreenCapture3.jpg" length="78637" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/4/ScreenCapture4.jpg" length="51028" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/5/ScreenCapture5.jpg" length="55917" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/6/ScreenCapture6.jpg" length="65534" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/7/ScreenCapture7.jpg" length="60960" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7413/8/ScreenCapture8.jpg" length="79491" type="image/jpeg"/></item><item>
<title>uniQure Strengthens Leadership Position in Gene Therapy [dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7087</link>
<description>uniQure Strengthens Leadership Position in Gene Therapy [dis:Parkinson]</description><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7087</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7087">uniQure Strengthens Leadership Position in Gene Therapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7087">Neurology7087</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 July 2013 | 13:28</font><br><br><div style="margin-bottom: 10px;">Comment: In the last 3 weeks, the company reported to start the build-out of a production plant in the US to leverage AAV-manufacturing strenght, the start of Ph1 to test its GDNF in patients with Parkinson's disease, and a €45M commercialization agreement with Chiesi.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the US Manufacturing Plant</FONT></STRONG> </div><div style="margin-bottom: 10px;">State-of-the-art 55,000 square foot in Lexington, Massachusetts for the production of commercial grade Adeno Associated Virus (AAV)-based gene therapy products to complement its current EMA-approved site in Amsterdam, the Netherlands.<wbr> </div><div style="margin-bottom: 10px;">The Company expects the facility to be operational by early 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Phase 1 Trial in Parkinson's Disease</FONT></STRONG> </div><div style="margin-bottom: 10px;">uniQure’s aim is to administer recombinant AAV (adeno-associated virus) vector that carries the gene for GDNF to the brain.<wbr> </div><div style="margin-bottom: 10px;">Investigator initiated clinical trial in Parkinson’s disease, led by Dr.<wbr> Krystof Bankiewicz MD, PhD, at UCSF, and Dr.<wbr> John D.<wbr> Heiss, MD, at the National Institute for Neurological Disorders and Stroke, part of the National Institutes of Health (NIH).<wbr> </div><div style="margin-bottom: 10px;">The study is a Phase I open-label dose escalation safety study that will include 24 patients divided over 4 cohorts.<wbr> The first patient was dosed on May 20, and so far there have been no safety issues.<wbr> The study is fully funded by the NIH.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement with Chiesi</FONT></STRONG> </div><div style="margin-bottom: 10px;">Collaboration agreements with Chiesi Farmaceutici SpA for: </div><div style="margin-bottom: 10px;"><UL><LI>
the commercialization of <A href="http://www.uniqure.com/products/glybera/">Glybera</A>, the first gene therapy to receive regulatory approval in Europe</LI>
<LI>
the co-development of a gene therapy for hemophilia B</LI>
</UL> </div><div style="margin-bottom: 10px;">In connection with this transaction, uniQure has received EUR 17 million (USD 21.<wbr>8 million) in collaboration financing and EUR 14 million (USD 18 million) in equity financing from Chiesi.<wbr> </div><div><EM>Source: uniQure</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7087">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-30T13:28:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Acino's HY13 Results Driven by Strong Sales in Emerging Markets [:Oncology:dis:Prostate, :Oncology:sub:Hybrids, comp:Acino, prod:Goserelin, prod:Leuprorelin, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids230</link>
<description>Acino's HY13 Results Driven by Strong Sales in Emerging Markets [:Oncology:dis:Prostate, :Oncology:sub:Hybrids, comp:Acino, prod:Goserelin, prod:Leuprorelin, headline]</description><category>dis:Prostate</category><category>sub:Hybrids</category><category>comp:Acino</category><category>prod:Goserelin</category><category>prod:Leuprorelin</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids230</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20130831&edate=20130501&rec=230">Acino's HY13 Results Driven by Strong Sales in Emerging Markets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20130831&edate=20130501&cat=comp%3aAcino"><font color="#e95e0b">:DKPHybrids:comp:Acino</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:DKPHybrids:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20130831&edate=20130501&cat=prod%3aGoserelin"><font color="#e95e0b">:DKPHybrids:prod:Goserelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20130831&edate=20130501&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=sub%3aHybrids"><font color="#e95e0b">:Oncology:sub:Hybrids</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids230">DKPHybrids230</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 July 2013 | 10:26</font><br><br><div style="margin-bottom: 10px;">Comment: The highlight in the first six months of 2013 was the launch of the rivastigmine transdermal system in Germany where it was one of the first generics to reach the market.<wbr> Alongside the financial results, management indicated that partnering discussions for leuprorelin and goserelin are ongoing.<wbr> From a clinical trial perspective, it was reported that the study of goserelin 1M is ongoing but 'delayed', and that trial for goserelin 3M will be starting after completion of the 1M study.<wbr> EU approval for leuprorelin 3M is expected for Q3 16, and Q2 17 for goserelin 3M.<wbr> A selection of key slides is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Implant - Estimated Approval Dates</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">Management outlined that the complexity of the clinical development entailed additional delays of the implant projects goserelin and leuprorelin in EU and Japan.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Development Pipeline</STRONG></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Acino Business by Segment</STRONG></FONT> </div><div style="margin-bottom: 10px;">Strategy: Entry into new countries both BtC (Ukraine, Russia, etc.<wbr>) and BtB (US, Japan, China, Brazil, etc.<wbr>) </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/3/ScreenCapture3.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/11/ScreenCapture11.jpg?user-agent=rss"></STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2"><STRONG>BtC BUSINESS</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">Strategy: consolidate, grow and expand sales of “Acino Switzerland” branded products</FONT></FONT> </div><div style="margin-bottom: 10px;">Acino Switzerland BtC product launches will accelerate (60 in 2013, 120 in 2014) </div><div style="margin-bottom: 10px;">Mepha/<wbr>Cephalon acquisition facilitates access to new markets in MENA, Africa, Latin America &amp; Asia, and paved the way for launch of own product portfolio under the brand “Acino Switzerland” </div><div style="margin-bottom: 10px;">Status product launches:  Launches of Clopacin® (clopidogrel besilate), Fentavera® (fentanyl patch), Metracin® (metoprolol succinate MUPS), Fuzocim® (alfuzosine-HCl); Doxacin® (doxazosin mesilate) and others are scheduled in several MENA &amp; African markets  Several approvals obtained in Africa, for example oxycodone in Kenya; key strategic products submitted in South Africa  Asian launch of Clopacin®, approval of Fentavera® in South Korea  Latin America filings are under way; Clopacin® approved in Ecuador  CIS countries: 30 dossiers dispatched, first sales expected by end 2012 In addition, a high number of product submissions in BtC markets  47 already approved, additional 86 in registration  Total of 500+ submission projects running.<wbr> </div><div style="margin-bottom: 10px;"><U>Increase BtC profitability</U> </div><div style="margin-bottom: 10px;"><UL><LI>Renegotiate contract terms with local distribution partners </LI>
<LI>Decrease in country overhead cost as % of sales as a result of growing business </LI>
<LI>Price increases where possible </LI>
<LI>Launch of new higher margin products </LI>
<LI>Reduce payment terms /<wbr> move to advance payments</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2"><STRONG>BtB BUSINESS</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">Performance (decline of 19.<wbr>8%) is impacted by marked volume losses</FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/6/ScreenCapture6.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><U>Growin the BtB Segment</U> </div><div style="margin-bottom: 10px;"><UL><LI>Optimize and foster existing (niche) portfolio </LI>
<LI>Launch new own developments (rivastigmine patch) </LI>
<LI>Identify Unique Selling Points and address them during development to create more value added products using advanced delivery systems </LI>
<LI>Selection of business partners with (brand) marketing approach, not lowest price strategy </LI>
<LI>Entering into licensing deals in markets like US, Japan, etc.<wbr> </LI>
<LI>Differentiated country-specific pricing with one partner</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>TM BUSINESS</STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/8/ScreenCapture8.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><U>Opportunities</U> </div><div><UL><LI>Differentiating features </LI>
<LI>Lead project Bayer fertility control patch </LI>
<LI>Strive for co-developments </LI>
<LI>Broaden and upgrade existing sites and equipment park</LI>
</UL> </div><!-- Comment details --><a name="dkphybrids230attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(22,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(205 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(84,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(41,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(50,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(30 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(29,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(108,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(77,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20130831&edate=20130501&rec=230">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-30T10:26:08+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/1/ScreenCapture1.jpg" length="23425" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/2/ScreenCapture2.jpg" length="70876" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/3/ScreenCapture3.jpg" length="209969" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/4/ScreenCapture4.jpg" length="86293" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/5/ScreenCapture5.jpg" length="42390" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/6/ScreenCapture6.jpg" length="51446" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/7/ScreenCapture7.jpg" length="30734" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/8/ScreenCapture8.jpg" length="30402" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/9/ScreenCapture9.jpg" length="111240" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/10/ScreenCapture10.jpg" length="120967" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/230/11/ScreenCapture11.jpg" length="79040" type="image/jpeg"/></item><item>
<title>Valeant to Reduce Staff Numbers [mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10535</link>
<description>Valeant to Reduce Staff Numbers [mkt:NorthAmerica]</description><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10535</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10535">Valeant to Reduce Staff Numbers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10535">PharmaWorld10535</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 July 2013 | 09:33</font><br><br><div style="margin-bottom: 10px;">Comment: In a filing with the US SEC, the company has disclosed it expects to reduce staff numbers by 10-15% (approx.<wbr> 2,700 jobs) once the acquisition of Bausch and Lomb is complete.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Disclosures</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management noted that: </div><div style="margin-bottom: 10px;"><UL><LI>Medicis Ops will be relocated to New Jersey from Scottsdale</LI>
<LI>Arizona Obagi business will be combined with Bausch &amp; Lomb location in California</LI>
</UL> </div><div style="margin-bottom: 10px;">Valeant HQ stays in Laval, Quebec.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Bausch &amp; Lomb Acquisition</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10463" class="defaultlink">PharmaWorld10463: Valeant Agrees to Acquire Baush & Lomb for $8.<wbr>7 Billion</a> </div><div><EM>Source: Valeant</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10535">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-30T09:33:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Taipei-Based Company Claims to Develop and Manufacture a New 'Botox' [class:BotulinumToxins, dis:Spasticity, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7083</link>
<description>Taipei-Based Company Claims to Develop and Manufacture a New 'Botox' [class:BotulinumToxins, dis:Spasticity, headline]</description><category>class:BotulinumToxins</category><category>dis:Spasticity</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7083</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7083">Taipei-Based Company Claims to Develop and Manufacture a New 'Botox'</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7083">Neurology7083</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 July 2013 | 17:32</font><br><br><div style="margin-bottom: 10px;">Comment: In a PR published in <EM>Focus Taiwan</EM>, Amaran Biotechnology Inc.<wbr> reported to have started the construction of a plant located in the Hsinchu Biomedical Science Park to produce 'Botox'.<wbr> Of note, Amaran has formed a strategic alliance with OBI Pharma, which is developing a botulinum toxin (currently in preclinical stage for muscle spasticity).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Plant</FONT></STRONG> </div><div style="margin-bottom: 10px;">The article mentionned that the plant has received investment totaling $33.<wbr>4M).<wbr> </div><div style="margin-bottom: 10px;">The plant will feature laboratories with a biological safety level of three, the second-highest on a scale of four, where 'Botox' can be worked with under the controls necessary to limit contamination of the work environment and the surrounding community.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">OBI Pharma</FONT></STRONG> </div><div style="margin-bottom: 10px;">Under a strategic alliance with OBI Pharma, the Hsinchu plant will also serve as a base manufacturer of breast cancer drug, OBI-822/<wbr>821 (currently in <A href="http://clinicaltrial.gov/ct2/show/study/NCT01516307">Phase 3</A>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7083/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The company website indicates it is developing <A href="http://www.obipharma.com/index.aspx?lang=eng&amp;fn=pipeline_content&amp;no=6">OBI-858</A>, a botulinum toxin in PC development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7083/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competitive Intelligence Question</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please help us identifying the level of threat of this news in forwarding any relevant information you can gather on Amaran Biotechnology, its plant and the timelines (management claimed to be able to roll-out the new 'Botox' in 2020).<wbr> </div><div><STRONG><FONT size="3">With many thanks to Alison Attard who has picked up the information.<wbr></FONT></STRONG> </div><!-- Comment details --><a name="neurology7083attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7083/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(20,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7083/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(44,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7083">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-29T17:32:58+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7083/1/ScreenCapture1.jpg" length="21232" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7083/2/ScreenCapture2.jpg" length="45206" type="image/jpeg"/></item><item>
<title>Highlights of Almirall 1H 13 Financial Results</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10534</link>
<description>Highlights of Almirall 1H 13 Financial Results</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10534</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10534">Highlights of Almirall 1H 13 Financial Results</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10534">PharmaWorld10534</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 July 2013 | 16:44</font><br><br><div style="margin-bottom: 10px;">Comment: Ebastina remains the best selling product, despite its -17.<wbr>5% decrease caused by lower prices and the arrival of generics in certain countries.<wbr> Meanwhile, Eklira® is now the company's second best-selling product, contributing €38.<wbr>7M.<wbr> LAS41008, for psoriasis, along with Sativex® for alleviating oncological pain, are both undergoing ph3 with topline results to be read out in 2014.<wbr> Key slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales by Product</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales by Region and TA</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">HY13 Highlights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Four Growth Platforms</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10534attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(56,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(49 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(87 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(103,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10534">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-29T16:44:03+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/1/ScreenCapture1.jpg" length="30084" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/2/ScreenCapture2.jpg" length="57537" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/3/ScreenCapture3.jpg" length="50158" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/4/ScreenCapture4.jpg" length="89082" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10534/5/ScreenCapture5.jpg" length="105992" type="image/jpeg"/></item><item>
<title>Pfizer to Separate Operations into Three Business Segments [:Endocrinology:comp:Pfizer]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10532</link>
<description>Pfizer to Separate Operations into Three Business Segments [:Endocrinology:comp:Pfizer]</description><category>comp:Pfizer</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10532</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10532">Pfizer to Separate Operations into Three Business Segments</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10532">PharmaWorld10532</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 July 2013 | 16:12</font><br><br><div style="margin-bottom: 10px;">Comment: The units will include 2 'Innovative Business' segments and 1 'Value Business' segment.<wbr> Each of the three segments will include developed markets and emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Insights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><OL><LI>
The Innovative business segments led by G Germano, will generally include products across multiple therapeutic areas that are expected to have market exclusivity beyond 2015.<wbr>  The therapeutic areas include Inflammation and Immunology, CV/<wbr>Metabolic, Neuroscience and Pain, Rare Diseases and Women’s /<wbr>Men’s Health.<wbr></LI>
<LI>
The Innovative business segment will include Vaccines, Oncology and Consumer Healthcare and will be led by Amy Schulman.<wbr></LI>
<LI>The Value business segment, led by John Young, will include products that generate strong, consistent cash flow.<wbr> </LI>
</OL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Timelines</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management outlined that the changes will go into effect in January 2014 in countries that do not require a consultation with labor unions.<wbr> </div><div><EM>Source: Pfizer</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10532">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-29T16:12:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Perrigo to Buy Ireland's Elan for $8.6bn [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10528</link>
<description>Perrigo to Buy Ireland's Elan for $8.6bn [sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10528</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10528">Perrigo to Buy Ireland's Elan for $8.<wbr>6bn</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10528">PharmaWorld10528</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 July 2013 | 14:34</font><br><br><div style="margin-bottom: 10px;">Comment: The deal ends a takeover saga in which Elan rejected three hostile bids.<wbr> The offer represents a 10.<wbr>5% premium to the Friday close.<wbr> After closing, the combined company will be based in Ireland.<wbr> Perrigo reported <SPAN style="BACKGROUND-COLOR: #ffffff">that they are "not going to get </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">into the branded pharma business or biotech business.<wbr>.<wbr>.<wbr> but looking</SPAN><SPAN style="BACKGROUND-COLOR: #ffffff"> at how best to monetize pipeline asset" (ELND005 neuropsychiatric program in Phase II studies).<wbr></SPAN> <BR> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Acquisition Summary</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Perrigo</FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">Perrigo receive escalated royalties from Tysabri, which </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">has high barriers to entry.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Generated a 19% compound annual growth rate over the </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">2008 to 2012 period.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Is well positioned for future growth and has further </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">opportunities for growth at other indications, other </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">geographies and for the treatment of other diseases.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Is without a doubt one of the most important and efficacious </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">treatments for people suffering from multiple sclerosis</SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">The transaction will give Perrigo access to a Ph2 central nervous system product that is approaching a key milestone.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">Perrigo will receive $1.<wbr>9bn in cash from </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">the Elan balance sheet.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">The company will have an opportunity to further enhance </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">its international platform via Irish legal domicile.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">Management anticipate this transaction will be accretive </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">to adjusted earnings per share in 2014 and will create meaningful synergy opportunities.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">It expects to realize more than $150M annually </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in after tax operating expense and tax savings as a </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">result of this combination.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Perrigo Portfolio</FONT></STRONG> </div><div style="margin-bottom: 10px;">Perrigo sells non-prescription products for conditions such as acid indigestion and nasal congestion, as well as generic drugs, nutritional supplements and animal treatments.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Elan's 3 Major Assets</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>- TYSABRI</STRONG> </div><div style="margin-bottom: 10px;">Elan's current portfolio includes royalties from Tysabri® (marketed and distibuted by Biogen Idec) along with a neuropsychiatric pipeline.<wbr> </div><div style="margin-bottom: 10px;">Tysabri® generated revenues of US$1.<wbr>6 billion in 2012, and has been growing at a compound annual growth rate of 19%.<wbr> </div><div style="margin-bottom: 10px;">Further upside if approved for Secondary Progressive Multiple Sclerosis (SPMS) - study completion expected in 2015 (readout).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>- THERAVANCE</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>- AOP ORPHAN</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><EM>Source: Elan; Perrigo</EM> </div><!-- Comment details --><a name="pharmaworld10528attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/7/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(119,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/8/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/9/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(38,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10528">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-29T14:34:41+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/7/ScreenCapture1.jpg" length="121995" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/8/ScreenCapture2.jpg" length="39027" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10528/9/ScreenCapture3.jpg" length="39175" type="image/jpeg"/></item><item>
<title>Prolor Has Started Registration Trial with Once-Weekly hGH for AGHD [dis:GrowthHormoneDeficiency, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7412</link>
<description>Prolor Has Started Registration Trial with Once-Weekly hGH for AGHD [dis:GrowthHormoneDeficiency, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:GrowthHormoneDeficiency</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7412</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7412">Prolor Has Started Registration Trial with Once-Weekly hGH for AGHD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7412">Endocrinology7412</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 July 2013 | 17:11</font><br><br><div style="margin-bottom: 10px;">Comment: The multi-center Ph3 will be recruiting approx.<wbr> 189 participants (23 years to 70 years) in the US.<wbr> PE wil assess change in trunk FM, expressed in kilograms measured with DXA, and safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01909479?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=06%2F26%2F2013&amp;rank=238"><STRONG><FONT size="3">NCT01909479</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: June 2013 - Completion date: March /<wbr> August 2015.<wbr>
 </div><div><DIV class="body3">Secondary Outcome Measures: 
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change in total FM, expressed in kilograms, measured with DXA, from baseline to 26 and 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change in lean body mass, expressed in kilograms measured with DXA, from baseline to 26 and 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change in trunk FM, expressed in kilograms measured with DXA, from baseline to 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change in trunk FM, expressed as % change from baseline, measured with DXA, from baseline to 26 and 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]</LI>
</UL></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7412">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-26T17:11:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AbbVie Q2 Growth Driven by Humira [dis:Gynea, prod:Lupron]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9083</link>
<description>AbbVie Q2 Growth Driven by Humira [dis:Gynea, prod:Lupron]</description><category>dis:Gynea</category><category>prod:Lupron</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9083</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9083">AbbVie Q2 Growth Driven by Humira</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aLupron"><font color="#e95e0b">:Oncology:prod:Lupron</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9083">Oncology9083</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 July 2013 | 15:59</font><br><br><div style="margin-bottom: 10px;">Comment: On July 26th, Abbvie hosted its Q2 financial results.<wbr> Revenue increased by 4.<wbr>4% to $4.<wbr>692 billion, driven primarily by strong sales of HUMIRA (+16%), and key products such as Synthroid, Creon, Zemplar and Duodopa.<wbr> Global sales of Lupron were nearly $200M.<wbr> Completion of enrollment in the HCV trial, ph3 initiation of the atrasentan programs, collaboration with Alvine Pharm.<wbr> for celiac disease (in Ph2), and with BMS for multiple myeloma were stressed as being significant advancements in AbbVie's pipeline.<wbr> The most detailed update of the Elagolix program in both endometriosis and UF was provided during Neurocrine Q2 the day before.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Elagolix Development Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;">Neurocrine's management reported the following: </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> The <FONT style="BACKGROUND-COLOR: #ffffff">endometriosis</FONT> ph3-study is on track, with AbbVie anticipation of completing randomization this fall, and top-line data from the ph3 in Q1 of 2014.<wbr> </div><div style="margin-bottom: 10px;">I'm also pleased to note that about a week ago, our Daisy PETAL study, which was the so-called 901 study -- very successful ph2b study with <FONT style="BACKGROUND-COLOR: #ffffff">endometriosis</FONT> patients -- was published electronically ahead of print publication in the Journal of <FONT style="BACKGROUND-COLOR: #ffffff">Endometriosis</FONT> and Pelvic Pain.<wbr> That manuscript is available there for subscribers to that journal or for purchase.<wbr> And the abstract is available, obviously, at no charge.<wbr> </div><div style="margin-bottom: 10px;">So that's a great piece of data to get out.<wbr> And as you recall, the co-primary endpoints of dysmenorrhea and non-menstrual pelvic pain that were solidified in that trial are the ones that the FDA was very pleased with and that we're taking forward into the ph3 trial.<wbr> </div><div style="margin-bottom: 10px;">AbbVie also tells us their uterine fibroid (UF) program is on track.<wbr> As you know, they're in the midst of the phase-IIb activities, and we look forward to additional updates from AbbVie as those studies move along .<wbr>.<wbr>.<wbr>".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Lupron Sales</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Q2 13 sales represent $199M ($144M in the US; $55M international).<wbr> </LI>
<LI>H1 13 sales represent $269M ($380M for the US; $111M international).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">AbbVie management outlined that " .<wbr>.<wbr>.<wbr> Lupron continues to hold a leadership position and maintain a significant share of the market.<wbr> For the full-year 2013, we expect Lupron sales to be roughly in line with 2012".<wbr> </div><div><EM>Source: Neurocrine; Abbvie</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9083">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-26T15:59:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Failure of Takeda's TAK-700 in Post-Chemo mCRPC [comp:Takeda, dis:Prostate, headline, comp:Astellas, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9081</link>
<description>Failure of Takeda's TAK-700 in Post-Chemo mCRPC [comp:Takeda, dis:Prostate, headline, comp:Astellas, prod:Zytiga]</description><category>comp:Takeda</category><category>dis:Prostate</category><category>headline</category><category>comp:Astellas</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9081</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9081">Failure of Takeda's TAK-700 in Post-Chemo mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9081">Oncology9081</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 July 2013 | 13:48</font><br><br><div style="margin-bottom: 10px;">Comment: Takeda has halted its ELM-PC 5 study due to futility for OS at interim analysis.<wbr> I<SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">n May the company characterized orteronel as one of its priority Ph3 projects.<wbr> The results therefore mark a setback in the post-chemo indication at least.<wbr> The missed endpoint may also allow Astellas/<wbr>Medivation's Xtandi (enzalutamide) to move further ahead in the post-chemo mCRPC setting, for which the product was recently approved in EU and is already marketed in the US.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Findings of the Pre-specified Interim Analysis</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3">- </FONT>Orteronel plus prednisone would likely not meet the primary endpoint of improved overall survival (OS) when compared to the control arm (HR 0.<wbr>894, p=0.<wbr>226).<wbr> </div><div style="margin-bottom: 10px;">- Advantage for orteronel plus prednisone for the secondary endpoint, radiographic progression-free survival (rPFS) over the control arm (HR 0.<wbr>755, p=0.<wbr>00029).<wbr> </div><div style="margin-bottom: 10px;">- No safety concerns.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Impact on Other Ongoing Studies</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management reported that the decision to unblind the <STRONG>ELM-PC 5 study</STRONG> is not expected to impact other ongoing company-sponsored clinical trials with orteronel, including the <STRONG>ELM-PC 4</STRONG> pivotal Ph3 study (C21004) comparing orteronel plus prednisone to placebo plus prednisone in patients with chemotherapy-naive mCRPC.<wbr> </div><div style="margin-bottom: 10px;">&gt; About ELM-PC 5 (C21005) <A href="http://clinicaltrials.gov/ct2/show/NCT01193257?term=C21005&amp;rank=1">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01193257?term=C21005&amp;rank=1</A> </div><div style="margin-bottom: 10px;">&gt; About ELM-PC 4 (C21004) <A href="http://clinicaltrials.gov/ct2/show/NCT01193244?term=c21004&amp;rank=1">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01193244?term=c21004&amp;rank=1</A> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- Interim analysis not expected until 2014 (based on comments from Takeda and posted information on the study).<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Competition with Medivation's Xtandi</STRONG></FONT> </div><div style="margin-bottom: 10px;">Analysts at JMP Securities expect interim data for Xtandi in <A href="http://clinicaltrials.gov/ct2/show/NCT01212991?term=prevail&amp;rank=6">PREVAIL</A> in 3Q13, although Medivation has guided to YE13 (survival benefit has already been proven in the post-chemo setting).<wbr> </div><div><EM>Source: Takeda; JMP Securities</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9081">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-26T13:48:22+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Will Recent Events Impact GSK Business in China ? [sub:Finance, mkt:China, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10525</link>
<description>Will Recent Events Impact GSK Business in China ? [sub:Finance, mkt:China, mkt:Intercontinental]</description><category>sub:Finance</category><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10525</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10525">Will Recent Events Impact GSK Business in China ?</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10525">PharmaWorld10525</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 July 2013 | 11:36</font><br><br><div style="margin-bottom: 10px;">Comment: GSK has appointed one of its top European executives as the new head of operations in China.<wbr> Herve Gisserot, senior vice president for Europe, will take over as general manager from Mark Reilly.<wbr> During Q2 financial results, management reported that although ' .<wbr>.<wbr>.<wbr> we are likely to see some impact to our performance in China', ' .<wbr>.<wbr>.<wbr> the guidance remains unchanged for the full year of earnings per share growth of 3 to 4% and sales growth of around 1%".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Q&amp;A Around Chinese Bribery Case</FONT></STRONG> </div><div style="margin-bottom: 10px;">It was made clear that the charges at this stage are primarily against individuals, who acted without corporate consent.<wbr> </div><div style="margin-bottom: 10px;">It seems there are currently no charges against GSK for economic damages (i.<wbr>e.<wbr> distorted drug pricing or similar).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Group Performance</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10525/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10525attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10525/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10525">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-26T11:36:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10525/1/ScreenCapture1.jpg" length="59990" type="image/jpeg"/></item><item>
<title>Exelixis to Start Registration Trial with Cabozantinib in 2nd-line HCC [:PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9080</link>
<description>Exelixis to Start Registration Trial with Cabozantinib in 2nd-line HCC [:PharmaWorld:sub:ClinicalTrial]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9080</comments><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9080</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9080">Exelixis to Start Registration Trial with Cabozantinib in 2nd-line HCC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9080">Oncology9080</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 July 2013 | 18:41</font><br><br><div style="margin-bottom: 10px;">Comment: Advancing the cabozantinib franchise in pivotal trials for HCC is one of the company key priorities.<wbr> The study is to assess the effect of the drug vs placebo on OS (as primary endpoint) in approx 760 patients with advanced HCC who have received prior sorafenib.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Details of the Study </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01908426?recr=Open&amp;fund=2&amp;rcv_s=06%2F25%2F2013&amp;rank=88"><STRONG><FONT size="3">NCT01908426</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Aug 2013 - Completion date: October 2016 </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures </DIV> </div><div><DIV class="body3">
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Progression-Free Survival (PFS) [ Time Frame: Up to 38 months ] [ Designated as safety issue: No ] 
Duration of PFS is defined as the time of randomization to the earlier of the following events: progressive disease or death due to any cause.<wbr>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Objective Response Rate (ORR) [ Time Frame: Up to 38 months ] [ Designated as safety issue: No ] 
ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment.<wbr> ORR is the proportion of subjects experiencing a confirmed complete response(CR) or confirmed partial response (PR).<wbr></LI>
</UL></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9156c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The company has reported it has initiated CELESTIAL, with Ghassan K.<wbr> Abou-Alfa, M.<wbr>D.<wbr>, (Associate Attending at Memorial Sloan-Kettering Cancer Center, New York) as lead investigator.<wbr> CELESTIAL is the fifth pivotal trial for cabozantinib overall, and the second phase 3 trial to initiate this year.<wbr> It was designed with the input of leading oncologists and HCC experts.<wbr> Additional details are provided below.<wbr> </div><div style="margin-bottom: 10px;">Locations: up to 200 sites globally in up to 30 countries.<wbr> </div><div style="margin-bottom: 10px;">Protocol: Patients will be randomized 2:1 to receive 60 mg of cabozantinib daily or placebo.<wbr> </div><div>Exploratory endpoints include patient-reported outcomes, biomarkers, and safety.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9156" class="commentpermalink">Oncology9156</a> / <span class="date">10 September 2013</span> /
<span class="time">14:30:56 o'clock CEST</span>
</font></div><a name="oncology9080attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9080/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(64,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9080">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-25T18:41:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9080/1/ScreenCapture1.jpg" length="65860" type="image/jpeg"/></item><item>
<title>New NICE Guidance Supports Routine Use of SIRT [headline, :PharmaWorld:mkt:UK]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7411</link>
<description>New NICE Guidance Supports Routine Use of SIRT [headline, :PharmaWorld:mkt:UK]</description><category>headline</category><category>mkt:UK</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7411</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7411">New NICE Guidance Supports Routine Use of SIRT</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7411">Endocrinology7411</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 July 2013 | 17:45</font><br><br><div style="margin-bottom: 10px;">Comment: The NICE guidance, released on 24<SUP>th</SUP> July 2013, confirmed that the scientific evidence of the safety and efficacy of SIRT for patients with HCC is now considered adequate, which means that eligible National Health Service (NHS) patients are now likely to have access to this treatment.<wbr>This decision should improve access to Sirtex' SIR-Spheres microspheres.<wbr> </div><div style="margin-bottom: 10px;"><P class="c4"><STRONG><FONT size="3">References</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">National Institute for Health and Clinical Excellence.<wbr> </div><div style="margin-bottom: 10px;">Selective internal radiation therapy for primary hepatocellular carcinoma (Interventional Procedure Guidance 460).<wbr> London: NICE, July 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline Evolution</FONT></STRONG> </div><div style="margin-bottom: 10px;">Early stage R&amp;D programs include radioprotector technology that seeks to protect healthy tissue from ionising radiation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Further Information</FONT></STRONG> </div><div style="margin-bottom: 10px;">SIR-Spheres microspheres are a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy (SIRT) to the liver.<wbr> </div><div style="margin-bottom: 10px;">SIR-Spheres microspheres were approved in Europe in 2002, and &gt;500 patients have received this treatment in Britain.<wbr> </div><div style="margin-bottom: 10px;"><P class="c4"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7411/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="c4"><STRONG><FONT size="3">Clinical Studies</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="c4">Sirtex is investing $60 million over five years into five major Post Marketing Clinical Studies involving leading institutions and 2,000 patients.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="c4">They are designed to demonstrate SIR-Spheres microspheres efficacy as a first-line treatment with three of the studies focused on metastatic colorectal cancer and two studies focused on hepatocellular carcinoma.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="c4">This global clinical studies program is expected to underpin the longterm growth potential of Sirtex with clinical data from the first study expected to be released in late 2014 or early 2015 and the remainder released progressively over the following few years.<wbr></P> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7411/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7411attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7411/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(17 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7411/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(59,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7411">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-25T17:45:59+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7411/1/ScreenCapture1.jpg" length="17457" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7411/2/ScreenCapture2.jpg" length="61105" type="image/jpeg"/></item><item>
<title>Roche Reports HY 2013 Results and Confirms FY Targets [comp:Roche, :Oncology:dis:Prostate, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7407</link>
<description>Roche Reports HY 2013 Results and Confirms FY Targets [comp:Roche, :Oncology:dis:Prostate, :PharmaWorld:sub:Finance]</description><category>comp:Roche</category><category>dis:Prostate</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7407</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7407">Roche Reports HY 2013 Results and Confirms FY Targets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7407">Endocrinology7407</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 July 2013 | 14:05</font><br><br><div style="margin-bottom: 10px;">Comment: Pharma sales rose 6%.<wbr> Performance was driven by US, Oncology, Tamiflu and Actemra.<wbr> Company stressed that emerging markets remain strong.<wbr> In the presentation, we have noted 3 drugs in development for prostate cancer (RG7450 Steap1 ADC in Ph1; PI3 Kinase/<wbr>mTOR dual inhibitor Ph1b/<wbr>2; RG7440 AKT inhibitor in Ph1b/<wbr>2).<wbr> The oral octreotide RG3806, currently in Ph3, is anticipated to be submitted in 2014.<wbr> Interestingly, management did not comment on the drug.<wbr> Of note, no question araised from the investors as well.<wbr> <FONT size="3"><FONT face="Calibri">Presented below are a selection of key slides.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Presenters</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL class="bullet-list"><LI>Severin Schwan, CEO Roche Group</LI>
<LI>Alan Hippe, Chief Financial and IT Officer</LI>
<LI>Daniel O'Day, COO Pharmaceuticals</LI>
<LI>Roland Diggelmann, COO Diagnostics</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Figures - Pharma Sales</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Oncology Franchise</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Oncology Focus</FONT></STRONG> </div><div style="margin-bottom: 10px;">Interest focused on GA101 which beats Rituxan (MabThera) in a late-stage trial, prompting hopes it is a viable successor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Genentech - Prostate Drugs in Development</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Antibody Drug Conjugates</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Small Molecules</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/7/ScreenCapture7.jpg?user-agent=rss"> </div><div><EM>Source: Roche HY2013 Presentation</EM> </div><!-- Comment details --><a name="endocrinology7407attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(38,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7407">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-25T14:05:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/1/ScreenCapture1.jpg" length="39029" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7407/3/ScreenCapture3.jpg" length="39769" type="image/jpeg"/></item><item>
<title>Lonza and Teva Discontinue Biosimilar JV [sub:Termination]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10523</link>
<description>Lonza and Teva Discontinue Biosimilar JV [sub:Termination]</description><category>sub:Termination</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10523</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10523">Lonza and Teva Discontinue Biosimilar JV</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aTermination"><font color="#e95e0b">:PharmaWorld:sub:Termination</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10523">PharmaWorld10523</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 July 2013 | 11:46</font><br><br><div style="margin-bottom: 10px;">Comment: The companies have decided to discontinue Teva-Lonza JV, which began in 2009.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Teva</FONT></STRONG> </div><div style="margin-bottom: 10px;">- To continue its biologics strategy and create a balanced portfolio of biosimilars, biobetters and innovative biologics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Lonza</FONT></STRONG> </div><div style="margin-bottom: 10px;">- To focus on core expertise in contract manufacturing and cell line development </div><div style="margin-bottom: 10px;">- To cease investing in non-strategic areas </div><div><EM>Source: Teva; Lonza</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10523">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-25T11:46:05+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Recordati Expands Business in Tunisia [mkt:Intercontinental, sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10522</link>
<description>Recordati Expands Business in Tunisia [mkt:Intercontinental, sub:Acquisition]</description><category>mkt:Intercontinental</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10522</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10522">Recordati Expands Business in Tunisia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10522">PharmaWorld10522</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 July 2013 | 17:17</font><br><br><div style="margin-bottom: 10px;">Comment: Recordati has acquired Opalia Pharma for around €37M.<wbr> The company ranks eighth in the Tunisian pharmaceutical market and is the third largest local pharmaceutical company.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Recordati</FONT></STRONG> </div><div style="margin-bottom: 10px;">Recordati is already generating significant and growing revenue from its export sales in the North African countries.<wbr> </div><div style="margin-bottom: 10px;">This acquisition represents a strategic platform to establish a direct presence in this area with the objective of extending coverage also to countries in Central Africa and in the Gulf states.<wbr> </div><div style="margin-bottom: 10px;">Recordati will gain access to branded generic drugs with leading products in dermatology, gastroenterology and respiratory.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Opalia SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Opalia manufactures most of its products in a modern, cGMP certified production facility specialized in liquid and semi-solid forms.<wbr> The company employs 322 people and sales in 2013 are estimated to be of around TND 40 million (around EUR 18.<wbr>5 million).<wbr> </div><div><EM>Source: Recordati</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10522">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-24T17:17:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Study to Assess Xeomin in Children/Adolescents with CP [comp:Merz, dis:Palsy, :PharmaWorld:sub:ClinicalTrial, dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7079</link>
<description>New Study to Assess Xeomin in Children/Adolescents with CP [comp:Merz, dis:Palsy, :PharmaWorld:sub:ClinicalTrial, dis:Spasticity]</description><category>comp:Merz</category><category>dis:Palsy</category><category>sub:ClinicalTrial</category><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7079</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7079">New Study to Assess Xeomin in Children/<wbr>Adolescents with CP</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7079">Neurology7079</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 July 2013 | 17:05</font><br><br><div style="margin-bottom: 10px;">Comment: The purpose of this Ph3 study is to determine whether injections of the toxin into muscles of the leg(s) or of leg(s) and one arm are safe in treating children/<wbr>adolescents long-term with spasticity due to cerebral palsy.<wbr> PE will assess the occurrence of treatment emergent adverse events.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01905683?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=06%2F24%2F2013&amp;rank=244"><STRONG><FONT size="3">NCT01905683</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Est Enrollment: 360 (female or male subject of 2 to 17 years age) </div><div style="margin-bottom: 10px;">Start date: July 2013 - Completion: Sept 2016.<wbr> </div><div>Location: 16 countries listed </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7079">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-24T17:05:04+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Corcept Partners with Idis to Give Physicians Global Access to Korlym(R) [dis:Cushing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7406</link>
<description>Corcept Partners with Idis to Give Physicians Global Access to Korlym(R) [dis:Cushing]</description><category>dis:Cushing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7406</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7406">Corcept Partners with Idis to Give Physicians Global Access to Korlym(R)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7406">Endocrinology7406</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 July 2013 | 16:08</font><br><br><div style="margin-bottom: 10px;">Comment: Korlym<SUP>®</SUP> (mifepristone) 300 mg Tablets now is available to patients outside of the U.<wbr>S through an Idis Access Program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Status in the US</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company has been offering Korlym in the United States since April 2012 as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Idis</FONT></STRONG> </div><div style="margin-bottom: 10px;">Idis has 25 years experience partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs.<wbr> </div><div style="margin-bottom: 10px;">Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world.<wbr> </div><div style="margin-bottom: 10px;">Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product's lifecycle from pre-approval to market exit, and in times of unexpected production shortages.<wbr> </div><div style="margin-bottom: 10px;">The company's European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.idispharma.com">www.<wbr>idispharma.<wbr>com</A>.<wbr> </div><div>Source: Corcept </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7406">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-24T16:08:10+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Positive PC Data Generated by Inovio's 'Universal' Cancer Vaccine</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9079</link>
<description>Positive PC Data Generated by Inovio's 'Universal' Cancer Vaccine</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9079</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9079">Positive PC Data Generated by Inovio's 'Universal' Cancer Vaccine</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9079">Oncology9079</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 July 2013 | 15:50</font><br><br><div style="margin-bottom: 10px;">Comment:The engineered cancer vaccine targets human telomerase reverse transcriptase (hTERT).<wbr> High hTERT levels have been observed in an estimated 85% of all human cancers while they are rarely seen in normal cells.<wbr> Inovio already has a near-clinical-stage candidate for prostate cancer, INO-5150, in development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Technology</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9079/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9079/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA<SUP>®</SUP> adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="4">Data Results in Animals</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Publication: These results appear in the American Association for Cancer Research journal, <I>Cancer Immunology Research</I>, in a paper entitled: "Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity".<wbr> </div><div>- Findings: <A href="http://ir.inovio.com/2013-07-24-Inovio-Pharmaceuticals-Potent-hTERT-DNA-Cancer-Vaccine-Shows-Potential-to-Reduce-Tumors-and-Prevent-Tumor-Recurrence">http:/<wbr>/<wbr>ir.<wbr>inovio.<wbr>com/<wbr>2013-07-24-Inovio-Pharmaceuticals-Potent-hTERT-DNA-Cancer-Vaccine-Shows-Potential-to-Reduce-Tumors-and-Prevent-Tumor-Recurrence</A>.<wbr> </div><!-- Comment details --><a name="oncology9079attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9079/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9079/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(127 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9079">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-24T15:50:10+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9079/1/ScreenCapture1.jpg" length="69087" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9079/2/ScreenCapture2.jpg" length="130092" type="image/jpeg"/></item><item>
<title>Novartis and Roche Attendance at Annual Gathering on Nanomedicines (June 23-26 Basel) [:Endocrinology:comp:Roche, :Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10520</link>
<description>Novartis and Roche Attendance at Annual Gathering on Nanomedicines (June 23-26 Basel) [:Endocrinology:comp:Roche, :Endocrinology:comp:Novartis]</description><category>comp:Roche</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10520</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10520">Novartis and Roche Attendance at Annual Gathering on Nanomedicines (June 23-26 Basel)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10520">PharmaWorld10520</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 July 2013 | 18:12</font><br><br><div style="margin-bottom: 10px;">Comment: The event is seen as a unique forum for creative scientists to propose new ideas and for established research organizations, industries and funding organizations to provide opportunities for further growth of this area.<wbr> This year's focus topic was : "<SPAN style="COLOR: #3b50a3"><FONT color="#000000">Nanomedicine &amp; Targeted Medicine – the paradigm of precise, highly effective and safe medicine with subtle influence for the benefit of patients and mankind”.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Roche and Novartis Presentations</FONT></STRONG> </div><div style="margin-bottom: 10px;">- <STRONG>Nanotubes for Oral Dosage Forms?</STRONG> Dr.<wbr> Carsten Timpe, Pharma Early Research and Development Formulation, Research NCE Basel, Senior Principal Scientist, F.<wbr> Hoffmann-La Roche AG, Basel (CH).<wbr> </div><div style="margin-bottom: 10px;">Dr Andreas Fisch, Fellow Pharmaceutical Development Parenterals at Novartis presented "<STRONG>Pharmaceutical Development Stages of Parenteral Nanomedicine: from discovery to Clinical Ph1</STRONG>".<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Bernd Riebesehl, Principal Fellow Novartis Pharma AG chaired the session titled: <STRONG>Pharmaceutical Development - Requirements to Get from Drug Candidate Selection to Market.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Presentations of Selected Pharma Companies </FONT></STRONG> </div><div style="margin-bottom: 10px;">- <STRONG>Not yet Realized Nanoapplications For Transdermal Route</STRONG> Dr.<wbr> Michael Horstmann, Acino AG, Aesch (CH).<wbr> </div><div style="margin-bottom: 10px;">- <STRONG>Targeted and Personalized Cancer Therapy via Tumor Stroma-Attacking Nanodrugs</STRONG> Dr.<wbr> Neil P.<wbr> Desai, Senior Vice President, Global Research &amp; Development, Abraxis BioScience LLC, Los Angeles (USA).<wbr> </div><div style="margin-bottom: 10px;">- <STRONG>Glutathione PEGylated Liposomes: a Safe Way to Enhance Drug Delivery Across the Blood-brain Barrier</STRONG> Dr.<wbr> Marco de Boer, Head of Research, to-BBB technologies BV, Leiden (NL).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>- Critical Considerations in Development, Scale-up and Manufacturing of Injectable Nanomedicines</STRONG> Dr.<wbr> Danny van Hoorn, Program Manager, OctoPlus NV, Leiden (NL).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>- NBTXR3, a Real Nanotherapeutic in Phase I development for Patients with Soft Tissue Sarcoma</STRONG> Dr.<wbr> Laurent Lévy, PhD, CEO of Nanobiotix,Paris (F).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Congress Program</FONT></STRONG> </div><div style="margin-bottom: 10px;">Annual Gathering on Clinical Nanomedicine and Targeted Medicine (Basel June 23-26).<wbr> </div><div><A href="https://www.clinam.org/images/stories/pdf/conference.pdf">https:/<wbr>/<wbr>www.<wbr>clinam.<wbr>org/<wbr>images/<wbr>stories/<wbr>pdf/<wbr>conference.<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10520">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-23T18:12:19+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novartis Supports First Online Community Dedicated to pNET [dis:pNET, comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7403</link>
<description>Novartis Supports First Online Community Dedicated to pNET [dis:pNET, comp:Novartis]</description><category>dis:pNET</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7403</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7403">Novartis Supports First Online Community Dedicated to pNET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7403">Endocrinology7403</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 July 2013 | 15:38</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis will be the site's corporate sponsor of he Pancreatic Neuroendocrine Tumor (PNET) Support Community, a peer-to-peer support community for patients and carers from around the world to share information and support.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Site</FONT></STRONG> </div><div style="margin-bottom: 10px;">For patients affected by pancreatic neuroendocrine tumours (PNET).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7403/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7403/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><A href="http://www.inspire.com/groups/pancreatic-neuroendocrine-tumor-pnet">http:/<wbr>/<wbr>www.<wbr>inspire.<wbr>com/<wbr>groups/<wbr>pancreatic-neuroendocrine-tumor-pnet</A> </div><!-- Comment details --><a name="endocrinology7403attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7403/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7403/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(69,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7403">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-23T15:38:50+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7403/1/ScreenCapture1.jpg" length="33406" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7403/2/ScreenCapture2.jpg" length="71023" type="image/jpeg"/></item><item>
<title>Eckert &amp; Ziegler Radiopharma to Join Octreopharm GmbH [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7400</link>
<description>Eckert &amp; Ziegler Radiopharma to Join Octreopharm GmbH [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7400</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7400">Eckert & Ziegler Radiopharma to Join Octreopharm GmbH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7400">Endocrinology7400</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 July 2013 | 11:34</font><br><br><div style="margin-bottom: 10px;">Comment: Octreopharm, a private Chinese-German pharma development JV, has a peptide currently in PC development as a potential solution for the detection of neuroendocrine tumors using positron emission tomography (PET).<wbr> Depending on the radionuclide it is coupled with, it could be used both in diagnosing (gallium-68) and treating (yttrium-90) such tumors.<wbr> Phase 1 is expected to start towards the end of 2014.<wbr> </div><div style="margin-bottom: 10px;">In addition to Eckert &amp; Ziegler AG, several Venture Capital Companies, a number of industry experts and Chinese investor Shaanxi Xinyida Investment Co.<wbr> Ltd.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="ii" id="endocrinology6682.05ii">Octreopharm is on the lookout for collaborations with pharmaceutical companies which focus on products for personalized medicine and new therapeutic agents.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="ii"><STRONG><FONT size="3">Comment of the Franchise</FONT></STRONG> </DIV> </div><div style="margin-bottom: 10px;"><DIV class="ii">This move shows a growing interest in radioactively labeled pharmaceuticals for NETs.<wbr> </DIV> </div><div style="margin-bottom: 10px;"><DIV class="ii">Octreopharm's project, still at a <STRONG>very early stage</STRONG> of development, has attracted the interest of one of the world's largest providers of isotope technology for medical, scientific and industrial use.<wbr></DIV> </div><div><DIV class="ii"><EM>Source: Eckert &amp; Ziegler AG</EM></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7400">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-23T11:34:41+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Actavis Considering Selling Western EU Activities [mkt:Europe, mkt:Italy, mkt:Spain, mkt:France, mkt:Germany]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10515</link>
<description>Actavis Considering Selling Western EU Activities [mkt:Europe, mkt:Italy, mkt:Spain, mkt:France, mkt:Germany]</description><category>mkt:Europe</category><category>mkt:Italy</category><category>mkt:Spain</category><category>mkt:France</category><category>mkt:Germany</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10515</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10515">Actavis Considering Selling Western EU Activities</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aFrance"><font color="#e95e0b">:PharmaWorld:mkt:France</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aItaly"><font color="#e95e0b">:PharmaWorld:mkt:Italy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aSpain"><font color="#e95e0b">:PharmaWorld:mkt:Spain</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10515">PharmaWorld10515</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 July 2013 | 14:12</font><br><br><div style="margin-bottom: 10px;">Comment: The company has mandated Rothschild to advise on the sale of units in Italy, Spain, France, Germany and the Netherlands.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">- The units in question have annual sales of slightly over €300M and posted a slight loss.<wbr> The planned sale comes because these activities haven't met a target of a 20% operating margin.<wbr> </div><div style="margin-bottom: 10px;">- To improve profitability after the acquisition of Warner Chilcott (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10453" class="defaultlink">PharmaWorld10453: Actavis Acquires Warner Chilcott</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10515/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: the WSJ</EM> </div><!-- Comment details --><a name="pharmaworld10515attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10515/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(87,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10515">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-22T14:12:39+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10515/1/ScreenCapture1.jpg" length="89507" type="image/jpeg"/></item><item>
<title>Merz North America Reinforce Dermatology Business [comp:Merz, sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7077</link>
<description>Merz North America Reinforce Dermatology Business [comp:Merz, sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica]</description><category>comp:Merz</category><category>sub:Aesthetics</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7077</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7077">Merz North America Reinforce Dermatology Business</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7077">Neurology7077</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 July 2013 | 11:21</font><br><br><div style="margin-bottom: 10px;">Comment: The company has acquired deoxyArbutin (skin-lightening agent) from Lasya Inc.<wbr>, and announced a collaboration with Foamix Ltd (to develop and commercialize an innovative medicated topical foam).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Merz North America's ambitions is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Foamix Mini Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="2">Foamix develops innovative topical foam products for dermatology and gynecology.<wbr> The company partners with global pharmaceutical companies to create patent protected topical products with a variety of drugs including new chemical entities.<wbr> Advantages of Foamix foam products include increased permeability and drug delivery, convenient form of presentation preferred by users, and enhanced efficacy in clinical studies.<wbr></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Lasya Mini Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Lasya, Incorporated, a 25 million dollar company, has offices in Cincinnati, OH and the Research Triangle Park, NC and is a research-based beauty care corporation that is committed to improving the lives of its customers as well as supporting the Cincinnati Children’s Hospital Medical Center.<wbr> A portion of every sale goes to support medical research for children.<wbr> The management team of Lasya, Incorporated has a combined total of over eighty years of skin science research and product development experience and together hold over 50 patents and patent applications.<wbr> </div><div><EM>Source: Merz NA</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7077">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-22T11:21:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>World’s First Toxin-free Treatment for Dynamic Wrinkles Approved in Canada [sub:Aesthetics, :PharmaWorld:sub:Devices, :PharmaWorld:Alert, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7073</link>
<description>World’s First Toxin-free Treatment for Dynamic Wrinkles Approved in Canada [sub:Aesthetics, :PharmaWorld:sub:Devices, :PharmaWorld:Alert, :PharmaWorld:mkt:Canada]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7073</comments><category>sub:Aesthetics</category><category>sub:Devices</category><category>Alert</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7073</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7073">World’s First Toxin-free Treatment for Dynamic Wrinkles Approved in Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:PharmaWorld:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7073">Neurology7073</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 July 2013 | 14:56</font><br><br><div style="margin-bottom: 10px;">Comment: Myoscience's iovera˚ has received regulatory approval in Canada.<wbr> The company presented the EU launch of the treatment at the IMCAS in Paris (Jan-Feb 2013), and AMWC in Monaco (April 2013).<wbr> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none"><STRONG><FONT size="3">Testimony</FONT></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">In his clinic in Paris, France, Dr.<wbr> Patrick Trevidic says: “I know from experience that there are patients who have hesitations about using botulinum toxin.<wbr> They still want to treat their wrinkles : iovera˚ for these patients is a more comfortable option because it injects nothing into the body.<wbr> .<wbr>.<wbr> Best of all the results are seen immediately which is very exciting.<wbr>”</DIV> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>Dr Yannis Alexandrides is one of the first physicians in the UK to be trained in and offer the new iovera toxin-free wrinkle treatment.<wbr></P></DIV> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none"><STRONG><FONT size="3">Technology - Focused Cold Therapy (FCT)</FONT></STRONG></DIV> </div><div style="margin-bottom: 10px;">The treatment is based upon myoscience’s platformtechnology, Focused Cold Therapy ™.<wbr> It works by using the body’s natural response to cold to temporarily relax the facial muscles that cause wrinkles.<wbr> </div><div style="margin-bottom: 10px;">The device delivers a precise cold dose to induce only 2nd Degree Wallerian Degeneration (2DWD).<wbr> </div><div style="margin-bottom: 10px;"><U>Characteristics</U>: simple, intuitive, IP protected, single patient use tips and reusable hand piece.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7073/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7073/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><EM>Source: Myoscience</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7148c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Myoscience has reported that the iovera<STRONG>*</STRONG> treatment is now available from the Vancouver Cosmetic Medicine and Dermatology Clinic, Doctors Alastair and Jean Carruthers and Doctor Shannon Humphrey.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Testimonies</STRONG> </div><div style="margin-bottom: 10px;">Doctor Jean Carruthers feels iovera˚ will be an important new tool for doctors that want to offer patients options, "We are all familiar with the safety and efficacy of cosmetic neuromodulation using neurotoxins.<wbr> The iovera˚ technology is a totally new approach to reducing wrinkles by treating nerves with cold.<wbr> After some months, the nerves recover and retreatment may be desired.<wbr>" </div><div>Doctor Shannon Humphrey is enthusiastic to be one of the first to offer the iovera˚ treatment, "iovera provides us with a new alternative to treat forehead wrinkles in a natural way that provides immediate results, something we feel many patients will find appealing.<wbr>" </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7148" class="commentpermalink">Neurology7148</a> / <span class="date">17 September 2013</span> /
<span class="time">18:20:11 o'clock CEST</span>
</font></div><a name="neurology7073attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7073/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(8,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7073">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-19T14:56:59+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7073/1/ScreenCapture1.jpg" length="8545" type="image/jpeg"/></item><item>
<title>Insights into Azedra(R) from Progenics' R&amp;D Day</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7398</link>
<description>Insights into Azedra(R) from Progenics' R&amp;D Day</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7398</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7398">Insights into Azedra(R) from Progenics' R&D Day</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7398">Endocrinology7398</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 July 2013 | 13:56</font><br><br><div style="margin-bottom: 10px;">Comment: Presented as the "late-stage, ultra-orphan neuroendocrine cancer opportunity" by the company, Azedra(R) uses the validated tumor-killing activity of I-131.<wbr> Clinical development indications include pheochromocytoma/<wbr>paraganglioma (ongoing resgistration study in the U.<wbr>S under SPA /<wbr> PE for efficacy achieved), neuroblastoma and carcinoid.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background and Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Application in Multiple Neuroendocrine Tumor Indications</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results in High-Risk Neuroblastoma Ph2a Single Dose MTD Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development Summary</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Azedra - Snapshot of Current/<wbr>Future Treatment Centers</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7398attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(51,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(47,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(60 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7398">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-19T13:56:13+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/1/ScreenCapture1.jpg" length="30242" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/2/ScreenCapture2.jpg" length="62091" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/3/ScreenCapture3.jpg" length="52741" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/4/ScreenCapture4.jpg" length="51171" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/5/ScreenCapture5.jpg" length="48487" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7398/6/ScreenCapture6.jpg" length="61394" type="image/jpeg"/></item><item>
<title>UCB's Shanghai Offices Visited by Chinese Authorities [mkt:China, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10511</link>
<description>UCB's Shanghai Offices Visited by Chinese Authorities [mkt:China, mkt:Intercontinental]</description><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10511</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10511">UCB's Shanghai Offices Visited by Chinese Authorities</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10511">PharmaWorld10511</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 July 2013 | 10:11</font><br><br><div style="margin-bottom: 10px;">Comment: The company reported that officials were also investigating a "number of other drug companies with operations in the country".<wbr> The officials were from the State Administration for Industry and Commerce (SAIC), and were seeking information on compliance.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Importance of China</FONT></STRONG> </div><div style="margin-bottom: 10px;">China is increasingly important for big drugmakers, which rely on growth in emerging markets to offset slower sales in Western markets.<wbr> </div><div style="margin-bottom: 10px;">IMS Health, which tracks pharmaceutical industry trends, expects China to overtake Japan as the world's second-biggest drugs market behind the United States by 2016.<wbr> </div><div><EM>Source: Thomson One</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10511">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-19T10:11:10+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>IND for Genmab's HuMax(R)-TF-ADC Submitted to FDA [dis:Bladder, dis:Gynea, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9077</link>
<description>IND for Genmab's HuMax(R)-TF-ADC Submitted to FDA [dis:Bladder, dis:Gynea, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Bladder</category><category>dis:Gynea</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9077</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9077">IND for Genmab's HuMax(R)-TF-ADC Submitted to FDA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9077">Oncology9077</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 July 2013 | 18:08</font><br><br><div style="margin-bottom: 10px;">Comment: Patient recruitment in clinical trial is expected to begin this year.<wbr> A maximum of 78 patients with cancer of the ovary, cervix, endometrium, bladder, prostate, head &amp; neck, esophagus or lung that have failed or are not eligible for standard treatments will be enrolled in the study.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>About HuMax-TF-ADC</STRONG></FONT> </div><div style="margin-bottom: 10px;">HuMax-TF-ADC is an antibody-drug conjugate (ADC) composed of a human antibody against tissue factor (TF) conjugated to the cytotoxic drug monomethyl auristatin E (MMAE).<wbr> </div><div style="margin-bottom: 10px;">HuMax-TF-ADC is being developed for the treatment of solid cancers.<wbr> TF is an attractive tumor target because of its high expression in a broad range of solid cancers.<wbr> After binding to TF, HuMax-TF-ADC enters the tumor cells where the cytotoxic agent is specifically released, leading to cell death.<wbr> </div><div style="margin-bottom: 10px;">HuMax-TF-ADC was demonstrated to have potent anti-tumor activity in <EM>in vivo</EM> studies in mouse models in which a diverse panel of patient-derived tumors was assessed.<wbr> HuMax?TF?ADC was shown to have an acceptable safety profile in non-clinical safety studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partnering/<wbr>Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;">Genmab is developing HuMax-TF-ADC using Seattle Genetics' ADC technology under an agreement between the companies.<wbr> </div><div style="margin-bottom: 10px;">Seattle Genetics may elect to co-develop HuMax-TF-ADC with Genmab at the end of Phase I clinical development.<wbr> </div><div><EM>Source: Genmab</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9077">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-18T18:08:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novartis Reports Solid Set of Numbers for Q2/H1 2013 [dis:BronchioNET, dis:MidGutNET, dis:Acromegaly, comp:Novartis, dis:Cushing, headline, :Oncology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7397</link>
<description>Novartis Reports Solid Set of Numbers for Q2/H1 2013 [dis:BronchioNET, dis:MidGutNET, dis:Acromegaly, comp:Novartis, dis:Cushing, headline, :Oncology:comp:Novartis]</description><category>dis:BronchioNET</category><category>dis:MidGutNET</category><category>dis:Acromegaly</category><category>comp:Novartis</category><category>dis:Cushing</category><category>headline</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7397</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7397">Novartis Reports Solid Set of Numbers for Q2/<wbr>H1 2013</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aBronchioNET"><font color="#e95e0b">:Endocrinology:dis:BronchioNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7397">Endocrinology7397</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 July 2013 | 15:15</font><br><br><div style="margin-bottom: 10px;"><FONT size="2">Comment: Novartis delivered growth across all four divisions in Q2.<wbr> Net sales increased +3% (in cc) to $14.<wbr>5 billion.<wbr> Pharma sales (+1% in cc) to $8 121M and Sandoz sales (+3%) to $2 216M.<wbr> </FONT><FONT size="2">Much of the pressure from Diovan <SPAN style="BACKGROUND-COLOR: #ffffff">generics will be pushed into 2014.<wbr> </SPAN>Emerging Market growth was led by China (+25% in cc) and Russia (+18% in cc).<wbr> Brazil was highlighted being a 'big market' for Novartis.<wbr> As presented in the last slide, filing of Signifor LAR for acromegaly is expected this year.<wbr> In 2015 the company plans to file Afinitor for non-functioning GI and lung NETs.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">Given the problems GSK is facing </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in China, management stressed they are confident with the company compliance </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">structure in the country.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Key messages from the Q&amp;A session are provided below.<wbr></SPAN></FONT> </div><div style="margin-bottom: 10px;"><STRONG>Participants from Novartis</STRONG> </div><div style="margin-bottom: 10px;"><U>Harry Kirsh</U>, CFO, <SPAN style="BACKGROUND-COLOR: #ffffff"><U>David Epstein</U>, Pharma, <U>Kevin Buehler, Jeff George</U>, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Sandoz, <U>Andrin Oswald, George Gun</U>, Animal Health, <U>Brian </U></SPAN><SPAN style="BACKGROUND-COLOR: #ffffff"><U>McNamara</U>, OTC, and <U>Tim Wright</U>, Head of Development.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #ffaaaa">Sandoz Outperformes Market in Most Key Regions</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT style="BACKGROUND-COLOR: #ffffff">Growth pretty well distributed :</FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #ffaaaa">Emerging Markets Growth</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT style="BACKGROUND-COLOR: #ffffff">Business continues to strengthen vs prior year :</FONT> </div><div style="margin-bottom: 10px;"><FONT size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/2/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><STRONG>Dynamic in China</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #ffaaaa">Planned Filings 2013 to 2017</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Filing of <STRONG>LCI699</STRONG> is planned in 2016 for Cushing.<wbr> The drug is a new aldosterone synthase inhibitor.<wbr> Novartis gained access to this programme through the purchase of Speedel AG in 2008.<wbr> (see ongoing trial @ <A href="http://clinicaltrials.gov/show/NCT01331239">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>show/<wbr>NCT01331239</A>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #ffaaaa">Key Messages from Q&amp;A Session</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>China compliance</STRONG> : " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">Now in terms of compliance obviously we have spent </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">a lot of time and money training from a compliance </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">standpoint and this has been a particular area of focus </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">over the last 24 months.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">As always we say this all the time that we have thousands </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">of employees and whenever no matter how much training </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">you do there could always be areas of bad behavior.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">As soon as we find that bad behavior we root it out </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">and we act on it and we would not be any different </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in China than we would be in any part of the world </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">so I'm confident that as long as the Markets in China </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">continue to grow like they're growing we're going to continue to see growth.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Maybe not 25% every quarter but my expectation is </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">we'll be ahead of market".<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><STRONG>Countries where </STRONG><SPAN style="BACKGROUND-COLOR: #ffffff"><STRONG>Sandoz have experienced a main pricing pressure</STRONG> </SPAN>: " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">In terms of specific countries where we see price </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">erosion I would say it's really year specific in Europe, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">depends on who takes price cuts.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">We saw 10% price cut in Switzerland this year.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Spain has been hit hard which has gone to a tendering </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">system so that's caused massive double digit price </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">erosion in that market and other years we've seen it </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in Italy and France and elsewhere.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Two other markets that I say where price erosion is </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">a bit higher would be Australia and Canada both impacted </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">by higher Constitution and higher gross to net spreads </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in terms of price erosion".<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><STRONG>D Vasella Contract</STRONG>:  " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">I would like Dan to continue his mentoring programs </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">which have been very impact full for a lot of our junior </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">people around the world.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">You ran the Company for a lot of years, got a lot </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">of good leadership, knowledge and ability and our people </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">get a lot out of it so I've asked him to continue to </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">do that but beyond that obviously, there would not </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">be any involvement because as you read from the Press </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Release you will not be attending the Board meetings </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">nor getting the Board minutes".<wbr></SPAN></SPAN></SPAN> </div><div><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"><EM>Source: Novartis Webcast and Q2:13 Presentation</EM></SPAN></SPAN></SPAN> </div><!-- Comment details --><a name="endocrinology7397attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(165,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(65,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7397">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-17T15:15:16+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/1/ScreenCapture1.jpg" length="72464" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/2/ScreenCapture2.jpg" length="38746" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/3/ScreenCapture3.jpg" length="169851" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7397/4/ScreenCapture4.jpg" length="66716" type="image/jpeg"/></item><item>
<title>Strong Results of J&amp;J Pharma Business in 2Q:13 [comp:JnJ, dis:Prostate, prod:Zytiga, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9074</link>
<description>Strong Results of J&amp;J Pharma Business in 2Q:13 [comp:JnJ, dis:Prostate, prod:Zytiga, headline]</description><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9074</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9074">Strong Results of J&J Pharma Business in 2Q:13</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9074">Oncology9074</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 July 2013 | 16:59</font><br><br><div style="margin-bottom: 10px;">Comment: WW Pharma sales of $7.<wbr>0 billion for the second quarter represented an increase of 11.<wbr>7% versus the prior year ($6.<wbr>3 billion).<wbr> By product category, Immunology sales (+17.<wbr>6%), Infectious Diseases (+23.<wbr>9%), Oncology (+53.<wbr>2%), and Neurosciences (+0.<wbr>4%).<wbr> Zytiga continues strong growth to $395M (from $232M for Q2:12), fueled by December approval of chemo na&iuml;ve indication (45% of the drug sales), and country rollouts.<wbr> Business practices in China were reported by management as being "run in a highly compliant manner , with very active compliance program in place".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Messages</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">ZYTIGA Business</SPAN> </div><div style="margin-bottom: 10px;">In the quarters ZYTIGA achieved operational sales growth of 70% with U.<wbr>S.<wbr> sales growing 54% due to very strong market growth of over 20% and increased market share in the combined metastatic castrate resistant prostate cancer market.<wbr> ZYTIGA has captured over 30% of that market and is up approximately 3.<wbr>5 points sequentially.<wbr> </div><div style="margin-bottom: 10px;">Operational sales outside the U.<wbr>S.<wbr> grew 85.<wbr>2% versus second quarter 2012 and on a sequential basis ZYTIGA was up over 20%.<wbr>  ZYTIGA is approved in more than 80 countries.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Positionning of Zytiga and Aragon's ARN-509</SPAN> </div><div style="margin-bottom: 10px;">Management reported that " .<wbr>.<wbr>.<wbr> We think it&rsquo;s a great complement to our portfolio.<wbr> If you look at the great job frankly that our team has been able to do with ZYTIGA, in the launch, regarding the clinical &ndash; I should backup.<wbr> Actually the actual approval of the compound, the ongoing clinical development, very impressive, the commercial penetration that we&rsquo;ve seen as well as the care programs for patients, we think it represents a significant capability.<wbr>" " .<wbr>.<wbr>.<wbr> And now when you complement that with the Aragon compound it will certainly enable us to leverage all of those skills onto a next phase.<wbr> We think that there could be potentially complementary utilization of both compounds together.<wbr> And again, as another example of us continuing to really make a difference for patients and for our business in this very exciting oncology area".<wbr> </div><div><EM>Source: J&amp;J Webcast</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9074">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-16T16:59:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Intarcia Has Started Registration Trials of its GLP-1 6/12-Month Implant [class:GLP1, dis:Diabetes, :PharmaWorld:sub:DrugDelivery]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7394</link>
<description>Intarcia Has Started Registration Trials of its GLP-1 6/12-Month Implant [class:GLP1, dis:Diabetes, :PharmaWorld:sub:DrugDelivery]</description><category>class:GLP1</category><category>dis:Diabetes</category><category>sub:DrugDelivery</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7394</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7394">Intarcia Has Started Registration Trials of its GLP-1 6/<wbr>12-Month Implant</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7394">Endocrinology7394</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 July 2013 | 11:43</font><br><br><div style="margin-bottom: 10px;">Comment: ITCA 650 is a continuous subcutaneous delivery of exenatide in Intarcia's DUROS&reg; delivery device (technology validated for the delivery of leuprolide as Viadur&reg;).<wbr> The four Ph3 trials (detailed below) will be recruiting approx.<wbr> 3,000 participants.<wbr> In 2011, Intarcia selected Quintiles to develop the implant WW.<wbr> Commercialization partner(s) with significant diabetes expertise is/<wbr>are sought.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ITCA 650 Characteristics/<wbr>Description</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Technology</SPAN> </div><div style="margin-bottom: 10px;"><A href="http://www.intarcia.com/products-technology/intarcia-platform-technology.html">http:/<wbr>/<wbr>www.<wbr>intarcia.<wbr>com/<wbr>products-technology/<wbr>intarcia-platform-technology.<wbr>html</A> </div><div style="margin-bottom: 10px;">DUROS&reg; delivery device is a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Intellectual Property</SPAN> </div><div style="margin-bottom: 10px;">Patent Protected through 2027.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trials Details</STRONG> </div><div style="margin-bottom: 10px;"><a href="http://clinicaltrials.gov/ct2/show/NCT01455896?term=intarcia&recr=Open&rank=3&submit_fld_opt=" class="defaultlink">NCT01455896</a> - A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 </div><div style="margin-bottom: 10px;">ITCA 650 vs placebo; PE will assess CV death, nonfatal MI, nonfatal stroke and unstable angina.<wbr> Est.<wbr> completion date: July 2018.<wbr> </div><div style="margin-bottom: 10px;"><a href="http://clinicaltrials.gov/ct2/show/study/NCT01455857?term=intarcia&recr=Open&rank=1&show_locs=Y#locn" class="defaultlink">NCT01455857</a> - A Study to evaluate ITCA 650 for the Treatment of Type 2 Diabetes </div><div style="margin-bottom: 10px;">ITCA 650 (2 doses) superiority vs placebo; PE will assess change in HbA1c.<wbr> Est.<wbr> completion date: July 2014.<wbr> </div><div style="margin-bottom: 10px;"><a href="http://clinicaltrials.gov/ct2/show/NCT01455870?term=intarcia&recr=Open&rank=2&submit_fld_opt=" class="defaultlink">NCT01455870</a>- A Study to Evaluate ITCA 650 Compared to Sitagliptin as Add-on Therapy for the Type 2 Diabetes </div><div style="margin-bottom: 10px;">Comparison of ITCA 650 to Sitagliptin as add-on therapy to Metformin; PE will assess change in HbA1c between Week 52 and Day 0.<wbr> Est.<wbr> completion date: July 2014.<wbr> </div><div style="margin-bottom: 10px;"><a href="http://clinicaltrials.gov/ct2/show/NCT01785771?term=intarcia&recr=Open&rank=4&submit_fld_opt=" class="defaultlink">NCT01785771</a> - A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients with High Baseline HbAc </div><div>PE will assess change in HbA1c between Week 39 and Day 0.<wbr> Est.<wbr> completion date: September 2014.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7394">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-16T11:43:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>China Market Primacy for Novartis [mkt:China, mkt:Intercontinental, :Oncology:comp:Novartis, :Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10510</link>
<description>China Market Primacy for Novartis [mkt:China, mkt:Intercontinental, :Oncology:comp:Novartis, :Endocrinology:comp:Novartis]</description><category>mkt:China</category><category>mkt:Intercontinental</category><category>comp:Novartis</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10510</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10510">China Market Primacy for Novartis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10510">PharmaWorld10510</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 July 2013 | 10:26</font><br><br><div style="margin-bottom: 10px;">Comment: In an interview with <EM>China Daily</EM>, Joe Jimenez (CEO) reported that the Chinese market presents unique challenges.<wbr> He outlined that China importance is impossible to overlook, and added that Novartis is investing a planned $1 billion to construct a new Shanghai R&amp;D center.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Importance for Novartis</STRONG> </div><div style="margin-bottom: 10px;">China's role is to provide top-line growth in helping Novartis see returns on R&amp;D investments made in its pipeline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>China Biosimilar Market</STRONG> </div><div style="margin-bottom: 10px;">Novartis is considering deeper involvement in biosimilars, particularly in China.<wbr> Imminent patent expiries for costly oncology biotech drugs are creating an opportunity for more modestly-priced biosimilars.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Latest Reference in Traction CI</STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9064" class="defaultlink">Oncology9064: Afinitor (everolimus) Launched in China</a>.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10510">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-16T10:26:21+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Ph3 Trial to Assess Merz' Xeomin in Bilateral Blepharospasm (BEB) [comp:Merz, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7072</link>
<description>Ph3 Trial to Assess Merz' Xeomin in Bilateral Blepharospasm (BEB) [comp:Merz, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Merz</category><category>prod:Xeomin</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7072</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7072">Ph3 Trial to Assess Merz' Xeomin in Bilateral Blepharospasm (BEB)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7072">Neurology7072</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 July 2013 | 15:56</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new registration trial which will serve to collect efficacy and safety data of two different doses of the drug in subjects suffering from Bilateral Blephorasm (BEB) who are BTX treatment-naïve.<wbr> PE will assess change from baseline in Jankovic rating scale severity subscore determined at V4 (Week 6).<wbr> This study also will substantiate the existing efficacy and safety database for the indication BEB.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - <A href="http://clinicaltrials.gov/ct2/show/NCT01896895?term=botox+OR+botulinum&amp;recr=Open&amp;fund=2&amp;rank=6&amp;submit_fld_opt=">NCT01896895</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Sponsor: Merz Pharm GmbH </div><div style="margin-bottom: 10px;">BTX treatment-naïve subjects are defined as those who have not received BTX treatment within the last 12 months for the treatment of BEB.<wbr> This definition aims to avoid bias by comparison of treatment effects in the subject's assessments.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Subjects to receive one injection with Xeomin (NT 201) or placebo at baseline of the placebo-controlled first cycle.<wbr> Thereafter, all subjects entering the Open-Label Extension Period (OLEX) to receive a second injection of NT 201 (second injection cycle).<wbr></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">n=60</P></DIV></DIV></DIV></DIV> </div><div style="margin-bottom: 10px;">Start date: Aug.<wbr> 2013 - Completion date: Oct.<wbr> 2015 /<wbr> March 2016 </div><div>Location: Malaysia; India; Sri Lanka; Greece; USA.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7072">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-15T15:56:53+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>CFO to Leave AstraZeneca [sub:People, :Oncology:comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10509</link>
<description>CFO to Leave AstraZeneca [sub:People, :Oncology:comp:AstraZeneca]</description><category>sub:People</category><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10509</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10509">CFO to Leave AstraZeneca</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10509">PharmaWorld10509</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 July 2013 | 13:09</font><br><br><div style="margin-bottom: 10px;">Comment: The 'surprising and sudden move' of Simon Lowth comes as a rather surprising news as the company is facing a challenging year.<wbr> He has been appointed CFO for the BG Group PLC, and will take up his new post in November.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Future Organisation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10509/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Simon Lowth, Chief Financial Officer (CFO) and Executive Director, will leave the company at the end of October, after the reporting of Q3 results.<wbr> </div><div>A search for Simon’s successor is under way.<wbr> </div><!-- Comment details --><a name="pharmaworld10509attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10509/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10509">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-15T13:09:44+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10509/1/ScreenCapture1.jpg" length="6164" type="image/jpeg"/></item><item>
<title>Allergan Launches New Dermal Filler Tailored for the Lips [comp:Allergan, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7070</link>
<description>Allergan Launches New Dermal Filler Tailored for the Lips [comp:Allergan, sub:Aesthetics]</description><category>comp:Allergan</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7070</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7070">Allergan Launches New Dermal Filler Tailored for the Lips</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7070">Neurology7070</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 July 2013 | 11:27</font><br><br><div style="margin-bottom: 10px;">Comment: Juvéderm® VOLBELLA® with lidocaine lasts up to 12 months in the lips with a single treatment (Eccleston D.<wbr> Clin, Cosmet &amp; Investig Derma, 2012; 5:1-6).<wbr> Launched during IMCAS in Paris, the new filler is not only designed for restoring lost lip volume, but also for defining lip contours, treating oral commissures, smoothing fine vertical lines around the lips, and plumping up the marionette lines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background from IMCAS (Paris - Jan.<wbr> 31 - Feb.<wbr> 3)</FONT></STRONG> </div><div style="margin-bottom: 10px;">Allergan dedicated the second part of its symposium to Juvéderm® VOLBELLA®, highlighting six main characteristics/<wbr>advantages: </div><div style="margin-bottom: 10px;"><UL><LI>Vycross technology HA 15 mg/<wbr><WBR>ml</WBR></LI>
<LI>Specifically designed for lips and perioral</LI>
<LI>Extremely soft and easy to mold</LI>
<LI>Less swelling compared to other lip treatments (Allergan Data on File)</LI>
<LI>Reduced edema potential</LI>
<LI>Significantly increased longevity (12 months)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>Poster Presentation</U></STRONG> </div><div style="margin-bottom: 10px;"><P style="FONT-WEIGHT: bold"><FONT size="1">Philipp-Dormston, WG et al.<wbr></FONT></P> </div><div style="margin-bottom: 10px;">The Juvéderm® VOLBELLA® with Lidocaine study was designed as a real world study to collect efficacy and safety data for volume enhancement and/<wbr>or correction of asymmetry of the lips in normal subjects requesting aesthetic improvement.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="1"><U>Study Design</U>: This was a 1 month, prospective, open label, multi-centre, post marketing observational study of 62 subjects, designed to evaluate the aesthetic impact of treatment with Juvéderm® VOLBELLA® with Lidocaine for volume enhancement of the lips or correction of asymmetry of the lips.<wbr> Aesthetic impact was evaluated by subject and physician immediately after injection and at the next follow up visit (within 4 weeks post treatment).<wbr> At the follow up visit, subjects were given an optional top up with Juvéderm® VOLBELLA® with Lidocaine as deemed necessary by the physician, within the standard practice of the clinic.<wbr> Subject and physician experience as assessed through satisfaction with the improvement of the lips and rating of the natural look and feel following treatment was measured by means of Subject (SQ) and Investigator Questionnaire (IQ) immediately after injection; </FONT> </div><div style="margin-bottom: 10px;"><FONT size="1"><U>‘1st Visit’</U> (SQ/<wbr>IQ1V) and within 4 weeks post treatment; <U>‘Follow up Visit’</U> (SQ/<wbr>IQFV).<wbr> The secondary objectives were to evaluate the injection characteristics of Juvéderm® VOLBELLA® with Lidocaine, tolerability of injection, time taken to return to social engagement as well as conducting a comparative evaluation with previous treatments.<wbr> Injection characteristics were measured by physician rated outcomes (malleability, need for massage, ease of injection).<wbr> Subjects were asked to rate their time to return to social engagement.<wbr> Tolerability was evaluated by both subject and physician rated outcomes (injection discomfort, presence of bruising and swelling).<wbr> The safety of Juvéderm® VOLBELLA® with Lidocaine was evaluated by patient reported Adverse Events and Serious Adverse Events (AEs/<wbr>SAEs).<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT size="1">For the primary endpoint, 83.<wbr>6% (n=51 out of 61) of subjects were at the first visit, ‘satisfied’, ‘very’ or ‘extremely’ satisfied with the improvement in their lips following treatment with Juvéderm® VOLBELLA® with Lidocaine.<wbr> All physicians were ‘very’ (72.<wbr>6%) or ‘extremely’ (27.<wbr>4%) satisfied with the improvements in their subject’s lips following the first treatment.<wbr> When rating the look and feel of the lips after the first injection, 61.<wbr>7% (n=37 out of 60 subjects available for follow up) of subjects considered the treatment looked and felt ‘very’ (46.<wbr>7%) or ‘extremely’ (15%) natural.<wbr> At the follow-up visit, no subject considered that the look and feel of their lips was not natural.<wbr> All physicians rated the look of their subject’s lips following treatment with Juvéderm® VOLBELLA® with Lidocaine as ‘very’ (69.<wbr>4%) or ‘extremely’ (30.<wbr>6%) natural.<wbr> Subjects and physicians considered administration of the product caused little discomfort during the first injection.<wbr> On a 10-point scale, where 0 = no discomfort and 10 = extreme discomfort, both subjects and physicians reported similar mean levels of discomfort during the first injection (1.<wbr>3 (+/<wbr>-1.<wbr>5) and 1.<wbr>2 (+/<wbr>-1.<wbr>0) respectively).<wbr> Concerning bruising in the lips after the 1st injection, 95% of subjects (n=60) reported little or no bruising.<wbr> Comparable results were also reported by the physicians; 98.<wbr>4% (n=62) reported little or no bruising.<wbr> At follow up of those subjects who did not receive a top-up treatment (n=44), approximately half (47.<wbr>7%) experienced no bruising at all.<wbr> Of the remaining subjects who experienced a degree of bruising, this resolved in all cases within 5-6 days.<wbr> Physicians rated that 91.<wbr>9% of subjects (n=62 evaluable subjects) experienced little or no swelling in the lips after the 1st injection which resolved within 5-6 days.<wbr> In the subset of subjects who did not receive a top-up injection (n=44), swelling resolved within 1-2 days in 79.<wbr>6% of subjects.<wbr> Physicians considered the product was very easy to inject as well as mould/<wbr>sculpt and required little or no massage.<wbr> After treatment with Juvéderm® VOLBELLA® with Lidocaine, approximately two thirds of subjects (62%) were able to return to social engagement on the same day as the procedure, with all patients returning to social engagement within 4-5 days.<wbr> When compared with their previous lip treatments, approximately half of all subjects (46.<wbr>2%) considered Juvéderm® VOLBELLA® with Lidocaine was significantly better at improving their lips, with 53.<wbr>8% reporting that their lips looked and felt significantly more natural and resulted in significantly less bruising and discomfort in 50% of subjects.<wbr> All subjects and physicians would recommend Juvéderm® VOLBELLA® with Lidocaine to others.<wbr> No device-related adverse events occurred during the study.<wbr> </FONT> </div><div><FONT size="1">Overall Juvéderm® VOLBELLA® with Lidocaine as a new treatment option for improvement of the lips was very well accepted by both subjects and physicians, associated with high levels of satisfaction and considered to result in a natural look and feel of the lips.<wbr> It was not only well tolerated, but nearly two thirds of patients (62%) were able to return to social engagement on the same day.<wbr></FONT> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7070">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-15T11:27:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Registration Trial of Sativex for Spasticity [dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7069</link>
<description>Registration Trial of Sativex for Spasticity [dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Spasticity</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7069</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7069">Registration Trial of Sativex for Spasticity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7069">Neurology7069</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 July 2013 | 17:21</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrial.<wbr>gov is listing a new Phase 3 which is designed to evaluate efficacy and tolerability of Sativex in children (8 to 18 years) with spasticity due to Cerebral Palsy or Traumatic Central Nervous System Injury and have not responded adequately to their existing anti-spasticity medications.<wbr> PE will assess change from baseline to the end of 12 weeks treatment in mean spasticity 0-10 NRS score.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01898520?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=06%2F12%2F2013&amp;rank=73"><STRONG><FONT size="3">NCT01898520</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Sponsor: GW Pharm.<wbr> </div><div style="margin-bottom: 10px;">Design: A 12 week randomised, double-blind, placebo-controlled,parallel group study followed by a 24-week open-label extension phase.<wbr> </div><div style="margin-bottom: 10px;">N= 72 </div><div style="margin-bottom: 10px;">Start date: Sept 2013 /<wbr> Completion date(s): Dec 2015 /<wbr> Dec 2016 </div><div>Location: UK </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7069">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-12T17:21:59+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>The Acromegaly Therapy Area Landscape (2) [:Endocrinology:TAL:Acromegaly, :Endocrinology:Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10508</link>
<description>The Acromegaly Therapy Area Landscape (2) [:Endocrinology:TAL:Acromegaly, :Endocrinology:Alert]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10508</comments><category>TAL:Acromegaly</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10508</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10508">The Acromegaly Therapy Area Landscape (2)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=TAL%3aAcromegaly"><font color="#e95e0b">:Endocrinology:TAL:Acromegaly</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10508">PharmaWorld10508</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 July 2013 | 17:13</font><br><br><div style="margin-bottom: 10px;">Comment: You will find attached an update version of the competitive landscape in acromegaly.<wbr> We encourage you to contribute to our internal knowledge by evaluating some of the "Key Intelligence Questions" included in the document.<wbr><WBR></WBR> </div><div style="margin-bottom: 10px;"><DIV class="i" id="oncology9052.04i">

<DIV class="ii" id="oncology9052.04ii">However, no matter what competitive information /<wbr><WBR> soft intelligence you have, please do keep us informed on any key developments in your countries</WBR></DIV></DIV> </div><div style="margin-bottom: 10px;">This slide kit has been created in close collaboration with Scientific Intelligence and the Endocrinology Franchise.<wbr> Next update is due in Q4:13.<wbr><WBR></WBR> </div><div><DIV class="i hovered" id="oncology9052.05i">

<DIV class="ii" id="oncology9052.05ii">We hope that you will find it a useful tool.<wbr></DIV></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10583c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: The Acromegaly Therapy Area Landscape (2)</span> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a>]</font></font></div><div style="margin-bottom: 10px;"><DIV class="cit">Please see below from <A href="http://www.ncbi.nlm.nih.gov/pubmed/23969184?dopt=Abstract" title="The Journal of clinical endocrinology and metabolism.">J Clin Endocrinol Metab.<wbr></A> 2013 Aug 22.<wbr> [Epub ahead of print] Findings show that the octreotide implant maintained reduced blood levels of GH and IGF-1 with continuous octreotide release over 6 months, which was well tolerated.<wbr></DIV> </div><div style="margin-bottom: 10px;"><H1>Efficacy and Safety of an Octreotide Implant in the Treatment of Patients with Acromegaly.<wbr></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Chieffo%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Chieffo C</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cook%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Cook D</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Xiang%20Q%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Xiang Q</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Frohman%20LA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23969184">Frohman LA</A>.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff">
<H3 class="label">Source</H3>
<P>1 Endo Health Solutions, Inc.<wbr>, Clinical Research &amp; Development, Malvern PA, USA;</P></DIV> </div><div><DIV class="abstr">
<H3>Abstract</H3>
<DIV>
<P>Context:Acromegaly is caused by excessive GH secretion and IGF-1 overproduction.<wbr> The goals of treatment are to reduce GH and IGF-1 values to normal and relieve associated symptoms.<wbr>Objective:To demonstrate that octreotide implant (84 mg) is safe and efficacious in patients with acromegaly who were responsive to prior monthly octreotide LAR injections.<wbr>Design:Phase 3, open-label study.<wbr> Before treatment, subjects received a stable monthly dose of octreotide LAR injections (10 to 40 mg) for ≥3 months.<wbr> Randomization was in a 3:1 ratio to either 6-month octreotide implant or monthly octreotide LAR injections.<wbr>Setting:This was a multicenter, international study conducted in private or institutional practices.<wbr>Subjects:Enrollment included 163 subjects (aged ≥18 years) with acromegaly.<wbr>Main Outcome Measure:To evaluate the efficacy, safety, and tolerability of the octreotide implant during 24 weeks of treatment.<wbr>Results:After 24 weeks, the success rate of the implant for maintenance of IGF-1 and GH levels was 86% (95% CI: 80.<wbr>3%) compared to 84% (95% CI: 73.<wbr>8%) for octreotide LAR.<wbr> Serum octreotide concentrations after implant insertion increased within 8 days and peaked between day 14 and 28.<wbr> Overall safety of the octreotide implant and octreotide LAR were similar.<wbr> Diarrhea and headache were more frequent with the implant, while cholecystitis and hypertension were more frequent with octreotide LAR.<wbr>Conclusions:In this pivotal phase 3 study, the octreotide implant maintained reduced blood levels of GH and IGF-1 with continuous octreotide release over 6 months, which was well tolerated.<wbr></P></DIV></DIV> </div><font size="-1">Roger BELUSA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10583" class="commentpermalink">PharmaWorld10583</a> / <span class="date">28 August 2013</span> /
<span class="time">15:11:35 o'clock CEST</span>
</font></div><a name="pharmaworld10508attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10508/1/Acromegaly%5fTherapy%20Area%20Landscape%5fFinal%20Version%20July%202013.ppt">Acromegaly_Therapy Area Landscape_Final Version July 2013.ppt</a>&nbsp;&nbsp;(1,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10508">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-12T17:13:47+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10508/1/Acromegaly%5fTherapy%20Area%20Landscape%5fFinal%20Version%20July%202013.ppt" length="1117696" type="application/x-dos_ms_powerpoint2"/></item><item>
<title>First Patient Treated in a Study of Bellicum's BPX-201 and AP1903 for mCRPC [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9072</link>
<description>First Patient Treated in a Study of Bellicum's BPX-201 and AP1903 for mCRPC [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9072</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9072">First Patient Treated in a Study of Bellicum's BPX-201 and AP1903 for mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9072">Oncology9072</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 July 2013 | 15:23</font><br><br><div style="margin-bottom: 10px;">Comment: The Phase I dose escalation trial in patients with metastatic castrate resistant prostate cancer (mCRPC) was designed to evaluate the safety, tolerability and clinical outcomes of BPX-201 and AP1903, which incorporate Bellicum's second generation DeCIDe™ immunotherapy technology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Mechanism of Action</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>BPX-201</STRONG> contains the patient’s own matured dendritic cells engineered with the DeCIDe “on switch,” and trained to target prostate cancer cells.<wbr> </div><div style="margin-bottom: 10px;">The small molecule drug <STRONG>AP1903</STRONG> is administered the day after the modified cells have been infused into the patient, activating the “on switch” in the injected cells and marshaling the body’s T cells to attack the cancer.<wbr> </div><div style="margin-bottom: 10px;">By waiting until the modified dendritic cells have migrated to nearby lymph nodes before activation, a more potent and durable antigen-specific T cell immune response may result.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study - NCT01823978</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <A href="http://clinicaltrials.gov/ct2/show/NCT01823978?term=BPX-201&amp;rank=1">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01823978?term=BPX-201&amp;rank=1</A> </div><div><EM>Source: Bellicum Pharm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9072">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-12T15:23:13+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>XTANDI ™ (enzalutamide) Available in the UK [comp:Astellas, dis:Prostate, :PharmaWorld:mkt:UK]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9071</link>
<description>XTANDI ™ (enzalutamide) Available in the UK [comp:Astellas, dis:Prostate, :PharmaWorld:mkt:UK]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>mkt:UK</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9071</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9071">XTANDI ™ (enzalutamide) Available in the UK</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9071">Oncology9071</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 July 2013 | 15:14</font><br><br><div style="margin-bottom: 10px;">Comment: The granting of the UK licence follows the submission of data from the AFFIRM trial (a multinational study evaluating enzalutamide (160 mg/<wbr>day) versus placebo in 1,199 men with advanced prostate cancer who were previously treated with docetaxel-based chemotherapy).<wbr> </div><div style="margin-bottom: 10px;">Enzalutamide is available in England via the Cancer Drugs Fund.<wbr> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9071">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-12T15:14:41+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Five Promising Parkinson Drugs Selected by the MJJF [dis:Parkinson, :PharmaWorld:sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7068</link>
<description>Five Promising Parkinson Drugs Selected by the MJJF [dis:Parkinson, :PharmaWorld:sub:Partnership]</description><category>dis:Parkinson</category><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7068</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7068">Five Promising Parkinson Drugs Selected by the MJJF</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7068">Neurology7068</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 July 2013 | 14:38</font><br><br><div style="margin-bottom: 10px;">Comment: Research projects from 5 biopharm companies comprise the 2013 first half of The Michael J.<wbr> Fox Foundation for Parkinson's Research (MJFF) Partnering Program, and are presented directly to industry groups who may wish to invest in further development of the project.<wbr> Below is the list of the selected drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Disease Modifying Research</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Ceregene's clinical research on a gene delivery approach to neurotrophic factors.<wbr> </div><div style="margin-bottom: 10px;">- MediGenesis's GDNF.<wbr> </div><div style="margin-bottom: 10px;">- NeuroPhage's NPT002 that targets alpha-synuclein.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Symptomatic Research</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Cynapsus' APL-130277, a thin film strip that dissolves under the toungue.<wbr> </div><div style="margin-bottom: 10px;">- NeuroDerm's research on continuous administration of levodoppa and carbidopa through a "pump-patch".<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7068">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-12T14:38:29+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: GSK Investigating Botox Marketing Practices in China</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7064</link>
<description>re: GSK Investigating Botox Marketing Practices in China</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7064</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7064">re: GSK Investigating Botox Marketing Practices in China</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7064">Neurology7064</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/14">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD</a> | 12 July 2013 | 14:05</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">GSK Investigating Botox Marketing Practices in China</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aMarketing"><font color="#e95e0b">:PharmaWorld:func:Marketing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Allegations claimed that GSK sales staff used improper tactics to market Botox in China.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7057">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057" class="commentpermalink">Neurology7057</a> / <span class="date">09 July 2013</span> /
<span class="time">15:28:45 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comments : <SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">At least 30 GSK employees, including 5 or 6 executives, are currently under house arrest in China in relation to an ongoing investigation into the company, <EM>The Telegraph</EM> reported.<wbr> The newspaper suggested that one of the executives includes the drugmaker's legal counsel in the country.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;">According to Chinese officials, a probe in Changsha, Shanghai and Zhengzhou found that GSK tried to establish new sales channels and increase drug prices in China by directly bribing GVT officials, pharmaceutical industry associations, hospitals and doctors.<wbr> <SPAN style="LINE-HEIGHT: 1.5em">GSK staff also reportedly used fake receipts in unspecified tax law violations.<wbr></SPAN> </div><div style="margin-bottom: 10px;">In response to the news, GSK said it is "willing to cooperate with the authorities in this inquiry,".<wbr> The company noted that it continually monitors its businesses to ensure they meet the company’s compliance procedures.<wbr> "We have done this in China and found no evidence of bribery or corruption of doctors or government officials," the company said, adding "however, if evidence of such activity whereby sales staff used improper tactics to market Botox (onabotulinumtoxinA), is provided we will act swiftly on it.<wbr>" </div><div style="margin-bottom: 10px;">Back in June, GlaxoSmithKline said it found no evidence of wrongdoing after concluding aprobe into allegations that the company's sales staff in China were involved in widespread bribery of doctors to prescribe drugs, between 2004 and 2010.<wbr> Earlier this week, the drugmaker confirmed that it is also investigating claims that sales staff used improper tactics to market Botox (onabotulinumtoxinA) in China.<wbr> </div><div style="margin-bottom: 10px;">According to a Credit Suisse A<SPAN style="LINE-HEIGHT: 1.5em">nalyst in a note published in 2012, China accounted for less than 3 percent of GlaxoSmithKline’s global sales, so the immediate impact of the latest news was unlikely to be that significant.<wbr> However, Credit Suisse said the accusations could not be ignored, adding "emerging markets are seen as important for future growth and the China market is going to be one of the biggest markets in the world, and you have to grow in line with the market.<wbr>"</SPAN> </div><div style="margin-bottom: 10px;">China's National Development and Reform Commission (NDRC) also recently launched a probe into production costs and prices charged at 60 foreign and Chinese pharmaceutical companies, including GSK.<wbr> </div><div>Source : abstracted from a news on FirstWorldPharma published July 12th.<wbr> </div><!-- Comment details --><font size="-1">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7064" class="commentpermalink">Neurology7064</a> / <span class="date">12 July 2013</span> /
<span class="time">14:05:43 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7064">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057">View thread  Neurology7057: GSK Investigating Botox Marketing Practices in China</a>]]></content:encoded><dc:date>2013-07-12T14:05:43+02:00</dc:date><dc:creator>len82156</dc:creator></item><item>
<title>Bladder Cancer Drug ImmuCyst Available in 2014 [dis:Bladder, comp:SanofiAventis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9070</link>
<description>Bladder Cancer Drug ImmuCyst Available in 2014 [dis:Bladder, comp:SanofiAventis]</description><category>dis:Bladder</category><category>comp:SanofiAventis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9070</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9070">Bladder Cancer Drug ImmuCyst Available in 2014</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aSanofiAventis"><font color="#e95e0b">:Oncology:comp:SanofiAventis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9070">Oncology9070</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 July 2013 | 12:09</font><br><br><div>Comment: Alliance Pharma expects bladder cancer drug ImmuCyst, manufactured by Sanofi SA's vaccines unit, to become available in the second half of 2014.<wbr><BR><BR>Production of ImmuCyst was suspended in mid-2012 after mould was found in Sanofi Pasteur's 100-year-old manufacturing plant in Toronto, Canada.<wbr><BR><BR>Alliance Pharma, which acquires, markets and distributes pharmaceutical products, said that turnover in the six months ended June 30 rose 4 percent to 22.<wbr>8 million pounds ($34.<wbr>07 million).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9070">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-11T12:09:27+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Merrimack to Raise $125M</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9069</link>
<description>Merrimack to Raise $125M</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9069</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9069">Merrimack to Raise $125M</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9069">Oncology9069</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 July 2013 | 12:01</font><br><br><div style="margin-bottom: 10px;">Comment: Funds will be used to finance the development of MM-398, currently in Ph3 testing for 2nd-line treatment of metastatic pancreatic cancer (data expectected this half).<wbr> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> JPMorgan; BofA Merrill Lynch; Cowen; Oppenheimer; Guggenheim Securities; and Brean Capital are underwriters.<wbr></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9069">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-11T12:01:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7063</link>
<description>re: Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7063</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7063">re: Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7063">Neurology7063</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/222">Philippe PICAUT</a> | 11 July 2013 | 10:59</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment; The Phase 3 study is currently recruitng approx.<wbr> 300 participants (2 to 17 years old) in Estonia.<wbr> PE will measure change from baseline (Day 1) in the Ashworth Scale (AS) score of plantar flexors at Day 29 of the 1st injection cycle, and Investigator's Global Impression of Change of Plantar Flexor Spasticity Scale (GICS-PF) at Day 29 of the 1st injection cycle.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7061">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7061" class="commentpermalink">Neurology7061</a> / <span class="date">10 July 2013</span> /
<span class="time">16:56:41 o'clock CEST</span>
</font></div><div>Design comparable to our study design with a co-primary endpoint between Ashworth and Physician global assessment to satisfy at minimum their US PMR and PMC.<wbr> There are many more countries included (USA, CZ, D, F.<wbr>, South Africa, Mexico, Australia, Romania, Poland, Turkey etc.<wbr>.<wbr>).<wbr> They are using quite a high top dose  as compared to Botox for instance.<wbr> Patients having a re-treatment interval of 12 to 16 weeks could be enrolled in an OL study to receive 4 treatment cycles.<wbr> </div><!-- Comment details --><font size="-1">Philippe PICAUT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7063" class="commentpermalink">Neurology7063</a> / <span class="date">11 July 2013</span> /
<span class="time">10:59:01 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7063">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7061">View thread  Neurology7061: Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy</a>]]></content:encoded><dc:date>2013-07-11T10:59:01+02:00</dc:date><dc:creator>php44614</dc:creator></item><item>
<title>Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy [dis:Palsy, dis:Spasticity, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:ClinicalTrial, comp:Merz, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7061</link>
<description>Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy [dis:Palsy, dis:Spasticity, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:ClinicalTrial, comp:Merz, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7061</comments><category>dis:Palsy</category><category>dis:Spasticity</category><category>mkt:Europe</category><category>sub:ClinicalTrial</category><category>comp:Merz</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7061</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7061">Three Different Dosage of Xeomin Tested in Spasticity of the Leg(s) in Cerebral Palsy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7061">Neurology7061</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 July 2013 | 16:56</font><br><br><div style="margin-bottom: 10px;">Comment; The Phase 3 study is currently recruitng approx.<wbr> 300 participants (2 to 17 years old) in Estonia.<wbr> PE will measure change from baseline (Day 1) in the Ashworth Scale (AS) score of plantar flexors at Day 29 of the 1st injection cycle, and Investigator's Global Impression of Change of Plantar Flexor Spasticity Scale (GICS-PF) at Day 29 of the 1st injection cycle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details<a href="http://clinicaltrials.gov/ct2/show/NCT01893411?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=06%2F10%2F2013&rank=45" class="defaultlink">NCT01893411</a></STRONG> </div><div style="margin-bottom: 10px;">Startd date: June 2013 - Completion: April 2015 /<wbr> August 2016 </div><div>Dosage: 16U; 12U; 4U per kg body weight </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7063c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Design comparable to our study design with a co-primary endpoint between Ashworth and Physician global assessment to satisfy at minimum their US PMR and PMC.<wbr> There are many more countries included (USA, CZ, D, F.<wbr>, South Africa, Mexico, Australia, Romania, Poland, Turkey etc.<wbr>.<wbr>).<wbr> They are using quite a high top dose  as compared to Botox for instance.<wbr> Patients having a re-treatment interval of 12 to 16 weeks could be enrolled in an OL study to receive 4 treatment cycles.<wbr> </div><font size="-1">Philippe PICAUT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7063" class="commentpermalink">Neurology7063</a> / <span class="date">11 July 2013</span> /
<span class="time">10:59:01 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7061">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-10T16:56:41+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Roche Stops Diabetes Drug Development [comp:Roche, dis:Diabetes, :PharmaWorld:sub:Termination]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7393</link>
<description>Roche Stops Diabetes Drug Development [comp:Roche, dis:Diabetes, :PharmaWorld:sub:Termination]</description><category>comp:Roche</category><category>dis:Diabetes</category><category>sub:Termination</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7393</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7393">Roche Stops Diabetes Drug Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aTermination"><font color="#e95e0b">:PharmaWorld:sub:Termination</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7393">Endocrinology7393</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 July 2013 | 14:41</font><br><br><div style="margin-bottom: 10px;">Comment: Roche will halt development of aleglitazar partly due to its undesired side effects (affecting organs such as their kidneys and hearts), </div><div style="margin-bottom: 10px;"><STRONG>Strategic Rationale</STRONG> </div><div style="margin-bottom: 10px;">As it went into the 7,000-patient late-stage study of aleglitazar, Roche took steps to reduce the possibility that its product might have the same problems as other medicines in the class.<wbr> It particular, it conducted a renal safety study to ensure its product was free of the kidney problems that undermined AstraZeneca's.<wbr><BR><BR>Drugs like aleglitazar are designed to turn on two protein receptors known as PPARs, one that regulates glucose and another lipids.<wbr> These dual PPAR drugs have long fascinated researchers as a potential way to help diabetics address multiple targets linked to heart disease.<wbr> </div><div><EM>Source: Thomson One</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7393">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-10T14:41:04+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AstraZeneca Enters Oncology Drug Collaboration [comp:AstraZeneca, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9067</link>
<description>AstraZeneca Enters Oncology Drug Collaboration [comp:AstraZeneca, dis:Prostate]</description><category>comp:AstraZeneca</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9067</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9067">AstraZeneca Enters Oncology Drug Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9067">Oncology9067</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 July 2013 | 14:13</font><br><br><div style="margin-bottom: 10px;">Comment: In collaboration with the U.<wbr> of Cambridge and Cancer Research UK, AstraZeneca will investigate tumour mutations and experimental drugs for prostate, pancreatic and other cancers.<wbr> The pharma company aims to advance its work in the area of personalized healthcare.<wbr> One of the three projects will test the effectiveness of olaparib and AZD2014 (TOR kinase inhibitor) in high-risk prostate cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Rationale for AZ</STRONG> </div><div style="margin-bottom: 10px;">- to move its UK-based global R&amp;D centre and corporate HQs to the Cambridge Biomedical Campus by 2016.<wbr> </div><div><EM>Source: First Word</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9067">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-10T14:13:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: GSK Investigating Botox Marketing Practices in China</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7060</link>
<description>re: GSK Investigating Botox Marketing Practices in China</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7060</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7060">re: GSK Investigating Botox Marketing Practices in China</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7060">Neurology7060</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/588">daj89889</a> | 10 July 2013 | 10:02</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">GSK Investigating Botox Marketing Practices in China</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aMarketing"><font color="#e95e0b">:PharmaWorld:func:Marketing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Allegations claimed that GSK sales staff used improper tactics to market Botox in China.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7057">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057" class="commentpermalink">Neurology7057</a> / <span class="date">09 July 2013</span> /
<span class="time">15:28:45 o'clock CEST</span>
</font></div><div>Agree with Brice, particularly since aesthetic and therapeutic indications are on the same label.<wbr> </div><!-- Comment details --><font size="-1">daj89889 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7060" class="commentpermalink">Neurology7060</a> / <span class="date">10 July 2013</span> /
<span class="time">10:02:53 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7060">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057">View thread  Neurology7057: GSK Investigating Botox Marketing Practices in China</a>]]></content:encoded><dc:date>2013-07-10T10:02:53+02:00</dc:date><dc:creator>daj89889</dc:creator></item><item>
<title>re: GSK Investigating Botox Marketing Practices in China</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7059</link>
<description>re: GSK Investigating Botox Marketing Practices in China</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7059</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7059">re: GSK Investigating Botox Marketing Practices in China</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7059">Neurology7059</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/283">brv82696</a> | 10 July 2013 | 09:43</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">GSK Investigating Botox Marketing Practices in China</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aMarketing"><font color="#e95e0b">:PharmaWorld:func:Marketing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Allegations claimed that GSK sales staff used improper tactics to market Botox in China.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7057">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057" class="commentpermalink">Neurology7057</a> / <span class="date">09 July 2013</span> /
<span class="time">15:28:45 o'clock CEST</span>
</font></div><div>This is an usual practice in China.<wbr> Are Botox in aesthetic and therapeutic marketed with the same brand name in China ? if yes, it will be interesting to get information about h<SPAN style="line-height: 1.5em;">ow could Allergan and GSK distinguish therapeutic and aesthetic Botox's sales in hospitals?</SPAN> </div><!-- Comment details --><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7059" class="commentpermalink">Neurology7059</a> / <span class="date">10 July 2013</span> /
<span class="time">09:43:18 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7059">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057">View thread  Neurology7057: GSK Investigating Botox Marketing Practices in China</a>]]></content:encoded><dc:date>2013-07-10T09:43:18+02:00</dc:date><dc:creator>brv82696</dc:creator></item><item>
<title>GSK Investigating Botox Marketing Practices in China [prod:Botox, :PharmaWorld:mkt:China, :PharmaWorld:func:Marketing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057</link>
<description>GSK Investigating Botox Marketing Practices in China [prod:Botox, :PharmaWorld:mkt:China, :PharmaWorld:func:Marketing]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057</comments><category>prod:Botox</category><category>mkt:China</category><category>func:Marketing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7057">GSK Investigating Botox Marketing Practices in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aMarketing"><font color="#e95e0b">:PharmaWorld:func:Marketing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7057">Neurology7057</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2013 | 15:28</font><br><br><div style="margin-bottom: 10px;">Comment: Allegations claimed that GSK sales staff used improper tactics to market Botox in China.<wbr> </div><div style="margin-bottom: 10px;">The WSJ reported that in the so-called Vasily programme, sales staff discussed rewarding doctors for prescribing Botox with cash payments, educational credits and other incentives.<wbr> </div><div>Source: BioCentury </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7059c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>This is an usual practice in China.<wbr> Are Botox in aesthetic and therapeutic marketed with the same brand name in China ? if yes, it will be interesting to get information about h<SPAN style="line-height: 1.5em;">ow could Allergan and GSK distinguish therapeutic and aesthetic Botox's sales in hospitals?</SPAN> </div><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7059" class="commentpermalink">Neurology7059</a> / <span class="date">10 July 2013</span> /
<span class="time">09:43:18 o'clock CEST</span>
</font></div><a name="Neurology7060c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Agree with Brice, particularly since aesthetic and therapeutic indications are on the same label.<wbr> </div><font size="-1">daj89889 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7060" class="commentpermalink">Neurology7060</a> / <span class="date">10 July 2013</span> /
<span class="time">10:02:53 o'clock CEST</span>
</font></div><a name="Neurology7064c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comments : <SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">At least 30 GSK employees, including 5 or 6 executives, are currently under house arrest in China in relation to an ongoing investigation into the company, <EM>The Telegraph</EM> reported.<wbr> The newspaper suggested that one of the executives includes the drugmaker's legal counsel in the country.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;">According to Chinese officials, a probe in Changsha, Shanghai and Zhengzhou found that GSK tried to establish new sales channels and increase drug prices in China by directly bribing GVT officials, pharmaceutical industry associations, hospitals and doctors.<wbr> <SPAN style="LINE-HEIGHT: 1.5em">GSK staff also reportedly used fake receipts in unspecified tax law violations.<wbr></SPAN> </div><div style="margin-bottom: 10px;">In response to the news, GSK said it is "willing to cooperate with the authorities in this inquiry,".<wbr> The company noted that it continually monitors its businesses to ensure they meet the company’s compliance procedures.<wbr> "We have done this in China and found no evidence of bribery or corruption of doctors or government officials," the company said, adding "however, if evidence of such activity whereby sales staff used improper tactics to market Botox (onabotulinumtoxinA), is provided we will act swiftly on it.<wbr>" </div><div style="margin-bottom: 10px;">Back in June, GlaxoSmithKline said it found no evidence of wrongdoing after concluding aprobe into allegations that the company's sales staff in China were involved in widespread bribery of doctors to prescribe drugs, between 2004 and 2010.<wbr> Earlier this week, the drugmaker confirmed that it is also investigating claims that sales staff used improper tactics to market Botox (onabotulinumtoxinA) in China.<wbr> </div><div style="margin-bottom: 10px;">According to a Credit Suisse A<SPAN style="LINE-HEIGHT: 1.5em">nalyst in a note published in 2012, China accounted for less than 3 percent of GlaxoSmithKline’s global sales, so the immediate impact of the latest news was unlikely to be that significant.<wbr> However, Credit Suisse said the accusations could not be ignored, adding "emerging markets are seen as important for future growth and the China market is going to be one of the biggest markets in the world, and you have to grow in line with the market.<wbr>"</SPAN> </div><div style="margin-bottom: 10px;">China's National Development and Reform Commission (NDRC) also recently launched a probe into production costs and prices charged at 60 foreign and Chinese pharmaceutical companies, including GSK.<wbr> </div><div>Source : abstracted from a news on FirstWorldPharma published July 12th.<wbr> </div><font size="-1">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7064" class="commentpermalink">Neurology7064</a> / <span class="date">12 July 2013</span> /
<span class="time">14:05:43 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7057">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-09T15:28:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Astellas to Prepare Pre-Launch of Xtandi in Ireland</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9065</link>
<description>Astellas to Prepare Pre-Launch of Xtandi in Ireland</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9065</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9065">Astellas to Prepare Pre-Launch of Xtandi in Ireland</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9065">Oncology9065</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 July 2013 | 11:40</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Joanne Caroll we have learnt that two recents article and add published in <EM>The Consultant </EM>mentionned that" Xtandi has also shown efficacy as monotherapy in men with hormone naive prostate cancer, with a PSA response rate of 93%, which represents a potential alternative to castration with GNRH analogues although further studies are required".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Rationale</STRONG> </div><div style="margin-bottom: 10px;">Perhaps Astellas' long term goal is to get different indications for Xtandi, and stop promoting Eligard ? </div><div style="margin-bottom: 10px;"><STRONG>CI Feedback</STRONG> </div><div>If you hear anything from your country to support this theory, please send your comments to the CI Team.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9065">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-08T11:40:47+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Botox® Reimbursem​ent for UI Extended in Australia [comp:Allergan, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7054</link>
<description>Botox® Reimbursem​ent for UI Extended in Australia [comp:Allergan, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</description><category>comp:Allergan</category><category>mkt:Australia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7054</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7054">Botox® Reimbursem​ent for UI Extended in Australia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7054">Neurology7054</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 July 2013 | 10:53</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Andrew Stork (Scientific Manager) we have learnt that the reimbursement listing for Botox&reg; for the treatment of urinary incontinence (UI) will be extended to include patients with specific neurological conditions, such as multiple sclerosis and adult spina bifida.<wbr> </div><div style="margin-bottom: 10px;">The amended listing becomes effective on 1 August 2013.<wbr> </div><div>Information source: <A href="http://www.health.gov.au/internet/ministers/publishing.nsf/Content/mr-yr13-tp-tp068.htm">http:/<wbr>/<wbr>www.<wbr>health.<wbr>gov.<wbr>au/<wbr>internet/<wbr>ministers/<wbr>publishing.<wbr>nsf/<wbr>Content/<wbr>mr-yr13-tp-tp068.<wbr>htm</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7054">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-08T10:53:24+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Afinitor (everolimus) Launched in China [comp:Novartis, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9064</link>
<description>Afinitor (everolimus) Launched in China [comp:Novartis, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</description><category>comp:Novartis</category><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9064</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9064">Afinitor (everolimus) Launched in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9064">Oncology9064</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 July 2013 | 10:18</font><br><br><div style="margin-bottom: 10px;">Comment: China Food and Drug Administration (CFDA) has approved the launch of Afinitor for renal cell carcinoma (RCC),  for patients who fail to respond to either Sunitinib or Sorafenib.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Guo Jun, Renal Cancer and Melanoma Department Director at Beijing Cancer Hospital, pointed out that surgery is currently the dominant renal cancer treatment because although it can be detected with abdominal ultrasonography, it does not respond to radiotherapy, chemotherapy or hormonotherapy.<wbr> He added that advances in biology and immunology may lead to renal cancer treatment breakthroughs.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9064">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-08T10:18:53+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>G-BA Issued Final Benefit Assessment for Zytiga [comp:Astellas, comp:JnJ, prod:Zytiga, :PharmaWorld:mkt:Germany, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9062</link>
<description>G-BA Issued Final Benefit Assessment for Zytiga [comp:Astellas, comp:JnJ, prod:Zytiga, :PharmaWorld:mkt:Germany, :PharmaWorld:mkt:Europe]</description><category>comp:Astellas</category><category>comp:JnJ</category><category>prod:Zytiga</category><category>mkt:Germany</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9062</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9062">G-BA Issued Final Benefit Assessment for Zytiga</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9062">Oncology9062</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 July 2013 | 09:58</font><br><br><div style="margin-bottom: 10px;">Comment: Germany's Federal Joint Committee (G-BA) said Zytiga abiraterone has "significant" additional benefit over "watchful waiting" to treat chemotherapy-na&iuml;ve patients with metastatic castration-resistant prostate cancer (CPRC).<wbr> </div><div style="margin-bottom: 10px;">The assessment is line with IQWiG's April assessment.<wbr> </div><div style="margin-bottom: 10px;">Astellas and J&amp;J will now negotiate prices for Zytiga with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband).<wbr> </div><div><EM>Source: Biocentury</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9062">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-08T09:58:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7053</link>
<description>re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7053</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7053">re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7053">Neurology7053</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/283">brv82696</a> | 05 July 2013 | 11:32</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</span>&nbsp;<br><span style="font-size: 12px;">This indication has been widely used by Korean doctors.<wbr> It seems that Allergan has organised an ad board to discuss on this indication.<wbr></span>&nbsp;<br><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051" class="commentpermalink">Neurology7051</a> / <span class="date">04 July 2013</span> /
<span class="time">14:01:37 o'clock CEST</span>
</font></div><div>Is masseter hypertrophy considered as a medical indication ? according to publication, 75% of patients with bruxism have masseter hypertrophy.<wbr> The prevalence of Bruxism is estimated at 5-8%.<wbr> </div><!-- Comment details --><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7053" class="commentpermalink">Neurology7053</a> / <span class="date">05 July 2013</span> /
<span class="time">11:32:58 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7053">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050">View thread  Neurology7050: Comparison of Two Botulinum Toxins for Masseter Hypertropy</a>]]></content:encoded><dc:date>2013-07-05T11:32:58+02:00</dc:date><dc:creator>brv82696</dc:creator></item><item>
<title>re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7052</link>
<description>re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7052</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7052">re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7052">Neurology7052</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/222">Philippe PICAUT</a> | 05 July 2013 | 09:23</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">This indication has been widely used by Korean doctors.<wbr> It seems that Allergan has organised an ad board to discuss on this indication.<wbr></span>&nbsp;<br><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051" class="commentpermalink">Neurology7051</a> / <span class="date">04 July 2013</span> /
<span class="time">14:01:37 o'clock CEST</span>
</font></div><div>As previously discussed we shall be moving quickly in dscussing and potentially designing a trial for the use of Dysport in this condition which is of high interest in the Asian population.<wbr> </div><!-- Comment details --><font size="-1">Philippe PICAUT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7052" class="commentpermalink">Neurology7052</a> / <span class="date">05 July 2013</span> /
<span class="time">09:23:04 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7052">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050">View thread  Neurology7050: Comparison of Two Botulinum Toxins for Masseter Hypertropy</a>]]></content:encoded><dc:date>2013-07-05T09:23:04+02:00</dc:date><dc:creator>php44614</dc:creator></item><item>
<title>Registration of GP Pharm's Lutrate® 1M in Poland [dis:Prostate, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9060</link>
<description>Registration of GP Pharm's Lutrate® 1M in Poland [dis:Prostate, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Regulatory]</description><category>dis:Prostate</category><category>mkt:Europe</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9060</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9060">Registration of GP Pharm's Lutrate® 1M in Poland</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9060">Oncology9060</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 July 2013 | 16:19</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to A.<wbr> Szczepanska (RAM), we have learnt that the drug was registered in May 2013 in Poland for the palliative treatment of advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">GP Pharm's Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">The product already has been registered in 23 EU country, and launched in Spain, where GP Pharm has its own oncology sales force.<wbr> </div><div style="margin-bottom: 10px;">GP Pharm's lack of EU wide commercial presence may involve the search of a partner for the launch and distribution of Lutrate.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%">Lutrate</SPAN><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%"> 1 month has been authorized following a decentralized procedure in which, in the first phase, Spain participates with the National Agencies of Germany, Italy, Greece and Portugal.<wbr> </SPAN></LI>
<LI><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%">According to the company, the second phase for approval is due to begin in 16 EU countries: UK, Ireland, Sweden, Finland, Denmark, Holland, Belgium, Latvia, Estonia, Lithuania, Poland, Czech Republic, Slovakia, Hungary, Romania and Bulgaria.<wbr> </SPAN></LI>
<LI><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%">In parallel, national approval procedures are expected to be submitted in France, Switzerland and Norway.<wbr> (source: <A href="http://www.gp-pharm.com/news.php?noticia=67">http:/<wbr>/<wbr>www.<wbr>gp-pharm.<wbr>com/<wbr>news.<wbr>php?noticia=67</A>).<wbr></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; LINE-HEIGHT: normal; TEXT-INDENT: 0in; MARGIN: 0pt 0in; unicode-bidi: embed; DIRECTION: ltr; VERTICAL-ALIGN: top; WORD-BREAK: normal; language: en-US; mso-line-break-override: none; punctuation-wrap: hanging"><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%"><STRONG><FONT face="Verdana" size="3">Partnership's Strategy</FONT></STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; LINE-HEIGHT: normal; TEXT-INDENT: 0in; MARGIN: 0pt 0in; unicode-bidi: embed; DIRECTION: ltr; VERTICAL-ALIGN: top; WORD-BREAK: normal; language: en-US; mso-line-break-override: none; punctuation-wrap: hanging"><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%"><FONT face="Verdana"><STRONG>Dec 2012</STRONG> - Lee’s Pharmaceutical Holdings Limited entered into a licensing agreement with GP Pharm to obtain the technological transfer for the registration, production, distribution and marketing of Leuprolide, throughout China, Hong Kong and Macau.<wbr> </FONT></SPAN></P> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%"><FONT face="Verdana">Under the agreement, GP Pharm agrees to manufacture for Lee’s the finished product ready for administration (1 month formulation–3.<wbr>75mg and 3 month depot); and/<wbr>or supplies the bulk product containing Leuprolide acetate (in the form of microcapsules) for the preparation of finished products.<wbr></FONT></SPAN></LI>
</UL> </div><div><SPAN style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; VERTICAL-ALIGN: baseline; FONT-WEIGHT: normal; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: +mn-ea; mso-bidi-font-family: +mn-cs; mso-fareast-theme-font: minor-fareast; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; mso-text-raise: 0%; mso-style-textoutline-type: none; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: black; mso-style-textfill-fill-alpha: 100.0%"><FONT face="Verdana"><STRONG>Oct 2012</STRONG> - Hikma Pharmaceuticals PLC, a pharmaceutical company, entered into a licensing agreement with GP Pharm for oncology compound Lutrate 1 month.<wbr> See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8542" class="defaultlink">Oncology8542: Hikma Signs License and Supply Agreement with GP Pharm for Lutrate 1M</a>.<wbr></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9060">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-04T16:19:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051</link>
<description>re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7051">re: Comparison of Two Botulinum Toxins for Masseter Hypertropy</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051">Neurology7051</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/283">brv82696</a> | 04 July 2013 | 14:01</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Comparison of Two Botulinum Toxins for Masseter Hypertropy</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The findings of the the 24-week double-blind randomized split-face study show that both BTX-A and BTX-B are effective.<wbr> BTX-B at a dose ratio of 1:70 has a comparable efficacy but a shorter duration of action than BTX-A.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7050">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050" class="commentpermalink">Neurology7050</a> / <span class="date">03 July 2013</span> /
<span class="time">18:06:04 o'clock CEST</span>
</font></div><div>This indication has been widely used by Korean doctors.<wbr> It seems that Allergan has organised an ad board to discuss on this indication.<wbr> <a name="Neurology7052c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>As previously discussed we shall be moving quickly in dscussing and potentially designing a trial for the use of Dysport in this condition which is of high interest in the Asian population.<wbr> </div><font size="-1">Philippe PICAUT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7052" class="commentpermalink">Neurology7052</a> / <span class="date">05 July 2013</span> /
<span class="time">09:23:04 o'clock CEST</span>
</font></div></div><!-- Comment details --><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051" class="commentpermalink">Neurology7051</a> / <span class="date">04 July 2013</span> /
<span class="time">14:01:37 o'clock CEST</span>
</font><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7053c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Is masseter hypertrophy considered as a medical indication ? according to publication, 75% of patients with bruxism have masseter hypertrophy.<wbr> The prevalence of Bruxism is estimated at 5-8%.<wbr> </div><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7053" class="commentpermalink">Neurology7053</a> / <span class="date">05 July 2013</span> /
<span class="time">11:32:58 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7051">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050">View thread  Neurology7050: Comparison of Two Botulinum Toxins for Masseter Hypertropy</a>]]></content:encoded><dc:date>2013-07-04T14:01:37+02:00</dc:date><dc:creator>brv82696</dc:creator></item><item>
<title>Grant to Help Accelerate Industrial Process Specific to Nanodrugs [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9056</link>
<description>Grant to Help Accelerate Industrial Process Specific to Nanodrugs [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9056</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9056">Grant to Help Accelerate Industrial Process Specific to Nanodrugs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9056">Oncology9056</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 July 2013 | 12:45</font><br><br><div style="margin-bottom: 10px;">Comment: BioAlliance Pharma received &euro;4.<wbr>3 million from bpifrance (ex OSEO) to accelerate the industrial development of Livatag&reg; (doxorubucin nanoparticle in ongoing Ph3 for primary liver cancer).<wbr> Of note in the company's pipeline, Irinotecan TransDrug(TM) in early development for rare digestive cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to its BD section, BioAlliance is seeking partners to license-out <STRONG>Livatag&reg;:</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>reformulated doxorubicin
</LI>
<LI>has just passed its second Data Safety Monitoring Board (DSMB) assessment.<wbr>
</LI>
<LI>At Ph2, an OS benefit of 17 months was shown in 28 patients, although serious respiratory side effects meant the trial was stopped early.<wbr>
</LI>
<LI>The new iv administration route approved for the Ph3 trial is so far proving safe.<wbr>
</LI>
<LI>The next safety datapoint will be the third DSMB meeting in November 2013.<wbr>
</LI>
<LI>Preliminary Ph3 RELIVE data are due in H116.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competition in 2nd-line HCC</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9056/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>BioAlliance&rsquo;s Transdrug Delivery System</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3">- <FONT size="2">In Livatag&reg;, doxorubicin is formulated in lyophilised bioerodible PIHCA nanoparticles.<wbr> In three human HCC cell lines shown to be resistant to free doxorubicin, 2 doxorubicin Transdrug overcame cell resistance due to the adsorption of nanoparticles onto the cell surface increasing doxorubicin diffusion.<wbr></FONT> </FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>BioAlliance Pharma SnapShot</STRONG></FONT> </div><div style="margin-bottom: 10px;">- HQ: Paris, France.<wbr> </div><div style="margin-bottom: 10px;">- founded in 1997 and today has currently 50 employees.<wbr> </div><div style="margin-bottom: 10px;">- listed on Eurolist Paris (now NYSE Euronext) in 2005 and has raised &euro;87m since IPO.<wbr> </div><div style="margin-bottom: 10px;">- dedicated to cancer and supportive care treatment.<wbr> </div><div style="margin-bottom: 10px;">- identifies and develops innovative products for orphan oncology and specialty markets.<wbr> </div><div style="margin-bottom: 10px;">- marketed product: Loramyc/<wbr>Oravig, a mucoadhesive gingival tablet for the treatment of oropharyngeal candidiasis in adults.<wbr> </div><div style="margin-bottom: 10px;">- pipeline product portfolio includes Sitavir/<wbr>Sitavig for the treatment of recurrent labial herpes in immunocompetent patients and Fentanyl Lauriad for the treatment chronic cancer pain.<wbr> </div><div style="margin-bottom: 10px;">- orphan oncology products portfolio includes Livatag for liver cancer is in Ph3 clinical stage; Validive which is in Ph2 clinical stage and AMEP for invasive melanoma, which is in Ph1.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9056/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Edison; BioAlliance Pharma</EM> </div><!-- Comment details --><a name="oncology9056attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9056/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(130,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9056">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-04T12:45:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9056/2/ScreenCapture2.jpg" length="133186" type="image/jpeg"/></item><item>
<title>Comparison of Two Botulinum Toxins for Masseter Hypertropy [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050</link>
<description>Comparison of Two Botulinum Toxins for Masseter Hypertropy [sub:Aesthetics]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050</comments><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7050">Comparison of Two Botulinum Toxins for Masseter Hypertropy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7050">Neurology7050</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2013 | 18:06</font><br><br><div style="margin-bottom: 10px;">Comment: The findings of the the 24-week double-blind randomized split-face study show that both BTX-A and BTX-B are effective.<wbr> BTX-B at a dose ratio of 1:70 has a comparable efficacy but a shorter duration of action than BTX-A.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Note</FONT></STRONG> </div><div style="margin-bottom: 10px;">This is a non-industry sponsored study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Abstract</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 0.84em/1.45em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed/23774030?dopt=Abstract#" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank" title="Dermatology (Basel, Switzerland).">Dermatology.<wbr></A> 2013 Jun 14.<wbr> [Epub ahead of print]</DIV> </div><div style="margin-bottom: 10px;"><H1 style="LINE-HEIGHT: 1.12em; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; MARGIN: 0.37em 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); FONT-SIZE: 1.23em; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study.<wbr></H1> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 0.92em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20DH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Lee DH</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Jin%20SP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Jin SP</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cho%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Cho S</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Feneran%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Feneran A</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Youn%20CS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Youn CS</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Won%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Won CH</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Park%20GH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Park GH</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kim%20BW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Kim BW</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=An%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">An J</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20SE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Chang SE</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20MW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23774030" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102)" target="_blank">Lee MW</A>.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 0.84em/1.09em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<P style="MARGIN: 0.5em 0px">Department of Dermatology, Seoul National University College of Medicine, Institute of Human-Environment Interface Biology, Seoul National University, Seoul, Korea.<wbr></P></DIV> </div><div><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 1.2em auto auto; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<DIV>
<P style="MARGIN: 0px 0px 0.5em">Background: Masseter hypertrophy can be ameliorated by botulinum toxin.<wbr> </P>
<P style="MARGIN: 0px 0px 0.5em">Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy.<wbr> </P>
<P style="MARGIN: 0px 0px 0.5em">Methods: Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study.<wbr> </P>
<P style="MARGIN: 0px 0px 0.5em">Results: Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy.<wbr> The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.<wbr>6 and 14.<wbr>2%, respectively).<wbr> At week 24, only masseters treated with BTX-A maintained a significant volume reduction.<wbr> Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements.<wbr> </P>
<P style="MARGIN: 0px 0px 0.5em">Conclusion: Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy.<wbr> BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A.<wbr></P></DIV></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7051c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>This indication has been widely used by Korean doctors.<wbr> It seems that Allergan has organised an ad board to discuss on this indication.<wbr> <a name="Neurology7052c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>As previously discussed we shall be moving quickly in dscussing and potentially designing a trial for the use of Dysport in this condition which is of high interest in the Asian population.<wbr> </div><font size="-1">Philippe PICAUT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7052" class="commentpermalink">Neurology7052</a> / <span class="date">05 July 2013</span> /
<span class="time">09:23:04 o'clock CEST</span>
</font></div></div><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7051" class="commentpermalink">Neurology7051</a> / <span class="date">04 July 2013</span> /
<span class="time">14:01:37 o'clock CEST</span>
</font><span style="font-weight: bold; font-style: italic;"></span><a name="Neurology7053c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Is masseter hypertrophy considered as a medical indication ? according to publication, 75% of patients with bruxism have masseter hypertrophy.<wbr> The prevalence of Bruxism is estimated at 5-8%.<wbr> </div><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7053" class="commentpermalink">Neurology7053</a> / <span class="date">05 July 2013</span> /
<span class="time">11:32:58 o'clock CEST</span>
</font></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7050">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-03T18:06:04+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>LG Life Sciences Exports Filler to China [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7049</link>
<description>LG Life Sciences Exports Filler to China [sub:Aesthetics]</description><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7049</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7049">LG Life Sciences Exports Filler to China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7049">Neurology7049</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2013 | 17:26</font><br><br><div style="margin-bottom: 10px;">Comment: Recently the company signed a contract with China's Huadong Medicine Ningbo to export Yvoire Classic and Yvoire Volume.<wbr> China's filler market has ample growth potential.<wbr> Samsung Securities estimates it at KRW47b (vs KRW75b for the Chinese toxin market), taking 62% of the total facial injections market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Marketing Timelines</FONT></STRONG> </div><div style="margin-bottom: 10px;">The 2 fillers should receive sales authorization in 3Q, starting sales in 4Q.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Marketing Partner</FONT></STRONG> </div><div style="margin-bottom: 10px;">Huadong Medicine Ningbo is a Chinese domestic player that focuses on the distribution of plasma derivatives, vaccines and other drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Fillers Overview</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7049/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Composition: cross-linked Hyaluronic Acid 22 mg/<wbr>ml </div><div style="margin-bottom: 10px;">Indication: Correction of facial wrinkles and folds </div><div style="margin-bottom: 10px;">Dosage/<wbr>Adm.<wbr>: mid dermis (Classic); deep dermis (Volume) </div><div style="margin-bottom: 10px;">Shelf Life: 24 months </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Filler Competition in China</FONT></STRONG> </div><div style="margin-bottom: 10px;">Restylane by Galderma Pharma and Juvederm by Allergan.<wbr> </div><div><EM>Source: Samsung Securities</EM> </div><!-- Comment details --><a name="neurology7049attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7049/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7049">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-03T17:26:35+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7049/1/ScreenCapture1.jpg" length="11415" type="image/jpeg"/></item><item>
<title>New Appointment at Merz North America [comp:Merz, :PharmaWorld:sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7047</link>
<description>New Appointment at Merz North America [comp:Merz, :PharmaWorld:sub:People]</description><category>comp:Merz</category><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7047</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7047">New Appointment at Merz North America</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7047">Neurology7047</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2013 | 13:35</font><br><br><div style="margin-bottom: 10px;">Comment: Greg Besase has been appointed VP, dermatology.<wbr> He joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.<wbr>S.<wbr> Dermatology Business Unit since February 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">U.<wbr>S Dermatology Brands</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
<STRONG>Onmel™</STRONG> prescription medicine used to treat fungal infections of the toenails.<wbr></LI>
<LI>
<STRONG>Naftin®</STRONG> to treat interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism <EM>Trichophyton rubrum.<wbr></EM></LI>
<LI>
<STRONG>Aluvea®</STRONG> for strenthening nails.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Besase Mini Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7047/1/ScreenCapture1.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Professional</STRONG> - Prior to joining Merz, Greg worked for Stiefel, a GSK Company, for nine years.<wbr> Greg held several positions with Stiefel including the Head of US Dermatology Marketing, Global Commercial Lead, Sr.<wbr> Product Manager (US), and District Sales Trainer.<wbr> </div><div style="margin-bottom: 10px;">Prior to Stiefel, he worked for ITS Technologies, Inc.<wbr> as a Regional Manager and later as a Business Development &amp; Territory Manager.<wbr> </div><div style="margin-bottom: 10px;">Prior to ITS Technologies, Inc.<wbr>, Greg also held sales &amp; marketing management roles with Advanced Programming Resources, Inc.<wbr> and AIM Executive, Inc.<wbr> Greg brings over 19 years of sales and marketing experience to his role as head of Merz’s Dermatology business unit.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Education</STRONG> - Greg earned his Bachelor’s degree in Business Administration from the University of Toledo in Toledo, Ohio.<wbr> He is based in Merz’s North American headquarters in Greensboro, North Carolina.<wbr> </div><div><EM>Source: Merz</EM> </div><!-- Comment details --><a name="neurology7047attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7047/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(20,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7047">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-03T13:35:55+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7047/1/ScreenCapture1.jpg" length="20902" type="image/jpeg"/></item><item>
<title>Priority Review Given to Roche's Alternative to Rituxan in the US [class:MonoclonalAntibody, :Endocrinology:comp:Roche]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9054</link>
<description>Priority Review Given to Roche's Alternative to Rituxan in the US [class:MonoclonalAntibody, :Endocrinology:comp:Roche]</description><category>class:MonoclonalAntibody</category><category>comp:Roche</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9054</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9054">Priority Review Given to Roche's Alternative to Rituxan in the US</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9054">Oncology9054</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2013 | 13:06</font><br><br><div style="margin-bottom: 10px;">Comment: Last week EU regulators cleared 2 biosimilar versions of Remicade, which represents a risk for Roche as all three of its top selling drugs (Avastin; Herceptin; and Rituxan/<wbr>MabThera) are monoclonal antibody biologics.<wbr> Together they generated 2012 sales of approx.<wbr> $3.<wbr>8 bilion in EU (10% of total sales).<wbr> The company hopes GA-101 will help fend off cheaper competition for Rituxan, which loses patent protection in Europe later this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">GA-101 (obinutuzumad) Expected to Replace Rituxan</FONT></STRONG> </div><div style="margin-bottom: 10px;">- FDA has accepted the company's BLA and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia (CLL).<wbr> </div><div style="margin-bottom: 10px;">- currently being investigated in a large clinical program, including multiple head-to-head Phase III studies versus rituximab in indolent non-Hodgkin’s lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">US Lags Behind Europe</FONT></STRONG> </div><div style="margin-bottom: 10px;">President Obama did authorize the FDA to approve biosimilars in the country when he signed the Patient Protection and Affordable Care Act (PPACA) in 2010.<wbr> </div><div style="margin-bottom: 10px;">However, the act itself was subject to a court case regarding its constitutionality and it was only in mid-2012 when a Supreme Court judgment ruled in favor of the act, thereby clearing the pathway for biosimilar approvals in country.<wbr> </div><div style="margin-bottom: 10px;">As of February 2013, no applications for biosimilar approvals were received by the FDA, and even though reports suggest that preparations to do so may already be underway at some firms, we can expect the U.<wbr>S.<wbr> to continue lagging Europe in the approval process.<wbr> </div><div style="margin-bottom: 10px;">The more time it takes for biosimilars to enter the U.<wbr>S.<wbr> market, the longer Roche’s drugs will dominate the market.<wbr> </div><div><EM>Source: Trefis; Roche</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9054">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-03T13:06:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: The ADT Competitive Area Landscape</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9053</link>
<description>re: The ADT Competitive Area Landscape</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9053</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9053">re: The ADT Competitive Area Landscape</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9053">Oncology9053</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/818">joc45686</a> | 03 July 2013 | 13:01</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The ADT Competitive Area Landscape</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Oncology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=TAL%3aADT"><font color="#e95e0b">:Oncology:TAL:ADT</font></a>]</font></font><br><span style="font-size: 12px;">Comment: As part of CI ongoing commitment to the 'Therapy Area Landscape' service, you will find attached an overview of the Decapeptyl(R) competitive landscape, with the strategy of the key players, and a detailed profile of their product candidates.<wbr><WBR></WBR></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9052">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9052" class="commentpermalink">Oncology9052</a> / <span class="date">02 July 2013</span> /
<span class="time">13:20:32 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Regarding Zytiga intelligence in Ireland suggests that there<SPAN style="line-height: 1.5em;"> are 4 centres in Ireland talking part in clinical trials.<wbr>  We can confirm only Cork University Hospital and Tallaght Hospital, Dublin  at this time.<wbr></SPAN> </div><div><SPAN style="line-height: 1.5em;">At present, </SPAN><SPAN style="line-height: 1.5em;"> Cork University Hospital ar</SPAN><SPAN style="line-height: 1.5em;">e also testing the effectiveness of Zytiga on women with breast cancer.<wbr> There is thought to be a good rationale for using Zytiga against advanced breast cancer since this can be androgen driven as well as estrogen driven and Zytiga cuts off the supplies of both androgens and estrogens reducing their levels to almost zero.<wbr> </SPAN> </div><!-- Comment details --><font size="-1">joc45686 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9053" class="commentpermalink">Oncology9053</a> / <span class="date">03 July 2013</span> /
<span class="time">13:01:26 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9053">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9052">View thread  Oncology9052: The ADT Competitive Area Landscape</a>]]></content:encoded><dc:date>2013-07-03T13:01:26+02:00</dc:date><dc:creator>joc45686</dc:creator></item><item>
<title>Medicis and Mentor Sign Five-Year Aesthetic Collaboration [comp:Allergan, comp:JnJ, comp:Mentor, comp:Medicis, sub:Aesthetics, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7044</link>
<description>Medicis and Mentor Sign Five-Year Aesthetic Collaboration [comp:Allergan, comp:JnJ, comp:Mentor, comp:Medicis, sub:Aesthetics, headline]</description><category>comp:Allergan</category><category>comp:JnJ</category><category>comp:Mentor</category><category>comp:Medicis</category><category>sub:Aesthetics</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7044</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7044">Medicis and Mentor Sign Five-Year Aesthetic Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Neurology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMedicis"><font color="#e95e0b">:Neurology:comp:Medicis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMentor"><font color="#e95e0b">:Neurology:comp:Mentor</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7044">Neurology7044</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2013 | 19:15</font><br><br><div style="margin-bottom: 10px;">Comment: Both companies have formed a collaboration to enter certain of their non-reimbursed products into a combined physician loyalty program, called the M2VP (Medicis-Mentor Valued Partner) program.<wbr> Interesting take from analysts @ Barclays reports that, "the collaboration suggests that J&amp;J/<wbr>Mentor is not close to commercializing its own botulinum toxin .<wbr>.<wbr>.<wbr> While the partnership represents a competitive challenge that Allergan would need to cope, it would be a silver lining if implies that the company’s flagship Botox franchise won’t face a new competitive entrant in the near future".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Does the Program Offer ?</STRONG> </div><div style="margin-bottom: 10px;">Territory: U.<wbr>S-based for now, but could be expanded.<wbr> </div><div style="margin-bottom: 10px;">The program will : </div><div style="margin-bottom: 10px;">- extend the offerings of Medicis' recently launched MVP Program to include the MENTOR(R) line breast implant products.<wbr> </div><div style="margin-bottom: 10px;">- offer numerous incentives that reward utilization of various products across the Mentor and Medicis portfolios.<wbr> </div><div style="margin-bottom: 10px;">- .<wbr>.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Allergan’s loyalty program</STRONG> </div><div style="margin-bottom: 10px;">- provides discounts for achieving certain volume levels.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Testimony</STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Tracy Hankins, a board certified plastic surgeon in Nevada, "I have utilized products from both companies for years and now I can earn valuable rebates and rewards in one easy to understand loyalty program.<wbr>" </div><div><EM>Source: Valeant; Barclays</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7044">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-02T19:15:51+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>The ADT Competitive Area Landscape [dis:Prostate, Alert, TAL:ADT, comp:Astellas, comp:AstraZeneca, comp:JnJ, comp:Takeda]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9052</link>
<description>The ADT Competitive Area Landscape [dis:Prostate, Alert, TAL:ADT, comp:Astellas, comp:AstraZeneca, comp:JnJ, comp:Takeda]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9052</comments><category>dis:Prostate</category><category>Alert</category><category>TAL:ADT</category><category>comp:Astellas</category><category>comp:AstraZeneca</category><category>comp:JnJ</category><category>comp:Takeda</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9052</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9052">The ADT Competitive Area Landscape</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Oncology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=TAL%3aADT"><font color="#e95e0b">:Oncology:TAL:ADT</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9052">Oncology9052</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2013 | 13:20</font><br><br><div style="margin-bottom: 10px;">Comment: As part of CI ongoing commitment to the 'Therapy Area Landscape' service, you will find attached an overview of the Decapeptyl(R) competitive landscape, with the strategy of the key players, and a detailed profile of their product candidates.<wbr><WBR></WBR> </div><div style="margin-bottom: 10px;">This slide kit has been created in close collaboration from the Franchise.<wbr> It will be updated in Q4:13, and include SI input.<wbr> </div><div style="margin-bottom: 10px;">We encourage you to contribute to our internal knowledge by evaluating some of the Key Intelligence Questions included in the document.<wbr> </div><div style="margin-bottom: 10px;">However, no matter what competitive information /<wbr> soft intelligence you have, please do keep us informed on any key developments in your countries.<wbr> </div><div>We hope that you will find it a useful tool.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9053c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Regarding Zytiga intelligence in Ireland suggests that there<SPAN style="line-height: 1.5em;"> are 4 centres in Ireland talking part in clinical trials.<wbr>  We can confirm only Cork University Hospital and Tallaght Hospital, Dublin  at this time.<wbr></SPAN> </div><div><SPAN style="line-height: 1.5em;">At present, </SPAN><SPAN style="line-height: 1.5em;"> Cork University Hospital ar</SPAN><SPAN style="line-height: 1.5em;">e also testing the effectiveness of Zytiga on women with breast cancer.<wbr> There is thought to be a good rationale for using Zytiga against advanced breast cancer since this can be androgen driven as well as estrogen driven and Zytiga cuts off the supplies of both androgens and estrogens reducing their levels to almost zero.<wbr> </SPAN> </div><font size="-1">joc45686 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9053" class="commentpermalink">Oncology9053</a> / <span class="date">03 July 2013</span> /
<span class="time">13:01:26 o'clock CEST</span>
</font></div><a name="oncology9052attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9052/1/DKP%5fTAL%5fFinal%20Version.pptx">DKP_TAL_Final Version.pptx</a>&nbsp;&nbsp;(775,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9052">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-02T13:20:32+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9052/1/DKP%5fTAL%5fFinal%20Version.pptx" length="794215" type="application/vnd.openxmlformats-officedocument.presentationml.presentation"/></item><item>
<title>Daewoong on Track to Export Care Tropin to Russia [class:GrowthHormone, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:Devices]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7392</link>
<description>Daewoong on Track to Export Care Tropin to Russia [class:GrowthHormone, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:Devices]</description><category>class:GrowthHormone</category><category>mkt:Russia</category><category>sub:Devices</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7392</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7392">Daewoong on Track to Export Care Tropin to Russia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7392">Endocrinology7392</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2013 | 12:52</font><br><br><div style="margin-bottom: 10px;">Comment: The Care Tropin pen syringe export has expanded to about 10 countries in just 2 years after its launch, the company reported.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Care Tropin Characteristics</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7392/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Design &amp; Advantages</STRONG> </div><div style="margin-bottom: 10px;">It has the reset button for easy dose adjustment and was designed for safe self-injection.<wbr> </div><div style="margin-bottom: 10px;">This easy-to-use syringe can find applications in bio-medicines such as growth hormone or insulin which needs to be self-injected over the long-term.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Countries</STRONG> </div><div style="margin-bottom: 10px;">Currently, Daewoong is exporting the Care Tropin pen syringe to 7 countries, including Indonesia, Vietnam, Iran, and completed the utility model right registration of the syringe in Taiwan and China in April and December, 2012, respectively.<wbr> </div><div><EM>Source: Daewoong<BR></EM> </div><!-- Comment details --><a name="endocrinology7392attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7392/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7392">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-02T12:52:06+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7392/1/ScreenCapture1.jpg" length="31720" type="image/jpeg"/></item><item>
<title>Enrollment of Neurocrine' NBI-98854 for Tardive Dyskenesia is Complete [dis:Dyskinesia, dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7041</link>
<description>Enrollment of Neurocrine' NBI-98854 for Tardive Dyskenesia is Complete [dis:Dyskinesia, dis:Huntington]</description><category>dis:Dyskinesia</category><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7041</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7041">Enrollment of Neurocrine' NBI-98854 for Tardive Dyskenesia is Complete</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aDyskinesia"><font color="#e95e0b">:Neurology:dis:Dyskinesia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7041">Neurology7041</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2013 | 11:00</font><br><br><div style="margin-bottom: 10px;">Comment: The final subject will randomize this week.<wbr> Topline data from the placebo-controlled portion of the Ph2b trial is expected in approximately ten weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the KINECT Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">The design of this twelve-week Ph2b study is a randomized, parallel, double-blind, placebo-controlled trial of 120 subjects with moderate to severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Characteristics</FONT></STRONG> </div><div style="margin-bottom: 10px;">VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) in pre-synaptic neurons.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Other Indications</FONT></STRONG> </div><div style="margin-bottom: 10px;">NBI-98854 may also be useful in other disorders such as Huntington's chorea, schizophrenia, and Tourette's syndrome.<wbr> </div><div><EM>Source: Neurocrine</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7041">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-02T11:00:53+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Pfizer and Amgen Interested in Acquering Biocad &gt; $1 Billion [:PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, class:MonoclonalAntibody]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9050</link>
<description>Pfizer and Amgen Interested in Acquering Biocad &gt; $1 Billion [:PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, class:MonoclonalAntibody]</description><category>mkt:Russia</category><category>mkt:Intercontinental</category><category>class:MonoclonalAntibody</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9050</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9050">Pfizer and Amgen Interested in Acquering Biocad > $1 Billion</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9050">Oncology9050</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 July 2013 | 11:44</font><br><br><div style="margin-bottom: 10px;">Comment: Any company acquiring Biocad will gain access expertise in the Russian market as well as experience delivering biologic products from the clinic to the market.<wbr> The company is the leading player in terms of monoclonal antibody drug development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Foreign investment in the Russian biosimilar market still in its infancy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Biocad</FONT></STRONG> </div><div style="margin-bottom: 10px;">HQ: St.<wbr> Petesburg </div><div style="margin-bottom: 10px;">Competitive Advantages over domestic players: utilisation of bacterial and mammalian based cell culture techniques.<wbr> </div><div style="margin-bottom: 10px;">Pipeline: focused on biosimilar and next-in-class monoclonal anitbodies (the company is known to develop biosimilar versions of Roche's Avastin, Herceptin and Rituxan).<wbr> </div><div style="margin-bottom: 10px;">Offices: China; India; Brazil (focus on expanding its commercial footprint in Southeast Asia, and Latin America).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Highlights of the Russian Biologics Market</FONT></STRONG> </div><div style="margin-bottom: 10px;">Value: approx $2.<wbr>1 billion.<wbr> </div><div style="margin-bottom: 10px;">Local expertise critical for success.<wbr> </div><div style="margin-bottom: 10px;">No firm regulatory framework for the approval of biosimilars.<wbr> </div><div style="margin-bottom: 10px;">Interchangeability of products for originator brands occurs freely once a biosimilar is launched.<wbr> </div><div style="margin-bottom: 10px;">Trials for new biosimilars are now required.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Players</FONT></STRONG> </div><div style="margin-bottom: 10px;">Roche is the leading provider of onco products to the Russian market (source: Credit Suisse).<wbr> </div><div style="margin-bottom: 10px;">AstraZeneca, Novartis, Novo Nordisk and Sanofi hae all invested in the construction of new domestic manufacturing sites since 2010.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9050">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-01T11:44:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Onyx Still Considering Selling Itself [news, :PharmaWorld:sub:Merger, comp:Amgen]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9049</link>
<description>Onyx Still Considering Selling Itself [news, :PharmaWorld:sub:Merger, comp:Amgen]</description><category>news</category><category>sub:Merger</category><category>comp:Amgen</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9049</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9049">Onyx Still Considering Selling Itself</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAmgen"><font color="#e95e0b">:Oncology:comp:Amgen</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aMerger"><font color="#e95e0b">:PharmaWorld:sub:Merger</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9049">Oncology9049</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 July 2013 | 10:52</font><br><br><div style="margin-bottom: 10px;">Comment: After the rejection of the Amgen offer (approx.<wbr> $10 billion), Onyx is "actively exploring" a merger partner.<wbr> Management said Amgen's cash offer of $120 a share, which represents a premium of about 38% to the company's Friday closing price, "significantly undervalued" its prospects.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Amgen</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Amgen has been looking for new ways to boost its product pipeline as sales for its flagship anemia drugs Aranesp and Epogen have been in a decline for years because of usage restrictions and safety concerns.<wbr> </div><div style="margin-bottom: 10px;">- Acquisition would have bolstered Amgen’s oncology pipeline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Onyx Assets</FONT></STRONG> </div><div style="margin-bottom: 10px;">Onyx sells <U>Nexavar</U>, a treatment for liver and kidney cancer, as well as colon cancer drug <U>Stivarga</U> in partnership with Bayer AG <BAYGN.DE>.<wbr> </BAYGN.DE> </div><div style="margin-bottom: 10px;">Last July, Onyx launched sales of blood cancer drug <U>Krypolis</U> for multiple myeloma after failure of at least 2 therapies.<wbr> (sales of $64mn in FY12 are expected to grow to over $265mn in FY13 and reach nearly $485mn by FY14.<wbr> Sales in 2016 are forecast to be nearly $975mn).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Onyx Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"> <img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">General Trends</FONT></STRONG> </div><div>Large pharmaceutical companies have increasingly been looking to acquire smaller biotech firms to gain access to new drugs, often cancer drugs which can command high prices, as they face significant revenue losses stemming from expired patents.<wbr> </div><!-- Comment details --><a name="oncology9049attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(48,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(109,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(17,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(84 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9049">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-07-01T10:52:50+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/1/ScreenCapture1.jpg" length="64305" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/2/ScreenCapture2.jpg" length="49715" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/3/ScreenCapture3.jpg" length="112014" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/4/ScreenCapture4.jpg" length="18094" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9049/5/ScreenCapture5.jpg" length="86056" type="image/jpeg"/></item><item>
<title>Positive Opinion Granted in EU to Dendreon's PROVENGE® [class:Vaccines, dis:Prostate, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9047</link>
<description>Positive Opinion Granted in EU to Dendreon's PROVENGE® [class:Vaccines, dis:Prostate, :PharmaWorld:mkt:Europe]</description><category>class:Vaccines</category><category>dis:Prostate</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9047</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9047">Positive Opinion Granted in EU to Dendreon's PROVENGE®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9047">Oncology9047</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 June 2013 | 16:35</font><br><br><div style="margin-bottom: 10px;">Comment: The CHMP will make a final recommendation to the <ORG>European Commission</ORG> (EC) within the coming months on the marketing authorization application for PROVENGE® in the EU.<wbr> A regulatory decision is anticipated from the EC in H2 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Approved Indication</FONT></STRONG> </div><div style="margin-bottom: 10px;">Treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Dendreon's CEO Comments</FONT></STRONG> </div><div style="margin-bottom: 10px;">John H.<wbr> Johnson said, "This recommendation represents a significant milestone for <ORG value="NASDAQ-NMS:DNDN">Dendreon</ORG> as we advance the global market opportunity for PROVENGE®.<wbr> We are finalizing our plans for a capital-efficient launch in <LOCATION value="LR/eur">Europe</LOCATION>, including evaluating our partnering options .<wbr>.<wbr>.<wbr>".<wbr> </div><div><EM>Source: Dendreon</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9047">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-28T16:35:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Celltrion and Hospira to Sell First Copies of J&amp;J's Remicade [news, dis:IBD, sub:Generics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1899</link>
<description>Celltrion and Hospira to Sell First Copies of J&amp;J's Remicade [news, dis:IBD, sub:Generics]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1899</comments><category>news</category><category>dis:IBD</category><category>sub:Generics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1899</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1899">Celltrion and Hospira to Sell First Copies of J&J's Remicade</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=sub%3aGenerics"><font color="#e95e0b">:GastroEnterology:sub:Generics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1899">GastroEnterology1899</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 June 2013 | 16:28</font><br><br><div style="margin-bottom: 10px;">Comment: The European Commission should give the two companies approval to market their versions, called Remsima and Inflectra, for the same medical conditions for which Remicade is marketed.<wbr> The EMA’s recommendations are the final stage before the European Commission, the European Union’s executive arm, approves or rejects a drug for sale to patients in the 27-nation region.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Steps</FONT></STRONG> </div><div style="margin-bottom: 10px;">The decision clears the way for biosimilar versions of other monoclonal antibodies, which account for some of the world’s best-selling medicines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Remsima &amp; Inflectra Indications</FONT></STRONG> </div><div style="margin-bottom: 10px;">Same as Remicade: RA; UC; ankylosing spondylitis, CD, psoriasis and psoriatic arthritis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Low Price</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Remsima will be more than 30% cheaper than the original drug, according to Kim Hyoung Ki (senior VP and CFO at Celltrion).<wbr> </div><div><EM>Source: Bloomberg</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology1912c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">European Commission approved Inflectra (infliximab), making the product the first biosimilar monoclonal antibody therapy authorised in the EU.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 22px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Savings Coming from Three Countries</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 22px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="background-color: #ffffff;">Hospira suggested that the launch of biosimilar monoclonal antibody products in Europe is expected to deliver savings of up to 20.<wbr>4 billion euros ($27 billion) by 2020, with the greatest savings coming from France, Germany and the UK.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 22px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Approvals in the US &amp; Japan</SPAN></STRONG> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="background-color: #ffffff;">At the time of the CHMP's recommendation, Celltrion said it was planning to seek approval of Inflectra in Japan later this year, while an application in the US is possible in 2015.<wbr></SPAN></SPAN> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1912" class="commentpermalink">GastroEnterology1912</a> / <span class="date">11 September 2013</span> /
<span class="time">10:45:18 o'clock CEST</span>
</font></div><a name="GastroEnterology2246c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">On Feb.<wbr>16th Hospira announced additional launches of Inflectra, the 1st biosimilar mAb, in major EU markets (Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, Netherlands, Spain and Sweden).<wbr> The drug has already been launched in CEE, and some smaller Western European markets due to earlier patent expiry, and has already been prescribed to treat patients in all its licensed indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Indications</FONT></STRONG> </div><div style="margin-bottom: 10px;">The drug covers several indications, and is indicated for the treatment of RA, psoriatric arthritis, ankylosing spondylitis, adult and ped IBD (Crohn's disease and ulcerative colitis), and plaque psoriasis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Country Coverage</FONT></STRONG> </div><div style="margin-bottom: 10px;">Europe - With the launch of the product in these new markets, Inflectra is now available in 24 EU countries </div><div>USA - Hospira's partner, Celltrion, has also submitted an application to the U.<wbr>S.<wbr> Food and Drug Administration for biosimilar infliximab.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2246" class="commentpermalink">GastroEnterology2246</a> / <span class="date">16 February 2015</span> /
<span class="time">14:09:58 o'clock CET</span>
</font></div><a name="GastroEnterology2262c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Mundipharma is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of relevant Remicade patents.<wbr> Hospira is to sell its product Inflectra in markets including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain and Sweden.<wbr> Another test for biosimilars is looming in the United States, where a FDA advisory committee will decide on March 17 whether to recommend Celltrion's biosimilar version of Remicade.<wbr> </div><div style="margin-bottom: 10px;">Copies of Remicade have been on sale for several months in some smaller European markets, such as Norway, but the move into major economies is a big step forward for products that could disrupt the multibillion-dollar biotechnology industry.<wbr><BR><BR>Jorgen Jahnsen, professor of medicine and gastroenterology at the University of Oslo, said that in Norway the use of biosimilar infliximab had already enabled the healthcare system to make considerable savings.<wbr> </div><div>source: thomsonOne </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2262" class="commentpermalink">GastroEnterology2262</a> / <span class="date">25 February 2015</span> /
<span class="time">11:05:20 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1899">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-28T16:28:15+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>First Rotavirus Vaccine for the Chinese Market [dis:Diarrhoea, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1898</link>
<description>First Rotavirus Vaccine for the Chinese Market [dis:Diarrhoea, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Diarrhoea</category><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1898</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1898">First Rotavirus Vaccine for the Chinese Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1898">GastroEnterology1898</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 June 2013 | 14:39</font><br><br><div style="margin-bottom: 10px;">Comment: International Medica, a nonprofit foundation, has been developing a oral rotavirus vaccine to protect very young infants.<wbr> The foundation reported it has sublicensed it to Shanghai BravoBio Co.<wbr>, Ltd.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT style="BACKGROUND-COLOR: #ffffff"><FONT face="Verdana"><FONT size="2">Based on the RRV-TV vaccine originally developed at the National Institutions of Health, International Medica has successfully completed a large safety and efficacy Ph2 trial in Africa in 998 young infants that received both doses of the vaccine before they were 2 months old.<wbr></FONT></FONT></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT style="BACKGROUND-COLOR: #ffffff"><STRONG><FONT face="Verdana" size="3">Shanghai BravoBio </FONT></STRONG><A href="http://www.bravobio.com/aboutus.html"><STRONG><FONT face="Verdana" size="3">SnapShot</FONT></STRONG></A></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">- private biotech</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">- HQ: Shanghai</FONT></SPAN> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">- Focus: to develop, manufacture and market preventive therapeutic and diagnostic biologics in China.<wbr></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1898">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-28T14:39:58+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Intelligence Review From ENDO 2013 [:PharmaWorld:congress:ENDO, comp:Genentech, comp:Roche, comp:Novartis, dis:Cushing, dis:Acromegaly, prod:Pasireotide, prod:Octreotide, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7385</link>
<description>Intelligence Review From ENDO 2013 [:PharmaWorld:congress:ENDO, comp:Genentech, comp:Roche, comp:Novartis, dis:Cushing, dis:Acromegaly, prod:Pasireotide, prod:Octreotide, headline]</description><category>congress:ENDO</category><category>comp:Genentech</category><category>comp:Roche</category><category>comp:Novartis</category><category>dis:Cushing</category><category>dis:Acromegaly</category><category>prod:Pasireotide</category><category>prod:Octreotide</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7385</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7385">Intelligence Review From ENDO 2013</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aGenentech"><font color="#e95e0b">:Endocrinology:comp:Genentech</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=congress%3aENDO"><font color="#e95e0b">:PharmaWorld:congress:ENDO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7385">Endocrinology7385</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 28 June 2013 | 13:24</font><br><br><div style="margin-bottom: 10px;">Comment: Additional data from the extension study of Phase 3 Pasireotide LAR in acromegaly confirmed suppression of GH (&lt;2.<wbr>5&micro;g/<wbr>L) and IGF-1 was maintained over 25 months and Pasireotide LAR was found to hold promise as a treatment option for patients with acromegaly inadequately controlled with octreotide LAR.<wbr> </div><div style="margin-bottom: 10px;">The Endocrine Society (ENDO) congress was held at the Moscone Conference Center in San Francisco (June 2013).<wbr> The congress was attended by a Consultant who provided Ipsen with the below overview.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Octreolin Intelligence Gathered</U></STRONG> </div><div style="margin-bottom: 10px;">1.<wbr> Two medical representatives confirmed that data from the phase 3 study of Octreolin in Acromegaly will be released at the end of 2013.<wbr> FDA will review the data to decide whether a trial will be necessary in the USA.<wbr> The lack of participation by the US in the phase 3 trial of Octreolin in acromegaly remains unclear.<wbr> One US KOL believes the reason for the delay was due to financial concerns by the company.<wbr> The general consensus by the majority of KOLs was that the FDA will not approve Octreolin unless it has been tested in the US.<wbr> </div><div style="margin-bottom: 10px;">2.<wbr> The representatives at the Genentech booth stressed that the company has a successful endocrinology franchise which Roche promised to build on when acquiring the company 2 years ago.<wbr> Octreolin will be a way of expanding Roche&rsquo;s oncology franchise whilst also building on Genentech&rsquo;s existing endocrinology franchise </div><div style="margin-bottom: 10px;"><STRONG><U>Long Acting Octreotide from DongKook</U></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>An Observational, Comparative Trial In Patients With Active Acromegaly Receiving A New Long-Acting Octreotide Formulation who Were Previously Treated With The Original Octreotide Formulation (Sandostatin Lar) - </STRONG>Author: Dr.<wbr> Wilson Gallardo, Neuroendocrinology Unit, (Unidad De Neuroendocrinolog&iacute;a), Guillermo Almenara-Irigoyen National Hospital, Lima, Peru </div><div style="margin-bottom: 10px;">The new long-acting octreotide formulation is a generic monthly depot from DongKook (Korea).<wbr> The author stated that the generic formulation had not been properly evaluated and noted that high levels of octreotide were detected during the first week which steadily decreased to no detectable levels by week 4.<wbr> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7384" class="defaultlink">Endocrinology7384: SMNE Rejects DongKook's Octreotide LAR for Acromegaly</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Poster (MON-4393)</STRONG> described an observational comparative trial in patients with active acromegaly receiving a new long acting octreotide formulation previously treated with Sandostatin LAR.<wbr> The study was undertaken in Peru where the drug has been introduced in the market.<wbr> The results showed that of the 18 patients enrolled, 77.<wbr>8% (n=14) had normalised IGF-1 values following Sandostatin LAR.<wbr> However following treatment with new long acting octreotide, only 38% (n=7) of patients had normalised IGF-1.<wbr> The clinical course of patients did not improve with the new long acting octreotide, uncontrolled patients showed greater evidence of disease activity.<wbr> Overall 44.<wbr>4% of patients (n=8) receiving new octreotide agent experienced adverse events which is twice the amount observed with Sandostatin LAR (22% n=4).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Novartis Summary</U></STRONG> </div><div style="margin-bottom: 10px;">Novartis had a notable presence at the meeting, the focus being on the introduction of Signifor (pasireotide) as a new treatment for Cushing&rsquo;s Disease, both at the booth and also at an evening symposium entitled <STRONG>&ldquo;Cushing&rsquo;s Disease: When Surgery Fails&rdquo;</STRONG> where three keynote speakers discussed the problems in diagnosis of Cushing&rsquo;s Syndrome, radiation treatment and advances in medical therapy.<wbr> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>A phase III study evaluating Pasireotide LAR in Cushing&rsquo;s Disease has just started with patient recruitment.<wbr> The study finish date is estimated at 2016.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>Intelligence gained from the Novartis medical representatives would not confirm either way whether the technology from Camurus would be used for pasireotide.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Key messages from the symposium:</STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI><STRONG>Lynette Nieman,</STRONG> MD (NICHD, NIH) described the plethora of signs and symptoms of Cushing&rsquo;s disease and the caveats associated with current tests used for diagnosis of Cushing&rsquo;s disease (UFC, salivary cortisol, dexamethasone suppression test).<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI><STRONG>John Suh,</STRONG> MD (Cleveland Clinic) described the various radiation modalities used for treating pituitary adenomas, Cushing&rsquo;s Disease and Nelson&rsquo;s syndrome.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI><STRONG>Stephan Petersenn,</STRONG> MD (ENDOC Center for Endocrine Tumours, Germany) presented a summary of the key advances in medical management of Cushing&rsquo;s Disease.<wbr> These included: Metyrapone and LC1699 (inhibitor of 11&beta;-Hydroxylase) where a proof of concept study was presented at ENEA 2012; carbegoline; pasireotide (data from phase 3 registration trial published in <EM>N Engl J Med</EM> 2012; 366 914-924) and Mifepristone (RU-486) a progesterone antagonist with glucocorticoid receptor antagonist activity which is licensed to control hyperglycaemia in Cushing&rsquo;s syndrome in the US.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Take home messages</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Pasireotide: always follow up with biochemical tests to exclude conditions such as adrenal insufficiency.<wbr> If patients do not show any improvement after 1-2 months of pasireotide treatment, then discontinue as probable non responders.<wbr>
</LI>
<LI>Mifepristone: disadvantage- there is no biochemical marker to monitor efficacy of drug.<wbr> Rely on clinical symptoms
</LI>
<LI>See PDF for slide booklet provided by NVS - attached
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>Pasireotide Posters Overview - Acromegaly</U></STRONG> </div><div style="margin-bottom: 10px;">Poster SUN-88 was entitled <STRONG>&ldquo;Inhibition of GH and IGF-1 is maintained with Pasireotide LAR and octreotide LAR in Patients with Acromegaly: 12 month Extension Phase of a double-blind, multicenter, randomised Phase III study&rdquo;, </STRONG>presented by M.<wbr> Sheppard (UK).<wbr> full poster can be viewed at <SPAN style="font-family: 'Arial','sans-serif'; font-size: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><A href="http://novartis.medicalcongressposters.com/Default.aspx?doc=d6067">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=d6067</A></SPAN> </div><div style="margin-bottom: 10px;">In a randomised, 12 month core study, 358 medically na&iuml;ve pts with acromegaly were randomised 1:1 to PAS LAR 40mg/<wbr>28 days or OCT LAR 20mg/<wbr>28 days.<wbr> At month 12, 120 pts continued on their randomised therapy in an extension phase and were evaluated in this analysis.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The second featured poster SUN-89 was entitled: <STRONG>&ldquo;Pasireotide LAR and Octreotide LAR Normalize Prolactin Levels in Patients with Acromegaly and Hyperprolactinemia: Results from a randomised, double-blind, 12-month, Phase III study&rdquo;</STRONG> Colao A et al.<wbr> Full poster can be viewed at <SPAN style="font-family: 'Arial','sans-serif'; font-size: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><A href="http://novartis.medicalcongressposters.com/Default.aspx?doc=794a8"><FONT color="#0000ff">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=794a8</FONT></A></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Results below: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/8/ScreenCapture8.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A <STRONG>key poster</STRONG> SUN 95 entitled: <STRONG>&ldquo;Improvement of Biochemical Control in Patients with Acromegaly Switched from Octreotide LAR to Pasireotide LAR: Crossover Extension to a double-blind, multicenter, randomised, Phase III study</STRONG>&rdquo;, by Freda P et al, suggested that pasireotide LAR holds promise as a treatment option for patients with acromegaly inadequately controlled with octreotide LAR.<wbr> Of the 81 patients inadequately controlled with octreotide LAR who switched to pasireotide LAR, 14 (17.<wbr>3%) had biochemical control 12 months after crossover.<wbr> Of the 38 patients inadequately controlled with pasireotide LAR who switched to octreotide LAR, none had biochemical control 12 months after crossover.<wbr> The full poster can be accessed on <A href="http://novartis.medicalcongressposters.com/Default.aspx?doc=dffab">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=dffab</A> </div><div style="margin-bottom: 10px;"><STRONG>Pasireotide Poster Review- Cushing&rsquo;s Disease</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>&ldquo;Evaluation of Late-night Salivary Cortisol during 12 months of Pasireotide Treatment in patients with Cushing&rsquo;s Disease&rdquo;,</STRONG> Biller BMK et al.<wbr> Full poster can be viewed at <A href="&ldquo;,&rdquo;http:/novartis.medicalcongressposters.com/Default.aspx?doc=49ff9&ldquo;,&rdquo;">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=49ff9</A> </div><div>&ldquo;<STRONG>Improvements in the Clinical Signs and symptoms of Cushing&rsquo;s Disease following 12 month&rsquo;s treatment with Pasireotide are not restricted to patients who achieve UFC Control&rdquo;,</STRONG> Pivonello R etal.<wbr> Full poster can be viewed at <A href="http://novartis.medicalcongressposters.com/Default.asox?doc=354b2">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>asox?doc=354b2</A> </div><!-- Comment details --><a name="endocrinology7385attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(46,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(49,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/11/Novartis%20Symposium%20ENDO%2013%20(1).pdf">Novartis Symposium ENDO 13 (1).pdf</a>&nbsp;&nbsp;(6,4 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7385">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-28T13:24:15+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/1/ScreenCapture1.jpg" length="47973" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/6/ScreenCapture6.jpg" length="50912" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7385/11/Novartis%20Symposium%20ENDO%2013%20(1).pdf" length="6686093" type="application/pdf"/></item><item>
<title>MedyTox' Neuramis Deep to Generate Synergy with Meditoxin in Korea [comp:MediTox, sub:Aesthetics, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7040</link>
<description>MedyTox' Neuramis Deep to Generate Synergy with Meditoxin in Korea [comp:MediTox, sub:Aesthetics, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</description><category>comp:MediTox</category><category>sub:Aesthetics</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7040</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7040">MedyTox' Neuramis Deep to Generate Synergy with Meditoxin in Korea</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7040">Neurology7040</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 June 2013 | 11:51</font><br><br><div style="margin-bottom: 10px;">Comment: In Korea, the leading sellers from a filler product perspective are Galderma's Restylane, Aleergan's Juvederm, and LG Lifesciences' Yvoire.<wbr> Release of Neuramis Deep is expected 3Q:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Neuramis Characteristics</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7040/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Stabilized Hyaluronic Acid &amp; Purification Enhancement (SHAPE Technology): </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7040/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Sources: MedyTox: Shinhan Investment Corp.<wbr></EM> </div><!-- Comment details --><a name="neurology7040attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7040/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7040/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(75,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7040">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-28T11:51:37+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7040/1/ScreenCapture1.jpg" length="31978" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7040/2/ScreenCapture2.jpg" length="77457" type="image/jpeg"/></item><item>
<title>DCVax-Direct Progresses in Ph1/2 Trial for All Solid Tumor Cancers</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9045</link>
<description>DCVax-Direct Progresses in Ph1/2 Trial for All Solid Tumor Cancers</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9045</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9045">DCVax-Direct Progresses in Ph1/<wbr>2 Trial for All Solid Tumor Cancers</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9045">Oncology9045</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2013 | 17:04</font><br><br><div style="margin-bottom: 10px;">Comment: Northwest Biotherapeutics has announced that its 60-patient Ph1/<wbr>2 clinical trial of DCVax-Direct for all inoperable solid tumor cancers has been initiated at the U.<wbr> of Texas MD Anderson Cancer Center in Houston, Texas.<wbr> Other sites in the US and UK to follow.<wbr> PE will assess number of patients with AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug's Advantages</FONT></STRONG> </div><div style="margin-bottom: 10px;">DCVax-Direct offers a potential new treatment option for the many clinical situations in which patients' tumors are considered inoperable either because of the location or type of cancer, or because of the spread of multiple tumors.<wbr> </div><div style="margin-bottom: 10px;">A large number of patients with lung, colon, pancreatic, liver, ovarian, melanoma, head and neck, and other cancers such as sarcomas face this situation today, and it carries a bleak prognosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Technology</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9045/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><A href="http://www.nwbio.com/product_candidates_platforms.php">http:/<wbr>/<wbr>www.<wbr>nwbio.<wbr>com/<wbr>product_candidates_platforms.<wbr>php</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01882946?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F27%2F2013&amp;rank=8"><STRONG><FONT size="3">NCT01882946</FONT></STRONG></A> </div><div style="margin-bottom: 10px;"><STRONG>PI</STRONG>: Dr.<wbr> Vivek Subbiah, MD (Assistant Professor in the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine) programs), </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: groups or “cohorts” of patients with numerous different types of cancers, including pancreatic, colon, liver, melanoma, and various other cancers </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG>: In the Ph1 stage, the trial will test various dose levels of DCVax-Direct.<wbr> </div><div style="margin-bottom: 10px;">The trial will then proceed directly into the Ph2 stage to test the efficacy of the DCVax-Direct treatment.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint for measurement of efficacy will be tumor regression (i.<wbr>e.<wbr>, shrinkage or elimination).<wbr> As is standard with Ph1/<wbr>2, this trial will not be blinded.<wbr> Accordingly, it is anticipated that early results of the trial may be emerging throughout the remainder of 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Other Ongoing Trials</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Company also previously received clearance from the FDA for a 612-patient Ph3 trial in prostate cancer, and clearance from the FDA for Ph1/<wbr>2 trials in multiple other cancers.<wbr> The Company also conducted a Ph1/<wbr>2 trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.<wbr> </div><div><EM>Source: Northwest Biotherapeutics</EM> </div><!-- Comment details --><a name="oncology9045attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9045/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(54,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9045">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-27T17:04:11+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9045/1/ScreenCapture1.jpg" length="55858" type="image/jpeg"/></item><item>
<title>New Data Confirms miR-34 is an Important Potential Target for Variety of Cancers [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9044</link>
<description>New Data Confirms miR-34 is an Important Potential Target for Variety of Cancers [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9044</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9044">New Data Confirms miR-34 is an Important Potential Target for Variety of Cancers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9044">Oncology9044</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2013 | 15:21</font><br><br><div style="margin-bottom: 10px;">Comment: The data are published in <EM>Molecular Therapy</EM> and reveals a novel mechanism through which miR-34 exerts its tumor suppressor function in cancers.<wbr> Mirna is currently conducting a Ph1 of MRX34, a miR-34-based therapy and the first microRNA mimic to advance into a human clinical trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Data</FONT></STRONG> </div><div style="margin-bottom: 10px;">The data published in the paper entitled: “TP53-independent function of miR-34a via HDAC1 and p21CIP1/<wbr>WAF1” demonstrate that the tumor suppressive activity of miR-34 is the same in p53-positive and p53-negative cancer cells.<wbr> </div><div style="margin-bottom: 10px;">The study further revealed the existence of a p53-independent pathway by which miR-34 induces the expression of p21, a potent tumor suppressor inhibiting uncontrolled cellular proliferation.<wbr> The endogenous level of p21 was shown to be critical for maximal miR-34 activity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8944" class="defaultlink">Oncology8944: Mirna is First to Advance MicroRNA into the Clinic for Cancer</a>.<wbr> - The Ph1 focuses on patients with unresectable primary liver cancer or metastatic cancer with liver involvement.<wbr> </div><div><EM>Source: Mirna</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9044">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-27T15:21:39+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>PeptiDream and Pfizer Mutually End Deal [sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10506</link>
<description>PeptiDream and Pfizer Mutually End Deal [sub:xLicensing]</description><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10506</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10506">PeptiDream and Pfizer Mutually End Deal</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10506">PharmaWorld10506</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2013 | 14:20</font><br><br><div style="margin-bottom: 10px;">Comment: PeptiDream has reported that it and Pfizer mutually terminated a 2010 deal (which objectives was to discover macrocyclic peptides to link to the pharma's CovX-Bodies).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Termination Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">PeptiDream retains rights to compounds discovered under the deal, inclusing macrocyclic peptides the company reported are "standalones", and sait it plans to "take them forward and potentially partnered them".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">Pfizer acquired CoVx Pharm in 2007 for the CovX Body technology, which linked  peptides to a single antibody as a scaffold to allow half-life extension and bioavailability.<wbr> </div><div><EM>Souce: Biocentury</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10506">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-27T14:20:18+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>SMNE Rejects DongKook's Octreotide LAR for Acromegaly [comp:Novartis, prod:Octreotide, sub:Generics, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7384</link>
<description>SMNE Rejects DongKook's Octreotide LAR for Acromegaly [comp:Novartis, prod:Octreotide, sub:Generics, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico, headline]</description><category>comp:Novartis</category><category>prod:Octreotide</category><category>sub:Generics</category><category>mkt:Intercontinental</category><category>mkt:Mexico</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7384</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7384">SMNE Rejects DongKook's Octreotide LAR for Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=sub%3aGenerics"><font color="#e95e0b">:Endocrinology:sub:Generics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aMexico"><font color="#e95e0b">:PharmaWorld:mkt:Mexico</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7384">Endocrinology7384</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2013 | 12:00</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to H.<wbr> Dumont (Endocrinology Franchise) we have got some strategic feedback on DongKook's Octreotide LAR.<wbr> In a letter sent by the Mexican National Endocrinology Society (SMNE- Sociedad Mexicana de Nutricion y Endocrinologia) to its members, it was outlined the "very bad quality" of the drug, a reduced efficacy, frequent AEs, and significant differences in the formulation (vs Sandostalin LAR).<wbr> The last paragraph concluded the rejection of the generic for "patient good's".<wbr> Additional details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages from the Content of the Letter</FONT></STRONG> </div><div style="margin-bottom: 10px;">(Full letter attached) </div><div style="margin-bottom: 10px;">On Oct.<wbr> 13 2012, Dr Jose Athie and Dr Nelson de Franco representatives from Novartis Oncology presented the recently approved Octreotide LAR from DongKook.<wbr> Representatives from the SMNE, Dr Francisco Velazquez as ell as Dr Wilson Gallardo, investigator of the Peruvian study, attended the meeting.<wbr> </div><div style="margin-bottom: 10px;">The objective was to discuss the recently approval of the drug by <A href="http://www.cofepris.gob.mx/Paginas/Inicio.aspx">COFEPRIS</A> (Comisión Federal para la Protección contra Riesgos Sanitarios).<wbr> </div><div style="margin-bottom: 10px;">Dr Gallardo presented the preliminary results on 18 patients (10 males + 8 females) - (see attached) Number of reported SEs is higher with DongKook's octreotide LAR (erythematous dermatitis, abdominal pain, vomiting and 1 case of severe bronchspasm).<wbr> </div><div style="margin-bottom: 10px;">It was reported that the DongKook's formulation is <SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">a polymer, and  includes impurities that lead to a erratic pharmacokinetic profile.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;">More importantly, according to analysis done by Novartis <SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> <FONT face="Verdana" size="2">the content of octreotide in this preparation is 50 % when it is compared with the original formulation.<wbr> According to pharmacokinetic of this product, the therapeutic level is obtain for less than 2 weeks (The area under the curve AUC is 20 % of LAR)</FONT></SPAN>.<wbr> </div><div style="margin-bottom: 10px;"><FONT face="Verdana"><FONT size="2"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Also outlined in the letter, the rejection of the product by the FDA, the EMA, and the Department of Health of Brazil.<wbr>  </FONT></SPAN></FONT></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">DongKook's Drug Status</FONT></STRONG> </div><div><UL><LI>Peru - see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=6946" class="defaultlink">Endocrinology6946: Dongkook Registers Octreotide In Peru</a>.<wbr></LI>
<LI>Chili - the product is registered.<wbr></LI>
<LI>Mexico - approved in 2012; already available in some public hospitals (although doctors are 'not happy').<wbr></LI>
<LI><FONT color="#222222">the product is not authorized in South Korea (country of origin<FONT face="Arial">)</FONT></FONT>.<wbr></LI>
</UL> </div><!-- Comment details --><a name="endocrinology7384attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7384/1/PeruvianStudy.pdf">PeruvianStudy.pdf</a>&nbsp;&nbsp;(49,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7384/2/SMNE%5fOctreotido%5fLar%5fGen%c3%a9rico1%20(1).pdf">SMNE_Octreotido_Lar_Genérico1 (1).pdf</a>&nbsp;&nbsp;(266,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7384">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-27T12:00:39+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7384/1/PeruvianStudy.pdf" length="50433" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7384/2/SMNE%5fOctreotido%5fLar%5fGen%c3%a9rico1%20(1).pdf" length="272825" type="application/pdf"/></item><item>
<title>Cumberland Pharma's Lactulose to Enter POC Trial for Bowel Cleasing [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1895</link>
<description>Cumberland Pharma's Lactulose to Enter POC Trial for Bowel Cleasing [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</description><category>sub:CRCPrevention</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1895</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1895">Cumberland Pharma's Lactulose to Enter POC Trial for Bowel Cleasing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1895">GastroEnterology1895</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2013 | 17:15</font><br><br><div style="margin-bottom: 10px;">Comment: The drug already is launched as Kristalose(R) for Oral solution, a prescription laxative.<wbr> It is the only prescription laxative available in pre-measured powder packets, making it easily portable.<wbr> PE of the Ph2 study will assess efficacy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Kristalose(R) (lactulose) Description</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1895/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01887470?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F26%2F2013&amp;rank=132"><STRONG><FONT size="3">Trial Details NCT01887470</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 40 (both genders) </div><div>Start date: June 2013 /<wbr> Completion date: October 2013 </div><!-- Comment details --><a name="gastroenterology1895attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1895/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(152,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1895">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-26T17:15:54+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1895/1/ScreenCapture1.jpg" length="156519" type="image/jpeg"/></item><item>
<title>First Patient Enrolled in Enzalutamide Global Ph2 for Breast Cancer [comp:Astellas, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9043</link>
<description>First Patient Enrolled in Enzalutamide Global Ph2 for Breast Cancer [comp:Astellas, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Astellas</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9043</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9043">First Patient Enrolled in Enzalutamide Global Ph2 for Breast Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9043">Oncology9043</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2013 | 14:09</font><br><br><div style="margin-bottom: 10px;">Comment: Medivation is conducting this study under its agreement with Astellas.<wbr> The results from the Ph 1 study in breast cancer will be presented at an upcoming scientific conference.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Design: open label, single-arm, multicenter trial </div><div style="margin-bottom: 10px;">Recruitment: approximately 80 patients with AR-positive, TNBC </div><div style="margin-bottom: 10px;">Location: United States, Canada and Europe.<wbr> </div><div style="margin-bottom: 10px;">PE: clinical benefit rate, defined as the proportion of patients with a best response of complete response, partial response or stable disease at ≥ 16 weeks.<wbr> </div><div style="margin-bottom: 10px;">Protocol: All patients will receive enzalutamide at a dose of 160 mg to be taken orally once daily.<wbr> </div><div><EM>Source: Medivation/<wbr>Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9043">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-26T14:09:18+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Lexicon Presents Diabetes Data at ADA [dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7383</link>
<description>Lexicon Presents Diabetes Data at ADA [dis:Diabetes]</description><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7383</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7383">Lexicon Presents Diabetes Data at ADA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7383">Endocrinology7383</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2013 | 11:49</font><br><br><div style="margin-bottom: 10px;">Comment: Key presentations include the PC data on LX2761 designed to reduce glucose absorption from GI tract, and the reduction of blood pressure and weight loss of LX4211.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">LX2761 - Key Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">Oral presentation titled “LX2761, an SGLT1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice.<wbr>” </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7383/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>LX2761 resulted in no urinary glucose excretion in mice while showing delayed intestinal glucose absorption and increased postprandial GLP-1 levels in mice, both alone and synergistically with the DPP-4 inhibitor sitagliptin.<wbr> Notably, blood glucose excursions after an oral glucose challenge were still decreased 15 hours after oral LX2761 administration.<wbr> Finally, LX2761 improved glycemic control in STZ-diabetic mice and in the KKAy mouse model of type 2 diabetes, as measured by reductions in hemoglobin A1c and oral glucose tolerance test results.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">LX4211 - Key Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">Oral presentation titled “LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, Reduces Blood Pressure in Patients with Type 2 Diabetes.<wbr>” </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7383/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><UL><LI>LX4211 lowers blood pressure to a greater extent in those patients who are in the greatest need of treatment, that is, those patients with hypertension.<wbr> Furthermore, patients with normal blood pressure showed little or no change on LX4211treatment, a promising finding in regard to future development of LX4211.<wbr></LI>
</UL> </div><!-- Comment details --><a name="endocrinology7383attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7383/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7383/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(44,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7383">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-26T11:49:47+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7383/1/ScreenCapture1.jpg" length="48116" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7383/2/ScreenCapture2.jpg" length="45733" type="image/jpeg"/></item><item>
<title>High-Dose of Octreotide LAR to Be Tested in POC Trial [comp:Novartis, headline, prod:Octreotide, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7381</link>
<description>High-Dose of Octreotide LAR to Be Tested in POC Trial [comp:Novartis, headline, prod:Octreotide, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Novartis</category><category>headline</category><category>prod:Octreotide</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7381</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7381">High-Dose of Octreotide LAR to Be Tested in POC Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7381">Endocrinology7381</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2013 | 11:26</font><br><br><div style="margin-bottom: 10px;">Comment: In collaboration with Novartis and sponsored by H.<wbr> Lee Moffitt Cancer Center and Research Institute (in the US), the Ph2 will evaluate the effects of 60mg IM q 4 wks of octreotide LAR on flushing, diarrhea, and QoL in patients <SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">whose disease-related symptoms are inadequately controlled by the maximum approved dose of octreotide LAR.<wbr> Please see below an anlysis of the Endocrinology Franchise.<wbr></FONT></FONT></SPAN> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3"><STRONG>Comment from the ENDOCRINOLOGY Franchise</STRONG></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">This is a high dose study in FNET.<wbr> Octreotide LAR is administered 60 mg q 4wks.<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">This is why it is a Phase II study.<wbr> ( Smpc max dose = 30 mg q 4wks.<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Besides no other particularities :</FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">- small sample size , n= 30</FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">- one center </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">- open label, one arm</FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">-midgut NET.<wbr>.<wbr>.<wbr>but with patients somehow resistant previously to usual dose 30 mg every 4 or even 3 weeks ( reduced interval).<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">- no clear indication of treatment period duration ( this would be a key information ?).<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">- tumor control is assessed as a secondary endpoint.<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">In conclusion, </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">this study seems to acknowledge the reality of insufficient symptomatic control with Octreotide LAR at highest registered dose </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">It could be admitted as well that reducing interval between injection ( &lt; every 4 weeks) is not a sufficient solution (at least according to the investigators ( who are also the sponsors) point of view.<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Nothing is planned for Octreotide IRF as rescue therapy</FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Please note this is an independant sponsored study</FONT></DIV> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3"><A href="http://clinicaltrials.gov/ct2/show/NCT01886287?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F25%2F2013&amp;rank=198"><STRONG>Trial Details NCT01886287</STRONG></A></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">PE: frequency of symptoms</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Recruitment: approx.<wbr> 30</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Start date: Aug 2013 - Completion date: April 2018</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">PI: Jonathan Strosberg, M.<wbr>D.<wbr></FONT></SPAN> </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7381">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-26T11:26:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ASCO 2013 - Taking a Deeper Look at Developments in Bladder Cancer and Prostate Cancer [dis:Bladder, dis:Prostate, :PharmaWorld:congress:ASCO, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9041</link>
<description>ASCO 2013 - Taking a Deeper Look at Developments in Bladder Cancer and Prostate Cancer [dis:Bladder, dis:Prostate, :PharmaWorld:congress:ASCO, headline]</description><category>dis:Bladder</category><category>dis:Prostate</category><category>congress:ASCO</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9041</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9041">ASCO 2013 - Taking a Deeper Look at Developments in Bladder Cancer and Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9041">Oncology9041</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 June 2013 | 16:38</font><br><br><div style="margin-bottom: 10px;">Comment: Yesterday Amauri Soares hosted a webex on ASCO highlights in prostate cancer and bladder cancer for the medical team, which he would like to share with all Traction users.<wbr> It provides a deep understanding of novel therapeutic approaches, prognosis and prediction outcomes, pathology and QoL.<wbr> </div><div style="margin-bottom: 10px;">A full copy of the presentation is attached and available to download.<wbr> We are grateful to Amauri for making it available to all.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Content</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9041attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(22,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/3/Post%20ASCO%20WEBEX%20June%2024%20(full%20version)%20(1).pptx">Post ASCO WEBEX June 24 (full version) (1).pptx</a>&nbsp;&nbsp;(13,3 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9041">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-25T16:38:50+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/1/ScreenCapture1.jpg" length="22152" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/2/ScreenCapture2.jpg" length="22905" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9041/3/Post%20ASCO%20WEBEX%20June%2024%20(full%20version)%20(1).pptx" length="13970578" type="application/vnd.openxmlformats-officedocument.presentationml.presentation"/></item><item>
<title>Ingram to Lead Allergan's Global Commercial Operations [sub:People, :Neurology:comp:Allergan, :Neurology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10503</link>
<description>Ingram to Lead Allergan's Global Commercial Operations [sub:People, :Neurology:comp:Allergan, :Neurology:news]</description><category>sub:People</category><category>comp:Allergan</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10503</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10503">Ingram to Lead Allergan's Global Commercial Operations</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10503">PharmaWorld10503</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 June 2013 | 15:56</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has named Douglas Ingram as President of the company.<wbr> He will report directly to D.<wbr> Pyott and be responsible for a broad portfolio of pharmaceutical, consumer and medical device products.<wbr> The company is facing the LEVADEX complete response letter (approval likely to be deferred until Q4 13), the DARPin set-back in Ph2 and now the forthcoming generic impact on RESTASIS for dry eye (#2 drug in the portfolio).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Restasis Generic Easier Than Expected</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="2" style="BACKGROUND-COLOR: #ffffff">On Friday, the FDA indicated that a generic version of RESTASIS could be accepted for approval without testing in humans if the drug's composition is sufficiently similar to that of RESTASIS.<wbr></FONT> </div><div style="margin-bottom: 10px;"><P style="PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.4em; LIST-STYLE-TYPE: disc; MARGIN: 0px 0px 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">Allergan expects sales of $850M to $890M for the drug in 2013.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.4em; LIST-STYLE-TYPE: disc; MARGIN: 0px 0px 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"><STRONG><FONT size="3">Other Issues</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.4em; LIST-STYLE-TYPE: disc; MARGIN: 0px 0px 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"><FONT size="2" style="BACKGROUND-COLOR: #ffffff">Background for Levadex (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6973" class="defaultlink">Neurology6973: Approval Of Allergan's New Migraine Medication Likely To Be Deferred Until Q413</a>), and DarPin (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6989" class="defaultlink">Neurology6989: Allergan Management Discuss 1Q:13 Performance</a>).<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.4em; LIST-STYLE-TYPE: disc; MARGIN: 0px 0px 10px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"><STRONG><FONT size="3">Previous Position at Allergan</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10503/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Served as Executive VP and President EU, Africa, and Middle-East.<wbr> In this role he was responsible for Allergan's regional pharma and medical device operations, with a focus on strategic planning, sales and marketing, development and general management.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">Prior to leading the EAME region, Mr.<wbr> Ingram served as Executive Vice President and Chief Administrative Officer.<wbr> During Mr.<wbr> Ingram's tenure in this role, at various times, he led Allergan's Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">Mr.<wbr> Ingram also served as Allergan's Secretary and Chief Ethics Officer from July 2001 to July 2010.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">Mr.<wbr> Ingram joined Allergan in 1996 as Senior Attorney and Chief Litigation Officer and was promoted to Associate General Counsel and Assistant Secretary, and later, to General Counsel.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">Before joining Allergan in 1996 he was an attorney with Gibson, Dunn &amp; Crutcher from 1998, practicing in the area of complex commercial litigation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Education</FONT></STRONG> </div><div style="margin-bottom: 10px;">Graduated magna cum laude with a Bachelor of Science degree from Arizona State U.<wbr> in 1985.<wbr> </div><div><EM>Source: Allergan</EM> </div><!-- Comment details --><a name="pharmaworld10503attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10503/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(7,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10503">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-25T15:56:44+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10503/1/ScreenCapture1.jpg" length="8103" type="image/jpeg"/></item><item>
<title>ASCO NET Intelligence - Part Two [:Oncology:headline, :PharmaWorld:congress:ASCO, prod:Pasireotide, prod:Octreotide, dis:pNET, comp:Novartis, comp:Pfizer]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7380</link>
<description>ASCO NET Intelligence - Part Two [:Oncology:headline, :PharmaWorld:congress:ASCO, prod:Pasireotide, prod:Octreotide, dis:pNET, comp:Novartis, comp:Pfizer]</description><category>headline</category><category>congress:ASCO</category><category>prod:Pasireotide</category><category>prod:Octreotide</category><category>dis:pNET</category><category>comp:Novartis</category><category>comp:Pfizer</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7380</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7380">ASCO NET Intelligence - Part Two</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7380">Endocrinology7380</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 June 2013 | 11:11</font><br><br><div style="margin-bottom: 10px;">Comment: Long term survival data from patients on the PROMID study showed no OS benefit (not a pre-specified endpoint) and the Pasireotide LAR vs Octreotide LAR in patients with Metastatic NETs with disease related symptoms inadequately controlled by SSAs did not meet its endpoint - symptom control at 6 months.<wbr> </div><div style="margin-bottom: 10px;">Although some interesting sessions, from the data presented at ASCO, we can say that nothing was practice changing with regards to NET.<wbr> </div><div style="margin-bottom: 10px;">The key takeaways are as follows: </div><div style="margin-bottom: 10px;"><UL><LI>Octreotide is still SOC for NETs</LI>
</UL> </div><div style="margin-bottom: 10px;">We are awaiting RADIANT 4 and S0518 study results to asses the role of everolimus and bevacizumab in NET (this study is closed and we are awaiting data).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Temsirolimus/<wbr>bevacizumab data are encouraging in PNETs</LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- Awaiting CALGB80701 and biomarker analysis</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><UL><LI>Pasireotide use in NET is unclear and a need for ‘cleaner data’ is required</LI>
<LI>PRRT is becoming more exciting in the US</LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- With both of these drugs, a call out for targeting tumor receptor types and downstream signaling pathways is needed</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><U>Abby B.<wbr> Siegel</U> detailed a number of relevant posters, providing us with a nice summary of the data.<wbr>  Below are the captured highlights of her talk.<wbr> </div><div style="margin-bottom: 10px;">Abby began by providing us with a summary of the recent Phase II data in NET highlighting that for asymptomatic, low tumor burden patients, watchful waiting or octreotide is appropriate and octreotide is also considered with clinically symptomatic or progressive disease with other options including hepatic regional therapy, surgery, everolimus or cytoxic therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Next she discussed <U>Rudolf Arnold</U> poster covering long term survival data from patients on the PROMID study (whether the antiproliferative response  in patients with low (≤ 10%) hepatic tumor load has an affect on overall survival).<wbr>   Patients included in the PROMID trial were followed until January 2013 at least once a year.<wbr>   This study showed no OS benefit although, survival was not a pre-specified endpoint and cross over was allowed.<wbr> OS in the placebo arm was 7 years, providing us with a benchmark.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>Results of the study: </B>41 of 85 patients died until January 2013.<wbr> 19 in the octreotide and 22 in the placebo arm.<wbr> Median OS for all 85 patients was 85 months, “not reached” in the O arm and 84 months in the P arm (p=0.<wbr>59, HR=0.<wbr>85 [CI 0.<wbr>46; 1.<wbr>56]).<wbr> </div><div style="margin-bottom: 10px;">Moving onto PNETs,  Abby described Everolimus and Sunitinib data which resulted in the respective approvals </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The next study, Hobday et al, asked the important question of could a doublet of MTOR inhibitor (TEM) and anti-angiogenic (BEV) improve outcomes in PNET? </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Co-primary endpoints were RR, 6 month PFS and was a multicenter, single arm phase II study.<wbr>  Inclusion criteria included progression within 7 months by RECIST (investigator assessed) and scans Q 8 weeks.<wbr>  11 patients remain on the trial.<wbr>  The single agent activity of BEV in PNET is being explored in an additional cohort of 25pts on this trial.<wbr> </div><div style="margin-bottom: 10px;">PFS was similar to the approved agents but the RR was incredible at 41% </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Waterfall plot of best responders </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">She then theorized it would be good to combine the approved agents for PNETs but they showed toxicity in phase I studies.<wbr>  On the other hand, Tem + Bev phase I results were promising (with the PFS is similar to the single agents).<wbr>  Therefore, the Tem + Bev is interesting and we need further data to understand effects in PNET with this combination.<wbr>  Especially since we have seen unexpected tox with these agents in phase II studies such as TORAVA in RCC patients </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Wrapping up, she defined the next steps in PNET as </div><div style="margin-bottom: 10px;"><UL><LI>A need for predictive biomarkers to select pts, mentioning FGF 4R and P-AKT both which are being investigated at Anderson</LI>
<LI>Results of the Everolimus + Octerotide +/<wbr>- Bev in PNET to understand MTOR inhibitors + Bev</LI>
<LI>Define the role of alkylating agents in PNET: capecitabine, TMZ and streptozosin </LI>
</UL> </div><div style="margin-bottom: 10px;">Moving on to Pasireotide, </div><div style="margin-bottom: 10px;"><U>Poster One</U>: Pasireotide LAR vs Octreotide LAR in pts with Metastatic NETs with disease related symptoms inadequately controlled by SSAs.<wbr>  The study was stopped early because it demonstrated futility in symptom control and the results presented are based on 110 pts (216 were planned) before study termination </div><div style="margin-bottom: 10px;">The study was negative for the primary endpoint —symptom control at 6 months.<wbr>  Although, there was a trend towards improved disease control  (secondary endpoint — OR 1.<wbr>96, p=0.<wbr>09) and an unplanned analysis suggested a PFS benefit for Pasireotide.<wbr> </div><div style="margin-bottom: 10px;">Study schema found below: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Overview of the Baseline Characteristics - favouring the OCT LAR arm </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Results show a  5 months longer PFS for Pts on the Pas  arm </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Although this was a negative trial in terms of symptom control at 6 months,  there was an effect on tumor shrinkage and PFS.<wbr>  Dr.<wbr> Wolin and colleagues also suggested that the dose of pasireotide may be too low and therefore they have started a phase I trial at 120mg/<wbr> 4 weeks to see if this may be the case.<wbr>  Also, Novartis has a large Ph3 trial to further investigate its anti-tumour effects in NET patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Next, she discussed <U>Horsch and colleagues</U> poster, looking at PRRT for Neuroendocrine Neoplasms — A Multi-intuitional Registry study with Prospective Follow up.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Germany PRRT Registry</LI>
<LI>A multi-institutional, prospective and board reviewed registry study for patients treated with peptide receptor radionuclide therapy.<wbr> 450 patients were included and followed for a mean of 24.<wbr>4 months.<wbr></LI>
<LI>Patients were treated with Lutetium-177 (54%), Yttrium-90 (17%) or both radionuclides (29%).<wbr> </LI>
<LI>Primary neuroendocrine neoplasms were derived of pancreas (38%), small bowel 30%), unknown primary (19%), lung (4%) and colorectum (3,5%)</LI>
<LI>Most neuroendocrine neoplasms were well differentiated with a proliferation rate below 20% in 54% and were pretreated by 1 or more therapies in 73%.<wbr></LI>
<LI>Median OS from time of treatment: 59 months (95% CI: 49-68)</LI>
<LI>There was a suggestion that  177LU was more effective than 90 Y</LI>
<LI>Grade 3-4 tox = 3% with 2 patients having AML</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><U>Other Posters of interest</U></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.<wbr>T.<wbr>M.<wbr>O.<wbr> (Italian Trials in Medical Oncology) group.<wbr></STRONG> </div><div style="margin-bottom: 10px;">The study aimed to assess efficacy and safety of everolimus in combination with octreotide long-acting repeatable (LAR) in patients with well differentiated NETs of gastroenteropancreatic and of lung origin.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>Results</B> </div><div style="margin-bottom: 10px;"><UL><LI>The ORR, calculated on the ITT population, was 20.<wbr>0% (95% CI 8.<wbr>9-31.<wbr>1): 2 patients (4%) had a complete response (CR), 8 (16%) a partial response (PR).<wbr> </LI>
<LI>Thirty-six patients (72%) achieved stable disease (SD).<wbr> </LI>
<LI>All CR and all PR as well as 91.<wbr>7% of SD had a duration ≥ 6 months.<wbr></LI>
<LI>Clinical benefit (CR+PR+SD) was 92%.<wbr> </LI>
<LI>At a median follow-up of 277 days, the median time to progression (TTP) was 16.<wbr>3 months (95% CI 10.<wbr>7-20.<wbr>1).<wbr> </LI>
<LI>§  Overall survival could not be assessed</LI>
<LI>Treatment-related adverse events (AEs) were mostly of grade 1 or 2; the only grade 4 AE was mucositis in 1 patient, while grade 3 AEs included skin rash in 1 case, stomatitis in 4 cases (8%) and diarrhea in 11 cases (22%).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>Dosing patterns for octreotide LAR in neuroendocrine tumor (NET) patients: NCCN NET outcomes database.<wbr></B> </div><div style="margin-bottom: 10px;">Among patients (pts) with neuroendocrine histology, 10 mg — 30 mg of octreotide-LAR administered intramuscularly every 4 weeks is FDA-approved for the long term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and pancreatic VIPomas.<wbr> </div><div style="margin-bottom: 10px;">In clinical practice, higher doses and/<wbr>or more frequent administration is often prescribed for pts who experience refractory symptoms (e.<wbr>g.<wbr>, flushing and/<wbr>or diarrhea) on the maximal labeled dose.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.<wbr></B> </div><div style="margin-bottom: 10px;">Phase II, single arm, non randomised multi-centre clinical trial </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/21/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Conclusions: </div><div style="margin-bottom: 10px;"><UL><LI>The updated results confirm the efficacy of PAZ as a sequencing treatment of pts with progressive NETS particular in those with pancreatic primary tumors</LI>
<LI>The combo with SSA + PAZ seems to be synergistic</LI>
<LI>sVEGF2 and baseline CTC are promising predictive biomarkers for PAZ in NETs</LI>
<LI>VEGF-A varies along time but it was not associated with clinical outcomes</LI>
</UL> </div><div style="margin-bottom: 10px;"><B>Long-term survival and clinical efficacy in patients with advanced pancreatic and small bowel metastatic neuroendocrine tumors (GEP-NET) after I.<wbr>V.<wbr> 90Y DOTATATE.<wbr> — this study was not presented at ASCO.<wbr>  See abstract below:</B> </div><div style="margin-bottom: 10px;"><B>Background: </B>Current therapeutic options for patients with progressive metastatic gastroenteropancreatic neuroendocrine tumour/<wbr>neoplasm (GEP-NET/<wbr>NEN) are limited.<wbr> Treatment with SST analogues is method of choice, due to good symptoms control.<wbr> [DOTA0, D-Phe1,Tyr3]octreotate[DOTATATE] has a higher affinity for SST2 receptors and thus is able to achieve longer disease control.<wbr> </div><div style="margin-bottom: 10px;">The aim of this study was to evaluate long term radiological and clinical therapeutic effect of 90Y-DOTATATE in patients with progressive somatostatin receptor—positive small bowel and pancreatic neuroendocrine tumour/<wbr>neoplasm (GEP-NET/<wbr>NEN).<wbr>The primary end point was assessing OS and PFS in long term follow-up.<wbr> </div><div style="margin-bottom: 10px;"><B>Methods: </B>67 patients progressing after treatment with SST analogues were inlcuded in the study.<wbr> The mean treatment activity was 3.<wbr>8GBq.<wbr> The mean interval between therapies was 7 weeks (range 6 -9 weeks).<wbr> Patients were treated up to mean a cumulative activity of 11.<wbr>2 GBq.<wbr> Due to pure beta emission (90Y) internal dosimetry was evaluated.<wbr> </div><div style="margin-bottom: 10px;"><B>Results: </B>Median overall survival (OS) and progression-free survival (PFS) are shown in the Table.<wbr> In univariate analysis Ki-67 (p=0.<wbr>048) was the only significant factor influencing OS in pancreatic tumors.<wbr> That was not confirmed in multivariate analysis.<wbr> In small bowel tumors we defined three factors influencing survival in univariate analysis.<wbr> These were: female gender (p=0.<wbr>023), performance status at the beginning of therapy (p=0.<wbr>031) and presence of liver metastases (p=0.<wbr>026).<wbr> Female gender (HR=0.<wbr>30, 95% CI 0.<wbr>11-0.<wbr>81; p=0.<wbr>018) was confirmed as positive prognostic factor in multivariate analysis.<wbr> Factos influencing PFS were also assessed and will be presented as well.<wbr> </div><div style="margin-bottom: 10px;"><B>Conclusions: </B>90Y DOTATATE PRRT is effective in long term outcome (OS and PFS) in patient with advances progressive pancreatic and small bowel GEP-NET.<wbr> This therapy is relatively safe as initial systemic therapy and after previous treatment with chemotherapy or somatostatine analogues as well.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/22/ScreenCapture22.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7380attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(38,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(73 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(44,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(125,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(34,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(63,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(77,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(77,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(57,2 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(74 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(122,8 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(62 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(63,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(91,8 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(81,3 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(121 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(51,2 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(61,3 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(16,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7380">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-25T11:11:57+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/1/ScreenCapture1.jpg" length="38653" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/2/ScreenCapture2.jpg" length="39515" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/3/ScreenCapture3.jpg" length="74720" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/4/ScreenCapture4.jpg" length="45943" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/5/ScreenCapture5.jpg" length="128295" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/6/ScreenCapture6.jpg" length="35695" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/7/ScreenCapture7.jpg" length="81910" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/8/ScreenCapture8.jpg" length="65246" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/9/ScreenCapture9.jpg" length="79313" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/10/ScreenCapture10.jpg" length="79660" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/11/ScreenCapture11.jpg" length="92223" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/12/ScreenCapture12.jpg" length="58596" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/13/ScreenCapture13.jpg" length="75727" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/14/ScreenCapture14.jpg" length="125732" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/15/ScreenCapture15.jpg" length="63481" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/16/ScreenCapture16.jpg" length="64653" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/17/ScreenCapture17.jpg" length="93989" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/18/ScreenCapture18.jpg" length="83205" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/19/ScreenCapture19.jpg" length="123931" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/20/ScreenCapture20.jpg" length="52384" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/21/ScreenCapture21.jpg" length="62792" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7380/22/ScreenCapture22.jpg" length="17091" type="image/jpeg"/></item><item>
<title>re: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9039</link>
<description>re: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9039</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9039</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9039">re: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9039">Oncology9039</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/480">Monica DE ABADAL</a> | 25 June 2013 | 07:13</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Zytiga was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2012, but Janssen-Cilag (subsidiary of J&amp;J) declined the listing in order to seek a higher price for the drug, resubmitting to the PBAC in July 2012, and then again in November 2012, with the PBAC on both occasions recommending the drug for a listing on a cost-minimisation basis with cabazitaxel.<wbr> Janssen-Cilag has now accepted the November 2012 decision.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9034">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9034" class="commentpermalink">Oncology9034</a> / <span class="date">24 June 2013</span> /
<span class="time">16:39:30 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><STRONG>This is the Sponsor's comments (JJ) on the Public Summary Document:</STRONG> </div><div style="margin-bottom: 10px;">Janssen-Cilag is pleased with various aspects of the PBAC&rsquo;s November 2012 recommendation.<wbr> </div><div style="margin-bottom: 10px;">Janssen-Cilag disagrees with the PBAC recommendation that the listing of abiraterone should be based partially on the basis of cost-minimisation with cabazitaxel.<wbr>  In addition, it is Janssen-Cilag&rsquo;s view that the PBAC&rsquo;s estimate of the total cost of treatment with G-CSF for patients experiencing febrile neutropenia when on cabazitaxel of less than $500 over 6 treatment cycles is a significant underestimate and is not reflective of drug costs, nor the costs of treating febrile neutropenia as an inpatient over a course of treatment.<wbr> </div><div style="margin-bottom: 10px;">Despite these concerns related to the recommendation by the PBAC, Janssen-Cilag believes that additional submissions would delay patient access.<wbr>  Janssen-Cilag is committed to listing abiraterone on the PBS as soon as possible and are moving forward with the listing of abiraterone.<wbr> </div><div><STRONG>The reimbursement is for the post-chemo setting only.<wbr> Zytiga is not yet approved for pre-chemo in Australia.<wbr> Abiraterone is still not listed (no price yet).<wbr> This will usually take place 2 to 4 months afterwards</STRONG> <a name="Oncology9124c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Commen : Zytiga Listed on Australia's PBS August Additions </div><div style="margin-bottom: 10px;">Australia's Pharmaceutical Benefits Scheme (PBS) has released the latest round of price reductions under the Expanded and Accelerated Price Disclosure (EAPD) scheme, which took effect from 1 August 2013.<wbr> According to its Minister of Health, the price cuts are described as meaning that patients would pay around AUD20 million (USD17.<wbr>9 million) less per year.<wbr> <SPAN style="line-height: 1.5em;">The 492 drugs face 25% price cuts on average (with for instance Sanofi's Plavix &ndash; facing the greatest loss of market value with 43.<wbr>7% cut or Simvastatin dealing with the second-largest reduction of 44.<wbr>66%.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The PBS has also released the list of august additions, most prominently including US Johnson &amp; Johnson's prostate cancer drug Zytiga (abiraterone) under following restrictions :</SPAN> </div><div style="margin-bottom: 10px;">Indication : Castration resistant metastatic carcinoma of the prostate </div><div><DIV>
<DIV label="Restriction">
<P>The required clinical criteria are :</P>
<P>1/<wbr> <SPAN style="line-height: 1.5em;">The treatment must be in combination with prednisone or prednisolone</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>2/<wbr> <SPAN style="line-height: 1.5em;">The treatment must not be used in combination with chemotherapy</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>3/<wbr> <SPAN style="line-height: 1.5em;">Patient must have failed treatment with docetaxel due to resistance or intolerance</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>4/<wbr> <SPAN style="line-height: 1.5em;">Patient must have a WHO performance status of 2 or less,</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>5/<wbr> <SPAN style="line-height: 1.5em;">Patient must not receive PBS-subsidised abiraterone if progressive disease develops while on abiraterone.<wbr></SPAN></P>
<P><SPAN style="line-height: 1.5em;">Source : Global Insight - Aug 1st</SPAN></P>

</DIV>
</DIV> </div><font size="-1">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9124" class="commentpermalink">Oncology9124</a> / <span class="date">27 August 2013</span> /
<span class="time">14:17:37 o'clock CEST</span>
</font></div></div><!-- Comment details --><font size="-1">Monica DE ABADAL / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9039" class="commentpermalink">Oncology9039</a> / <span class="date">25 June 2013</span> /
<span class="time">07:13:11 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9039">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9034">View thread  Oncology9034: Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</a>]]></content:encoded><dc:date>2013-06-25T07:13:11+02:00</dc:date><dc:creator>moa77328</dc:creator></item><item>
<title>ASCO Data Review Covering Prostate Cancer - Part One</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9036</link>
<description>ASCO Data Review Covering Prostate Cancer - Part One</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9036</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9036">ASCO Data Review Covering Prostate Cancer - Part One</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9036">Oncology9036</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 24 June 2013 | 17:38</font><br><br><div style="margin-bottom: 10px;">Comment: There was no real practice changing data but interesting data was presented nevertheless.<wbr> J&amp;J hit back heavily on the AFFIRM data, VENICE was a negative trial and AZ’s SARD, AZD3514 is no longer in development.<wbr><B><U> </U></B> </div><div style="margin-bottom: 10px;">Below is a review of the key highlights from the relevant education sessions, oral abstracts and posters.<wbr> </div><div style="margin-bottom: 10px;">During Dr.<wbr> Sartor’s talk, he reviewed two phase III trials: TRAPEZE and VENICE, a small assessment of F-18 PET and a small retrospective post-hoc analysis of corticosteroid use in COU-301.<wbr> Only TRAPEZE and VENICE are described below followed by Robert Montgomery’s review of the Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">TRAPEZE trial is a four arm study in mCRPC with a complex primary endpoint - bony clinical progression free survival composite withg OS and SREs as secondary endpoints.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">OS data with ZA comparison and with Sr89 comparison was not very exciting.<wbr> However, the SRE free interval attracted some discussion.<wbr> The median survival time for those treated with ZA was 18.<wbr>1 months as compared with 13.<wbr>1 months for those who were treated without ZA.<wbr> Clinical progression free survival with Sr89 comparison-the median survival time for those treated with Sr89 was 9.<wbr>8 months as compared with 8.<wbr>8 months for those treated without Sr89.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">So what did we learn from TRAPEZE: there was no OS benefit and the clinical progression free survival and clinical benefit may not equate and the multivariate analysis is incomplete.<wbr> However, Zoledronate improved the SREs.<wbr> The learnings from TRAPEZE implied that SSE reduction cannot be used to conclude that zoledronate or denosumab add benefit when used with agents that influence SSEs.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Moving on to VENICE: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">This was a negative trial, the overall survival did not show significant difference in placebo and aflibercept.<wbr> Aflibercept is also associated with a higher risk of dose reductions and treatment terminating AEs in this population.<wbr> As an aside, both Bev and Sunitinib also failed to prolong OS and had higher AE rates than controls.<wbr> The implication: using anti-VEGF strategy is questionable and it is now known that docetaxel/<wbr>prednisone is not easy to beat.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In response to the AFFIRM data, J&amp;J had a poster review on Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA) — Presented by Robert B.<wbr> Montgomery.<wbr> Robert commenced his discussion by outlining the use of CS in prostate cancer alongside the benefits and disadvantages </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Focusing first on the AFFIRM trial - almost 30% of the patients entering the study were already on CS, with this group having worse prognostic features.<wbr> AFFIRM data shows that CS leads to progression of PC and concluded that baseline use of CS increases the risk of death </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Whereas, COU-AA-301 characterised the progression effect of CS on AR with 1,195 patients randomized by 2:1.<wbr> The primary endpoint was Overall Survival, while TTPP, rPFS, and PSA response were secondary end points.<wbr> It was a positive study that led to the approval of AA by FDA in post-docetaxel setting.<wbr> This table shows the comparison between baseline characteristics of patients who were on steroids with those who were not on steroids.<wbr> It was found that patients who were on steroids were more likely to have poor prognostic features except for liver metastases.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Patients who were not on steroids and who were treated with AA and P had a median time to death of 17.<wbr>3 months as compared with 12.<wbr>7 months of those who were treated with only P.<wbr> Patients who were on steroids and were treated with AA and P had a median time to death of 13.<wbr>4 months as compared with a median of 9.<wbr>3 months for patients who were treated only with P.<wbr> Patients who were not on steroids had a 3 months greater median time to PSA progression as compared with those who were on steroids.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/12/ScreenCapture12.jpg?user-agent=rss"> All these factors of the study were evaluated using the univariate cox model.<wbr> The relevant factors were again run through a multivariate cox model with a stepwise selection procedure.<wbr> Limited factors were used in the model to optimize it.<wbr> </div><div style="margin-bottom: 10px;">Reference to another presentation was given that showed all the relevant factors.<wbr> The baseline CS use had a hazard ratio of approximately 1.<wbr>5 for those who were on steroid use.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Table was shown with relevant features that had prognostic significance which made the model work.<wbr> It was found that CS was not a key contributor to the model.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The following slide depicts the comparisons/<wbr>differences of AFFIRM and COU-AA-301.<wbr> Limitations of the studies were also shared - It was not known that for how long the patients were on steroids prior to study entry.<wbr> Unknown prognostic factors were not accounted for.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Conclusions are as follows: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Moving on to Enzalutamide - Matthew Raymond Smith, presented a poster on the Efficacy and safety of enzalutamide (ENZA) mono-therapy in hormone-naive prostate cancer (HNPC) </div><div style="margin-bottom: 10px;">The presentation discusses the efficacy and safety of ENZA mono-therapy over androgen deprivation therapy.<wbr> He started by walking us through the unmet needs stating that there remains an unmet need for a therapy that has high efficacy but no side effects.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Enzalutamide was evaluated as mono-therapy in a Phase 2 open label single arm efficacy study in patients with hormone naïve prostate cancer.<wbr> The study involved patients with histologically confirmed prostate cancer for which ADT is indicated.<wbr> All patients were treated with enzalutamide 160 mg for 24 weeks.<wbr> The primary endpoint of the trial was PSA response.<wbr> </div><div style="margin-bottom: 10px;">After screening, the patients were enrolled and all patients were treated with ENZA mono-therapy.<wbr> The primary efficacy analysis was performed at 25 weeks.<wbr> Patients who had clinical benefits at 25 weeks were continued for treatment until progression or toxicity.<wbr> A 30 day safety follow up was done after the last dose.<wbr> The study enrolled 67 subjects with median age 73 years.<wbr> The median duration of PC diagnosis was one year.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">ENZA mono-therapy resulted in marked PSA declines in all patients.<wbr> The maximum PSA decline was &gt;80% in all 67 patients.<wbr> Median PSA decrease was 99.<wbr>6%.<wbr> 62 of the 67 subjects achieved primary endpoint of more than 80% PSA decline.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/21/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Similar PSA decline at 25 weeks were observed; with PSA decline generally consistent between metastatic and non-metastatic disease.<wbr> </div><div style="margin-bottom: 10px;">16 patients were evaluated for objective response, 3 demonstrated complete response with RECIST criteria while 5 demonstrated partial response.<wbr> The proportion of patients with complete and partial response was 50%.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/22/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">16 patients were evaluated for objective response, 3 demonstrated complete response with RECIST criteria while 5 demonstrated partial response.<wbr> The proportion of patients with complete and partial response was 50%.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/23/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">One or more adverse events were reported in 89.<wbr>6% of patients.<wbr> All of the common treatment emergent AE were either Grade 1 or 2.<wbr> During the poster sessions, Doctors were discussing the amount of fatigue their patients are experiencing highlighting that in some cases, it is not as placebo like as one first thought </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/24/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Treatment with ADT reduces bone mineral densities, no significant change was observed in bone mass density in patients treated with ENZA.<wbr> The estimated decline in bone mineral densities is 35% in first year.<wbr> The other metabolic changes post treatments with ENZA increase in fat body mass, triglycerides and total cholesterol.<wbr> In summary, ENZA mono-therapy achieved a high PSA response rate and marked PSA decline.<wbr> Measurable disease response rate was 50%.<wbr> As opposed to castration, ENZA mono-therapy was associated with stable bone mineral density.<wbr> </div><div style="margin-bottom: 10px;">Finally, data on AZD3514 - A First-in-Human Study of the Oral Selective Androgen Receptor Down-Regulating Drug (SARD) AZD3514 in Patients With CRPC Presented by Aurelius Gabriel Omlin.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/26/ScreenCapture26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The preclinical data of AZD3514 were presented at the AACR 2012.<wbr> Discussing the two results, one on AR expression in LNCap cells 24 hours after the treatment with AZD3514 and the inhibition of PSA (AR regulated function) and TMPRS52 mRNA in LNCaP cells, after treatment with AZD3514 .<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/27/ScreenCapture27.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The primary objective of these studies was to evaluate the safety and tolerability of AZD3514 when given orally to patients with CRPC.<wbr> Following is the study design and objectives </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/28/ScreenCapture28.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A total of seven cohorts were enrolled in this study, exploring various dosages </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/29/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">With regards primary end-points the trials demonstrated very few grade 3 and no grade 4 toxicities.<wbr> Although, tolerability with AZD3514 was problematic </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/30/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">None of the adverse events met the DLT definition criterion.<wbr> Continuous dosing (for 12 weeks) was a problem with 41% of the patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/31/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Nausea was closely related to dosage.<wbr> <SPAN lang="EN-US" style="FONT-SIZE: 12pt; LINE-HEIGHT: 115%; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Despite nausea and vomiting related problems the pharmacokinetics the trial demonstrated good results in dose proportional increase in plasma concentration</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; LINE-HEIGHT: 115%; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/33/ScreenCapture33.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; LINE-HEIGHT: 115%; FONT-FAMILY: 'Arial','sans-serif'">Based on pre-clinical models, the maximum activity of AZD3514 to down regulate AR was associated with minimal plasma concentration achieved at steady state and exposure of above IC50 for more than 18 hours.<wbr> This was however, not achievable on this trial.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/34/ScreenCapture34.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Despite the insufficient exposure to achieve IC50 coverage for 18 hours, decrease in PSA level of more than 50% was demonstrated in several patients.<wbr> Only 2 of the 23 patients with soft tissue patients have demonstrated RECIST.<wbr> At 1000mg OD dosage the patient showed 40% reduction on lymph nodes and maximum PSA decline of 39%.<wbr> At 500mg once daily has bone metastases only and demonstrated PSA decline of 62% </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/35/ScreenCapture35.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Analyzing a change in circulating tumor cells (CTC), 7 of the 22 patients demonstrated CTC cells conversions (unfavorable to favorable) from &gt;5 to &lt;5.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/36/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Reasons for discontinuation include disease progression, adverse event, and clinical progression.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/37/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">An extra cohort was studied, which included 6 patients received AZD3514 in combination with Abiraterone.<wbr> The mandatory pre and post treatment biopsies were conducted but the level of antitumor activity was unsatisfactory.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/38/ScreenCapture38.jpg?user-agent=rss"> </div><div>In conclusion, AZD3514 when given orally to patients in CRPC was considered safe however, demonstrated poor tolerability due to nausea and vomiting and insufficient drug exposure to down regulate AR.<wbr> AZD3514 has inferior anti-tumor activity compared to Abiraterone and enzalutamide.<wbr> Thus, the development of the compound by AstraZencea as a selective androgen receptor down-regulator in mCRPC has been terminated.<wbr> However, targeting AR is an important target in CRPC.<wbr> </div><!-- Comment details --><a name="oncology9036attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(50,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(40,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(40,9 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(69 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(94,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(54,6 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(62,9 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(40,4 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/24/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(55,6 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/25/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/26/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/27/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(46,3 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/28/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(79,7 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/29/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(58,5 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/30/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(70,7 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/31/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(75,7 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/32/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/33/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(71,8 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/34/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(57,7 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/35/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(74 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/36/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(62,7 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/37/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(64,1 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/38/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(48,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9036">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-24T17:38:42+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/7/ScreenCapture7.jpg" length="51846" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/10/ScreenCapture10.jpg" length="41042" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/11/ScreenCapture11.jpg" length="41867" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/19/ScreenCapture19.jpg" length="70703" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/20/ScreenCapture20.jpg" length="96328" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/21/ScreenCapture21.jpg" length="55899" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/22/ScreenCapture22.jpg" length="64421" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/23/ScreenCapture23.jpg" length="41346" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/24/ScreenCapture24.jpg" length="56913" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/25/ScreenCapture25.jpg" length="54534" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/26/ScreenCapture26.jpg" length="56102" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/27/ScreenCapture27.jpg" length="47436" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/28/ScreenCapture28.jpg" length="81578" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/29/ScreenCapture29.jpg" length="59869" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/30/ScreenCapture30.jpg" length="72428" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/31/ScreenCapture31.jpg" length="77487" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/32/ScreenCapture32.jpg" length="73167" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/33/ScreenCapture33.jpg" length="73480" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/34/ScreenCapture34.jpg" length="59043" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/35/ScreenCapture35.jpg" length="75745" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/36/ScreenCapture36.jpg" length="64213" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/37/ScreenCapture37.jpg" length="65682" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9036/38/ScreenCapture38.jpg" length="49377" type="image/jpeg"/></item><item>
<title>FIM for AstraZeneca's AZD8186 for Prostate Cancer [comp:AstraZeneca, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9035</link>
<description>FIM for AstraZeneca's AZD8186 for Prostate Cancer [comp:AstraZeneca, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada]</description><category>comp:AstraZeneca</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9035</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9035">FIM for AstraZeneca's AZD8186 for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9035">Oncology9035</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2013 | 17:17</font><br><br><div style="margin-bottom: 10px;">Comment: This is a Ph1, open-label, multicentre study of the drug administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient advanced solid malignancies.<wbr> AZD8186 is a novel highly selective inhibitor of the PIK3CB/<wbr>PIK3C Disoforms.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01884285?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F24%2F2013&amp;rank=150"><STRONG><FONT size="3">NCT01884285</FONT></STRONG></A> </div><div style="margin-bottom: 10px;"><DIV class="body3">

<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG>Part A</STRONG>, dose escalation, and <STRONG>Part B</STRONG>, expansion cohort(s) at the intended therapeutic dose(s).<wbr></P></DIV> </div><div style="margin-bottom: 10px;">PE will assess safety and tolerability in terms of adverse events, serious adverse events (including death) and safety measures: ECG, physical examination, pulse, blood pressure, weight and laboratory variables.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 48 </div><div style="margin-bottom: 10px;">Completion dates: Dec 2014 /<wbr> March 2015 </div><div style="margin-bottom: 10px;">Location: Canada (PI: Lillian Sui, MD Princess Hospital) </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9035">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-24T17:17:06+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga [prod:Zytiga, comp:JnJ, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9034</link>
<description>Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga [prod:Zytiga, comp:JnJ, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9034</comments><category>prod:Zytiga</category><category>comp:JnJ</category><category>sub:Pricing</category><category>mkt:Australia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9034</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9034">Australia's Health Minister Defends Deferred Reimbursement Decisions Against Zytiga</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9034">Oncology9034</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2013 | 16:39</font><br><br><div style="margin-bottom: 10px;">Comment: Zytiga was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2012, but Janssen-Cilag (subsidiary of J&amp;J) declined the listing in order to seek a higher price for the drug, resubmitting to the PBAC in July 2012, and then again in November 2012, with the PBAC on both occasions recommending the drug for a listing on a cost-minimisation basis with cabazitaxel.<wbr> Janssen-Cilag has now accepted the November 2012 decision.<wbr> </div><div style="margin-bottom: 10px;">Australia's health minister Tanya Plibersek's statement reiterates the PBAC's independence from government interference, stating: "The Australian Government does not interfere in the decision-making process of the independent expert PBAC.<wbr>" </div><div><EM>Source: IHS /<wbr> Global Insight</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9039c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><STRONG>This is the Sponsor's comments (JJ) on the Public Summary Document:</STRONG> </div><div style="margin-bottom: 10px;">Janssen-Cilag is pleased with various aspects of the PBAC&rsquo;s November 2012 recommendation.<wbr> </div><div style="margin-bottom: 10px;">Janssen-Cilag disagrees with the PBAC recommendation that the listing of abiraterone should be based partially on the basis of cost-minimisation with cabazitaxel.<wbr>  In addition, it is Janssen-Cilag&rsquo;s view that the PBAC&rsquo;s estimate of the total cost of treatment with G-CSF for patients experiencing febrile neutropenia when on cabazitaxel of less than $500 over 6 treatment cycles is a significant underestimate and is not reflective of drug costs, nor the costs of treating febrile neutropenia as an inpatient over a course of treatment.<wbr> </div><div style="margin-bottom: 10px;">Despite these concerns related to the recommendation by the PBAC, Janssen-Cilag believes that additional submissions would delay patient access.<wbr>  Janssen-Cilag is committed to listing abiraterone on the PBS as soon as possible and are moving forward with the listing of abiraterone.<wbr> </div><div><STRONG>The reimbursement is for the post-chemo setting only.<wbr> Zytiga is not yet approved for pre-chemo in Australia.<wbr> Abiraterone is still not listed (no price yet).<wbr> This will usually take place 2 to 4 months afterwards</STRONG> <a name="Oncology9124c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Commen : Zytiga Listed on Australia's PBS August Additions </div><div style="margin-bottom: 10px;">Australia's Pharmaceutical Benefits Scheme (PBS) has released the latest round of price reductions under the Expanded and Accelerated Price Disclosure (EAPD) scheme, which took effect from 1 August 2013.<wbr> According to its Minister of Health, the price cuts are described as meaning that patients would pay around AUD20 million (USD17.<wbr>9 million) less per year.<wbr> <SPAN style="line-height: 1.5em;">The 492 drugs face 25% price cuts on average (with for instance Sanofi's Plavix &ndash; facing the greatest loss of market value with 43.<wbr>7% cut or Simvastatin dealing with the second-largest reduction of 44.<wbr>66%.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The PBS has also released the list of august additions, most prominently including US Johnson &amp; Johnson's prostate cancer drug Zytiga (abiraterone) under following restrictions :</SPAN> </div><div style="margin-bottom: 10px;">Indication : Castration resistant metastatic carcinoma of the prostate </div><div><DIV>
<DIV label="Restriction">
<P>The required clinical criteria are :</P>
<P>1/<wbr> <SPAN style="line-height: 1.5em;">The treatment must be in combination with prednisone or prednisolone</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>2/<wbr> <SPAN style="line-height: 1.5em;">The treatment must not be used in combination with chemotherapy</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>3/<wbr> <SPAN style="line-height: 1.5em;">Patient must have failed treatment with docetaxel due to resistance or intolerance</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>4/<wbr> <SPAN style="line-height: 1.5em;">Patient must have a WHO performance status of 2 or less,</SPAN></P>
</DIV>
<DIV label="Restriction">
<P>5/<wbr> <SPAN style="line-height: 1.5em;">Patient must not receive PBS-subsidised abiraterone if progressive disease develops while on abiraterone.<wbr></SPAN></P>
<P><SPAN style="line-height: 1.5em;">Source : Global Insight - Aug 1st</SPAN></P>

</DIV>
</DIV> </div><font size="-1">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9124" class="commentpermalink">Oncology9124</a> / <span class="date">27 August 2013</span> /
<span class="time">14:17:37 o'clock CEST</span>
</font></div></div><font size="-1">Monica DE ABADAL / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9039" class="commentpermalink">Oncology9039</a> / <span class="date">25 June 2013</span> /
<span class="time">07:13:11 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9034">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-24T16:39:30+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Enzalutamide (XTANDI™) Gets Green Light in EU for Post-Chemo mCRPC [comp:Astellas, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9031</link>
<description>Enzalutamide (XTANDI™) Gets Green Light in EU for Post-Chemo mCRPC [comp:Astellas, dis:Prostate, headline]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9031</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9031">Enzalutamide (XTANDI™) Gets Green Light in EU for Post-Chemo mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9031">Oncology9031</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2013 | 15:03</font><br><br><div style="margin-bottom: 10px;">Comment: The EU authorisation is based on results from the Ph3 AFFIRM study.<wbr> The next significant catalyst coming up for Medivation is the release of interim data for XTANDI™ in chemotherapy-naïve prostate cancer patients (end of Sept.<wbr> 2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Market Penetration</FONT></STRONG> </div><div style="margin-bottom: 10px;">Analysts at Aegis Capital expect rapid market penetration for enzalutamide in EU, thanks to the extensive compassionate use patient program that Astellas has been implementing there.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;">Upon receiving marketing authorisation in Europe, Astellas will provide Medivation with a $15 million milestone payment, as reflected in Astellas’ current fiscal year (from 1st April 2013 to 31st March 2014) financial forecast.<wbr> </div><div>S<EM>ources: Aegis Capital; Astellas/<wbr>Medivation</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9031">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-24T15:03:17+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Update for the GLP-1 Drug Class Presented at ADA Conference [comp:EliLilly, class:GLP1, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7379</link>
<description>Key Update for the GLP-1 Drug Class Presented at ADA Conference [comp:EliLilly, class:GLP1, dis:Diabetes]</description><category>comp:EliLilly</category><category>class:GLP1</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7379</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7379">Key Update for the GLP-1 Drug Class Presented at ADA Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aEliLilly"><font color="#e95e0b">:Endocrinology:comp:EliLilly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7379">Endocrinology7379</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2013 | 14:44</font><br><br><div style="margin-bottom: 10px;">Comment: Eli Lilly presented first detailed data from its Ph3 program of once-weekly diraglutide, indcluding data from the AWARD-1 (vs Byetta), AWARD-3 (vs metformin), and AWARD-5 (vs sitagliptin) studies.<wbr> While details of Lilly's device have not been disclosed, it is understood that it will be launched with a ready-to-use formulation that does not require preparation by the patient and uses a thin 29 gauge needle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Upcoming Data of AWARD-6</FONT></STRONG> </div><div style="margin-bottom: 10px;">Results of the AWARD-6 (vs Victoza) are due to report around the end of 2013 or early 2014.<wbr> </div><div style="margin-bottom: 10px;">To date, none of the available or development stage once-weekly GLP-1 agonists have been able to demonstrate non-inferior efficacy to Victoza.<wbr> It seems dulaglutide could be the first product to achieve this target and as such it represents a competitive threat to Novo Nordisk (Victoza), AstraZeneca (Bydureon) and GlaxoSmithKline (albiglutide).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">GLP-1 Drug Comparison</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7379/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Deutsche Bank Report</EM> </div><!-- Comment details --><a name="endocrinology7379attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7379/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(232,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7379">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-24T14:44:12+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7379/1/ScreenCapture1.jpg" length="238172" type="image/jpeg"/></item><item>
<title>Findings from an Overactive Bladder Survey Conducted in Women by Allergan [comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7037</link>
<description>Findings from an Overactive Bladder Survey Conducted in Women by Allergan [comp:Allergan, prod:Botox]</description><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7037</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7037">Findings from an Overactive Bladder Survey Conducted in Women by Allergan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7037">Neurology7037</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 June 2013 | 13:47</font><br><br><div style="margin-bottom: 10px;">Comment: The survey was conducted by Allergan and endored by the Women's Health Foundation.<wbr> Key messages are provided below </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Survey</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Prevalence and burden of OAB in the US</STRONG> </div><div style="margin-bottom: 10px;">Approx.<wbr> 39 million Americans have OAB [<FONT size="1">World J Urol 2003; 20:327–336</FONT>] and 40% of all women in the United States live with OAB symptoms (<A href="http://www.urologyhealth.org/urology/index.cfm?article=112"><FONT size="1">http:/<wbr>/<wbr>www.<wbr>urologyhealth.<wbr>org/<wbr>urology/<wbr>index.<wbr>cfm?article=112</FONT></A>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Period</STRONG> </div><div style="margin-bottom: 10px;">Between April 12<SUP>th</SUP> and April 23<SUP>rd</SUP>, 2013 among 1,045 nationally representative American women ages 45 and older and an oversample to 528 American women ages 50+, using an email invitation and an online survey (sent by Kelton).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Messages</STRONG> </div><div style="margin-bottom: 10px;">27% of women surveyed noted that they would immediately call their doctor to schedule an appointment if they were experiencing symptoms of OAB (such as urine leakage or the frequent urge to go to the bathroom).<wbr> </div><div style="margin-bottom: 10px;">When women do talk to their physicians about OAB, they may receive a prescription for pills to manage their symptoms.<wbr> In one study, the majority of patients (73.<wbr>5 percent), however, stopped taking their pills within one year due to side effects and/<wbr>or lack of results (<FONT size="1">D’Souza AO et al.<wbr> J Manag Care Pharm.<wbr> 2008;14(3):291-301</FONT>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BOTOX® Approved Indication</STRONG> </div><div style="margin-bottom: 10px;">- to treat overactive bladder symptoms, such as a strong need to urinate with leakage, urgency and frequency in adults when another type of medication (anticholinergic) does not work well enough or cannot be taken.<wbr> </div><div><EM>Source: Allergan</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7037">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-21T13:47:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Prana's Parkinson's Drug Shows Disease-Modifying Capability [dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7035</link>
<description>Prana's Parkinson's Drug Shows Disease-Modifying Capability [dis:Parkinson]</description><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7035</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7035">Prana's Parkinson's Drug Shows Disease-Modifying Capability</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7035">Neurology7035</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 June 2013 | 13:26</font><br><br><div style="margin-bottom: 10px;">Comment: At MDS2013 Prana presented data which indicates PBT434 shows significantly DMD capability in multiple animal models of Parkinson, with potential utility in a range of movement disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">MOA: prevent alpha synuclein from aggretating and also prevents the toxic consequences of iron combining wit dopamine.<wbr> </div><div style="margin-bottom: 10px;">Status: first clinical trials planned in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Prana Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Poster Key Messages</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">Title: -</FONT> </FONT>"PBT434, a novel 8-hydroxyquinazolinone, preserves nigro-striatal circuitry, improves motor performance and inhibits alpha synuclein accumulation in animal models of Parkinson’s disease by modulation of iron homeostasis".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><STRONG><FONT size="3">Please see full poster attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130831&edate=20130501&rs=/link%20Neurology7039%403" class="defaultlink">@3</a></FONT></STRONG> </div><!-- Comment details --><a name="neurology7035attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(79,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(66,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/3/Prana%5fMDS%20sydney%202013%20poster%20%2d%2020%20Jun.pdf">Prana_MDS sydney 2013 poster - 20 Jun.pdf</a>&nbsp;&nbsp;(1,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7035">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-21T13:26:55+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/1/ScreenCapture1.jpg" length="81285" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/2/ScreenCapture2.jpg" length="67654" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7035/3/Prana%5fMDS%20sydney%202013%20poster%20%2d%2020%20Jun.pdf" length="1208782" type="application/pdf"/></item><item>
<title>Dr Reddy Reports Injectable Segment as a Key Growth Driver for the US Market [mkt:NorthAmerica, :Endocrinology:prod:Octreotide, :Oncology:prod:Lupron]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10500</link>
<description>Dr Reddy Reports Injectable Segment as a Key Growth Driver for the US Market [mkt:NorthAmerica, :Endocrinology:prod:Octreotide, :Oncology:prod:Lupron]</description><category>mkt:NorthAmerica</category><category>prod:Octreotide</category><category>prod:Lupron</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10500</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10500">Dr Reddy Reports Injectable Segment as a Key Growth Driver for the US Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aLupron"><font color="#e95e0b">:Oncology:prod:Lupron</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10500">PharmaWorld10500</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 June 2013 | 14:33</font><br><br><div style="margin-bottom: 10px;">Comment: The company pipeline efforts in injectables focus on complex generics and oncology.<wbr> Long acting injectables are potential opportunities in the longer term – earliest patent expiries are for Sandostatin and Lupron formulations in CY2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Move with Acquisition of OctoPlus</FONT></STRONG> </div><div style="margin-bottom: 10px;">Long acting injectables are a key opportunity over the next 5 years and OctoPlus acquisition should help Dr Reddy to be among the early generic entrants.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline Efforts in Injectables</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company has 7 known filings in this segment that include Copaxone and Angiomax.<wbr> </div><div style="margin-bottom: 10px;">These filings along with the success in Fondaparinux (anti-coagulant launched in July 2011) provide comfort on the opportunities being targeted in the injectable segment.<wbr> In March 2013, Dr Reddy received approval for generic version of Zometa and Reclast (launched in April 2013).<wbr> </div><div style="margin-bottom: 10px;">The company has not disclosed the number of pending injectable filings in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Injectable approvals in the US</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Filings in the US</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><EM>Source: Kotak Institutional Equities Research; Dr Reddy</EM> </div><!-- Comment details --><a name="pharmaworld10500attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(114,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(162,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(59,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(58,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10500">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-20T14:33:34+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/1/ScreenCapture1.jpg" length="117208" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/2/ScreenCapture2.jpg" length="166678" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/3/ScreenCapture3.jpg" length="60705" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10500/4/ScreenCapture4.jpg" length="60225" type="image/jpeg"/></item><item>
<title>Prana Presents New Benchmark Test to Assess HD Patients in Trials [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7034</link>
<description>Prana Presents New Benchmark Test to Assess HD Patients in Trials [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7034</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7034">Prana Presents New Benchmark Test to Assess HD Patients in Trials</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7034">Neurology7034</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2013 | 17:08</font><br><br><div style="margin-bottom: 10px;">Comment: The poster presented at MDS in Sydney details HD-PROP, a test which is aimed at asking trial participants 3 questions in relation to their HD at the start of the trial (What problem is most bothersome? In what way is this problem bothersome? How severe is this problem?).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Poster Presented</FONT></STRONG> </div><div style="margin-bottom: 10px;">“The Huntington‘s Disease patient-reported outcome of problems: feasibility and applicability in clinical research (HD-PROP)” </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is HD-PROP ?</FONT></STRONG> </div><div style="margin-bottom: 10px;">- aims to overcome some of the challenges associated with assessing clinically relevant outcomes in HD where progressive motor, cognitive and psychiatric symptoms can interfere with comprehension of lengthy patient self-report questionnaires and communication of responses </div><div style="margin-bottom: 10px;">- created by clinical investigators involved in Prana’s Phase 2 clinical trial of PBT2 known as the REACH2HD Study.<wbr> This 109 patient trial is fully recruited and nearing completion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Quoting Pf Ira Shoulson: “Patient-reported outcomes are an important area of focus for the US Food and Drug Administration (FDA) and along with clinical measures provide a more complete understanding of the relevance as well as safety and effectiveness of potential treatments.<wbr>” </div><div>Full poster attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130831&edate=20130501&rs=/link%20Neurology7034%401" class="defaultlink">@1</a> </div><!-- Comment details --><a name="neurology7034attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7034/1/Huntington%20disease%20patient%2dreported%20outcomes%20Poster.pdf">Huntington disease patient-reported outcomes Poster.pdf</a>&nbsp;&nbsp;(500 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7034">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-19T17:08:37+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7034/1/Huntington%20disease%20patient%2dreported%20outcomes%20Poster.pdf" length="511972" type="application/pdf"/></item><item>
<title>Safinamide Ph3 Results Presented at MDS2013 [dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7033</link>
<description>Safinamide Ph3 Results Presented at MDS2013 [dis:Parkinson]</description><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7033</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7033">Safinamide Ph3 Results Presented at MDS2013</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7033">Neurology7033</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2013 | 11:57</font><br><br><div style="margin-bottom: 10px;">Comment: Results presented showed that in the SETTLE study safinamide has been shown to improve motor fluctuations (ON and OFF time) by 2 hours/<wbr>day without any worsening in troublesome dyskinesia.<wbr> These new results indicate that the above benefit is accompanied by a clinically important improvement in motor symptoms without worsening of other ADL or dopaminergic complications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG>: The SETTLE study established the clinically and statistically significant benefit of safinamide 50-100 mg/<wbr>day on motor fluctuations without any increase in troublesome dyskinesia in patients who were stabilized on optimized doses of levodopa and other dopaminergic treatments.<wbr> Statistically significant differences from placebo add-on were noted on motor symptoms (UPDRSIII).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Objective</STRONG>: To determine the clinical relevance of the significant benefits of safinamide on motor symptoms (UPDRSIII) by determination of responder rates.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Methods</STRONG>: The SETTLE Study enrolled 552 PD fluctuating patients who were on stable, optimized, doses of L-dopa and other PD medications in 23 countries.<wbr> Analyses were performed to determine the proportion of patients who improved by at least 20% or 30% in motor symptoms (UPDRSIII).<wbr> Additionally, analyses were performed to determine the proportion of patients who improved by at least 20% or 30% with no worsening in activities of daily living (UPDRSII) and complication of dopaminergic treatment (UPDRSIV) in the ITT population.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results</STRONG>: Statistically significantly higher proportion of patients on safinamide improved by 20% (p=0.<wbr>0062) and 30% (p=0.<wbr>0267) in UPDRSIII.<wbr> Analysis to determine the proportion of patients who improved by 20% (p&lt;0.<wbr>05) and 30% (p&lt;0.<wbr>05) without worsening in UPDRSII and UPDRSIV also demonstrated significant benefit of safinamide compared to placebo add-on.<wbr> </div><div><EM>Source: Newron</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7033">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-19T11:57:15+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New VP of Marketing Commercial Strategy and Operations at Lexicon [sub:People, :Endocrinology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10497</link>
<description>New VP of Marketing Commercial Strategy and Operations at Lexicon [sub:People, :Endocrinology:news]</description><category>sub:People</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10497</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10497">New VP of Marketing Commercial Strategy and Operations at Lexicon</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10497">PharmaWorld10497</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2013 | 11:40</font><br><br><div style="margin-bottom: 10px;">Comment: John Northcott will develop the commercial functions for Lexicon and lead the commercialization of Lexicon’s products, with initial focus on telotristat etiprate for carcinoid syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Previous Positions</FONT></STRONG> </div><div style="margin-bottom: 10px;">Has held commercial roles in both U.<wbr>S.<wbr> and Global marketing for Avastin® with Genentech and the Roche Group </div><div style="margin-bottom: 10px;">In addition, Mr.<wbr> Northcott has experience in a variety of therapeutic areas from previous commercial positions at other pharmaceutical companies including Merck and Pfizer.<wbr> </div><div><EM>Source: Lexicon</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10497">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-19T11:40:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Astellas Looking to Sell its Dermatology Assets [:Oncology:comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10496</link>
<description>Astellas Looking to Sell its Dermatology Assets [:Oncology:comp:Astellas]</description><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10496</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10496">Astellas Looking to Sell its Dermatology Assets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10496">PharmaWorld10496</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2013 | 11:29</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas' dermatology portfolio which includes Protopic (eczema drug) could be worth between $500M and $1 billion.<wbr> Astellas is discussing breaking up the business and selling the pieces to different parties.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">- US patent for Protopic is set to expire next year.<wbr> </div><div style="margin-bottom: 10px;">- Astellas' business model as recently presented is to maintain and expand franchises in urology/<wbr>transplantation, develop oncology franchise and improve R&amp;D productivity with optimization of resource allocation.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10496">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-19T11:29:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS [dis:Gynea, :GastroEnterology:dis:IBS, :PharmaWorld:sub:Partnership, :GastroEnterology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023</link>
<description>Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS [dis:Gynea, :GastroEnterology:dis:IBS, :PharmaWorld:sub:Partnership, :GastroEnterology:news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023</comments><category>dis:Gynea</category><category>dis:IBS</category><category>sub:Partnership</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9023">Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023">Oncology9023</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2013 | 11:09</font><br><br><div style="margin-bottom: 10px;">Comment: The Belgium based, private company presented at ENDO2013 preclinical PK and efficacy data of its oral small-molecule NK3 receptor antagonist program.<wbr> ESN364, the lead candidate issued from this program, is scheduled for FIM in 4Q:13 (endometriosis and polycystic ovary syndrome).<wbr> Of note, the company is actively seeking partner for ESN282 (inflammatory diseases such as ulcerative colitis).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ESN314 Preclinical Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">The study provides the first demonstration that the oral administration of ESN314 decreases the plasma levels of Lutenizing Hormone (LH), but not Follicle-Stimulating Hormone (FSH) in non-rodent models.<wbr> This selective reduction of plasma LH offers a more refined modulation of the HPG axis than the existing GnRH antagonist therapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Discovery Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9023/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Euroscreen</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9380c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Euroscreen has announced initiation of the Phase I clinical trial for ESN364.<wbr> The main study objective is the assessment of the safety, tolerability and pharmacokinetics of ESN364 in healthy male and female volunteers.<wbr> </div><div style="margin-bottom: 10px;">In addition, hormone levels will also be monitored as biomarkers of on-target activity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: Approximately 64 healthy subjects will participate in the study.<wbr> </div><div><STRONG>Timelines and Next Steps</STRONG>: Successful completion of this European Phase I clinical trial will enable the initiation of Proof-Of-Concept Phase II studies of ESN364 in patients suffering from sex-hormone related disorders such as Endometriosis, Poly-Cystic Ovarian Syndrome (PCOS), Uterine Fibroids, and possibly other related diseases.<wbr> Phase II studies are projected to start in Q4, 2014.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9380" class="commentpermalink">Oncology9380</a> / <span class="date">18 December 2013</span> /
<span class="time">10:38:44 o'clock CET</span>
</font></div><a name="Oncology10152c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Following "fully-consistent Ph1 results", the company now plans to start 2 Ph2 trials (3-month dosing, 72 patients) for uterine fibroids and Poly Cystic Ovarian Syndrome in January 2015.<wbr> Company claims the results obtained give  a strong competitive advantage compared to GnRH ligand products to provide a superior product with regard to both safety and efficacy for a large scope of indications such as UF, PCOS and Endometriosis in the treatment of Women&rsquo;s Health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Results</STRONG> </div><div style="margin-bottom: 10px;">The Ph1 trial enrolled 64 healthy subjects (40 male and 24 female).<wbr> </div><div style="margin-bottom: 10px;">Safety was evaluated by means of intensive ECG and vital signs monitoring as well as via the necessary clinical laboratory assessments throughout the entire study (up to 21 days of daily dosing and up to 84 days of follow-up in female volunteers).<wbr> </div><div>No clinically relevant changes were observed in the clinical lab parameters, ECG and/<wbr>or vital signs.<wbr> The reported adverse events were mild-to-moderate in intensity, reversible and of limited duration and non-significant in relation to ESN364 treatment based upon comparison to the placebo group.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10152" class="commentpermalink">Oncology10152</a> / <span class="date">08 December 2014</span> /
<span class="time">10:57:18 o'clock CET</span>
</font></div><a name="Oncology10406c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Euroscreen has initiated two POC trials in UF (Uterine fibroids) and PCOS (Polycystic ovary syndrome).<wbr> The launch of these trials builds upon the efficacy data established in Ph1 wherein ESN364 lowered plasma levels of estrogen and progesterone as a result of its selective effect on pulsatile LH secretion.<wbr> The demonstrated selective modulation of gonadotropins mitigates the risk of the induction of menopausal-like adverse events, such as loss of bone mineral density and the induction of hot flashes.<wbr> Thus, in contrast to the existing GnRH products, the non-castrating drug profile of ESN364 presents an opportunity for chronic dosing without any need for add-back therapy for the chronic treatment of Women&rsquo;s Health Disorders.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10406" class="commentpermalink">Oncology10406</a> / <span class="date">21 April 2015</span> /
<span class="time">11:00:08 o'clock CEST</span>
</font></div><a name="oncology9023attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9023/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9023">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-19T11:09:30+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9023/1/ScreenCapture1.jpg" length="36222" type="image/jpeg"/></item><item>
<title>Prosensa to Raise $60M [dis:MuscularDystrophy, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7032</link>
<description>Prosensa to Raise $60M [dis:MuscularDystrophy, :PharmaWorld:sub:Finance]</description><category>dis:MuscularDystrophy</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7032</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7032">Prosensa to Raise $60M</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMuscularDystrophy"><font color="#e95e0b">:Neurology:dis:MuscularDystrophy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7032">Neurology7032</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2013 | 10:10</font><br><br><div style="margin-bottom: 10px;">Comment: The company amended its IPO and now plans to sell 5 million shares at $11-13.<wbr> Prosensa is one of three companies vying to gain the 1st approved drug fro Duchenne muscular dystrophy (DMD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Drisapersen (PRO051) is in Ph3 testing </div><div style="margin-bottom: 10px;">- Data expected 4Q:13 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=4669" class="defaultlink">Neurology4669: GSK Acquires Prosensa's DMD Drug for Up to €460M</a>.<wbr> </div><div><EM>Source: Biocentury; Prosensa</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7032">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-19T10:10:12+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Positive Results of Versartis' hGH for PGHD Presented at ENDO 2013 [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7376</link>
<description>Positive Results of Versartis' hGH for PGHD Presented at ENDO 2013 [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7376</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7376">Positive Results of Versartis' hGH for PGHD Presented at ENDO 2013</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7376">Endocrinology7376</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2013 | 16:28</font><br><br><div style="margin-bottom: 10px;">Comment: The company presented the first results from its ped Ph1b/<wbr>2a trials in a poster presented by G.<wbr> M.<wbr> Bright (VP, Medical Affairs).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Poster /<wbr> Results in Children</FONT></STRONG> </div><div style="margin-bottom: 10px;">“A Phase 1b/<wbr>2a Study of a New Long-acting Growth Hormone (VRS-317) in Pre-pubertal Children with Growth Hormone Deficiency (GHD)” </div><div style="margin-bottom: 10px;"><UL><LI>a single dose of VRS-317 was very well tolerated in children with GHD.<wbr></LI>
<LI>the drug levels and IGF-I responses increase in intensity and duration with increasing dose.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">Bright stated that: “These results confirm and extend the VRS-317 results recently published on adult GHD patients and allow VRS-317 to be optimized for up to once-monthly dosing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results in Adults</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company’s first double-blind, placebo-controlled, single ascending dose study of VRS-317 in growth hormone deficient adults was published ahead of print in the Journal of Clinical Endocrinology &amp; Metabolism (JCEM) on April 12, 2013 [doi:10.<wbr>1210/<wbr>jc.<wbr>2013-1437] and was published in final print in the June issue of JCEM [J Clin Endocrinol Metab, June 2013, 98(6):2595–2603] (see attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130831&edate=20130501&rs=/link%20Endocrinology7378%401" class="defaultlink">@1</a>).<wbr> </div><div><EM>Source: Versartis</EM> </div><!-- Comment details --><a name="endocrinology7376attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7376/1/Yuen%20JCEM%202013%20VRS317%20in%20AGHD.pdf">Yuen JCEM 2013 VRS317 in AGHD.pdf</a>&nbsp;&nbsp;(520 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7376">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-18T16:28:11+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7376/1/Yuen%20JCEM%202013%20VRS317%20in%20AGHD.pdf" length="532450" type="application/pdf"/></item><item>
<title>Apireo Announces Start of Further Ph1 in Healthy Volunteers [dis:Acromegaly]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7375</link>
<description>Apireo Announces Start of Further Ph1 in Healthy Volunteers [dis:Acromegaly]</description><category>dis:Acromegaly</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7375</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7375">Apireo Announces Start of Further Ph1 in Healthy Volunteers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7375">Endocrinology7375</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2013 | 14:36</font><br><br><div style="margin-bottom: 10px;">Comment: On June 18th, the company reported the start of a further Ph1 designed to confirm the superior side effect profile of Somatoprim vs octreotide.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">In this randomized in- patient cross-over study, healthy volunteers will be treated with single administrations of the highest approved dose of octreotide as well as different doses of Somatoprim.<wbr> </div><div style="margin-bottom: 10px;">The effect of each treatment on safety and tolerability parameters as well as the side effect profile will be tested.<wbr> </div><div style="margin-bottom: 10px;">Results are expected by the fourth quarter of 2013.<wbr> </div><div><EM>Source: Aspireo</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7375">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-18T14:36:12+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AstraZeneca Increases Proximity to Bioscience Clusters [comp:AstraZeneca, :PharmaWorld:func:RnD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9021</link>
<description>AstraZeneca Increases Proximity to Bioscience Clusters [comp:AstraZeneca, :PharmaWorld:func:RnD]</description><category>comp:AstraZeneca</category><category>func:RnD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9021</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9021">AstraZeneca Increases Proximity to Bioscience Clusters</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9021">Oncology9021</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2013 | 14:23</font><br><br><div style="margin-bottom: 10px;">Comment: As announced at its Investor Day, AstraZeneca is picking Cambridge site as global research centre, and HQs.<wbr> R&amp;D centre in Alderley Park will be shut down.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Cambridge Site</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG>: Cambridge Biomedical Campus </div><div style="margin-bottom: 10px;"><STRONG>Staff</STRONG>: around 2000 by 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Objective</STRONG>: to focus research at 3 centres: UK, US, and Sweden.<wbr> </div><div style="margin-bottom: 10px;">The site will bring together its small molecule nand biologics R&amp;D activity.<wbr> </div><div style="margin-bottom: 10px;">The facility will become its main site for oncology research, and will also focus on cardiovascular and meatbolic diseases, respiratory, inflammation and autoimmune diseases, and conditions of the CNS.<wbr> </div><div><EM>Source: AstraZeneca</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9021">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-18T14:23:19+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Strategy Behind J&amp;J's Acquisition of Aragon [comp:JnJ, prod:Zytiga, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9020</link>
<description>Strategy Behind J&amp;J's Acquisition of Aragon [comp:JnJ, prod:Zytiga, dis:Prostate]</description><category>comp:JnJ</category><category>prod:Zytiga</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9020</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9020">Strategy Behind J&J's Acquisition of Aragon</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9020">Oncology9020</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2013 | 13:49</font><br><br><div style="margin-bottom: 10px;">Comment: The Aragon acquisition is seen as a strategic complement to Zytiga franchise (patent expires in 2016/<wbr>US).<wbr> Under the control of J&amp;J, the ARN-509 Ph3 planning is to begin shortly (after 3Q:13), and could investigate 1st-and 2nd-line metastatic and non-metastatic CRPC, ass well as Ph2-type trials assessing ARN-509/<wbr>Zytiga combination therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">J&amp;J Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Extend J&amp;J's prostate cancer franchise </div><div style="margin-bottom: 10px;">- Gain access to a potential best-in-class treatment </div><div style="margin-bottom: 10px;">- To spinn off other assets </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9020/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ARN-509 mini-snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Patent</STRONG>: 2028/<wbr>2027 in the U.<wbr>S.<wbr>/<wbr>EU at the earliest </div><div style="margin-bottom: 10px;"><STRONG>MOA</STRONG>: similar than Medivation's Xtandi.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy</STRONG>: SE profile: ARN-509 could prove to be more potent than Xtandi with a more favorable side-effect profile (no seizures seen to date).<wbr> ARN-509 could have a place in the 2nd-line setting in patients who progress after treatment with Zytiga, but importantly, could replace Xtandi as a 1st-line therapy.<wbr> </div><div>Source: Leerink Swann </div><!-- Comment details --><a name="oncology9020attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9020/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(59,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9020">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-18T13:49:22+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9020/1/ScreenCapture1.jpg" length="61117" type="image/jpeg"/></item><item>
<title>RaQualia to Raise $35M [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1894</link>
<description>RaQualia to Raise $35M [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1894</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1894">RaQualia to Raise $35M</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1894">GastroEnterology1894</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2013 | 11:09</font><br><br><div style="margin-bottom: 10px;">Comment: Last year, RaQualia reported it was restructuring to focus on 4 compounds in development for gastrointestinal diseases (please see below).<wbr> The Company believes that it is critical to continue to strengthen its ability to attract potential licensees based on its business strategy, in order to establish optimal licensing arrangements for its development compounds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Fundraising Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">There are four main objectives for this fundraising: </div><div style="margin-bottom: 10px;"><UL><LI>planning and initiating a Phase II clinical trial for our 5-HT4 Partial Agonist (RQ-10), </LI>
<LI>planning and initiating an early clinical trial for our 5-HT2B Antagonist (RQ-00310941) and Motilin Receptor Agonist (RQ-00201894), </LI>
<LI>investment in R&amp;D activities for the continuous discovery and creation of new development candidates, and </LI>
<LI>new capital expenditures for research equipment with a view towards enhancing the productivity of R&amp;D systems following the realization of a leaner organizational structure and more efficient deployment of working capital associated therewith</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Core Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>5-HT4 Partial Agonist</STRONG> (RQ-00000010) - A First-in-Human (FIH) study of the compound was initiated in the U.<wbr>K.<wbr> in May 2012.<wbr> A single ascending dose study, multiple ascending dose study, and study to investigate the effects of food, gender and age were completed in October.<wbr> The Company is currently analyzing the data and preparing a final report.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1894/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Financial Overview</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1894/2/ScreenCapture2.jpg?user-agent=rss"> </div><div>Source: RaQualia </div><!-- Comment details --><a name="gastroenterology1894attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1894/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(74,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1894/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1894">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-18T11:09:43+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1894/1/ScreenCapture1.jpg" length="76542" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1894/2/ScreenCapture2.jpg" length="93889" type="image/jpeg"/></item><item>
<title>J&amp;J Acquires Aragon for &gt;$1 Billion [dis:Prostate, comp:JnJ, headline, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9018</link>
<description>J&amp;J Acquires Aragon for &gt;$1 Billion [dis:Prostate, comp:JnJ, headline, :PharmaWorld:sub:Acquisition]</description><category>dis:Prostate</category><category>comp:JnJ</category><category>headline</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9018</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9018">J&J Acquires Aragon for >$1 Billion</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9018">Oncology9018</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 June 2013 | 15:59</font><br><br><div style="margin-bottom: 10px;">Comment: J&amp;J announced a definitive agreement to acquire Aragon, a company developing ARN-509 (an androgen receptor antagonist similar to enzalutamide).<wbr> This acquisition, expected to close in 3Q 2013, is seen as a strategic importance for J&amp;J's Zytiga likely to lose market share to Medivation's drug over the course of the coming month and years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Excluded Indication</FONT></STRONG> </div><div style="margin-bottom: 10px;">The deal does not include development of Aragon's treatment for breast cancer, which will be spun off into a separate company called Seragon Pharmaceuticals ahead of the deal and will be run by Aragon's chief executive officer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">J&amp;J will make an upfront cash payment of $650mm, plus additional contingent payments of up to $350mm based on reaching predetermined milestones.<wbr> </div><div style="margin-bottom: 10px;">Prior to closing, Aragon will transfer all assets other than its androgen receptor antagonist program to a newly formed company, which Aragon will spin off.<wbr> </div><div style="margin-bottom: 10px;">J&amp;J will not have an ownership stake in the new company nor retain any rights to these products or programs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Legal Action Ongoing</FONT></STRONG> </div><div style="margin-bottom: 10px;">Analysts believe Medivation still has a high probability of success in ongoing litigation against UCLA and Aragon.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="i hovered">
<UL><LI><SPAN style="COLOR: #000000">In February 2011, Medivation filed suit against the University of California and Aragon alleging that the university breached a 2005 deal with Medivation when it granted Aragon rights to ARN-509, which Medivation said is based on technology similar to its prostate cancer drug <A href="http://www.biocentury.com/products/xtandi" target="_blank" title="Xtandi product news and analysis from BCIQ"><SPAN style="COLOR: #000000">Xtandi</SPAN></A> enzalutamide.<wbr><WBR> Under the 2005 deal, Medivation has rights to the university's small molecule androgen receptor antagonists, including Xtandi.<wbr></WBR><WBR> The court ruled Medivation has exclusive rights to a specific series of compounds identified by a chemical structure that does not include ARN-509, which is in Phase II testing for castration-resistant prostate cancer (CRPC).<wbr></WBR><WBR> </WBR></SPAN></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;">Even if ARN-509 is ruled the property of Aragon, they believe that J&amp;J will have to conduct head-to-head trials against XTANDI™ just to get ARN-509 onto the market.<wbr> </div><div><EM>Source: ThomsonOne; Aegis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9018">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-17T15:59:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Takeda and Sanofi to Cooperate in China [mkt:China, mkt:Intercontinental, :Oncology:comp:SanofiAventis, :Oncology:comp:Takeda]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10490</link>
<description>Takeda and Sanofi to Cooperate in China [mkt:China, mkt:Intercontinental, :Oncology:comp:SanofiAventis, :Oncology:comp:Takeda]</description><category>mkt:China</category><category>mkt:Intercontinental</category><category>comp:SanofiAventis</category><category>comp:Takeda</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10490</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10490">Takeda and Sanofi to Cooperate in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aSanofiAventis"><font color="#e95e0b">:Oncology:comp:SanofiAventis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10490">PharmaWorld10490</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 June 2013 | 10:47</font><br><br><div style="margin-bottom: 10px;">Comment: The objective of this cooperation is to expand Takeda's drug sales in China.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Takeda CEO reported that because emerging markets represent approx.<wbr> 70% of global drug market growth, his company must develop long-term localized strategies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">In April 2013 Takeda and Sanofi agreed to co-promote alogliptin (submitted for marketing authorization in China for type 2 diabetes).<wbr> </P> </div><div><UL dir="ltr"><LI>
Per the agreement, Takeda will grant the exclusive Chinese rights for the drug to Sanofi.<wbr> (commercial terms not cisclosed).<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10490">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-17T10:47:04+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Russia to Support Hi-Tech Production of Pharmaceuticals [mkt:Russia, mkt:Intercontinental, sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10489</link>
<description>Russia to Support Hi-Tech Production of Pharmaceuticals [mkt:Russia, mkt:Intercontinental, sub:Pricing]</description><category>mkt:Russia</category><category>mkt:Intercontinental</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10489</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10489">Russia to Support Hi-Tech Production of Pharmaceuticals</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10489">PharmaWorld10489</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 June 2013 | 15:04</font><br><br><div style="margin-bottom: 10px;">Comment: Vladimir Putin has signed a "list of instructions" according to which the Russian government, along with the national business associations, has been tasked with "providing an enabling environment for domestic manufacturers of drugs", by preparing measures that include additional measures to support hi-tech production of pharmaceutical substances for the creation of drugs, including those listed on the list vital and essential drugs (ZHNVLP).<wbr> </div><div style="margin-bottom: 10px;">These are to be prepared by 1 September.<wbr> Furthermore, the "list" also includes the development of proposals for introducing additional preferences within the public procurement system for goods manufactured on the territory of the country.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">The "list of instructions" reflects Russia's ongoing objective of boosting the domestic pharmaceutical industry and enabling innovativeness within the industry.<wbr> It is also in line with the objective of increasing the volume of domestic production of medicines on the ZHNVLP list to 90% by 2018.<wbr> </div><div style="margin-bottom: 10px;">Additionally, the preparation of measures for further preference within the public procurement system for goods manufactured in the country also reflects the government's ongoing support for domestic manufacturers.<wbr> </div><div style="margin-bottom: 10px;">There is a 15% price preference given to Russian and Belarusian produced goods within public tenders, with the Russian Ministry of Economic Development and Ministry of Industry and Trade also having previously introduced a proposal according to which foreign medicines would be barred from participating in tenders for state purchases if there are two or more domestically produced alternatives.<wbr> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10489">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-14T15:04:54+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Interim Data Further Supports Safety of Novo Nordisk's Victoza® [comp:NovoNordisk, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7373</link>
<description>Interim Data Further Supports Safety of Novo Nordisk's Victoza® [comp:NovoNordisk, dis:Diabetes]</description><category>comp:NovoNordisk</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7373</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7373">Interim Data Further Supports Safety of Novo Nordisk's Victoza®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7373">Endocrinology7373</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 June 2013 | 12:57</font><br><br><div style="margin-bottom: 10px;">Comment: The observed relative risks of both pancreatitis and pancreatic cancer for Victoza<SUP>®</SUP> were similar to, or numerically lower than, that of the comparators in each cohort, as previously communicated.<wbr> </div><div style="margin-bottom: 10px;">The results of the study were presented as part of a complete overview of available Victoza<SUP>®</SUP> safety data, including non-clinical and clinical data as well as data from post-marketing commitments that together reconfirmed the safety profile of Victoza<SUP>®</SUP>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Scientific Workshop</FONT></STRONG> </div><div style="margin-bottom: 10px;">Data were presented at a scientific workshop in the U.<wbr>S arranged by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Objectives</STRONG>: regulators, academic and scientific experts as well as representatives from the pharmaceutical industry came together to discuss suspected mechanisms linking pancreatitis, diabetes and pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company's Presentation</FONT></STRONG> </div><div style="margin-bottom: 10px;">Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk presented interim data from an ongoing prospective, matched cohort epidemiological study comparing Victoza<SUP>®</SUP> with 4 other widely used anti-diabetic drug classes in each cohort.<wbr> </div><div style="margin-bottom: 10px;">The study comprised &gt;100,000 patient years of treatment, with between 14,000 and 19,000 patients on Victoza<SUP>®</SUP> and comparator treatment in each cohort.<wbr> </div><div><EM>Source: Novo Nordisk</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7373">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-14T12:57:14+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1892</link>
<description>re: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1892</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1892">re: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1892">GastroEnterology1892</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 June 2013 | 12:34</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=sub%3aDiagnostic"><font color="#e95e0b">:GastroEnterology:sub:Diagnostic</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Methylene Blue MMX<SUP>®</SUP> (for the diagnosis of lesions, polyps and adenomas in the colon) will be presented to approx.<wbr> 500 specialists from around the world during the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano/<wbr>Italy.<wbr> The Methylene blue-MMX<SUP>®</SUP> tablet, currently assessed in Ph2, is an oral colon-release formulation in form of coated tablets, containing methylene blue.<wbr> The company expects market entry end 2013.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1800">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1800" class="commentpermalink">GastroEnterology1800</a> / <span class="date">16 June 2011</span> /
<span class="time">09:50:28 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">On June 14th, the FDA reported that the design and planned analysis of the Ph3 study proposed by Cosmo adequately address the objectives necessary to support a regulatory submission for the marketing authorization of the product.<wbr> Cosmo is now completing the preparations for the clinical trial, expected to complete latest Q1:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>EU Status</STRONG> </div><div style="margin-bottom: 10px;">EMA has previously approved the access to the centralized procedure for the future Marketing Authorization.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ph3 Locations</STRONG> </div><div style="margin-bottom: 10px;">The trial will be conducted in major North American and European hospitals.<wbr> </div><div>Source: Cosmo </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1892" class="commentpermalink">GastroEnterology1892</a> / <span class="date">14 June 2013</span> /
<span class="time">12:34:38 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1892">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1800">View thread  GastroEnterology1800: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</a>]]></content:encoded><dc:date>2013-06-14T12:34:38+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Indication of Amgen's XGEVA® (denosumab) Approved in the U.S</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9017</link>
<description>New Indication of Amgen's XGEVA® (denosumab) Approved in the U.S</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9017</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9017">New Indication of Amgen's XGEVA® (denosumab) Approved in the U.<wbr>S</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9017">Oncology9017</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 June 2013 | 11:19</font><br><br><div style="margin-bottom: 10px;"><FONT size="2">Comment: Amgen now can market XGEVA® for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone (GCTB), when surgery is not practical.<wbr> The drug was approved by the <ORG>FDA</ORG> for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors in 2010</FONT> </div><div style="margin-bottom: 10px;"><STRONG>Base of the Approval Dossier</STRONG> </div><div style="margin-bottom: 10px;"><FONT size="2"><STRONG>Trials Results</STRONG>: positive results from 2 open-label trials that enrolled patients with GCTB that was either recurrent, unresectable, or for which planned surgery was likely to result in severe morbidity.<wbr> The overall objective response rate of the 187 patients evaluated was 25%.<wbr> The estimated median time to response was 3 months.<wbr> In the 47 patients with an objective response, 51 percent (24/<wbr>47) had a duration of response lasting at least eight months.<wbr> Three patients experienced disease progression following an objective response.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2"><STRONG>Safety</STRONG>: the most common adverse reactions were arthralgia, headache, nausea, back pain, fatigue, and pain in the extremity.<wbr>  The most common serious adverse reactions were osteonecrosis of the jaw and osteomyelitis.<wbr></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Amgen Comprehensive Approach to Aggressing Cancer</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9017/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9017attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9017/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(94 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9017">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-14T11:19:38+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9017/1/ScreenCapture1.jpg" length="96232" type="image/jpeg"/></item><item>
<title>First and Only Medicine for IBS-C Approved in EU [dis:IBS, dis:Constipation]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1891</link>
<description>First and Only Medicine for IBS-C Approved in EU [dis:IBS, dis:Constipation]</description><category>dis:IBS</category><category>dis:Constipation</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1891</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1891">First and Only Medicine for IBS-C Approved in EU</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1891">GastroEnterology1891</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 June 2013 | 17:26</font><br><br><div style="margin-bottom: 10px;">Comment: Almirall and Ironwood announced the launch of Constella® (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Availability</FONT></STRONG> </div><div style="margin-bottom: 10px;">Constella® is now available in Germany, the UK and Nordic countries, and is expected to be launched in several other European countries in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Treatment Options</FONT></STRONG> </div><div>Prior to the approval of Constella®, IBS-C treatment options consisted mainly of therapies for individual symptoms such as antispasmodics or unlicensed antidepressants for pain and laxatives for constipation.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1891">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-13T17:26:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Advanced Accelerator Applications (AAA) Reports Completion of €4.8M Capital Increase [dis:pNET, headline, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7371</link>
<description>Advanced Accelerator Applications (AAA) Reports Completion of €4.8M Capital Increase [dis:pNET, headline, :PharmaWorld:sub:Finance]</description><category>dis:pNET</category><category>headline</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7371</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7371">Advanced Accelerator Applications (AAA) Reports Completion of €4.<wbr>8M Capital Increase</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7371">Endocrinology7371</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 June 2013 | 12:58</font><br><br><div style="margin-bottom: 10px;">Comment: The financing will help the expansion plans and finance trials of Radio Metabolic Therapy and diagnostic products, including Lutathera®, currently in ph3 for the diagnosis and treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).<wbr> This is the 1st tranche of financing that AAA is raising from the 10M new shares that the Company issued on March 8th, 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Lutathera® Update</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Status</STRONG> </div><div style="margin-bottom: 10px;">- Lutathera® has orphan drug status and has already been used in thousands of patients by specialist clinicians with significant results.<wbr> </div><div style="margin-bottom: 10px;">- Market approvals in the US and EU expected in 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sites of the Ph3 trials</STRONG> </div><div style="margin-bottom: 10px;">- 50 hospitals in EU (located in Italy, France, Germany, Portugal, Spain, Belgium and UK) and in the US (California, Iowa, Massachusetts, Florida, New York, Texas, Minnesota, Pennsylvania, Louisiana and North Carolina).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Business Development</STRONG> </div><div style="margin-bottom: 10px;">- Lutathera® was acquired in June 2010 following AAA’s purchase of BioSynthema, a MNM research company based in St.<wbr> Louis, Missouri, US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">AAA at a Glance</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Privately owned company registered in Bourg en Bresse, France.<wbr> </div><div style="margin-bottom: 10px;">- AAA owns 100% of its subsidiaries in Italy, Switzerland, Spain and USA.<wbr> </div><div style="margin-bottom: 10px;">- Focus on molecular imaging and personalized medicine for the treatment of diseases including cancer.<wbr> </div><div style="margin-bottom: 10px;">- EU leader in the production and commercialization of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) products, with 16 production and R&amp;D facilities in France, Italy, Switzerland, Spain, Portugal, Israel and the US.<wbr> </div><div><EM>Source: AAT</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7371">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-13T12:58:43+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Major Opportunity for GW Pharm's Sativex [dis:Spasticity, :PharmaWorld:mkt:France]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7031</link>
<description>Major Opportunity for GW Pharm's Sativex [dis:Spasticity, :PharmaWorld:mkt:France]</description><category>dis:Spasticity</category><category>mkt:France</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7031</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7031">Major Opportunity for GW Pharm's Sativex</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aFrance"><font color="#e95e0b">:PharmaWorld:mkt:France</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7031">Neurology7031</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2013 | 15:07</font><br><br><div style="margin-bottom: 10px;">Comment: A new decree proposed by the French minister of health Marisol Touraine allows the French National Agency for Drug Safety (ANSM) to grant marketing authorisation to pharmaceutical treatments based on cannabinoids and cannabis derivates.<wbr> The decree was published on the French Official Gazette on 7 June.<wbr> </div><div style="margin-bottom: 10px;">The decree allows for manufacturing operations, transportation, import, export, possession, supply, sale, purchase, or use of these specialty treatments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">The decree opens the doors for marketing authorisation of cannabis-based medicines.<wbr> </div><div style="margin-bottom: 10px;">The drug has been already launched internatinally and has been added to the reimbursement list of some European Union countries.<wbr> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7031">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-12T15:07:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>POC Trial of Auris Medical's NMDA Antagonist for Tinnitus To Approach Completion [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10484</link>
<description>POC Trial of Auris Medical's NMDA Antagonist for Tinnitus To Approach Completion [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10484</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10484">POC Trial of Auris Medical's NMDA Antagonist for Tinnitus To Approach Completion</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10484">PharmaWorld10484</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2013 | 11:09</font><br><br><div style="margin-bottom: 10px;">Comment: Last month, the company presented key safety outcomes at the TRI Tinnitus Conference.<wbr> They also showed high acceptance of intratympanic injections by th epatients.<wbr> AM-101 clinical programme comprises a total of 3 double-blind, randomized, placebo-controlled trials, of which 2 have been completed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Details of the Programme</FONT></STRONG> </div><div style="margin-bottom: 10px;">- In the first trial, a Phase I/<wbr>II study involving 24 patients, the safety of a single dose administration of AM-101 was demonstrated in a dose escalation up to 0.<wbr>81 mg/<wbr>mL.<wbr> It also revealed minimal systemic exposure from the treatment.<wbr> These results have been published previously (Mühlmeier et al.<wbr>, 2012).<wbr> </div><div style="margin-bottom: 10px;">- At the TRI Tinnitus Conference, key safety outcomes from the second study, a Phase IIb clinical trial, were presented for the first time.<wbr> The study enrolled a total of 248 patients who were treated 3 times over 3 consecutive days either with AM-101 at 0.<wbr>27 or 0.<wbr>81 mg/<wbr>mL or placebo.<wbr> Study participants were monitored over 90 days.<wbr> The primary safety endpoint was the occurrence of clinically relevant hearing deterioration from baseline to Day 30, defined as increase in the pure tone hearing threshold ≥15 dB in any two contiguous test frequencies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Last Financial Operation</FONT></STRONG> </div><div style="margin-bottom: 10px;">April 16, 2013 - Auris Medical AG raised CHF47.<wbr>1m (US$50.<wbr>7m) in series C financing round.<wbr> The finance was provided by Sofinnova Ventures, Inc.<wbr> and Sofinnova Partners SAS.<wbr> In conjunction with the funding, Jim Healy, general partner at Sofinnova Ventures, and Antoine Papiernik, managing partner at Sofinnova Partners, joined Auris’s board of directors.<wbr> </div><div style="margin-bottom: 10px;">The company intends to use the proceeds to advance its two clinical projects, AM-101 for the treatment of acute tinnitus and AM-111 for the treatment of acute inner ear hearing loss, through Phase III studies and market launch.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Mini SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Founded in April 2003 in Switzerland.<wbr> </LI>
<LI>H/<wbr>Q: Basel, Switzerland</LI>
<LI><TR><TD align="left" valign="top">Auris Medical is also working with a network of specialised partners, including some of the world's leading scientists in the area of inner ear disorders.<wbr> </TD>
</TR>

</LI>
</UL> </div><div><EM>Source: Auris Medical AG</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10484">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-12T11:09:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Autifony's Lead Product Enters FIM for Hearing Loss and Tinnitus [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10483</link>
<description>Autifony's Lead Product Enters FIM for Hearing Loss and Tinnitus [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10483</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10483">Autifony's Lead Product Enters FIM for Hearing Loss and Tinnitus</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10483">PharmaWorld10483</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2013 | 10:53</font><br><br><div style="margin-bottom: 10px;">Comment: AUT00063, novel first-in-class Kv3 potassium channel modulator, targets auditory processing in the brain.<wbr> To fund the programme to POC, Autifony announced that Pfizer Venture Investments has invested £5M.<wbr> The company intents to find a partner at the end of the Phase II.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Ph1 Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: RCT</LI>
<LI>Location: UK</LI>
<LI>Objective: to assess the safety, tolerability and pharmacokinetics of orally administered single and multiple dose regimens of the drug.<wbr></LI>
<LI>Recruitment: approx 60 (young and elderly volunteers).<wbr></LI>
<LI>Completion date: Q1 2014.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Mini Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK's Neuroscience Centre of Excellence for Drug Discovery.<wbr></LI>
<LI>Privately funded by leading venture capital investors.<wbr> </LI>
<LI>Head office is at the Imperial College Incubator in London.<wbr> </LI>
<LI>The company works closely with hearing research experts at University College London’s Ear Institute, Yale University, and other academic collaborators around the world to progress its pioneering research.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2013 Sientific Presentations</FONT></STRONG> </div><div style="margin-bottom: 10px;">Tinnitus Research Initiative Conference (May 2013) </div><div style="margin-bottom: 10px;"><UL><LI>“AUT3, a Kv3.<wbr>1 positive modulator, suppresses chronic noise-induced tinnitus in a rat model” (Turner et al.<wbr>).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">ARO Annual Meeting (February 2013) </div><div style="margin-bottom: 10px;"><UL><LI>“Pharmacological activators and inhibitors of Kv3.<wbr>1 potassium currents“ (Brown et al.<wbr>).<wbr></LI>
<LI>“Impact of Kv3 Channel Modulator AUT3 on In Vivo Auditory Processing in Mice“ (Hesse et al.<wbr>).<wbr></LI>
</UL> </div><div><EM>Source: Autifony Therapeutics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10483">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-12T10:53:44+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Gedeon Richter Expands Marketing Rights for its Lead Gynae Drug [dis:Gynea, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9014</link>
<description>Gedeon Richter Expands Marketing Rights for its Lead Gynae Drug [dis:Gynea, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Gynea</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9014</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9014">Gedeon Richter Expands Marketing Rights for its Lead Gynae Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9014">Oncology9014</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2013 | 10:23</font><br><br><div style="margin-bottom: 10px;">Comment: The licensing agreement signed with HRA Pharma will expand marketing agreeement in Latin America, a key market for Gedeon Richter.<wbr> Esmya(R), ulipristal acetate, is indicated for the treatment of uterine myoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partnership Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">Follwoing the acquisition of PregLem (in late 2010), Watson received exclusive licenting rights to develop and market the drug in the USA and Canada.<wbr> </div><div style="margin-bottom: 10px;">InLate 2011, Gedeon Richter obtained from HRA Pharma an extension to the CIS and China.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Gedeon Richter Portfolio</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Gyneacology, CNS and cardiovascular.<wbr> </div><div style="margin-bottom: 10px;">- Significant player in the female HC field WW.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline in Endometriosis</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9014attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(116,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(20 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(37,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9014">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-12T10:23:13+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/1/ScreenCapture1.jpg" length="119318" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/2/ScreenCapture2.jpg" length="20441" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9014/3/ScreenCapture3.jpg" length="38578" type="image/jpeg"/></item><item>
<title>re: CEE Countries Affected by Parallel Exports</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10482</link>
<description>re: CEE Countries Affected by Parallel Exports</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10482</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10482">re: CEE Countries Affected by Parallel Exports</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10482">PharmaWorld10482</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/69">Paul Belnat</a> | 12 June 2013 | 09:47</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">CEE Countries Affected by Parallel Exports</span>&nbsp;<br><span style="font-size: 12px;">Comment: Reports of increased levels of parallel exports of expensive pharmaceuticals from countries in the Central and Eastern Europe (CEE) region have become more frequent recently.<wbr> Although in previous years the spotlight has been on Slovakia, where legal changes have been introduced to counteract the adverse consequences of parallel exports of drugs on the population, currently it is Slovakia's neighbours – the Czech Republic, Hungary, and Poland – where the problem is becoming more serious.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10480">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10480" class="commentpermalink">PharmaWorld10480</a> / <span class="date">11 June 2013</span> /
<span class="time">17:30:53 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">The issue of cross-border trade has been given a high priority by the national health authorities in EE.<wbr> </div><div style="margin-bottom: 10px;">In PL, the local association is urging all players of the pharmaceutical value chain to notify relevant authorities if shortages of drugs occur.<wbr> In parallel, the pharmaceutical inspectorate puts up a list of drugs which are threatened by shortages and imposes wholesalers to report the exports of drugs from the list.<wbr> The inspectorate can forbid exports of drug(s) from the list.<wbr> </div><div style="margin-bottom: 10px;">in RO, which surprisingly is not quoted in the above paper, export can represent up to 40% of some therapeutic classes.<wbr> The local association is proposing a new pricing methodology to address that issue.<wbr> </div><div style="margin-bottom: 10px;">Finally in HU, on 10 May 2013, the Government submitted a Bill to Parliament which contains provisions to restrict parallel trade of medicines subject to certain conditions.<wbr>  Article 95 of the Bill provides that the competent authority <STRONG>may prohibit the export of a medicine through wholesale trade for up to one year </STRONG>if there is a risk to patient supply due to excessive export of the medicine if (i) there is no other medicine available with a similar therapeutic effect; or (ii) terminating the import of the medicine to Hungary would cause disturbances in medicine supply.<wbr> A fine of up to <STRONG>HUF 500 million (approximately &euro;1.<wbr>7 million) </STRONG>may be imposed by the HA in case of infringement.<wbr> </div><div>P.<wbr>Belnat </div><!-- Comment details --><font size="-1">Paul Belnat / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10482" class="commentpermalink">PharmaWorld10482</a> / <span class="date">12 June 2013</span> /
<span class="time">09:47:42 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10482">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10480">View thread  PharmaWorld10480: CEE Countries Affected by Parallel Exports</a>]]></content:encoded><dc:date>2013-06-12T09:47:42+02:00</dc:date><dc:creator>pab99547</dc:creator></item><item>
<title>CEE Countries Affected by Parallel Exports</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10480</link>
<description>CEE Countries Affected by Parallel Exports</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10480</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10480</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10480">CEE Countries Affected by Parallel Exports</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10480">PharmaWorld10480</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 June 2013 | 17:30</font><br><br><div style="margin-bottom: 10px;">Comment: Reports of increased levels of parallel exports of expensive pharmaceuticals from countries in the Central and Eastern Europe (CEE) region have become more frequent recently.<wbr> Although in previous years the spotlight has been on Slovakia, where legal changes have been introduced to counteract the adverse consequences of parallel exports of drugs on the population, currently it is Slovakia's neighbours – the Czech Republic, Hungary, and Poland – where the problem is becoming more serious.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Scale of parallel exports in Poland underestimated</B></P> </div><div style="margin-bottom: 10px;">In a major report in Polish newspaper <I>Gazeta Wyborcza, </I>it is reported that the scale of parallel exports of drugs from Poland is underestimated, with the country's chief pharmaceutical inspector, Zofia Ulz, estimating that as much as 30% of the whole market by value may be subject to parallel exports.<wbr> IMS Health is reported as estimating that drugs with a value of as much as PLN3 billion (USD931.<wbr>246 million) are parallel exported each year, and although most of this is exported legally, around one-third is not.<wbr> In comparison, the value of the parallel export market in 2010 was estimated at around just PLN800 million.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Price of some innovative drugs 59% lower than European average</B></P> </div><div style="margin-bottom: 10px;">Ulz is reported as stating that the medicines that are parallel-exported are often expensive, innovative ones with no equivalents on the market, and among the therapeutic areas represented are oncology, cardiology, and asthma, while there is a particularly bad problem with parallel exports of insulin.<wbr> Ulz is reported as stating that the average price of the most commonly parallel-exported medicines is as much as 59% lower than the European average, which is the reason behind the phenomenon.<wbr> Another cause is the fixed margins applied for pharmacies and wholesalers as part of the Reimbursement Act from the beginning of 2012, which has meant that wholesalers and pharmacists have sought other means to boost their income.<wbr> It is reported that pharmacies lost in the region of PLN1 billion of their income because of the introduction of fixed margins.<wbr> In the case of pharmacies, there are legal issues, because they are only able to sell directly to patients through retail, and to sell medicines abroad for them is in breach of the law.<wbr> </div><div style="margin-bottom: 10px;">The source describes how some pharmacy owners will order extra amounts of medicines in addition to their main order, which they then sell to wholesalers who sell them abroad – despite the fact that they are not allowed to sell the medicines to wholesalers – but they are able to do this in a way that makes it appear entirely legal.<wbr> Additionally, a similar thing is reported to be happening in Polish hospitals, with orders placed for more than required, and the additional medicines being sold abroad illegally.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Czech hospitals reportedly involved in export "fraud"</B></P> </div><div style="margin-bottom: 10px;">In the Czech Republic, a similar situation is occurring in the hospital market, with the already well-known phenomenon of the disappearance of a proportion of the medicines used in specialised treatment centres – including centres for oncology, multiple sclerosis, and cardiology – which are where most of the use of innovative drugs in the Czech Republic is concentrated.<wbr> As Czech news agency ČTK reports, on the basis of an article in Czech newspaper <I>Lidové noviny</I>, a hospital may order a large amount of medicines, agreeing a discount on them with the wholesaler, but it does not take all the medicines, retaining only one-tenth of them, then invoicing the health insurance fund for the regular price, while the wholesaler sells the rest abroad at a big profit.<wbr> This is reported to affect cancer, multiple sclerosis, and rheumatoid arthritis drugs.<wbr> </div><div style="margin-bottom: 10px;">Officially, the value of parallel exports of medicines from the Czech Republic is around CZK0.<wbr>5 billion (USD25.<wbr>759 million), although experts suggest that billions of koruna worth of drugs are being parallel exported.<wbr> Recently, a legislative change was introduced in the country under which pharmacy operators have been obliged to inform the State Institute for Drug Control whether they are ordering medicines for retail sale or for export; however, as the source reports, this measure has been proven to be ineffective in the face of the very lucrative nature of parallel exports of such medicines.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Hungarian legal change planned to combat parallel exports</B></P> </div><div style="margin-bottom: 10px;">In Hungary, among the drugs most affected by parallel exports are anticoagulants and medicines to treat multiple sclerosis and various cancers.<wbr> As Hungarian medical news provider Weborvos reports<I>, </I>under a proposal for a legal change, it is suggested that parallel exports should only be allowed when the needs of the Hungarian market are catered for.<wbr> Weborvos comments that the increasingly low prices of medicines resulting from the blind-bid tenders for off-patent medicines are contributing to an increase in parallel export activity, as well as the ever lower profit margins of wholesalers.<wbr> </div><div style="margin-bottom: 10px;">Another reason for the lack of certain medicines on the Hungarian market, according to the National Institute for Quality and Organisational Development in Healthcare and Medicines and the National Institute of Pharmacy, quoted by the source, is that wholesalers with a smaller market share are having problems obtaining certain medicines from manufacturers.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Outlook and implications</B></P> </div><div style="margin-bottom: 10px;">Other CEE countries are clearly looking at the case of Slovakia and considering their own response.<wbr> Indeed, in Poland, there are already plans in the pipeline for legal changes that would bring in a sort of "early warning" system for shortages of the kind that has been introduced in Slovakia.<wbr> Increased monitoring and inspection of pharmacies and wholesalers is also planned.<wbr> It would seem that in Hungary, a similar plan is being proposed.<wbr> </div><div style="margin-bottom: 10px;">In all three countries under discussion, there have been changes in the pricing and reimbursement of pharmaceuticals that are sure to have resulted in the reduction in the prices of many off-patent and some patented drugs, on account of the use of jumbo reference-pricing groups.<wbr> Thus, while solving one problem – that of the high prices of medicines – a new one is created in the form of parallel exports.<wbr> Controlling and restricting parallel exports is a potentially contentious area too, as was discovered by the Greek authorities, where the situation with parallel exports has been especially difficult, and where the European Commission intervened when the Greek authorities were judged to be imposing excessive restrictions on the free movement of goods.<wbr> </div><div style="margin-bottom: 10px;">In the case of Poland and the Czech Republic, Germany is the main market for parallel-exported drugs.<wbr> Pharmaceutical companies will be hoping that the governments of these countries can do something to reduce it, as it is damaging to the integrity of their prices in higher price, higher income markets.<wbr> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10482c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The issue of cross-border trade has been given a high priority by the national health authorities in EE.<wbr> </div><div style="margin-bottom: 10px;">In PL, the local association is urging all players of the pharmaceutical value chain to notify relevant authorities if shortages of drugs occur.<wbr> In parallel, the pharmaceutical inspectorate puts up a list of drugs which are threatened by shortages and imposes wholesalers to report the exports of drugs from the list.<wbr> The inspectorate can forbid exports of drug(s) from the list.<wbr> </div><div style="margin-bottom: 10px;">in RO, which surprisingly is not quoted in the above paper, export can represent up to 40% of some therapeutic classes.<wbr> The local association is proposing a new pricing methodology to address that issue.<wbr> </div><div style="margin-bottom: 10px;">Finally in HU, on 10 May 2013, the Government submitted a Bill to Parliament which contains provisions to restrict parallel trade of medicines subject to certain conditions.<wbr>  Article 95 of the Bill provides that the competent authority <STRONG>may prohibit the export of a medicine through wholesale trade for up to one year </STRONG>if there is a risk to patient supply due to excessive export of the medicine if (i) there is no other medicine available with a similar therapeutic effect; or (ii) terminating the import of the medicine to Hungary would cause disturbances in medicine supply.<wbr> A fine of up to <STRONG>HUF 500 million (approximately &euro;1.<wbr>7 million) </STRONG>may be imposed by the HA in case of infringement.<wbr> </div><div>P.<wbr>Belnat </div><font size="-1">Paul Belnat / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10482" class="commentpermalink">PharmaWorld10482</a> / <span class="date">12 June 2013</span> /
<span class="time">09:47:42 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10480">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-11T17:30:53+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Tecnofarma to Distribute Xtandi (enzalutamide) in Latin America [comp:Astellas, :PharmaWorld:sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9012</link>
<description>Tecnofarma to Distribute Xtandi (enzalutamide) in Latin America [comp:Astellas, :PharmaWorld:sub:Partnership]</description><category>comp:Astellas</category><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9012</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9012">Tecnofarma to Distribute Xtandi (enzalutamide) in Latin America</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9012">Oncology9012</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 June 2013 | 10:26</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas has signed a distribution agreement with Tecnofarma for Latin America, excluding Brazil.<wbr> Of note, Valeant acquired Tecnofarma in July 2009 for $35M.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Terms</FONT></STRONG> </div><div style="margin-bottom: 10px;">Not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Astellas</FONT></STRONG> </div><div style="margin-bottom: 10px;">Expand oncology business in the country.<wbr> </div><div style="margin-bottom: 10px;">Tecnofarma has a strong Latin American sales and marketing oncology organization.<wbr> </div><div style="margin-bottom: 10px;">Astellas already has a relationship through the distribution of Mycamine(R) (indicated for the treatment of candidemia) in the country.<wbr> </div><div>Source: ThomsonOne </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9012">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-11T10:26:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FIM to Evaluate Everolimus with TheraSpere for Advanced NETs [comp:Novartis, headline, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7369</link>
<description>FIM to Evaluate Everolimus with TheraSpere for Advanced NETs [comp:Novartis, headline, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</description><category>comp:Novartis</category><category>headline</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7369</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7369">FIM to Evaluate Everolimus with TheraSpere for Advanced NETs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7369">Endocrinology7369</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 June 2013 | 17:22</font><br><br><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Comment: The phase 1 is to find the highest tolerable dose of the combination of everolimus with TheraSphere that can be given to patients with advanced NETs that have spread to the liver.<wbr> The safety of everolimus and TheraSphere will also be studied.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is TheraSphere ?</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.nordion.com/therasphere/physicians_intl/about_therasphere.asp">TheraSphere</A> is a medical device containing a radioactive material called yttrium-90 (Y-90).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7369/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Tiny glass beads called microspheres are filled with Y-90 and then injected through an artery directly into the liver.<wbr> This allows a large dose of radiation to be given directly to the tumor, which may lower the risk of side effects from the radiation to other parts of the body and/<wbr>or to healthy liver tissue.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7369/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The radiation from TheraSphere stays in the body and begins to lose its effect within 12 days.<wbr> The glass microspheres will stay in the body from that point on.<wbr> The radiation will eventually decay (go away).<wbr> By the time a participant leaves the hospital, the amount of radiation outside of the body will be low enough to not be a threat to others.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01864070?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F10%2F2013&amp;rank=181"><STRONG><FONT size="3">NCT01864070</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 22 </div><div style="margin-bottom: 10px;">Start date: Nov 2013 - Completion date: Nov 2017 </div><div>Location: USA (1)PI: Nageshwara V.<wbr> Dasari, MBBS </div><!-- Comment details --><a name="endocrinology7369attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7369/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(51,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7369/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7369">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-10T17:22:23+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7369/1/ScreenCapture1.jpg" length="53088" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7369/2/ScreenCapture2.jpg" length="53041" type="image/jpeg"/></item><item>
<title>Pfizer's Strategy on New Drug Development</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9009</link>
<description>Pfizer's Strategy on New Drug Development</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9009</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9009">Pfizer's Strategy on New Drug Development</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9009">Oncology9009</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 June 2013 | 14:10</font><br><br><div style="margin-bottom: 10px;">Comment: Ian Reed (CEO) has told Wall St.<wbr> Cheat Sheet he would like to develop JVs with other drugmakers in order to expand into international markets, share costs, risks, and commercial benefits.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Focused Areas</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management cited vaccines, oncology and neurodegenrative business as areas in which partnership would be useful.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Pfizer has already partnered with J&amp;J to develop a new Alzheimer drug (<A href="http://www.reuters.com/article/2013/02/13/us-alzheimers-johnsonjohnson-idUSBRE91C0SX20130213">http:/<wbr>/<wbr>www.<wbr>reuters.<wbr>com/<wbr>article/<wbr>2013/<wbr>02/<wbr>13/<wbr>us-alzheimers-johnsonjohnson-idUSBRE91C0SX20130213</A>).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Human Resources</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reed believes that getting better scientists on the board of directors will help the company continue to make a new generation of innovative treatments in the coming years.<wbr> </div><div><EM>Source: First Word</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9009">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-10T14:10:53+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Onco/Uro Surveys Look at Provenge Xtandi and Capesaris [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9008</link>
<description>Onco/Uro Surveys Look at Provenge Xtandi and Capesaris [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9008</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9008">Onco/<wbr>Uro Surveys Look at Provenge Xtandi and Capesaris</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9008">Oncology9008</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 June 2013 | 12:00</font><br><br><div style="margin-bottom: 10px;">Comment: Wedbush conducted the survey of 31 medical oncologists and 20 urologists to monitor the dynamics of the prostate cancer markets.<wbr> Finding show a flat future use of Provenge, urologists looking to drive more use of Xtandi in months ahead, and awareness on Capesaris.<wbr> More details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages from the Surveys</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Dendreon's Provenge</STRONG> </div><div style="margin-bottom: 10px;">Percentage of surveyed oncologists and urologists who have used Provenge has increased to 68% and 70%, respectively, from 55% for each group in September 2012.<wbr> </div><div style="margin-bottom: 10px;">Among those not using Provenge, difficulty of use is listed as the most important reason why, surpassing reimbursement difficulties, which was the most important reason listed in September 2012.<wbr> </div><div style="margin-bottom: 10px;">o Lack of appropriate patients has also diminished significantly as a reason for not using Provenge.<wbr> </div><div style="margin-bottom: 10px;">Provenge use is DOWN to a median of 15% (from 20% in September) of prostate cancer patients treated by surveyed physicians.<wbr> This corresponds to the prior survey’s prediction of estimated future Provenge use in 15% of patients.<wbr> </div><div style="margin-bottom: 10px;">Similarly, surveyed physicians predict 15% of patients will be treated with Provenge 6 months from now.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>J&amp;J' Xtandi</STRONG> </div><div style="margin-bottom: 10px;">A majority of surveyed physicians have used Xtandi, with 74% and 55% of surveyed oncologists and urologists, respectively, reporting use.<wbr> </div><div style="margin-bottom: 10px;">Among those using Xtandi, 71% of use is reportedly in patients who have progressed after chemotherapy, with 29% reporting (off-label) use in chemotherapy-naïve patients (26% of oncologists, 36% of urologists).<wbr> </div><div style="margin-bottom: 10px;">In comparison with main competitor Zytiga, 41% of all surveyed doctors use Xtandi as often or more often than Zytiga (12% more often, 29% as often).<wbr> Urologists were more likely to prescribe Xtandi “more often” than Zytiga, with 18% stating as such, compared to 9% of oncologists.<wbr> However, 53% of all surveyed physicians use Zytiga more often, breaking down to 61% of oncologists and 36% of urologists.<wbr> </div><div style="margin-bottom: 10px;">Nearly 2/<wbr>3 of all surveyed physicians (65%) prescribe Xtandi on-label, after chemotherapy, with 79% stating they prescribe it after Zytiga.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>GTx' Capesaris</STRONG> </div><div style="margin-bottom: 10px;">Awareness of Capesaris, GTXI’s Phase II selective estrogen receptor modulator (SERM) was similar to our September 2012 survey, at 69% of all surveyed physicians from the recent survey compared to 77% from September 2012, and of those, the 75% awareness level currently displayed by surveyed urologists was the same as the prior survey’s level.<wbr> </div><div style="margin-bottom: 10px;">There was an increase in enthusiasm as measured by “definitely would prescribe” responses from urologists, based on potential attributes Capesaris could show in clinical trials (reducing free testosterone, PSA, hot flashes and changes in bone density and blood lipid levels).<wbr> The “definitely would prescribe” percentage in urologists increased to 35-45% from 15-20% in September in the current survey.<wbr> </div><div style="margin-bottom: 10px;">Capesaris holds its position as a potential early therapy with majorities of surveyed physicians stating that, if approved, they would prescribe it before other branded products--Zytiga, Xtandi and Provenge.<wbr> These answers support the idea that Capesaris could find an early position in the sequence of prostate cancer treatments.<wbr> </div><div style="margin-bottom: 10px;">Positive data from GTXI’s Phase II studies of Capesaris expected in H2:13, showing an acceptably low rate of VTEs, and better control of testosterone, especially free testosterone, which appears to have a disproportionate effect on PSA.<wbr> </div><div style="margin-bottom: 10px;">Positive pivotal data for enobosarm from the Phase III studies (POWER 1 and POWER 2) in the cancer-related muscle-wasting setting expected in Q3:13.<wbr> At ASCO, GTXI management noted that the drop-out rate for its pivotal POWER 1 and POWER 2 Phase III trials was lower than the expected 30% rate, likely increasing the statistical powering of the study.<wbr> </div><div style="margin-bottom: 10px;">Because of positive expectations for the POWER 1 and 2 studies, we are lowering our discount rate that we apply to enobosarm revenues from 35% to 25%, resulting in our increased price target.<wbr> </div><div><STRONG>Full Reports available on demand to Brigitte Deschamps</STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9008">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-10T12:00:55+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J CEO Sees Opportunities in Chinese Middle-Class Expansion [mkt:China, mkt:Intercontinental, :Oncology:comp:JnJ]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10479</link>
<description>J&amp;J CEO Sees Opportunities in Chinese Middle-Class Expansion [mkt:China, mkt:Intercontinental, :Oncology:comp:JnJ]</description><category>mkt:China</category><category>mkt:Intercontinental</category><category>comp:JnJ</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10479</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10479">J&J CEO Sees Opportunities in Chinese Middle-Class Expansion</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10479">PharmaWorld10479</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 June 2013 | 11:32</font><br><br><div style="margin-bottom: 10px;">Comment: A.<wbr> Gorsky has declared the company will attach greater importance to China amid middle-class expansion that could soon reach 800 million people, bringing with it huge demand for HC products.<wbr> </div><div style="margin-bottom: 10px;">Gorsky added that approx 9% of China's population is &gt;65, a number that is expected to hit 25% in 20-30 years.<wbr> Seniors require 5-7 times more health products that people in younger age groups.<wbr> </div><div style="margin-bottom: 10px;">He emphasized that Chinese urbanization will impact HC demands, as people seek disease treatments that were unavailable to them in rural settings.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10479">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-10T11:32:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic NET</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7368</link>
<description>re: Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic NET</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7368</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7368">re: Phase I/<wbr>II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic NET</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7368">Endocrinology7368</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 June 2013 | 13:14</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Phase I/<wbr>II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic NET</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aNET"><font color="#e95e0b">:Endocrinology:dis:NET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: This research study will test the safety of RAD001 in combination with temozolomide.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=4140">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology4140" class="commentpermalink">Endocrinology4140</a> / <span class="date">20 December 2007</span> /
<span class="time">15:02:53 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;"><P style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 0.5em; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">A total of 43 patients were enrolled, including 7 in cohort 1 and 36 in cohort 2.<wbr> Treatment was associated with known toxicities of each drug; no synergistic toxicities were observed.<wbr> Among 40 evaluable patients, 16 (40%) experienced a partial response.<wbr> The median progression-free survival duration was 15.<wbr>4 months.<wbr> Median overall survival was not reached.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 0.5em; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><STRONG>In Conclusion</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 0.5em; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Temozolomide and everolimus can be safely administered together in patients with advanced pancreatic NET, and the combination is associated with encouraging antitumor activity.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 0.5em; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Future studies evaluating the efficacy of combination therapy compared to treatment with either agent alone are warranted.<wbr></P> </div><div><P style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 0.5em; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px/15px arial, helvetica, clean, sans-serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Cancer.<wbr></SPAN><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px/15px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> 2013 Jun 3.<wbr> doi: 10.<wbr>1002/<wbr>cncr.<wbr>28142.<wbr> [Epub ahead of print]</SPAN></P> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7368" class="commentpermalink">Endocrinology7368</a> / <span class="date">07 June 2013</span> /
<span class="time">13:14:10 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7368">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology4140">View thread  Endocrinology4140: Phase I/<wbr>II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic NET</a>]]></content:encoded><dc:date>2013-06-07T13:14:10+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Senior VP Oncology and CMO Has Joined Mirna Therapeutics [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9004</link>
<description>New Senior VP Oncology and CMO Has Joined Mirna Therapeutics [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9004</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9004">New Senior VP Oncology and CMO Has Joined Mirna Therapeutics</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9004">Oncology9004</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 June 2013 | 14:57</font><br><br><div style="margin-bottom: 10px;">Comment: Dr Sinil Kim will be responsible for managing and directing the clinical development of MRX34, the first MicroRNA to enter a clinical trial in cancer.<wbr> Prior to joining Mirna,  he was Senior Director at Pfizer, and previously Director of Clinical Oncology at BMS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MRX34 Ongoing Clinical Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;">Mirna filed its first IND in Q1 2013 and is currently conducting a Phase I Clinical Trial in patients with unresectable primary liver cancer or metastatic cancer with liver involvement (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8944" class="defaultlink">Oncology8944: Mirna is First to Advance MicroRNA into the Clinic for Cancer</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Mirna's Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9004/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Dr Kim Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9004/1/ScreenCapture1.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Professional activity</STRONG> - Prior to joining Mirna Therapeutics, Dr.<wbr> Kim was most recently a Senior Director at Pfizer Inc.<wbr> in San Diego, CA, where he served as the Global Clinical Lead for Inlyta® (axitinib) and Torisel® (temsirolimus) programs.<wbr> </div><div style="margin-bottom: 10px;">Previously, Dr.<wbr> Kim served as Director of Clinical Oncology at Bristol-Myers Squibb Company, where he worked on the clinical development of Erbitux® (cetuximab).<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Kim was cofounder of DepoTech in San Diego, CA, where he invented several liposomal drug products, including DepoCyt® (cytarabine liposome injection), DepoDur® (morphine sulfate extended-release liposome injection) and Exparel® (bupivacaine liposome injectable suspension).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Education</STRONG> - A board certified medical oncologist, Dr.<wbr> Kim obtained both his Bachelor of Science and medical degrees from the University of Washington in Seattle.<wbr> His residency in internal medicine and post-doctoral fellowship in hematology/<wbr>oncology were served, respectively, at the University of California, Irvine, and the University of California, San Diego.<wbr> </div><div><EM>Source: Mirna Therapeutics</EM> </div><!-- Comment details --><a name="oncology9004attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9004/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(12 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9004/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(71 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9004">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-06T14:57:50+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9004/1/ScreenCapture1.jpg" length="12262" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9004/2/ScreenCapture2.jpg" length="72712" type="image/jpeg"/></item><item>
<title>Galderma Reports Development of Botulinum Toxin [class:BotulinumToxins, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7028</link>
<description>Galderma Reports Development of Botulinum Toxin [class:BotulinumToxins, :PharmaWorld:mkt:NorthAmerica]</description><category>class:BotulinumToxins</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7028</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7028">Galderma Reports Development of Botulinum Toxin</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7028">Neurology7028</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 June 2013 | 14:41</font><br><br><div style="margin-bottom: 10px;">Comment: In a PR issued June 5, the company claimed the first cohort of patients already treated in the initial clinical study.<wbr> Ipsen was informed of this news ahead of time, and is still in the process of gathering additional details on that topic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Clinical Program</FONT></STRONG> </div><div style="margin-bottom: 10px;">It is indicated that the 1st study is expected to complete in a short period of time with a 2nd to begin before the end of the year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Galderma</FONT></STRONG> </div><div>CEO reported the company aims to strengthen its portfolio in territories where Galderma does not have access to Azzalure/<wbr>Dysport (N.<wbr>America).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7028">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-06T14:41:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Exenatide Evaluated as Treatment for Parkinson's Disease</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7026</link>
<description>re: Exenatide Evaluated as Treatment for Parkinson's Disease</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7026</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7026">re: Exenatide Evaluated as Treatment for Parkinson's Disease</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7026">Neurology7026</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 June 2013 | 12:43</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Exenatide Evaluated as Treatment for Parkinson's Disease</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The U.<wbr> College (London) has started a PhII RCT to make an initial evaluation of possible benefits of the drug among approx 40 patients with moderate symptoms of PD.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=5139">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology5139" class="commentpermalink">Neurology5139</a> / <span class="date">06 August 2010</span> /
<span class="time">12:15:44 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Results show that exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient.<wbr> </SPAN><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group.<wbr> Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.<wbr>7 points, compared with mean decline of 2.<wbr>2 points in control patients (P = 0.<wbr>037).<wbr> </SPAN> </div><div><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In conclusion, these results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD.<wbr> Trial registration.<wbr></SPAN> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7026" class="commentpermalink">Neurology7026</a> / <span class="date">06 June 2013</span> /
<span class="time">12:43:21 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7026">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology5139">View thread  Neurology5139: Exenatide Evaluated as Treatment for Parkinson's Disease</a>]]></content:encoded><dc:date>2013-06-06T12:43:21+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Lexicon's LX4211 Shows Potential in Type 1 Diabetes (T1DM) [dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7367</link>
<description>Lexicon's LX4211 Shows Potential in Type 1 Diabetes (T1DM) [dis:Diabetes]</description><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7367</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7367">Lexicon's LX4211 Shows Potential in Type 1 Diabetes (T1DM)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7367">Endocrinology7367</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 June 2013 | 12:35</font><br><br><div style="margin-bottom: 10px;">Comment: Lexicon recently released preliminary data from 3 insulin pump patients in the POC study testing LX4211 in Type 1 diabetics.<wbr> As previously disclosed, the company is continuing into the expansion phase of the trial which is placebo controlled.<wbr> Analysts at Wedbush believe T1DM to provide an additional $790M in revenues.<wbr> Management continues to anticipate a partnership announcement for LX4211 before the onset of the Ph3 in H2 13.<wbr> Currently, discussions are ongoing with multiple companies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for LX4211 in T1DM</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">POC Study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Progress into Placebo Controlled Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">Lexicon anticipates data release in Q4 2013.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/3/ScreenCapture3.jpg?user-agent=rss"> </div><div>Source: Lexicon; Webbush </div><!-- Comment details --><a name="endocrinology7367attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(88,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(121,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7367">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-06T12:35:55+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/1/ScreenCapture1.jpg" length="84563" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/2/ScreenCapture2.jpg" length="90440" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/3/ScreenCapture3.jpg" length="88483" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7367/4/ScreenCapture4.jpg" length="123982" type="image/jpeg"/></item><item>
<title>Endo Announces New Strategic Direction and Key Priorities</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10475</link>
<description>Endo Announces New Strategic Direction and Key Priorities</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10475</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10475">Endo Announces New Strategic Direction and Key Priorities</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10475">PharmaWorld10475</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 June 2013 | 11:05</font><br><br><div style="margin-bottom: 10px;">Comment: Strategic alternatives will be explored for HealthTronics (urology services and products provider acquired in 2012 for $223M) and branded pharmaceutical discovery/<wbr>early-stage platform (no details given regarding the molecules).<wbr> Focus will be on Qualitest (generic unit), Endo Pharm (branded unit), and AMS (pelvic unit) as well as R&amp;D projects with hear-term revenue potential.<wbr> In addition headcount will be reduced by approx.<wbr> 15% WW.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Segments at a Glance</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Priorities for Next 12-18 Months</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Endo Pharm.<wbr></FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Qualitest</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">American Medical Systems (AMS)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">HealthTronics</FONT></STRONG> </div><div style="margin-bottom: 10px;">Also see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=6351" class="defaultlink">Oncology6351: Endo Acquires HealthTronics to Expand its Delivery of Diversified Uro Treatment and Diagnostic Solutions</a>.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2013 - Revised Financial Guidance</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10475attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(84,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(94,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(74,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(68,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(74,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(37 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10475">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-06T11:05:40+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/1/ScreenCapture1.jpg" length="79807" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/2/ScreenCapture2.jpg" length="86167" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/3/ScreenCapture3.jpg" length="96561" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/4/ScreenCapture4.jpg" length="76232" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/5/ScreenCapture5.jpg" length="69817" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/6/ScreenCapture6.jpg" length="76441" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10475/7/ScreenCapture7.jpg" length="37867" type="image/jpeg"/></item><item>
<title>Novartis CEO Reported China is Strategic Market [mkt:China, mkt:Intercontinental, :Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10474</link>
<description>Novartis CEO Reported China is Strategic Market [mkt:China, mkt:Intercontinental, :Endocrinology:comp:Novartis]</description><category>mkt:China</category><category>mkt:Intercontinental</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10474</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10474">Novartis CEO Reported China is Strategic Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10474">PharmaWorld10474</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 June 2013 | 10:37</font><br><br><div style="margin-bottom: 10px;">Comment: J.<wbr> Jimenez (CEO) reported to Xinhua that the company will continue to invest in the country.<wbr> The company's Chinese business grew by 24% in 2012, and recorded a 21% rise in net sales growth during 1Q 13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">To focus on innovation and the provision of a full range of HC products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Novartis Assets in China</FONT></STRONG> </div><div style="margin-bottom: 10px;">Seven facilities, including a new R&amp;D center in Shanghai (with an investment of &gt; $1 billion).<wbr> </div><div><EM>Source: First Word</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10474">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-06T10:37:30+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Repros' Presentation at Jefferies 2013 H/C Conference [dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9000</link>
<description>Repros' Presentation at Jefferies 2013 H/C Conference [dis:Gynea]</description><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9000</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9000">Repros' Presentation at Jefferies 2013 H/<wbr>C Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9000">Oncology9000</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2013 | 14:47</font><br><br><div style="margin-bottom: 10px;">Comment: Management gave a short overview of the Proellex programs (in Ph2 for UF and endometriosis), and Androxal (in Ph3 for secondary hypogonadism), as it will be hosting an Investor &amp; Analyst Day on June 6th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Proellex Take Home Messages</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>2013 Milestones</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>ZPE-202 </STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01728454?term=proellex&amp;rank=19"><STRONG>Ph2</STRONG></A><STRONG> endometriosis study</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>ZPV-200 <A href="http://clinicaltrials.gov/ct2/show/NCT01451424?term=ZPV-200&amp;rank=3">Ph2</A> Vaginal Proellex</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Androxal Take Home Messages</FONT></STRONG> </div><div><UL><LI>- because of obesity, 30% of American Males are at risk of secondary hypogonadism &gt; co-morbidities include diabetes and CV disease.<wbr></LI>
<LI>- approved testosterone products worsen the underlying condition.<wbr></LI>
<LI>- Repros believe only Androxal + diet + excercise can reverse this disorder.<wbr></LI>
</UL> </div><!-- Comment details --><a name="oncology9000attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(94,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(61,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(16,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=9000">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-05T14:47:23+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/1/ScreenCapture1.jpg" length="70115" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/2/ScreenCapture2.jpg" length="96568" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/3/ScreenCapture3.jpg" length="62795" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/4/ScreenCapture4.jpg" length="56132" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9000/5/ScreenCapture5.jpg" length="16515" type="image/jpeg"/></item><item>
<title>Biogen Idec Highlighted Three Pillars of Growth at Jefferies 2013 H/C Conference</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7023</link>
<description>Biogen Idec Highlighted Three Pillars of Growth at Jefferies 2013 H/C Conference</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7023</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7023">Biogen Idec Highlighted Three Pillars of Growth at Jefferies 2013 H/<wbr>C Conference</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7023">Neurology7023</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2013 | 11:18</font><br><br><div style="margin-bottom: 10px;">Comment: The first of the three pillars concerns the company's core products such as industry-leading MS Franchise (Avonex; Tysabri; Tecfidera;Fampyra) and Rituxan (standard of care for NHL and CLL).<wbr> The second one is linked to new potential product launches such as Alprolix (rFIXFc), Eloctate (rFVIIIFc) and Plegridy (Interferon C), and the third one focuses more on an innovative pipeline to sustain long-term value creation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Core Business</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>AVONEX</STRONG> - maintaining a leading position in 1st-line MS use, and gaining share within the injectable class.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>TYSABRI</STRONG> - with a solid growth trajectory driven by powerful efficacy; in development for SPMS (a large portion of the MS market) for which there is no effective therapies; ASCEND data readout expected in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>TECFIDERA</STRONG> - approved by the FDA May 27,2013; providing a strong oral option for MS treatment.<wbr> EC approval expected 2H 2013 (Germany first EU country).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Potential Product Launches</FONT></STRONG> </div><div style="margin-bottom: 10px;">- ALPROLIX - BLA submission accepted by the FDA (March 2013).<wbr> </div><div style="margin-bottom: 10px;">- ELOCTATE - BLA submission accepted by the FDA (May 2013).<wbr> </div><div style="margin-bottom: 10px;">- PLEGRIDY - FDA filing announced last month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline and R&amp;D</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7023/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Innovative Science</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7023/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7023attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7023/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7023/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(99,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7023">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-05T11:18:48+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7023/1/ScreenCapture1.jpg" length="67631" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7023/2/ScreenCapture2.jpg" length="101457" type="image/jpeg"/></item><item>
<title>Janssen to Start Ph2 of Abiraterone with Different Steroids [comp:JnJ, prod:Zytiga, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8999</link>
<description>Janssen to Start Ph2 of Abiraterone with Different Steroids [comp:JnJ, prod:Zytiga, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:JnJ</category><category>prod:Zytiga</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8999</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8999">Janssen to Start Ph2 of Abiraterone with Different Steroids</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8999">Oncology8999</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 17:26</font><br><br><div style="margin-bottom: 10px;">Comment: The study will assess safety/<wbr>clinical benefit of abiraterone and prednisone or abiraterone and dexamethasone in prostate cancer patients.<wbr> PE will evaluate Number of participants experiencing neither hypokalemia nor hypertension treatment-emergent adverse events up to Week 24.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01867710?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F04%2F2013&amp;rank=41"><STRONG><FONT size="3">NCT01867710</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">In addition the impact of the study drug on quality of life and pain will be evaluated.<wbr> </div><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">The study will also collect data on subsequent treatment of patients after they come off the study drug (up to a maximum of 5 years after the study starts).<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">By analyzing blood samples, the study aims to identify if some markers could help to understand if the treatment with abiraterone is effective and also help to understand if patients can become resistant.<wbr></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Recruitment: n=144</P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Start date: MAy 2013 - Competion Dates May 2018 /<wbr> November 2014</P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Location: Belgium</P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><EM>Source: clinicaltrials.<wbr>gov</EM></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8999">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T17:26:26+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>PROLOR Initiates Global Ph3 with hGH-CTP for AGHD [class:GrowthHormone, dis:GrowthHormoneDeficiency, :PharmaWorld:sub:ClinicalTrial, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7362</link>
<description>PROLOR Initiates Global Ph3 with hGH-CTP for AGHD [class:GrowthHormone, dis:GrowthHormoneDeficiency, :PharmaWorld:sub:ClinicalTrial, headline]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>sub:ClinicalTrial</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7362</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7362">PROLOR Initiates Global Ph3 with hGH-CTP for AGHD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7362">Endocrinology7362</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 16:15</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph3 RCT will evaluate the efficacy/<wbr>safety of hGH-CTP injected weekly in adults with GHD.<wbr> PE will assess change in truncal fat mass from baseline to 6 months after initiation of treatment.<wbr> Importantly, the company has announced that it will be able to submit sooner than previously anticipated.<wbr> Information on the regulary route is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Route</FONT></STRONG> </div><div style="margin-bottom: 10px;">Following regulatory review of the hGH-CTP Phase II data, PROLOR obtained clearance to use a pivotal Phase III trial design that includes a six-month assessment of efficacy and safety, followed by a subsequent six-month period of safety assessment.<wbr> PROLOR's previous estimate and guidance had noted that a 12-month period of subsequent safety assessment might be required.<wbr> This reduction of six months in the length of the required safety assessment and resulting reduction in the overall trial duration may enable PROLOR to submit an application for hGH-CTP marketing approval sooner than previously anticipated, subject to successful completion of the Phase III trial.<wbr> </div><div style="margin-bottom: 10px;">In the U.<wbr>S.<wbr>, the Food and Drug Administration (FDA) has confirmed that the regulatory pathway for hGH-CTP is via a Biologics License Application (BLA), which would be submitted subject to the successful completion of the Phase III trial.<wbr> The BLA pathway provides the manufacturer with 12 years of data exclusivity in the U.<wbr>S.<wbr>, starting at the time of FDA approval.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Locations of the Ph3 Trials</FONT></STRONG> </div><div>US; EU; Israel </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7362">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T16:15:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Chelsea Therapeutics May Represent an Attractive Acquisition Target [dis:Parkinson, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7021</link>
<description>Chelsea Therapeutics May Represent an Attractive Acquisition Target [dis:Parkinson, headline]</description><category>dis:Parkinson</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7021</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7021">Chelsea Therapeutics May Represent an Attractive Acquisition Target</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7021">Neurology7021</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 15:44</font><br><br><div style="margin-bottom: 10px;">Comment: Analysts at Wedbush believe Chelsea Therapeutics to be an attractive acquisition target if Northera is approved.<wbr> The company may likely need additional cash resources to complete an additional Ph3 trial and potentially launch Northera in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Northera Development</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>MOA/<wbr>Indication</STRONG>: Pro-drug of norepinephrine for neurogenic orthostatic hypertension (NOH), an acute drop in blood pressure which can result in dizziness and injuries due to falls.<wbr> </div><div style="margin-bottom: 10px;">The condition is associated with patients having movement disorders such as Parkinson's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Est.<wbr> Timelines</STRONG>: resubmission of the Northera NDA in late Q2/<wbr>early Q3 2013, potential approval around year-end 2013/<wbr>early 2014 and potential launch in mid-2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Financial Position</FONT></STRONG> </div><div>The company ended Q1 with about $25.<wbr>1 million in cash, cash equivalents and short-term investments.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7021">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T15:44:35+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Messages from Lexicon Management at Jefferies H/C Conference [:GastroEnterology:dis:IBS, :Endocrinology:dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10473</link>
<description>Key Messages from Lexicon Management at Jefferies H/C Conference [:GastroEnterology:dis:IBS, :Endocrinology:dis:Diabetes]</description><category>dis:IBS</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10473</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10473">Key Messages from Lexicon Management at Jefferies H/<wbr>C Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10473">PharmaWorld10473</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 15:10</font><br><br><div style="margin-bottom: 10px;">Comment: Lexicon reported a strong financial position, with cash and investments of $197.<wbr>2M (at March 31 2013), to support its business model.<wbr> Next quarter, the company is to report Ph2 results of telotristat for UC, and in H2 2013 Ph1 results of LX4211 for renal impairment.<wbr> Management anticipates progression into Ph3 of LX4211 for type 2 diabetes with a corporate partner.<wbr> See additional details below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Telotristat in UC</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Upcoming 2013 Clinical Milestones</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10473attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(69,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(78,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10473">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T15:10:09+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/1/ScreenCapture1.jpg" length="43139" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/2/ScreenCapture2.jpg" length="70990" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10473/3/ScreenCapture3.jpg" length="80759" type="image/jpeg"/></item><item>
<title>Key Messages from Medivation Management at Jefferies H/C Conference [comp:Astellas, dis:Prostate, prod:MDV3100, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8995</link>
<description>Key Messages from Medivation Management at Jefferies H/C Conference [comp:Astellas, dis:Prostate, prod:MDV3100, prod:Zytiga]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:MDV3100</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8995</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8995">Key Messages from Medivation Management at Jefferies H/<wbr>C Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8995">Oncology8995</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 14:34</font><br><br><div style="margin-bottom: 10px;">Comment: Pat Machado, Chief Business and Financial Officer, started his presentation reporting the recent approval of XTANDI in Canada.<wbr> He outlined that more substantial growth opportunities to come lie in the earlier patient populations (pre-chemo setting).<wbr> Management reported it is "anxiously awaiting the PREVAIL data this year as the gateway to expanding development of the drug further upstream".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Phase III PREVAIL - Strategic Advantages</FONT></STRONG> </div><div style="margin-bottom: 10px;">Design: metastatic second and third line patients; 1700 patient study, which the company fully accrued in May 2012.<wbr> </div><div style="margin-bottom: 10px;">If the PREVAIL readout is positive, Xtandi will be the only oral agent with a proven OS benefit in second and third line patients (other drugs with survival benefit demonstrated in that population is Taxotere and Provenge).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Robust Uptake in the U.<wbr>S</FONT></STRONG> </div><div style="margin-bottom: 10px;">&gt;98% coverage on both the Medicare and the private pay side since the launch of the drug.<wbr> </div><div style="margin-bottom: 10px;">&gt;19,000 bottles of Xtandi written by &gt; 2800 individual prescribers and &gt;400 institutions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partner Relationship</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the US, Medivation share profits on a 50-50 basis.<wbr> In Q113, U.<wbr>S net sales of Xtandi reached $75M ($37.<wbr>7M for Medivation).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competition in Post-Chemo (4th-line)</FONT></STRONG> </div><div style="margin-bottom: 10px;">Zytiga plus prednisone; Jevtana; Provenge.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Intellectual Property</FONT></STRONG> </div><div>Composition patents in the US runs until 2027 and in EU/<wbr>Japan till 2026.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8995">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T14:34:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Michael J. Fox Foundation Awards $1M to NeuroDerm [dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7020</link>
<description>Michael J. Fox Foundation Awards $1M to NeuroDerm [dis:Parkinson]</description><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7020</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7020">Michael J.<wbr> Fox Foundation Awards $1M to NeuroDerm</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7020">Neurology7020</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 13:12</font><br><br><div style="margin-bottom: 10px;">Comment: For the second time, NeuroDerm was awarded a $1M grant by the Foundation in order to support the upcoming <A href="http://clinicaltrials.gov/ct2/show/NCT01725802?term=neuroderm&amp;rank=2">Ph2</A> trial of ND0612, the company's patch for Parkinson's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Competitive Advantage</FONT></STRONG> </div><div style="margin-bottom: 10px;">- The drug is a proprietary levodopa/<wbr>carbidopa liquid formula for continuous administration through a sc delivery patch, that would maintain constant levodopa plasma concentrations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Safety</FONT></STRONG> </div><div style="margin-bottom: 10px;">In human trials, the drug has been shown to be safe and tolerable for the FIM.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Plasma levels of LD increased linearly with the ND0612 dose.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company's Focus</FONT></STRONG> </div><div style="margin-bottom: 10px;">Neuroderm reformulates and/<wbr>or co-formulates well established drugs to enable new routes of administration that achieve a better, or a new, clinical effect.<wbr> </div><div style="margin-bottom: 10px;">The company focuses on CNS diseases and its leading products include novel dermal delivery for the treatment of Parkinson ’s disease, ADD/<wbr>ADHD and other CNS disorders and diseases.<wbr> </div><div><EM>Source: NeuroDerm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7020">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T13:12:59+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>GW' Cannabinoids-derived Platform Shows Potential [:Endocrinology:dis:Diabetes, :GastroEnterology:dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10471</link>
<description>GW' Cannabinoids-derived Platform Shows Potential [:Endocrinology:dis:Diabetes, :GastroEnterology:dis:IBD]</description><category>dis:Diabetes</category><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10471</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10471">GW' Cannabinoids-derived Platform Shows Potential</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10471">PharmaWorld10471</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 12:01</font><br><br><div style="margin-bottom: 10px;">Comment: In a recent report from Canaccord, analysts have estimated that the company's drug discovery and development cannabinoid platform will yield additional promising drug candidate (i;e for ulcerative colitis and type 2 diabetes).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cannabinoid-Derived Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Compounds for type 2 diabetes (GWP42004), and UC (GWP42003) are currently in Phase 2 development.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Phase 2 dose-ranging trial of GWP42004 expected to start H2/<wbr>13</LI>
<LI>1st POC data in UC due early 2014</LI>
</UL> </div><div style="margin-bottom: 10px;">- Earlier-stage cannabinoid compounds include epilepsy, schizophrenia and glioma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">GW Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;">Sativex is currently in a US Phase 3 program for cancer pain with top-line results from two Phase 3 trials due in 2014.<wbr> </div><div style="margin-bottom: 10px;">The company is currently in communications with FDA around US approval requirements for Sativex in MS spasticity.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10471/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10471attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10471/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(59,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10471">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T12:01:35+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10471/1/ScreenCapture1.jpg" length="60940" type="image/jpeg"/></item><item>
<title>Norgine's MOVIPREP Launched in Japan for Bowel Cleansing [sub:CRCPrevention, comp:Norgine]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1889</link>
<description>Norgine's MOVIPREP Launched in Japan for Bowel Cleansing [sub:CRCPrevention, comp:Norgine]</description><category>sub:CRCPrevention</category><category>comp:Norgine</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1889</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1889">Norgine's MOVIPREP Launched in Japan for Bowel Cleansing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=comp%3aNorgine"><font color="#e95e0b">:GastroEnterology:comp:Norgine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1889">GastroEnterology1889</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2013 | 11:32</font><br><br><div style="margin-bottom: 10px;">Comment: In 2008 Norgine licensed MOVIPREP Japanese rights to Ajinimoto.<wbr> For this market, a new flavour was developed in order to meet the tastes and preference of the patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">CI Analysis</FONT></STRONG> </div><div style="margin-bottom: 10px;">- MOVIPREP is now the 1st Norgine's product onto the Japanese market.<wbr> </div><div style="margin-bottom: 10px;">- With MOVIPREP, Ajinimoto has been adding a new choice for patients in addition to NIFLEC®: </div><div style="margin-bottom: 10px;"><UL><LI>launched in 1992, is an orally-available gastrointestinal lavage solution.<wbr></LI>
<LI>widely used in pretreatment for colonoscopic examination as well as in pretreatment for colon surgery.<wbr></LI>
<LI>excellent cleansing effect on the digestive system and furthermore does not require diet restrictions which are usually necessary until the day before examination.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MOVIPREP Indication</FONT></STRONG> </div><div style="margin-bottom: 10px;">Bowel preparation prior to colonoscopy and colon surgery </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MOVIPREP Characteristics</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reduced dosage and volume </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Market Access</FONT></STRONG> </div><div style="margin-bottom: 10px;">MOVIPREP was included onto Japan's National Health Insurance drug price standard list on May 31 2013.<wbr> </div><div><EM>Source: Norgine</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1889">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-04T11:32:14+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Addex Completes Restructuring and Announces Product Strategy [dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7019</link>
<description>Addex Completes Restructuring and Announces Product Strategy [dis:Parkinson]</description><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7019</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7019">Addex Completes Restructuring and Announces Product Strategy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7019">Neurology7019</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 June 2013 | 16:54</font><br><br><div style="margin-bottom: 10px;">Comment: Dr.<wbr>Bharatt Chowrira has stepped down with immediate effect from his position as CEO of the Addex Group.<wbr> The Board has asked Tim Dyer, co-founder and CFO, to head the Addex Group's plan to further reduce operating costs and seek investment, grants and partners to advance its pipeline and technology platform assets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">People on the Move</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the interim, an operational subcommittee of the Board, headed by André J.<wbr> Mueller, Chairman of Addex, will directly supervise the Addex Group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Product Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">Continuation of: </div><div style="margin-bottom: 10px;">- ADX71149 partnership with Janssen Pharmaceuticals, Inc.<wbr> ADX71149, an mGluR2 positive allosteric modulator (PAM) jointly developed with Janssen, is currently in Phase 2 clinical development for schizophrenia and anxious depression and funded entirely by Janssen.<wbr> </div><div>- Dipraglurant, an mGluR5 negative allosteric modulator will also continue to be investigated for use in Parkinson’s disease in collaboration with The Michael J.<wbr> Fox Foundation for Parkinson’s Research.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7019">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-03T16:54:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8994</link>
<description>re: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8994</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8994">re: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8994">Oncology8994</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/854">Frederic SCAËROU</a> | 03 June 2013 | 16:31</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The publication covers the new agents for bacillus Calmette-Guerin-refractory bladder cancer.<wbr> <SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">BCG has been established as the primary treatment of high-risk NMIBC.<wbr> If patients do not respond or later recur, the most reliable treatment option is cystectomy.<wbr> For those who are unwilling or unable to undergo this significant procedure, there is a multitude of alternative intravesical therapies.<wbr></FONT></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8976">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976" class="commentpermalink">Oncology8976</a> / <span class="date">28 May 2013</span> /
<span class="time">14:31:47 o'clock CEST</span>
</font></div><div>Here is the reprint of the Ahn's review.<wbr> </div><!-- Comment details --><font size="-1">Frederic SCAËROU / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8994" class="commentpermalink">Oncology8994</a> / <span class="date">03 June 2013</span> /
<span class="time">16:31:51 o'clock CEST</span>
</font><br><a name="oncology8994attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8994/1/Ahn%20J%20et%20al.%202013.pdf">Ahn J et al. 2013.pdf</a>&nbsp;&nbsp;(215,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8994">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976">View thread  Oncology8976: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</a>]]></content:encoded><dc:date>2013-06-03T16:31:51+02:00</dc:date><dc:creator>frs07298</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8994/1/Ahn%20J%20et%20al.%202013.pdf" length="220751" type="application/pdf"/></item><item>
<title>Approval of XTANDI™ in Canada [comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8991</link>
<description>Approval of XTANDI™ in Canada [comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:mkt:Canada]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:MDV3100</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8991</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8991">Approval of XTANDI™ in Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8991">Oncology8991</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 June 2013 | 15:35</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas, Medivation's commercial partner for XTANDI™, submitted an application for approval to the Japanese regulatory authorities just over a week ago.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">XTANDI™ was approved in the U.<wbr>S.<wbr> for the same indication in August 2012, which covers the patient population treated in the Phase 3 AFFIRM study, and that the drug is currently in front of the European Medicines Agency (EMA) for approval in this indication as well.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significant Value Drivers Likely to Come from Ongoing Trials</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to analysts at Aegis Capital Corp.<wbr>, : </div><div><UL><LI>an interim analysis of the PREVAIL Phase 3 data in pre-chemo patients pending in the coming months</LI>
<LI>the European approval of XTANDI™ in the post-chemo setting, anticipated in 2Q 2013</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8991">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-06-03T15:35:01+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Positive Opinion for BioPartners' Once-Weekly Somatropin Granted by EMA for Growth Hormone Deficiciency [class:GrowthHormone, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7358</link>
<description>Positive Opinion for BioPartners' Once-Weekly Somatropin Granted by EMA for Growth Hormone Deficiciency [class:GrowthHormone, :PharmaWorld:mkt:Europe]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7358</comments><category>class:GrowthHormone</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7358</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7358">Positive Opinion for BioPartners' Once-Weekly Somatropin Granted by EMA for Growth Hormone Deficiciency</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7358">Endocrinology7358</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 May 2013 | 19:52</font><br><br><div style="margin-bottom: 10px;">Comment: The CHMP's recommendation is now referred to the European Commission (EC), which grants approval for the EU, Norway and Iceland.<wbr> The EC decision is anticipated in the middle of the third quarter of 2013.<wbr> The drug is in joint development with LG Life Sciences.<wbr> <a name="Endocrinology7442c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">On August 8th, the European Commission granted a marketing authorisation to Somatropin Biopartners in the EU, Norway and Iceland.<wbr> </div><div style="margin-bottom: 10px;">Somatropin Biopartners allows for a once-weekly injection instead of the currently available therapies that require once-daily injections of growth hormone.<wbr> Poor adherence and noncompliance have been identified as a major cause of suboptimal efficacy of current growth hormone replacement therapy in children as well as adults.<wbr> </div><div>Source: Biopartners </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7442" class="commentpermalink">Endocrinology7442</a> / <span class="date">30 August 2013</span> /
<span class="time">15:41:49 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Indication</FONT></STRONG> </div><div style="margin-bottom: 10px;">Treatment of growth hormone deficiency (GHD) in paediatric and adult patients.<wbr> </div><div style="margin-bottom: 10px;"><H3>Somatropin Biopartners</H3> </div><div style="margin-bottom: 10px;">Somatropin Biopartners contains recombinant human growth hormone as the active ingredient in an innovative formulation based on sterile microparticular powder, to be reconstituted as a suspension in medium chain triglycerides prior to injection.<wbr> </div><div style="margin-bottom: 10px;">In Ph3 comparative trials in children and adults, respectively, which were conducted as part of a joint development programme with LG Life Sciences Ltd.<wbr>, Somatropin Biopartners proved to be safe and effective, showing sustained growth in children and beneficial effects on body composition in adults.<wbr> </div><div><EM>Source: Biopartners</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7358">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-31T19:52:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Boehringer Ingelheim Reports Stong 2012 Performance and Strategy in China [mkt:China, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10469</link>
<description>Boehringer Ingelheim Reports Stong 2012 Performance and Strategy in China [mkt:China, mkt:Intercontinental]</description><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10469</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10469">Boehringer Ingelheim Reports Stong 2012 Performance and Strategy in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10469">PharmaWorld10469</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 May 2013 | 16:51</font><br><br><div style="margin-bottom: 10px;">Comment: The company China's prescription medicine business grew by 32% in 2012 with sales of € 358M.<wbr> Management indicated it will accelerate its strategic business development in the country, expand plans for production facility and in biopharmaceuticals.<wbr> The company is also to explore further growth opportunities through external acquisitions and partnerships, such as in the area of Traditional Chinese Medicines (TCM).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Four Key Strategic Areas for BI in China</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Prescription medicine</LI>
<LI>Consumer healthcare</LI>
<LI>Animal health</LI>
<LI>Biopharmaceutical</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Core Products</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Mucosolvan® ampoules (Respiratory Disease), Micardis® (Hypertension), Spiriva® (COPD), Sifrol® (Parkinson’s Disease) and Actilyse (lytic treatment for stroke).<wbr> </div><div style="margin-bottom: 10px;">In addition, the company is actively introducing : </div><div style="margin-bottom: 10px;">- Pradaxa® – the first new oral anticoagulant for stroke prevention in patients with atrial fibrillation for over 50 years – approved by China’s SFDA in February 2013.<wbr> </div><div style="margin-bottom: 10px;">- Trajenta®, for patients with Type 2 diabetes, DPP-4 inhibitor class of drugs jointly promoted by Boehringer Ingelheim and Eli Lilly -approved by the SFDA in March 2013.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10469/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Full PR @ <A href="http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/25_april_2013_china.html">http:/<wbr>/<wbr>www.<wbr>boehringer-ingelheim.<wbr>com/<wbr>news/<wbr>news_releases/<wbr>press_releases/<wbr>2013/<wbr>25_april_2013_china.<wbr>html</A> </div><!-- Comment details --><a name="pharmaworld10469attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10469/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(89,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10469">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-31T16:51:16+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10469/1/ScreenCapture1.jpg" length="91650" type="image/jpeg"/></item><item>
<title>Key Messages from AbbVie Annual Stockholders Meeting [:Oncology:dis:Gynea, :Neurology:dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10467</link>
<description>Key Messages from AbbVie Annual Stockholders Meeting [:Oncology:dis:Gynea, :Neurology:dis:Parkinson]</description><category>dis:Gynea</category><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10467</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10467">Key Messages from AbbVie Annual Stockholders Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10467">PharmaWorld10467</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 May 2013 | 16:13</font><br><br><div style="margin-bottom: 10px;">Comment: Since AbbVie started on January 1 2013 and as of May 3, the company delivered a 33.<wbr>6% total return to stockholders (ahead of BMS (25.<wbr>7%), Amgen (24.<wbr>2%), J&amp;J (23.<wbr>3%), Novartis (20.<wbr>3%) .<wbr>.<wbr>.<wbr>).<wbr> Market Cap is currently $70.<wbr>7 billion.<wbr> Management expects to obtain 15 major regulatory approvals between 2013 and 2017.<wbr> Of note, the levodopa-carbidopa intestinal gel for advanced Parkinson's disease approved in 40 EU countries (submitted in the US).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Late-Stage Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Duopa is administered in gel form, directly into the small intestine via a procedurally-implanted tube connected to a portable pump that delivers continuous supply of levodopa-carbidopa intestinal gel during awake hours.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Mid- and Early-Stage Pipeline</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10467attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10467">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-31T16:13:14+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/1/ScreenCapture1.jpg" length="33748" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/2/ScreenCapture2.jpg" length="33342" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/3/ScreenCapture3.jpg" length="50037" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10467/4/ScreenCapture4.jpg" length="51548" type="image/jpeg"/></item><item>
<title>Filler Toxin Combination for Lower Face Hemifacial Spasm (LFHS) [class:BotulinumToxins, sub:Aesthetics, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7015</link>
<description>Filler Toxin Combination for Lower Face Hemifacial Spasm (LFHS) [class:BotulinumToxins, sub:Aesthetics, news]</description><category>class:BotulinumToxins</category><category>sub:Aesthetics</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7015</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7015">Filler Toxin Combination for Lower Face Hemifacial Spasm (LFHS)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7015">Neurology7015</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 May 2013 | 14:53</font><br><br><div style="margin-bottom: 10px;">Comment: The treatment of LFHS with periorbital injections of higher doses of botulinum toxin can create disfiguring and indesirable weakness in the lower face (LF) during active facial movements.<wbr> The use of asymmetric hyaluronidate filler injections to the LF provides a refinement allowing for a lowered neurotoxin dose.<wbr> The filler creates a ballasting effect and involuntary facial movement.<wbr> The conventional filler effect also further reduces asymmetric nasolabial folds and marionette lines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Publication Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">Fifteen of 18 patients with LF spasms found the filler toxin in combination an improvement over neurotoxin alone.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7015/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7015attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7015/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7015">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-30T14:53:33+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7015/1/ScreenCapture1.jpg" length="32065" type="image/jpeg"/></item><item>
<title>AstraZeneca Exits Branded Generics Market in China [comp:AstraZeneca, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8988</link>
<description>AstraZeneca Exits Branded Generics Market in China [comp:AstraZeneca, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</description><category>comp:AstraZeneca</category><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8988</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8988">AstraZeneca Exits Branded Generics Market in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8988">Oncology8988</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 May 2013 | 09:56</font><br><br><div style="margin-bottom: 10px;">Comment: The company <SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">has announced its strategic decision to cease investment in the Chinese branded generics market in order to concentrate on patented brands that target the growing markets in second- and third-tier city and county-level hospitals.<wbr> As such, the company's newly-constructed manufacturing facility in Taizhou, Jiangsu province, will shift from generics to patented products.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT size="2"><FONT face="Verdana"><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">In March 2013</FONT>, </SPAN></FONT></FONT><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">CEO Pascal Soriot had stated that the company was considering deeper involvement in biosimilars, particularly strategic development in China.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Soriot believes that imminent patent expiries for costly oncology and immunology biotech drugs are creating opportunity for more modestly-priced biosimilars.<wbr></FONT></SPAN> </div><div><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"><EM>Source: GBI</EM></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8988">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-30T09:56:22+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FIM to Test AMS ' JetTouch Needle-Free Endoscopic Injection in the Bladder [dis:Bladder, :PharmaWorld:sub:ClinicalTrial, :Neurology:comp:Allergan, :PharmaWorld:mkt:UK, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8985</link>
<description>FIM to Test AMS ' JetTouch Needle-Free Endoscopic Injection in the Bladder [dis:Bladder, :PharmaWorld:sub:ClinicalTrial, :Neurology:comp:Allergan, :PharmaWorld:mkt:UK, headline]</description><category>dis:Bladder</category><category>sub:ClinicalTrial</category><category>comp:Allergan</category><category>mkt:UK</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8985</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8985">FIM to Test AMS ' JetTouch Needle-Free Endoscopic Injection in the Bladder</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8985">Oncology8985</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 May 2013 | 18:39</font><br><br><div style="margin-bottom: 10px;">Comment: The new study will assess how well the JetTouch system is able to deliver a solution safely into the bladder wall.<wbr> PE is to evaluate safety and ability.<wbr> Of note, the company signed last year with Allergan an agreement to develop and seek regulatory approval for the delivery of BOTOX® (for OAB), with the same system.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01862601?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=04%2F29%2F2013&amp;rank=17"><STRONG><FONT size="3">NCT01862601</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Sponsor: American Medical System (AMS), part of Endo Pharm.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 20 healthy individuals (male and female) aged 18-55 without urinary complaints or documented urinary tract dysfunctions.<wbr> </div><div style="margin-bottom: 10px;">Start date: July 2013 - Completion date: September 2013 </div><div style="margin-bottom: 10px;">Location: UK (2 sites) </div><div style="margin-bottom: 10px;">PI: Christopher R Chapple, BSc MD DHC FRCS (Urol) FEBU Consultant Urological Surgeon, Royal Hallamshire Hospital.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6447" class="defaultlink">Neurology6447: Joint Agreement Between Allergan and Endo for the Delivery of BOTOX®</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8985">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-29T18:39:19+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ECE Intelligence Part III - Pfizer Symposium  - Acromegaly [comp:Pfizer, dis:Acromegaly, prod:Pegvisomant, headline, :PharmaWorld:congress:ECE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7356</link>
<description>ECE Intelligence Part III - Pfizer Symposium  - Acromegaly [comp:Pfizer, dis:Acromegaly, prod:Pegvisomant, headline, :PharmaWorld:congress:ECE]</description><category>comp:Pfizer</category><category>dis:Acromegaly</category><category>prod:Pegvisomant</category><category>headline</category><category>congress:ECE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7356</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7356">ECE Intelligence Part III - Pfizer Symposium  - Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aPegvisomant"><font color="#e95e0b">:Endocrinology:prod:Pegvisomant</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7356">Endocrinology7356</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/199">clm11175</a> | 29 May 2013 | 18:15</font><br><br><div style="margin-bottom: 10px;">Comment : The Pfizer satellite symposium focused on changes in acromegaly management during the last decade and on the efficacy and safety of pegvisomant in the “real life”.<wbr> Results of ongoing observational studies were analyzed <EM>as AcroBEL, "UK Acromegaly Register", "German Acromegaly Register", “Spanish Acromegaly Registry"(REA), ACROSTUDY, </EM><EM>German Pegvisomant Observational Study (GPOS).<wbr>.<wbr></EM> </div><div>Then the expert debate between AJ van der Lely and J Jorgensen was interrupted in an unexpected but spectacular manner.<wbr> An attendee, who was actually S Neggers, gave his own conclusions.<wbr> Then, playing a role game, M Buchfelder et N Moller from the audience took successively the discussion lead.<wbr> They challenged the major points of the pegvisomant positioning in an assertive and convincing manner.<wbr> </div><!-- Comment details --><a name="endocrinology7356attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7356/1/Sympo%20Pfizer.doc">Sympo Pfizer.doc</a>&nbsp;&nbsp;(9,9 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7356/2/FranckECE2013%5fcombo%20SSA%20peg%5fposter.pptx">FranckECE2013_combo SSA peg_poster.pptx</a>&nbsp;&nbsp;(2,9 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7356">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-29T18:15:46+02:00</dc:date><dc:creator>clm11175</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7356/1/Sympo%20Pfizer.doc" length="10340352" type="application/msword"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7356/2/FranckECE2013%5fcombo%20SSA%20peg%5fposter.pptx" length="3069459" type="application/vnd.openxmlformats-officedocument.presentationml.presentation"/></item><item>
<title>re: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8983</link>
<description>re: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8983</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8983">re: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8983">Oncology8983</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/473">Anne Kornowski</a> | 29 May 2013 | 16:59</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The publication covers the new agents for bacillus Calmette-Guerin-refractory bladder cancer.<wbr> <SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">BCG has been established as the primary treatment of high-risk NMIBC.<wbr> If patients do not respond or later recur, the most reliable treatment option is cystectomy.<wbr> For those who are unwilling or unable to undergo this significant procedure, there is a multitude of alternative intravesical therapies.<wbr></FONT></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8976">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976" class="commentpermalink">Oncology8976</a> / <span class="date">28 May 2013</span> /
<span class="time">14:31:47 o'clock CEST</span>
</font></div><div>A collaborative review was published in 2012 (Yates et al, <A href="http://www.ncbi.nlm.nih.gov/pubmed/22959049" title="European urology.">Eur Urol.<wbr></A> 2012 Dec;62(6):1088-96. doi: 10.<wbr>1016/<wbr>j.<wbr>eururo.<wbr>2012.<wbr>08.<wbr>055.<wbr> Epub 2012 Sep 3).<wbr> </div><!-- Comment details --><font size="-1">Anne Kornowski / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8983" class="commentpermalink">Oncology8983</a> / <span class="date">29 May 2013</span> /
<span class="time">16:59:56 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8983">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976">View thread  Oncology8976: Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</a>]]></content:encoded><dc:date>2013-05-29T16:59:56+02:00</dc:date><dc:creator>ank40391</dc:creator></item><item>
<title>Amgen and Astellas Form JV for Japan [comp:Astellas, headline, :PharmaWorld:mkt:Japan, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8981</link>
<description>Amgen and Astellas Form JV for Japan [comp:Astellas, headline, :PharmaWorld:mkt:Japan, Alert]</description><category>comp:Astellas</category><category>headline</category><category>mkt:Japan</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8981</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8981">Amgen and Astellas Form JV for Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Oncology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8981">Oncology8981</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 May 2013 | 13:47</font><br><br><div style="margin-bottom: 10px;">Comment: Amgen Astellas BioPharma KK, expected to be operating Oct.<wbr> 1st, will co-develop and sell 5 drugs currently in Amgen's pipeline (please see details below), with the 1st commercial launch in Japan potentially occuring in 2016 (at the earliest).<wbr> Of note AMG145 for cholesterol shows promise as a successor to Lipitor for high cholesterol, and AMG785 as a viable product alongside anti-inflammatory Celecox in the orthopedic space.<wbr> These additions should enhance Astellas' mid/<wbr>long-term pipeline and drive earnings together with Xtandi, Vesicare and mirabegron.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">JV Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Led and staffed by employees of both companies (and new hires)</LI>
<LI>Astellas will conduct distribution/<wbr>sales, while promotion and development will be done jointly by the JV and Astellas (each bearing 50% of the development and promotional costs).<wbr> </LI>
<LI>Astellas will pay a royalty to Amgen based on sales and Amgen will supply the products, while profits will be split.<wbr> Amgen will make the JV a wholly-owned subsidiary in 2020, but Astellas will still have selling rights thereafter.<wbr> </LI>
<LI>No lump-sum or milestone payments will be made, so we see limited impact on F3/<wbr>14</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Rationale for Amgen</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2">- Geo Expansion &amp; Acceleration of Dev.<wbr> and Commercialization</FONT> </div><div style="margin-bottom: 10px;"><FONT size="2">- Access to robust sales channels in Japan</FONT> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/6/ScreenCapture6.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="2">In February, management told a meeting of investors and anlaysts that the company planned to expand its business into major Asian markets in 2015 and 2016.<wbr></FONT> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/7/ScreenCapture7.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Experimental Drugs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/8/ScreenCapture8.jpg?user-agent=rss"></U> </div><div style="margin-bottom: 10px;"><STRONG>AMG-145</STRONG> - human monoclonal antibody that inhibits Proprotein Convertase Subtilisin/<wbr>Kexin Type 9 (PCSK9).<wbr> It is being investigated as a treatment for hyperlipidemia.<wbr> </div><div style="margin-bottom: 10px;">The drug shows promise as a successor to Lipitor for high cholesterol.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>AMG-785</STRONG> (romosozumab) - humanized monoclonal antibody that inhibits the action of sclerostin.<wbr> It is being developed in collaboration with UCB for the treatment of postmenopausal osteoporosis.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>AMG-102</STRONG> (rilotumumab) - human monoclonal antibody that inhibits the action of hepatocyte growth factor/<wbr>scatter factor.<wbr> investigated for gastric cancer.<wbr> (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8297" class="defaultlink">Oncology8297: 1st Data Demonstrating A Potential Treatment Biomarker For Gastric Cancer</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>AMG-103</STRONG> (blinatomumab) - anti-CD19 x anti-CD3 (BiTE®) bispecific antibody investigated for ALL; NHL.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>AMG-337</STRONG> - small molecule inhibitor of MET, investigated for gastric cancer.<wbr> </div><div><EM>From Amgen; ThomsonOne</EM> </div><!-- Comment details --><a name="oncology8981attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(39,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(41,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(26,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(26,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(40,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(39 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(34,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(48 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8981">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-29T13:47:14+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/1/ScreenCapture1.jpg" length="40835" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/2/ScreenCapture2.jpg" length="42193" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/3/ScreenCapture3.jpg" length="26881" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/4/ScreenCapture4.jpg" length="27116" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/5/ScreenCapture5.jpg" length="41134" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/6/ScreenCapture6.jpg" length="39891" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/7/ScreenCapture7.jpg" length="35595" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8981/8/ScreenCapture8.jpg" length="49108" type="image/jpeg"/></item><item>
<title>Peptidomimetics Identified as Novel Class of Drugs for Advanced Prostate Cancer [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8980</link>
<description>Peptidomimetics Identified as Novel Class of Drugs for Advanced Prostate Cancer [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8980</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8980">Peptidomimetics Identified as Novel Class of Drugs for Advanced Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8980">Oncology8980</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 May 2013 | 12:55</font><br><br><div style="margin-bottom: 10px;">Comment: In a new study available online at <EM>Nature Communications</EM> a team of researchers at UT Southwestern Medical Center found that they could disrupt androgen receptor signaling using a novel class of drugs called peptidomimetics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Peptidomimetics MoA</FONT></STRONG> </div><div style="margin-bottom: 10px;">The peptidomimetic agents block the activity of the androgen receptor even in the presence of androgen by attacking the protein in a different spot from where the androgen binds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">The researchers tested their drug in mouse and human tissue models.<wbr> The novel drug proved non-toxic and prevented androgen receptor signaling in cancer cells.<wbr> </div><div style="margin-bottom: 10px;">Further testing is needed before a drug could move to Phase 1 clinical trials that involve human participants.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Reference of the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8980/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><P class="journal">Nature Communications 4, 1923 doi:10.<wbr>1038/<wbr>ncomms2912</P> </div><!-- Comment details --><a name="oncology8980attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8980/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8980">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-29T12:55:10+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8980/1/ScreenCapture1.jpg" length="67942" type="image/jpeg"/></item><item>
<title>Sanofi Presentation at Bank of America Merrill Lynch H/C Conference [comp:SanofiAventis, :PharmaWorld:func:RnD, :Neurology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8977</link>
<description>Sanofi Presentation at Bank of America Merrill Lynch H/C Conference [comp:SanofiAventis, :PharmaWorld:func:RnD, :Neurology:news]</description><category>comp:SanofiAventis</category><category>func:RnD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8977</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8977">Sanofi Presentation at Bank of America Merrill Lynch H/<wbr>C Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aSanofiAventis"><font color="#e95e0b">:Oncology:comp:SanofiAventis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8977">Oncology8977</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 May 2013 | 15:17</font><br><br><div style="margin-bottom: 10px;">Comment: Paul Chew (Senior VP, Chief Medical Offcier, Chief Scientific Officer, US) outlined growth platforms grew by +8.<wbr>6% in Q1:13 (the emerging markets being the largest in term of sales).<wbr> Management also reported that the company is less focused on coporate directed R&amp;D, and is taking advantage of regional hubs.<wbr> Although the global MS market is still dominated by ABCRE (Avonex, Betaseron, Copaxone, Rebif, Extavia) he anticipates Aubagio to be almost half the market by 2019.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Seven Growth Platforms </FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Adapting the Structure of R&amp;D</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/4/ScreenCapture4.jpg?user-agent=rss">P.<wbr> Chew indicated that Sanofi has: </div><div style="margin-bottom: 10px;">- a hub in Boston, with Genzyme, Pasteur and pharma in one location in Cambridge, very closed to Harvard, close to MIT.<wbr> </div><div style="margin-bottom: 10px;">- academic alliances with Harvard, MIT, Caltech, Hopkins and other areas as well because " .<wbr>.<wbr>.<wbr> we know that not all of the innovation will come from within the four walls of Sanofi".<wbr> </div><div style="margin-bottom: 10px;">He added that " .<wbr>.<wbr>.<wbr> So we need to ensure that success going forward with an efficient global R&amp;D organization around the hub model.<wbr> We have the hubs in Germany, France and Boston leveraging the economies of scale in the collocation there .<wbr>.<wbr>.<wbr> " </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> focusing on the high-value products.<wbr> Not quantity, but quality.<wbr> And working with new models of external innovation and acquisitions, externalization through, for example, Regeneron and Genzyme, but by no means the only ones".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Focus on MS</FONT></STRONG> </div><div style="margin-bottom: 10px;">The global MS market is still dominated by ABCRE (Avonex, Betaseron, Copaxone, Rebif, Extavia).<wbr> </div><div style="margin-bottom: 10px;">Management expects " .<wbr>.<wbr>.<wbr> the landscape to look quite different in seven years because right now the ABCRE injectables are going to be declining as we have the availability of oral therapies, including Aubagio, anticipated to be almost half the market by 2019".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8977attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(77,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(69,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(68,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8977">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-28T15:17:37+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/1/ScreenCapture1.jpg" length="46552" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/2/ScreenCapture2.jpg" length="79244" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/3/ScreenCapture3.jpg" length="70731" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8977/4/ScreenCapture4.jpg" length="70399" type="image/jpeg"/></item><item>
<title>Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC) [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976</link>
<description>Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC) [dis:Bladder]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976</comments><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8976">Overview of Treatment Options for Non-muscle Invasive Bladder Cancer (NMIBC)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8976">Oncology8976</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 May 2013 | 14:31</font><br><br><div style="margin-bottom: 10px;">Comment: The publication covers the new agents for bacillus Calmette-Guerin-refractory bladder cancer.<wbr> <SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">BCG has been established as the primary treatment of high-risk NMIBC.<wbr> If patients do not respond or later recur, the most reliable treatment option is cystectomy.<wbr> For those who are unwilling or unable to undergo this significant procedure, there is a multitude of alternative intravesical therapies.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Information on recent and ongoing trials are provided in the publication.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Source: </FONT></SPAN><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 11px/15px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed/23540780#" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102); TEXT-DECORATION: underline" title="The Urologic clinics of North America.">Urol Clin North Am.<wbr></A></SPAN><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px/15px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> 2013 May;40(2):219-32. doi: 10.<wbr>1016/<wbr>j.<wbr>ucl.<wbr>2013.<wbr>01.<wbr>008.<wbr> Epub 2013 Mar 5.<wbr></SPAN></SPAN> </div><div><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8976/1/ScreenCapture1.jpg?user-agent=rss"></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8983c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>A collaborative review was published in 2012 (Yates et al, <A href="http://www.ncbi.nlm.nih.gov/pubmed/22959049" title="European urology.">Eur Urol.<wbr></A> 2012 Dec;62(6):1088-96. doi: 10.<wbr>1016/<wbr>j.<wbr>eururo.<wbr>2012.<wbr>08.<wbr>055.<wbr> Epub 2012 Sep 3).<wbr> </div><font size="-1">Anne Kornowski / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8983" class="commentpermalink">Oncology8983</a> / <span class="date">29 May 2013</span> /
<span class="time">16:59:56 o'clock CEST</span>
</font></div><a name="Oncology8994c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Here is the reprint of the Ahn's review.<wbr> </div><font size="-1">Frederic SCAËROU / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8994" class="commentpermalink">Oncology8994</a> / <span class="date">03 June 2013</span> /
<span class="time">16:31:51 o'clock CEST</span>
</font></div><a name="oncology8976attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8976/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(18,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8976">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-28T14:31:47+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8976/1/ScreenCapture1.jpg" length="18873" type="image/jpeg"/></item><item>
<title>Oncology Drug Discovery Collaboration Between Horizon and AstraZeneca [comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8975</link>
<description>Oncology Drug Discovery Collaboration Between Horizon and AstraZeneca [comp:AstraZeneca]</description><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8975</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8975">Oncology Drug Discovery Collaboration Between Horizon and AstraZeneca</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8975">Oncology8975</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 May 2013 | 12:11</font><br><br><div style="margin-bottom: 10px;">Comment: The exclusive collaboration and license agreement will explore Horizon's HD-001, which has the potential to be developed into a treatment based on  modulation of a novel kinase.<wbr> </div><div style="margin-bottom: 10px;">Susan Galbraith, Head of the Oncology Innovative Medicines Unit at AstraZeneca, said: “Horizon’s novel kinase target programme coupled with their target validation technology allows us to broaden our oncology research efforts beyond our own internal capabilities.<wbr> AstraZeneca has a proven track record of collaborating on early stage discovery projects withinnovative organizations like Horizon, partnering their cutting-edge science with our strong oncology expertise to bring new medicines to cancer patients.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;">Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totaling up to $75M, as well as tiered royalties.<wbr> </div><div><EM>Source: Horizon Discovery</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8975">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-28T12:11:20+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novo Could Launch Liraglutide for Obesity End of 2014 [comp:NovoNordisk, class:GLP1]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7355</link>
<description>Novo Could Launch Liraglutide for Obesity End of 2014 [comp:NovoNordisk, class:GLP1]</description><category>comp:NovoNordisk</category><category>class:GLP1</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7355</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7355">Novo Could Launch Liraglutide for Obesity End of 2014</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7355">Endocrinology7355</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 May 2013 | 11:24</font><br><br><div style="margin-bottom: 10px;">Comment: <SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">Ph3 trial data showed patients treated with liraglutide (NN8022), which is already marketed under the brand name Victoza for type 2 diabetes, achieved an average 8% weight loss.<wbr> Establishing presence in obesity is one of the company's 5 strategic focus.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7355/1/ScreenCapture1.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3" style="BACKGROUND-COLOR: #ffffff"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7355/2/ScreenCapture2.jpg?user-agent=rss"></STRONG></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3" style="BACKGROUND-COLOR: #ffffff"><STRONG>Liraglutide Cost</STRONG></FONT></SPAN> </div><div><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">Approx.<wbr> $25 a day as an obesity treatment, compared with about $5 per day for Arena Pharmaceuticals' Belviq and Vivus' Qsymia.<wbr></FONT></SPAN></SPAN> </div><!-- Comment details --><a name="endocrinology7355attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7355/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(119,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7355/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7355">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-28T11:24:05+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7355/1/ScreenCapture1.jpg" length="122563" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7355/2/ScreenCapture2.jpg" length="103559" type="image/jpeg"/></item><item>
<title>Roche' Presentation at UBS [:Endocrinology:comp:Roche]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10466</link>
<description>Roche' Presentation at UBS [:Endocrinology:comp:Roche]</description><category>comp:Roche</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10466</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10466">Roche' Presentation at UBS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10466">PharmaWorld10466</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 May 2013 | 16:41</font><br><br><div style="margin-bottom: 10px;">Comment: Alan Hippe (CFO) outlined strategy, R&amp;D productivity as well as growth platforms, and pipeline milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Q1: 13 - Pipeline Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Q:1 13 - US and Emerging Markets Driving Sales Growth</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategy - Tailor Made Access Option</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth Platforms</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10466attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(26,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(35,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(77,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10466">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-27T16:41:03+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/1/ScreenCapture1.jpg" length="27025" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/2/ScreenCapture2.jpg" length="53041" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/3/ScreenCapture3.jpg" length="49454" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/4/ScreenCapture4.jpg" length="36392" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10466/5/ScreenCapture5.jpg" length="79452" type="image/jpeg"/></item><item>
<title>Valeant Agrees to Acquire Baush &amp; Lomb for $8.7 Billion [:Neurology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10463</link>
<description>Valeant Agrees to Acquire Baush &amp; Lomb for $8.7 Billion [:Neurology:news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10463</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10463">Valeant Agrees to Acquire Baush & Lomb for $8.<wbr>7 Billion</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10463">PharmaWorld10463</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 May 2013 | 14:21</font><br><br><div style="margin-bottom: 10px;">Comment: Acquiring Bausch and Lomb could contribute meaningful progress relative to two of Valeant’s high-profile strategic objectives: 1) becoming a Top-15 global pharma company, and 2) expanding its ophthalmology footprint.<wbr> Valeant has identified Ophthalmology as one of its three priority categories.<wbr> With respect to scale, a Bausch &amp; Lomb transaction could expand Valeant’s revenues by ~50% to exceed $8 billion in F2014 and grow its ophthalmology revenues approximately 10-fold.<wbr> The transaction is expected to close in the third quarter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Terms</FONT></STRONG> </div><div style="margin-bottom: 10px;">Valeant will pay aggregate consideration of $8.<wbr>7 billion in cash, of which approximately $4.<wbr>5 billion will go to an investor group led by Warburg Pincus and approximately $4.<wbr>2 billion will be used to repay Bausch + Lomb's outstanding debt.<wbr> Valeant expects to achieve at least $800 million in annual cost savings by end of 2014.<wbr> Bausch + Lomb’s expects to have revenues of approximately $3.<wbr>3 billion and adjusted EBITDA in 2013 of approximately $720 million.<wbr> </div><div style="margin-bottom: 10px;">The transaction is expected to be immediately accretive to Valeant's cash earnings per share.<wbr> Assuming the transaction occurred on January 1, 2013 and assuming the full realization of synergies, the acquisition would have been approximately 40% accretive to Valeant’s expected 2013 Cash EPS.<wbr> </div><div style="margin-bottom: 10px;">The transaction will be financed with debt and approximately $1.<wbr>5 - $2.<wbr>0 billion of new equity.<wbr> Valeant has secured fully committed debt financing for the transaction from Goldman Sachs Bank USA.<wbr> Taking into account the anticipated equity raise, Valeant’s debt to pro forma adjusted EBITDA ratio will be approximately 4.<wbr>6 times.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Valeant's Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">Bausch &amp; Lomb would bring to Valeant its well-known contact lenses, drugs to treat eye conditions such as glaucoma, and instruments and devices used in eye surgery.<wbr> (approx.<wbr> 17% of Bausch &amp; Lomb's $3 billion in revenues last year came from that business).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10463/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competition in the Field</FONT></STRONG> </div><div style="margin-bottom: 10px;">Big players including Novartis AG <NOVN.VX>and Abbott Laboratories.<wbr></NOVN.VX> </div><div><EM>Source: Valeant; Wall Street Journal; ThomsonOne; Companies Websites/<wbr>PR.<wbr></EM> </div><!-- Comment details --><a name="pharmaworld10463attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10463/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10463">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-27T14:21:23+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10463/1/ScreenCapture1.jpg" length="77409" type="image/jpeg"/></item><item>
<title>Bayer's Visanne (Endometriosis) Not Included on the National Reimbursement List in Sweden [comp:BayerSchering, dis:Gynea, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8972</link>
<description>Bayer's Visanne (Endometriosis) Not Included on the National Reimbursement List in Sweden [comp:BayerSchering, dis:Gynea, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Pricing]</description><category>comp:BayerSchering</category><category>dis:Gynea</category><category>mkt:Europe</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8972</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8972">Bayer's Visanne (Endometriosis) Not Included on the National Reimbursement List in Sweden</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8972">Oncology8972</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 May 2013 | 14:40</font><br><br><div style="margin-bottom: 10px;">Comment: The decision of the Swedish Dental and Pharmaceutical Benefits Agency (TLV) was based on a cost-effectiveness analysis that compared Visanne to other progestogens which are already included on the Swedish reimbursement list for this indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">The TLV maintains that data supplied by Bayer do not provide an adequate base for demonstrating Visanne improvements in terms of efficacy or side-effects compared to other progestogens.<wbr> </div><div style="margin-bottom: 10px;">In addition, the price proposed for Visanne has been evaluated as "considerably" more expensive compared to the costs of the comparators.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Restricted Reimbursement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Finally, the TLV has stressed that, in order to decide if Visanne should have a restricted reimbursement, the company will need to demonstrate its marginal benefit in a clearly identifiable group of patients which would offset its higher cost, compared to treatment with other progestogens.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Visanne was granted marketing authorisation in Europe in 2009.<wbr> </div><div style="margin-bottom: 10px;">The TLV decision represents a setback for Bayer as the inclusion into the Swedish reimbursement list would have certainly had a positive impact on product sales.<wbr> </div><div style="margin-bottom: 10px;">The drug was approved for reimbursement in Poland and the Czech Republic in 2011.<wbr> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8972">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-24T14:40:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Submission of Enzalutamide Leverages Astellas Oncology Position in Japan [comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:mkt:Japan, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8971</link>
<description>Submission of Enzalutamide Leverages Astellas Oncology Position in Japan [comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:mkt:Japan, headline]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:MDV3100</category><category>mkt:Japan</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8971</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8971">Submission of Enzalutamide Leverages Astellas Oncology Position in Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8971">Oncology8971</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 May 2013 | 12:59</font><br><br><div style="margin-bottom: 10px;">Comment: <FONT style="BACKGROUND-COLOR: #ffffff">Astellas has submitted an application for marketing approval of enzalutamide to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.<wbr> </FONT>This new milestone will leverage Astellas Oncology position in Japan where Gonax (degarelix 1M) was launched end of 2012.<wbr> Of note, Firmagon (degarelix 3M) is listing in the company's pipeline as being in Ph3 development in Japan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Background in Traction CI</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8930" class="defaultlink">Oncology8930: Key Messages from Astellas FY012 Results</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Dossier</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT style="BACKGROUND-COLOR: #ffffff">This filing application is based mainly on results obtained from the global Phase 3 trial (the AFFIRM trial)<STRONG>*</STRONG> and a Phase 1-2 trial conducted in Japan<STRONG>**.<wbr></STRONG></FONT> </div><div><DIV id="news-detail-contents">
<BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P><FONT style="BACKGROUND-COLOR: #ffffff"><STRONG>*</STRONG></FONT><FONT style="BACKGROUND-COLOR: #ffffff">A multi-country, double-blind, placebo-controlled study in patients with advanced castration-resistant prostate cancer who had previously undergone docetaxel-based chemotherapy.<wbr></FONT></P>
<P><FONT style="BACKGROUND-COLOR: #ffffff"><STRONG>**</STRONG>An open-label, study.<wbr> Phase 1 enrolled patients with advanced castration-resistant prostate cancer and Phase 2 enrolled patients with advanced castration-resistant prostate cancer who had received docetaxel therapy.<wbr></FONT></P></BLOCKQUOTE>
<P>Source: Astellas</P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8971">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-24T12:59:55+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Recap from J&amp;J's R&amp;D and Business Meeting [comp:JnJ, headline, prod:Zytiga, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8969</link>
<description>Recap from J&amp;J's R&amp;D and Business Meeting [comp:JnJ, headline, prod:Zytiga, dis:Prostate]</description><category>comp:JnJ</category><category>headline</category><category>prod:Zytiga</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8969</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8969">Recap from J&J's R&D and Business Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8969">Oncology8969</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 May 2013 | 12:31</font><br><br><div style="margin-bottom: 10px;">Comment: Management presented the scope and potential of its pipeline, remaining focused on addressing areas of high unmet needs.<wbr> New product launches (led by Zytiga, Xarelto and ibrutinib) continue to grow and the business is delivering consistent increase.<wbr> J&amp;J expects that both oncologists and urologists will drive Zytiga growth.<wbr> Thus far, the company has not seen resistance from urologists because of Zytiga use in combination with prednisone and monitoring of hepatotoxicity.<wbr> Further, management indicates that prednisone use may benefit patients in feeling less fatigued and could actually translate into an advantage for Zytiga.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #b1eeae">CI Comment</FONT></STRONG> </div><div style="margin-bottom: 10px;">No mention of J&amp;J's botulinum toxin in the presentation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Oncology - Zytiga Update</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Marketing Exclusivity</STRONG> - Zytiga has NCE (new chemical entity) marketing exclusivity until April 28, 2016.<wbr> Provided there are no patents to challenge, a generic manufacturer can file a P3 application with the FDA upon NCE expiration, or April 28, 2016.<wbr> If a P4 is filed, then the generic manufacturer can file one year prior to expiration of NCE exclusivity or April 28, 2015.<wbr> There will then be a 30-month stay (that begins April 28, 2016) and thus, will expire October 28, 2018 (unless there is a positive court decision prior).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Reimbursement </STRONG>- Zytiga gained approval in the chemo-naive mCRPC patient in 2012.<wbr> Chemo-naïve reimbursement is still an ongoing process in the EU with rollout continuing across various regions – however, Zytiga has received reimbursement in Germany (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8899" class="defaultlink">Oncology8899: Zytiga Receives Second Positive Verdict in Germany</a>), and in 2 Nordic countries.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Market Share</STRONG> - Zytiga currently holds 30% share (Apr-13) in the mCRPC market (up ~3 points from 4Q12) with an approximate 20% share in the chemo naives and a 57% share in the chemo refractory population.<wbr> Share remains stable in the chemo refractory market and has been steadily rising in the chemo naïve population since Jan-13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Zytiga Sales</STRONG> - There are an estimated 28,000 chemo naïve patients and 10,000 chemo refractory treated every month in the US.<wbr> Approximately 45% of Zytiga sales are in the pre-chemo setting.<wbr> </div><div style="margin-bottom: 10px;">Since launch, nearly 2/<wbr>3 of Xtandi use has been in Zytiga-experienced patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Promising Early Satge Pipeline Across 5 Core Areas</FONT></STRONG> </div><div style="margin-bottom: 10px;">J&amp;J’s has significantly restructured its pharmaceutical business over the years.<wbr> Several years back the company started to realign its R&amp;D into more of a end-to-end strategy focused on 5 therapeutic areas.<wbr> </div><div style="margin-bottom: 10px;">1) <STRONG>Immunology</STRONG> -- sirukumab (anti-IL-6) for RA, guselkumab (anti-IL-23) for RA and psoriasis, and the JAK inhibitor ASP015K that is currently in a ~900-patient global Phase IIb trial for RA that includes anti-TNF naïve and experienced patients; </div><div style="margin-bottom: 10px;">2) <STRONG>Neuroscience</STRONG> -- several Alzheimer's compounds including Bapineuzumab follow-on AAB- 003, a therapeutic vaccine AAC-001, and a BACE inhibitor for Prodromal Alzheimer’s; </div><div style="margin-bottom: 10px;">3) <STRONG>Infectious Diseases &amp; Vaccines</STRONG> -- FlueCell with proof-of-concept on 2-13-2014, Flu monoclonal antibody (mAb), which will have proof-of-concept in 2014, and Rabies mAb; </div><div style="margin-bottom: 10px;">4) <STRONG>Cardiovascular &amp; Metabolism</STRONG> -- JNJ-54452840, a novel β1-Andrenergic Receptor autoantibody that holds potential as a novel approach to heart failure treatment; </div><div style="margin-bottom: 10px;">5) <STRONG>Oncology</STRONG> -- daratumumab, which has a breakthrough therapy designation from the FDA for refractory Multiple Myeloma and is currently in Phase I/<wbr>II trials, and siltuximab for multi-centric Castleman's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Line Extensions and Global Expansions</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Line extensions of existing products</STRONG> - particularly Simponi, Stelara, Velcade and Xarelto.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Emerging markets</STRONG> - 20% of Pharma sales -- up from 12% in 2007 -- and oncology drugs in particular are performing well there.<wbr> J&amp;J continues to leverage its product portfolio through line extension launches globally, particularly in Japan and China.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline Products of Interest for J&amp;J</FONT></STRONG> </div><div style="margin-bottom: 10px;">1) ibrutinib (partnered with PCYC), an oral once-daily treatment for B-cell malignancies; 2) Sirturo, the first drug to treat tuberculosis with a new mechanism of action in 40 years; and 3) sirukumab, the first anti-IL-6 cytokine monoclonal antibody for rheumatoid arthritis, partenred with GSK.<wbr> </div><div><STRONG><FONT size="3">Full Presentation Attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130831&edate=20130501&rs=/link%20Oncology8970%407" class="defaultlink">@7</a></FONT></STRONG> </div><!-- Comment details --><a name="oncology8969attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(33,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(99,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(91 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(38,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/7/JNJ%5fPharm%5fBusiness%5fReview%5f2013.pdf">JNJ_Pharm_Business_Review_2013.pdf</a>&nbsp;&nbsp;(18,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8969">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-24T12:31:33+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/1/ScreenCapture1.jpg" length="70793" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/2/ScreenCapture2.jpg" length="59991" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/3/ScreenCapture3.jpg" length="34396" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/4/ScreenCapture4.jpg" length="101660" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/5/ScreenCapture5.jpg" length="93177" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/6/ScreenCapture6.jpg" length="39412" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8969/7/JNJ%5fPharm%5fBusiness%5fReview%5f2013.pdf" length="18983172" type="application/pdf"/></item><item>
<title>PeptiDream Amends IPO [sub:Finance, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10460</link>
<description>PeptiDream Amends IPO [sub:Finance, headline]</description><category>sub:Finance</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10460</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10460">PeptiDream Amends IPO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:PharmaWorld:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10460">PharmaWorld10460</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 May 2013 | 10:15</font><br><br><div style="margin-bottom: 10px;">Comment: PeptiDream <SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">now plans to sell 1.<wbr>7 million shares at Y1,920-Y2,500 in an IPO on the Tokyo Stock Exchange's market of the high-growth and emerging stocks (Mothers).<wbr> The company said one of the motivations for an IPO was concern over a potential take-out by one of the company's partners.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">At the Y2,210 mid-point, PeptiDream would raise Y3.<wbr>8 billion ($36.<wbr>6 million) and be valued at Y35.<wbr>6 billion ($346.<wbr>2 million).<wbr> Mizuho is the lead underwriter.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Verdana"><FONT size="2"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">PeptiDream said it expects the offer to be priced on or after May 31, with the shares slated to start trading in June.<wbr> Earlier this month, PeptiDream said it planned to sell the shares at Y1,720-Y1,920.<wbr> The company's founders plan to sell an additional 1 million shares in the IPO</FONT>.<wbr></SPAN><BR></FONT></FONT> </div><div style="margin-bottom: 10px;"><STRONG>Partnerships</STRONG> </div><div style="margin-bottom: 10px;">PeptiDream has active target discovery deals among wich Novartis, Ipsen, MedImmune/<wbr>AstraZeneca and Amgen.<wbr> </div><div><EM>Source: BioCentury</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10460">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-24T10:15:26+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>GSK To Cut Drug Prices in China [mkt:China, mkt:Intercontinental, sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10459</link>
<description>GSK To Cut Drug Prices in China [mkt:China, mkt:Intercontinental, sub:Pricing]</description><category>mkt:China</category><category>mkt:Intercontinental</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10459</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10459">GSK To Cut Drug Prices in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10459">PharmaWorld10459</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 May 2013 | 10:07</font><br><br><div style="margin-bottom: 10px;">Comment: The rationale reported by the company is that price cuts will expand drug sales volumes, as it extends its reach to financially-disadvantaged patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Goals of Price Reductions</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to Simon Dingemans (CFO) <SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">price reductions are central to driving access and comprehensive healthcare coverage.<wbr> </FONT></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3"><STRONG>2012 Sales</STRONG></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">GSK</FONT><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">'s China sales were up 20% to approx.<wbr> £1 billion ($1.<wbr>52 billion), equal to 3.<wbr>8% of global revenue.<wbr></FONT></SPAN> </div><div><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Source: GBI</FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10459">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-24T10:07:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Merck &amp; Co. Discontinues Development of Preladenant for Parkinson [dis:Parkinson, news, :PharmaWorld:sub:Termination]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7014</link>
<description>Merck &amp; Co. Discontinues Development of Preladenant for Parkinson [dis:Parkinson, news, :PharmaWorld:sub:Termination]</description><category>dis:Parkinson</category><category>news</category><category>sub:Termination</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7014</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7014">Merck & Co.<wbr> Discontinues Development of Preladenant for Parkinson</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aTermination"><font color="#e95e0b">:PharmaWorld:sub:Termination</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7014">Neurology7014</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 May 2013 | 09:53</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph3 for the Adenosine A2A receptor antagonist included three RCT.<wbr> Two of these assessed preladenant when combined to levodopa in patients with moderate-to-severe PD, and one evaluated the drug as monotherapy in early stages of the disease.<wbr> Merck said the decision to discontinue the studies was not based on any safety findings.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Halting the Development</FONT></STRONG> </div><div style="margin-bottom: 10px;">Preliminary review of data from 3 Ph3 trials failed to provide evidence of the drug's efficacy when compared to placebo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analysts Forecasts</FONT></STRONG> </div><div>Cowen &amp; Co.<wbr> had predicted preladenant would generate annual sales of $200M by 2016.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7014">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-24T09:53:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ECE Intelligence Part II - Novartis symposium Part 2 - Cushing's disease [Alert, comp:Novartis, dis:Cushing, :PharmaWorld:congress:ECE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7352</link>
<description>ECE Intelligence Part II - Novartis symposium Part 2 - Cushing's disease [Alert, comp:Novartis, dis:Cushing, :PharmaWorld:congress:ECE]</description><category>Alert</category><category>comp:Novartis</category><category>dis:Cushing</category><category>congress:ECE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7352</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7352">ECE Intelligence Part II - Novartis symposium Part 2 - Cushing's disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7352">Endocrinology7352</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/199">clm11175</a> | 23 May 2013 | 17:53</font><br><br><div style="margin-bottom: 10px;">Comment:  this part focused on the difficulties of diagnosing &amp; monitoring Cushing's disease and of choosing a medical appropriate treatment for each patient.<wbr> There were no investigational drugs discussed nor on-going trials, but only medical therapy currently in use, approved or not for Cushing's disease.<wbr> Pasireotide use was analyzed in this context without particular highlight.<wbr> J Newell Price showed the results of monitoring pasireotide treatment with salivary cortisol, the corresponding study presented at the same time at the poster session.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="ii" id="endocrinology7351.05ii"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: small arial; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Please find the detailed Cushing session in the word document attached.<wbr></SPAN></DIV> </div><div><DIV class="ii"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: small arial; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Please find hereby the pasireotide poster related to treatment monitoring through late night salivary cortisol.<wbr> Those results have indeed been cited during this session.<wbr></SPAN></DIV> </div><!-- Comment details --><a name="endocrinology7352attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7352/1/NOVARTIS%20SYMPO%20Cushing.doc">NOVARTIS SYMPO Cushing.doc</a>&nbsp;&nbsp;(53,7 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7352/2/NewellPriceECE2013%5fCushing%20PIII%20pasireotide%20salivary%20cortisol.pdf">NewellPriceECE2013_Cushing PIII pasireotide salivary cortisol.pdf</a>&nbsp;&nbsp;(341,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7352">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-23T17:53:30+02:00</dc:date><dc:creator>clm11175</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7352/1/NOVARTIS%20SYMPO%20Cushing.doc" length="56353280" type="application/msword"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7352/2/NewellPriceECE2013%5fCushing%20PIII%20pasireotide%20salivary%20cortisol.pdf" length="349787" type="application/pdf"/></item><item>
<title>ECE Intelligence Part I - Novartis symposium Part 1 - Acromegaly [Alert, comp:Novartis, dis:Acromegaly, :PharmaWorld:congress:ECE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7351</link>
<description>ECE Intelligence Part I - Novartis symposium Part 1 - Acromegaly [Alert, comp:Novartis, dis:Acromegaly, :PharmaWorld:congress:ECE]</description><category>Alert</category><category>comp:Novartis</category><category>dis:Acromegaly</category><category>congress:ECE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7351</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7351">ECE Intelligence Part I - Novartis symposium Part 1 - Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7351">Endocrinology7351</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/199">clm11175</a> | 23 May 2013 | 17:30</font><br><br><div style="margin-bottom: 10px;">Comment: this year ECE was held in Copenhagen and attended by around 2800 delegates.<wbr>  There were no major results neither new clinical trials presented in pituitary and NETs sessions for our competitors but rather guidelines and state of the art for managing these pathologies.<wbr> </div><div style="margin-bottom: 10px;">Both Novartis and Pfizer symposia wanted to be educational, atmosphere was sober (no audience vote,  no promotional &ldquo;film&rdquo;or material,  no ipads) and focused on every day&rsquo;s life practioners experience and data coming from observational studies and registers.<wbr> </div><div style="margin-bottom: 10px;">Novartis Satellite Symposium focused on pituitary tumors, one part related to Cushing&rsquo;s disease and  the other one on acromegaly.<wbr> The acromegaly part was entirely led by Annamaria Colao.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG> </STRONG>There were no results from PAOLA study, no mention of previous pasireotide trials in acromegaly nor mention of any clinical trial in acromegaly.<wbr>
</LI>
<LI>The focus was on disease control, more particularly on suboptimal control or absence of control of the disease in the &ldquo;real life&rdquo; of  a non negligible part of patients.<wbr>
</LI>
<LI>Medical treatment ( in particular classical SSA)  results were seen through &ldquo;real life&rdquo; (registers and observational studies)
</LI>
</UL> </div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: small arial; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Please find the detailed acromegaly session in the word document attached.<wbr></SPAN> </div><!-- Comment details --><a name="endocrinology7351attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7351/1/Novartis%20sympo%20Acro.doc">Novartis sympo Acro.doc</a>&nbsp;&nbsp;(6,9 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7351">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-23T17:30:43+02:00</dc:date><dc:creator>clm11175</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7351/1/Novartis%20sympo%20Acro.doc" length="7218176" type="application/msword"/></item><item>
<title>Assessment of Routine Medical Practice of Firmagon® in Argentina [dis:Prostate, prod:Firmagon, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8968</link>
<description>Assessment of Routine Medical Practice of Firmagon® in Argentina [dis:Prostate, prod:Firmagon, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Prostate</category><category>prod:Firmagon</category><category>mkt:Intercontinental</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8968</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8968">Assessment of Routine Medical Practice of Firmagon® in Argentina</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aFirmagon"><font color="#e95e0b">:Oncology:prod:Firmagon</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8968">Oncology8968</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 May 2013 | 17:13</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new prospective, observational study aimed at collecting and analyzing data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina.<wbr> PE will evaluae PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01861236?term=degarelix&amp;rank=49"><STRONG><FONT size="3">NCT01861236</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 200 men with advanced prostate cancer that receive Firmagon therapy in the context of usual clinical practice.<wbr> </div><div style="margin-bottom: 10px;">Start date: March 2013 - Completion date: Dec 2014 /<wbr> Dec 2017 </div><div style="margin-bottom: 10px;">Location: 1 site </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8968">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-23T17:13:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Astellas' Vesomni Approved in the Netherlands for BPH [:PharmaWorld:mkt:Europe, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8965</link>
<description>Astellas' Vesomni Approved in the Netherlands for BPH [:PharmaWorld:mkt:Europe, dis:Prostate]</description><category>mkt:Europe</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8965</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8965">Astellas' Vesomni Approved in the Netherlands for BPH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8965">Oncology8965</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 May 2013 | 13:34</font><br><br><div style="margin-bottom: 10px;">Comment: Vesomni is a once-daily, fixed-dose combination of the antimuscarinic solifenacin and alpha blocker tamsulosin.<wbr> Approval in the Netherlands kicks off the mutual recognition process for EU-wide registration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Indication</FONT></STRONG> </div><div style="margin-bottom: 10px;">Treatment for lower urinary tract symptoms (LUTS) in men with BPH who are not responding to current therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Registration Dossier</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Dutch approval is based on the results of the phase III NEPTUNE study, which found that Vesomni improved LUTS in men aged over 45 with both voiding and storage symptoms, performing better than both placebo and tamsulosin monotherapy.<wbr> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8965/1/ScreenCapture1.jpg?user-agent=rss"></EM> </div><div><EM>Source</EM>: <A href="http://www.pmlive.com/pharma_news/astellas_gets_first_ok_for_prostate_drug_vesomni_478629?utm_campaign=dailycontent&amp;utm_medium=email&amp;utm_source=fulllist">http:/<wbr>/<wbr>www.<wbr>pmlive.<wbr>com/<wbr>pharma_news/<wbr>astellas_gets_first_ok_for_prostate_drug_vesomni_478629?utm_campaign=dailycontent&amp;utm_medium=email&amp;utm_source=fulllist</A> </div><!-- Comment details --><a name="oncology8965attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8965/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(119,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8965">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-23T13:34:48+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8965/1/ScreenCapture1.jpg" length="122712" type="image/jpeg"/></item><item>
<title>AOTM's Transparency Board Favours Reimbursement of Zytiga in One Indication on Condition of Price Drop [prod:Zytiga, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8962</link>
<description>AOTM's Transparency Board Favours Reimbursement of Zytiga in One Indication on Condition of Price Drop [prod:Zytiga, :PharmaWorld:mkt:Europe]</description><category>prod:Zytiga</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8962</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8962">AOTM's Transparency Board Favours Reimbursement of Zytiga in One Indication on Condition of Price Drop</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8962">Oncology8962</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2013 | 18:55</font><br><br><div style="margin-bottom: 10px;">Comment: The Transparency Board of the Agency for Health Technology Assessment in Poland (AOTM) has recommended that the reimbursement of Zytiga (abiraterone acetate) be continued as a guaranteed benefit, as a second-line treatment, in the treatment of castration-resistant metastatic prostate cancer in men whose disease has progressed during or after chemotherapy containing docetaxel.<wbr> </div><div style="margin-bottom: 10px;">However, the Board stipulates that the continued reimbursement of the drug is dependent on its price being reduced to a level within the cost-effectiveness threshold observed in Poland.<wbr> The Board continues to say that while second-line treatment of this condition has documented evidence of its efficacy, it remains associated with a considerable frequency of adverse events, adding that the financing model for Zytiga should involve a drug programme that includes a defined algorithm for the monitoring of patients.<wbr> </div><div style="margin-bottom: 10px;">At the same time, the Board has recommended that Zytiga be withdrawn from reimbursement in the treatment of men with metastatic, castration-resistant prostate cancer without symptoms, or with mild or slight symptoms, after failed treatment with androgen suppression therapy, in the case of patients for whom chemotherapy is not clinically indicated.<wbr> This is because, as it states, the drug's clinical effectiveness in this indication is not yet fully documented, while it is associated with significant toxicity, which are not balanced with the potential health benefits – and its cost is above the cost-effectiveness threshold in Poland.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Considering the fact that – according to the AOTM's document – Zytiga is already subject to reimbursement – either within the National Health Fund's list of standard "chemotherapy" treatments, or in the "non-standard chemotherapy" programme, there is a possibility that a similar situation could develop as has developed in the case of two Celgene (United States) drugs, in the case of which the Transparency Board also recommended price reductions to within the cost-effectiveness threshold </div><div style="margin-bottom: 10px;">The cost per quality-adjusted life year (QALY) threshold introduced in Poland is seemingly being applied quite literally, rather than being seen as a "guideline", as was stated when it was first introduced.<wbr> Meanwhile, the rejection of Zytiga in the other indication may indeed be based on clinical concerns, but it is also sure that the economic concerns are of an equal importance.<wbr> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8962">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-22T18:55:39+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Update on LG Life Sciences' hGH Pipeline [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7350</link>
<description>Update on LG Life Sciences' hGH Pipeline [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7350</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7350">Update on LG Life Sciences' hGH Pipeline</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7350">Endocrinology7350</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2013 | 18:46</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its financial results for 1Q:13, the company has provided an update on R&amp;D investment and pipeline.<wbr> The once-a-week SR-hGH has been submitted in the US for AGHD (Ph3 completed for PGHD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D and Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7350/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2013 Guidance</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7350/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7350attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7350/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(89,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7350/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(30,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7350">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-22T18:46:43+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7350/1/ScreenCapture1.jpg" length="91996" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7350/2/ScreenCapture2.jpg" length="31321" type="image/jpeg"/></item><item>
<title>Local Pharma Company to Distribute Sanofi's Profact (Buserelin) in Germany [dis:Prostate, :PharmaWorld:mkt:Germany, :PharmaWorld:mkt:Europe, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8958</link>
<description>Local Pharma Company to Distribute Sanofi's Profact (Buserelin) in Germany [dis:Prostate, :PharmaWorld:mkt:Germany, :PharmaWorld:mkt:Europe, headline]</description><category>dis:Prostate</category><category>mkt:Germany</category><category>mkt:Europe</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8958</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8958">Local Pharma Company to Distribute Sanofi's Profact (Buserelin) in Germany</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8958">Oncology8958</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2013 | 16:26</font><br><br><div style="margin-bottom: 10px;">Comment: Soft information sent by Claudia Schymczyk (Marketing Manager) has indicated that <FONT size="3"><FONT size="2">APOGEPHA</FONT><STRONG> </STRONG></FONT>, an independent mid-sized family-owned company highly focused in urology, may be promoting the drug from July 1st.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for the feedback</FONT></STRONG> </div><div style="margin-bottom: 10px;">- MS of Profact has been decreasing since many years, it has a "fat" needle and no real advantages.<wbr> </div><div style="margin-bottom: 10px;">Profact Market Shares </div><div style="margin-bottom: 10px;"><UL><LI>3.<wbr>2009: 16,8% </LI>
<LI>3.<wbr>2013: 11,2 %</LI>
</UL> </div><div style="margin-bottom: 10px;">- Profact is a LHRHa, the same class as Decapeptyl.<wbr> </div><div style="margin-bottom: 10px;">- The new situation has to be closely watched as APOGEPHA may push the promotion of the drug, and come with a 'reduced' price.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">APOGEPHA Products</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Focused in Urology.<wbr> </div><div style="margin-bottom: 10px;">Main products are Propiverine (trademarks Mictonorm®, Mictonorm Uno®, Mictonetten®, Detrunorm®, Detrunorm® XL and BUP-4®) used for the treatment of urinary incontinence and overactice bladder in adults and children.<wbr> </div><div style="margin-bottom: 10px;">Apogepha has also a bicalutamide generic in their portfolio called Androcal® in 50mg and 150mg dosage.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">APOGEPHA Mini Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">APOGEPHA has been active in the German pharmaceutical market for more than 125 years and is looking to expand its operation through various partnerships.<wbr> </div><div>- Link to the company website : <A href="http://www.apogepha.de/de/apogepha-international/about-us.html">http:/<wbr>/<wbr>www.<wbr>apogepha.<wbr>de/<wbr>de/<wbr>apogepha-international/<wbr>about-us.<wbr>html</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8958">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-22T16:26:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Biogen Idec Starts Ph3 with its Pegylated Interferon Beta-1a for RMS</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7013</link>
<description>re: Biogen Idec Starts Ph3 with its Pegylated Interferon Beta-1a for RMS</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7013</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7013">re: Biogen Idec Starts Ph3 with its Pegylated Interferon Beta-1a for RMS</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7013">Neurology7013</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2013 | 13:27</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Biogen Idec Starts Ph3 with its Pegylated Interferon Beta-1a for RMS</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMultipleSclerosis"><font color="#e95e0b">:Neurology:dis:MultipleSclerosis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The company has started a phase III program called ADVANCE for BIIB-017 that will seek to enroll 1260 patients and follow 2 doses of PEG-IFN b-1a over 2 years.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=4327">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology4327" class="commentpermalink">Neurology4327</a> / <span class="date">25 May 2009</span> /
<span class="time">09:44:20 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Biogen Idec submitted a BLA to FDA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple sclerosis (MS).<wbr> </div><div style="margin-bottom: 10px;">The company said it expects to submit MAA to EMA "in the coming weeks.<wbr>" </div><div><EM>Source: Biocentury</EM> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7013" class="commentpermalink">Neurology7013</a> / <span class="date">22 May 2013</span> /
<span class="time">13:27:07 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7013">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology4327">View thread  Neurology4327: Biogen Idec Starts Ph3 with its Pegylated Interferon Beta-1a for RMS</a>]]></content:encoded><dc:date>2013-05-22T13:27:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Immunotherapy May be Used in up to 60% of Cancers [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8957</link>
<description>Immunotherapy May be Used in up to 60% of Cancers [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8957</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8957">Immunotherapy May be Used in up to 60% of Cancers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8957">Oncology8957</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2013 | 13:19</font><br><br><div style="margin-bottom: 10px;">Comment: Analysts at U.<wbr>S bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as BMS and Roche Holding.<wbr> Other leading players with a range of drugs, vaccines and cell therapy treatments in the cancer immunotherapy field include GlaxoSmithKline <GSK.L>, AstraZeneca <AZN.L>, Novartis <NOVN.VX>, Merck &amp; Co <MRK.N>and Amgen.<wbr></MRK.N></NOVN.VX></AZN.L></GSK.L> </div><div style="margin-bottom: 10px;">Bristol-Myers Squibb's nivolumab (PD-1 inhibitor) and Roche's MPDL3280A (PD-1 inhibitor) had an impressive effect against a variety of cancers.<wbr> Preliminary results were released last week, and further details will be presented at ASCO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analyst Forecasts</FONT></STRONG> </div><div style="margin-bottom: 10px;">Analysts believe that the immunotherapy field could also benefit from a new FDA initiative to speed approval of important and innovative drugs.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8957">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-22T13:19:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Update on Ascendis' Once-Weekly Growth Hormone Candidate [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7348</link>
<description>Update on Ascendis' Once-Weekly Growth Hormone Candidate [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7348</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7348">Update on Ascendis' Once-Weekly Growth Hormone Candidate</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7348">Endocrinology7348</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 May 2013 | 19:19</font><br><br><div style="margin-bottom: 10px;">Comment: The results of the 6-month growth velocity efficacy trial in hGH deficient children are expected 4Q:13.<wbr> Submissions for pediatric and adult GHD in EU and the U.<wbr>S.<wbr> have been planned for 4Q:15.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ACP-001 Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7348/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Ascendis Presentation</EM> </div><!-- Comment details --><a name="endocrinology7348attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7348/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7348">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-21T19:19:54+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7348/1/ScreenCapture1.jpg" length="73750" type="image/jpeg"/></item><item>
<title>Medivation Highlights From The UBS Global Healthcare Conference [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8953</link>
<description>Medivation Highlights From The UBS Global Healthcare Conference [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8953</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8953">Medivation Highlights From The UBS Global Healthcare Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8953">Oncology8953</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 21 May 2013 | 17:24</font><br><br><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">Comment: Medivation is aiming to place <SPAN style="LINE-HEIGHT: 1.5em">enzalut</SPAN><SPAN style="LINE-HEIGHT: 1.5em">amide into as many settings within prostate cancer as possible (data allowing) and has the trial suite along with the capital to do so.<wbr></SPAN></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">At the UBS Global Healthcare Conference, Medivation reviewed its milestones/<wbr>successes and discussed future goals.<wbr> Medivation’s main goal in Prostate Cancer is to expand the use of Xtandi as far upstream as possible.<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">On-going trials supporting this goal are detailed below:</FONT></P> </div><div style="margin-bottom: 10px;"><UL style="PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; MARGIN: 0px 0px 0px 40px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><LI style="PADDING-BOTTOM: 0px; LIST-STYLE-TYPE: disc; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"><FONT face="Verdana" size="2"><STRONG>AFFIRM</STRONG> targets 4<SUP>th</SUP> line patients</FONT></LI>
<LI style="PADDING-BOTTOM: 0px; LIST-STYLE-TYPE: disc; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"><FONT face="Verdana" size="2"><STRONG>PREVAIL</STRONG> targets 2<SUP>nd</SUP> and 3<SUP>rd</SUP> line patients – moving Xtandi up to patients who have just failed Lupron</FONT></LI>
<LI style="PADDING-BOTTOM: 0px; LIST-STYLE-TYPE: disc; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"><FONT face="Verdana" size="2"><STRONG>STRIVE</STRONG> and <STRONG>TERRAIN</STRONG> are head-to-head trials targeting Casodex, taking Xtandi use to 2<SUP>nd</SUP> line</FONT></LI>
<LI style="PADDING-BOTTOM: 0px; LIST-STYLE-TYPE: disc; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"><FONT face="Verdana" size="2">Phase II hormone-naïve trial targets 1<SUP>st</SUP> line</FONT></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Medivation also outlined key aspects of their trials.<wbr> Highlights captured in the table below.<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="0" cellspacing="0" style="BORDER-BOTTOM-COLOR: rgb(0,0,0); TEXT-TRANSFORM: none; BORDER-TOP-COLOR: rgb(0,0,0); TEXT-INDENT: 0px; BORDER-SPACING: 0px; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; LETTER-SPACING: normal; BORDER-RIGHT-COLOR: rgb(0,0,0); BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: default; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><TBODY><TR><TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="73">
<P><STRONG>AFFIRM</STRONG></P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>post-chemo</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>1,200 patients</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="347">
<P>Median survival 18.<wbr>4 months compared to 13.<wbr>6 months of the placebo arm, 37% reduction in the risk of death.<wbr></P>
<P>A 4.<wbr>8-month benefit in survival compared to placebo, which has not been bettered by any agent.<wbr></P>
<P>All secondary endpoints were achieved.<wbr></P>
<P>No real difference with placebo arm in terms of AEs</P></TD>
</TR>
<TR><TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="73">
<P><STRONG>PREVAIL</STRONG></P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>pre-chemo</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>1,717 Patients</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="347">
<P>The co-primary endpoints of the study are OS and PFS.<wbr> The trial goal is to support registration in second-line and third-line patients.<wbr> Medivation believe that there is data to suggest that the effect in the pre-chemo population may be better than the post-chemo population</P></TD>
</TR>
<TR><TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="73">
<P><STRONG>STRIVE </STRONG>(US)</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>2<SUP>nd</SUP> line – H2H bicalutamide</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>Metastatic patients</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="347">
<P>Endpoints: Affecting time to PSA and time to radiographic progression</P></TD>
</TR>
<TR><TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="73">
<P><STRONG>TERRAIN </STRONG>(EU)</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>2<SUP>nd</SUP> line – H2H bicalutamide</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>Both metastatic and non-metastatic patients</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="347">
<P>Endpoints: Affecting time to PSA and time to radiographic progression</P></TD>
</TR>
<TR><TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="73">
<P><STRONG>Hormone-Naïve Trial</STRONG></P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>1<SUP>st</SUP> line pts</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>Enrolled 67 patients who had not received any therapy, not even Lupron</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="347">
<P>Median PSA reduction of 99.<wbr>6% and 93% of patients had a PSA response of 80% or greater</P></TD>
</TR>
<TR><TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="73">
<P><STRONG>Neoadjuvant Study</STRONG></P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>Prior to prostatectomy</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="85">
<P>50 patients</P></TD>
<TD style="BORDER-BOTTOM-COLOR: rgb(0,0,0); PADDING-BOTTOM: 0.5em; LINE-HEIGHT: 1.5em; BORDER-TOP-COLOR: rgb(0,0,0); MARGIN: 8px; PADDING-LEFT: 0.5em; PADDING-RIGHT: 0.5em; FONT-FAMILY: 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; COLOR: rgb(0,0,0); BORDER-RIGHT-COLOR: rgb(0,0,0); FONT-SIZE: 12px; BORDER-LEFT-COLOR: rgb(0,0,0); CURSOR: text; PADDING-TOP: 0.5em" valign="top" width="347">
<P><EM>“These patients are going to get XTANDI for six months in a cocktail, and then when they go on to get their prostatectomy, the pathologist will then take the prostate and look at it under very fine sectioning and see is there any cancer left in that prostate.<wbr> Because if there isn’t and we know they had cancer to begin with, and there isn’t any cancer left in the prostate, that’s important because obviously we’re trying to find ways of moving upstream in patients to see if we can increase the number of patients who actually might not only benefit from the drug but even be cured by a drug”</EM></P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Key milestones which we discussed during the wrap up are found below: </FONT></P> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8953/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8953attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8953/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(134,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8953">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-21T17:24:56+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8953/1/ScreenCapture1.jpg" length="137899" type="image/jpeg"/></item><item>
<title>ASCO Preview and Oncology Update [dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8951</link>
<description>ASCO Preview and Oncology Update [dis:Prostate, news]</description><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8951</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8951">ASCO Preview and Oncology Update</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8951">Oncology8951</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 May 2013 | 17:11</font><br><br><div style="margin-bottom: 10px;">Comment: Analysts at Leerink Swann hosted a call with 2 KOLs to discuss the landscape for new therapeutic agents in prostate cancer.<wbr> Overall the 2 KOLs (one urologist and one oncologist) were focused on determining the optimal sequence of treatment of Xtandi and Zytiga to achieve the best outcomes in patients and less focused on cross-trial comparisons of efficacy.<wbr> More details available below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Viewpoint</FONT></STRONG> </div><div style="margin-bottom: 10px;">Physicians were impressed with the hormone naïve data for Xtandi, but would want to see longer follow-up and a head-to-head comparison with Casodex to prescribe the agent in this setting but there is clear interest in potentially expanding the use of Xtandi to earlier stage patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages</FONT></STRONG> </div><div style="margin-bottom: 10px;">- KOLs are not particularly concerned with statistical significance of overall survival in the Xtandi PREVAIL study, as survival benefit has already been proven in the post-chemo setting </div><div style="margin-bottom: 10px;">- With two well tolerated, highly effective anti-androgens available, the key question facing physicians are how to sequence these agents and to find predictors of resistance or response in patients, rather than cross-trial comparisons.<wbr> </div><div style="margin-bottom: 10px;">- Provenge DTC advertisements have increased patient inquiries but have not yet led to increases in treatment.<wbr> </div><div style="margin-bottom: 10px;">- In the pipeline, KOLs are most excited about immunotherapy such as anti-PD1 (BMY and others), ipilimumab (BMY), and Prostvac (Bavarian Nordic).<wbr> </div><div><STRONG><FONT size="3">Full Report Available on Demand to Brigitte Deschamps.<wbr></FONT></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8951">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-21T17:11:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Argentina's Pharma Market Expected to Triple in a Decade [mkt:Intercontinental, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10455</link>
<description>Argentina's Pharma Market Expected to Triple in a Decade [mkt:Intercontinental, news]</description><category>mkt:Intercontinental</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10455</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10455">Argentina's Pharma Market Expected to Triple in a Decade</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10455">PharmaWorld10455</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 May 2013 | 16:51</font><br><br><div style="margin-bottom: 10px;"><P class="tableContentLarge">Comment: The Argentine domestic market is expected to almost triple in a decade, increasing from a value of USD5.<wbr>6 billion in 2012 to USD15 billion by 2020.<wbr> The fast growth achieved in the sector is expected to be driven by a strong presence of domestic manufacturers, high-quality production capabilities, and positive clinical trial regulations.<wbr> With this potential sector boost, Argentina is expected to become one of the fastest growing pharmaceutical markets in Latin America, with a number of local players such as Roemmers and Bago becoming some of the best performing companies in the region.<wbr></P> </div><div style="margin-bottom: 10px;">The size of the Argentine market is expected to almost triple in a decade, increasing from a value of USD5.<wbr>6 billion in 2012 to USD15 billion by 2020, according to <I>Pharma Times</I>.<wbr> According to the source, domestic manufacturers currently account for more than 50% of Argentina's drug market, with key domestic players including Roemmers and Bago, while multinationals such as Bayer (Germany), Novartis (Switzerland), Roche (Switzerland), Abbott (UK), and GlaxoSmithKline (UK) also operating in the country.<wbr> </div><div style="margin-bottom: 10px;">The generic drug sector in Argentina has also grown, with sales increasing as a result of legislation included in the Health Emergency Act mandating physicians to include the generic names of prescribed drug products, which allows for generic substitution by pharmacists.<wbr> According to the source, in the past, Argentina's regulations governing international property rights have also provided an advantage to domestic companies, which were free to manufacture and market products similar to patented versions.<wbr> Furthermore, according to the source, Argentina is also regarded as a favourable destination for cost-effective clinical trials within Latin America, and was one of the first countries in the region to implement the recommendation of the World Health Organization (WHO) on good manufacturing practice (GMP) and control standards, endorsing compliance to an international set of quality standards for pharmaceutical production.<wbr> Clinical trials in the country are compliant to those of the International Conference on Harmonization-Good Clinical Practice (ICH-GCP).<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Outlook and implications</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">The fast growth achieved in the sector is expected to be driven by a strong presence of domestic manufacturers, high-quality production capabilities and positive clinical trial regulations that are expected to boost the sector.<wbr> </div><div style="margin-bottom: 10px;">Unlike other Latin American countries, the trend towards domestic pharmaceutical production has existed for a few decades in Argentina, given the fact that local players are incentivised by the government since they are provided with benefits such as favourable tariff protection while the costs of raw materials imports undercut the transfer pricing which is generally applicable for multinationals.<wbr> </div><div style="margin-bottom: 10px;">On the other hand, Argentina's pharmaceutical sector is also facing a number of barriers, including the fact that they lack the vast production capacities of Chinese and Indian manufacturers, and are unable to compete with the lower process that these foreign firms are able to offer.<wbr> Argentina is also facing competition from upcoming pharmaceutical markets such as Mexico and Brazil.<wbr> Furthermore, although investment in research and development has increased in the last few years, local makers have not been able to develop new chemical entities, making it difficult for domestic firms to be competitive with innovative multinational companies.<wbr> </div><div style="margin-bottom: 10px;">Nevertheless, with this potential sector boost, Argentina is expected to become one of the fastest growing markets in Latin America, with local players such as Roemmers and Bago rising to become some of the top companies in the region.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10455">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-21T16:51:37+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>XenoPort Discontinues Arbaclofen Placarbil Program [dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7011</link>
<description>XenoPort Discontinues Arbaclofen Placarbil Program [dis:Spasticity]</description><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7011</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7011">XenoPort Discontinues Arbaclofen Placarbil Program</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7011">Neurology7011</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/13">fab42334</a> | 21 May 2013 | 14:00</font><br><br><div style="margin-bottom: 10px;"><A name="13ec47e1fb1a5fca_47031_target"></A><SPAN style="LINE-HEIGHT: 1.5em; COLOR: #000000">Comment : Xenoport has announced discontinuation of the development of arbaclofen placarbil based on top-line data showing that twice-daily doses of the product missed the co-primary endpoints in a Phase III trial to treat spasticity in multiple sclerosis (MS) patients.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000"><SPAN style="LINE-HEIGHT: 1.5em">XenoPort had an SPA from FDA for the trial, which enrolled 228 patients.<wbr> In 2011, XenoPort discontinued development of arbaclofen placarbil -- a transported prodrug of R-</SPAN><SPAN style="COLOR: #000000">baclofen</SPAN><SPAN style="LINE-HEIGHT: 1.5em">, a </SPAN><SPAN style="COLOR: #000000">GABA B receptor</SPAN><SPAN style="LINE-HEIGHT: 1.5em"> agonist -- to treat gastroesophageal reflux disease (GERD)</SPAN><A href="http://pub.biocentury.com/c.html?ufl=5&amp;rtr=on&amp;s=x8pb1d,1hrmo,7y8,jbi9,bzn1,7wh9,j795" style="LINE-HEIGHT: 1.5em" target="_blank"></A></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">XenoPort markets <SPAN style="COLOR: #000000">Horizant</SPAN> gabapentin enacarbil, a transported prodrug of gabapentin, to treat restless legs syndrome (RLS) and to manage postherpetic neuralgia (PHN).<wbr> The company's next most advanced product is <SPAN style="COLOR: #000000">XP21279</SPAN>, a sustained-release transported prodrug of L-dopa in Phase II testing to treat Parkinson's disease (PD).<wbr></SPAN> </div><div><SPAN style="COLOR: #000000"><SPAN style="COLOR: #000000">Source : </SPAN></SPAN><SPAN style="LINE-HEIGHT: 1.5em">BioCentury Extra for Monday, May 20, 2013</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7011">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-21T14:00:04+02:00</dc:date><dc:creator>fab42334</dc:creator></item><item>
<title>Actavis Acquires Warner Chilcott</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10453</link>
<description>Actavis Acquires Warner Chilcott</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10453</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10453">Actavis Acquires Warner Chilcott</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10453">PharmaWorld10453</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 20 May 2013 | 14:51</font><br><br><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.5em">Comment: Actavis to acquire Warner Chilcott in a stock-for-stock transaction valued at $8.<wbr>5 billion to create a leading global specialty pharmaceutical company.<wbr></SPAN> </div><div style="margin-bottom: 10px;">When fully operational, the combination is estimated to have around $11 billion in annual revenue.<wbr> It will be the third-largest U.<wbr>S.<wbr> specialty pharmaceutical company focused on core therapeutic categories of Women’s Health, Gastroenterology, Urology and Dermatology.<wbr> See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10443" class="defaultlink">PharmaWorld10443: Actavis in Early Talks to Buy Warner Chilcott for >$4.<wbr>5bn</a>.<wbr> </div><div style="margin-bottom: 10px;">The combined entity is expected to provide a firm foundation to support the launch of new products over the next several years, particularly in Women's Health.<wbr> </div><div style="margin-bottom: 10px;">This includes Minastrin 24 Fe, Esmya, metronidazole vaginal gel 1.<wbr>5%, the progestin-only contraceptive patch and other women's health products in development from the recent acquisition of Uteron Pharma SA.<wbr> </div><div>The newly created company, expected to be called Actavis Plc or a variant thereof, will be led by the current Actavis leadership team.<wbr> The transaction is expected to close by the end of 2013.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10453">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-20T14:51:58+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>KOL Viewpoints On Bayer’s Newly Approved Xofigo [dis:Prostate, comp:BayerSchering]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8949</link>
<description>KOL Viewpoints On Bayer’s Newly Approved Xofigo [dis:Prostate, comp:BayerSchering]</description><category>dis:Prostate</category><category>comp:BayerSchering</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8949</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8949">KOL Viewpoints On Bayer’s Newly Approved Xofigo</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8949">Oncology8949</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 20 May 2013 | 14:05</font><br><br><div style="margin-bottom: 10px;">Comment: KOLs lean towards combination use with Xofigo.<wbr> </div><div style="margin-bottom: 10px;">Early KOL opinion suggests that combination therapy is integral to the uptake of Xofigo as there seems to be a muted enthusiasm for use as a monotherapy in advanced CRPC patients.<wbr> </div><div style="margin-bottom: 10px;">However, buoyed by the median 3.<wbr>6 month OS benefit, KOLs appear to have little hesitation about using the product in a combinational setting once it becomes available, also advocating its use at earlier stages within the treatment paradigm.<wbr> </div><div style="margin-bottom: 10px;">Other notable barriers include: </div><div style="margin-bottom: 10px;"><UL><LI>Impracticalities of administration and the stigma attached to radio pharmaceuticals </LI>
<LI>Only licensed radiopharmaceutical physicians based at specialist facilities will be able to prescribe Xofigo in the US </LI>
<LI>Bayer's existing sales force in the cancer space (via Nexavar and Stivarga) will need to be increased or it will be rather stretched as the company will have to target both urologists and radiologists in addition to oncologists </LI>
<LI>Priced at $69,000 for a single treatment course (of six injections), the cost of Xofigo is comparable to Zytiga and Xtandi although if used is in combination, the cost will go up exponentially 
<UL><LI>Dendreon's Provenge could be the one loser, given that patients are unlikely to be prescribed two infused therapies that have a combined cost of between $160,000 and $170,000.<wbr> </LI>
</UL></LI>
</UL> </div><div style="margin-bottom: 10px;">On the positive side, KOLs appear to be sold on the notion that Xofigo as an alpha emitter is significantly more targeted than beta emitters (its shorter wavelength should reduce damage to nearby healthy tissues).<wbr> </div><div>FDA approval of Xofigo (last Wednesday) came more than three months ahead of a scheduled PDUFA date.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8949">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-20T14:05:04+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Sanofi To Overhaul Toulouse Research Site</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10452</link>
<description>Sanofi To Overhaul Toulouse Research Site</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10452</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10452">Sanofi To Overhaul Toulouse Research Site</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10452">PharmaWorld10452</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 20 May 2013 | 13:37</font><br><br><div style="margin-bottom: 10px;">Comment:  Rather than exiting the facility as was suggested last year, Sanofi will now reorganise the Toulouse site and preserve around 500 of the 612 staff employed there.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">In September last year, Sanofi stated it would cut around 900 jobs in France by 2015 as well as selling the Toulouse site -which would bring the total job losses to around 1500 personnel.<wbr>   Sanofi and the French government have been at loggerheads over the proposed move and now, it seems there has been a resolution.<wbr>    The move to close down the site in the first place was to counter revenue lost from patent expiries on drugs such as Plavix.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The Toulouse site (Oncology R&amp;D) will continue to operate over the next five years while Sanofi evaluates options including the creation of a technology platform to provide services for itself and other companies as well as establishing local start-ups.<wbr> </SPAN> </div><div><SPAN style="line-height: 1.5em;">Sanofi also noted that it still plans to regroup its research activities in France in the regions of Paris and Lyon, in Strasbourg and to transform the Montpellier R&amp;D site into a strategic development centre.<wbr></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10452">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-20T13:37:50+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>NICE Gives a 'Yes' for Astellas' Betmiga</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10451</link>
<description>NICE Gives a 'Yes' for Astellas' Betmiga</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10451</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10451">NICE Gives a 'Yes' for Astellas' Betmiga</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10451">PharmaWorld10451</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 20 May 2013 | 12:51</font><br><br><div style="margin-bottom: 10px;">Comment:  NICE has issued final draft guidance recommending Astellas' Betmiga (mirabegron) for reimbursement.<wbr> </div><div style="margin-bottom: 10px;">Mirabegron was approved in the EU this January and is recommended for overactive bladder syndrome in people unsuited to antimuscarinic drugs because they are contraindicated, clinically ineffective or cause unacceptable side-effects.<wbr> </div><div>NICE still recommends bladder training and lifestyle advice as first-line treatments.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10451">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-20T12:51:33+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Novo Nordisk Converts Facility for Future Production of Semaglutide (Once-Weekly GLP-1) [class:GLP1, class:GrowthHormone, comp:NovoNordisk, :PharmaWorld:func:MSO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7347</link>
<description>Novo Nordisk Converts Facility for Future Production of Semaglutide (Once-Weekly GLP-1) [class:GLP1, class:GrowthHormone, comp:NovoNordisk, :PharmaWorld:func:MSO]</description><category>class:GLP1</category><category>class:GrowthHormone</category><category>comp:NovoNordisk</category><category>func:MSO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7347</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7347">Novo Nordisk Converts Facility for Future Production of Semaglutide (Once-Weekly GLP-1)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aMSO"><font color="#e95e0b">:PharmaWorld:func:MSO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7347">Endocrinology7347</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 May 2013 | 13:42</font><br><br><div style="margin-bottom: 10px;">Comment: The 380 million Danish Kroner investment will be used to convert the existing Kalundborg manufacturing plant.<wbr> Other ongoing investment projects in Denmark include a new domicile in Bagsværd and a new facility in Kalundborg for the production of biopharmaceuticals (such as haemophilia medicine and growth hormone).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Novo Nordisk in Kalundborg</FONT></STRONG> </div><div style="margin-bottom: 10px;">Established in 1969.<wbr> </div><div style="margin-bottom: 10px;">Covering an area of 135 hectares.<wbr> </div><div style="margin-bottom: 10px;">Since 1999, Novo Nordisk has invested more than 7.<wbr>5 billion kroner in the facility and, as a result, has created more than 1,000 new jobs.<wbr> </div><div><EM>Source: Novo Nordisk</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7347">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-16T13:42:47+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Top Messages from MedyTox' 1Q:13 Results [comp:MediTox, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7010</link>
<description>Top Messages from MedyTox' 1Q:13 Results [comp:MediTox, :PharmaWorld:sub:Finance]</description><category>comp:MediTox</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7010</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7010">Top Messages from MedyTox' 1Q:13 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7010">Neurology7010</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 May 2013 | 10:36</font><br><br><div style="margin-bottom: 10px;">Comment: Medytox registered 1Q13 sales of W8.<wbr>8bn (up 27.<wbr>4% y-y).<wbr> Growth drivers were 1/<wbr> the joint sales contract with Pacific Pharma, allowing Pacific Pharma to sell ‘Meditoxin’ for cosmetic use in the domestic market, and 2/<wbr> the increase of the total exports (18.<wbr>6% y-y to W2.<wbr>9bn) thanks to the addition of new exports to Central America and Latin America.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">1Q:13 Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="1">(Units: Wbn, %)</FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7010/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partnership with Pacific Pharma</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6464" class="defaultlink">Neurology6464: Medy-Tox and Pacific Pharma Have Signed Joint Marketing Agreement</a>.<wbr> </div><div><EM>Source: Woori Investment</EM> </div><!-- Comment details --><a name="neurology7010attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7010/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(55,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7010">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-16T10:36:22+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7010/1/ScreenCapture1.jpg" length="57202" type="image/jpeg"/></item><item>
<title>re: J&amp;J Seeks Approval For Simponi in Ulcerative Colitis</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1888</link>
<description>re: J&amp;J Seeks Approval For Simponi in Ulcerative Colitis</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1888</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1888">re: J&J Seeks Approval For Simponi in Ulcerative Colitis</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1888">GastroEnterology1888</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 May 2013 | 09:45</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Comment: Janssen  has submitted an sBLA to the U.<wbr>S.<wbr> FDA and a Type 
II Variation to the EMA requesting approval of SIMPONI® (golimumab) for the 
treatment of adult patients with moderately to severely active ulcerative 
colitis (UC) who have had an inadequate response to conventional therapy.<wbr></span>&nbsp;<br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1847" class="commentpermalink">GastroEnterology1847</a> / <span class="date">17 July 2012</span> /
<span class="time">13:14:45 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">FDA approved an expanded indication for Simponi (golimumab) to treat adults with moderate to severe ulcerative colitis who did not respond to conventional treatment or requires continuous steroid use.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The approval was based on 2 clinical studies demonstrating that the tumour necrosis factor-alpha inhibitor was associated with a higher clinical response rate than placebo.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-transform: none; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Simponi is currently approved to treat psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis.<wbr> </SPAN></SPAN> </div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-transform: none; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The drug had sales of $607 million in 2012 and analysts estimate that sales could double to $1.<wbr>2 billion by 2017.<wbr></SPAN></SPAN> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1888" class="commentpermalink">GastroEnterology1888</a> / <span class="date">16 May 2013</span> /
<span class="time">09:45:46 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1888">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1847">View thread  GastroEnterology1847: J&J Seeks Approval For Simponi in Ulcerative Colitis</a>]]></content:encoded><dc:date>2013-05-16T09:45:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Tokai Raised $35.5M Series E Financing [dis:Prostate, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8947</link>
<description>Tokai Raised $35.5M Series E Financing [dis:Prostate, :PharmaWorld:sub:Finance]</description><category>dis:Prostate</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8947</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8947">Tokai Raised $35.<wbr>5M Series E Financing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8947">Oncology8947</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 May 2013 | 09:15</font><br><br><div style="margin-bottom: 10px;">Comment: The proceeds will be used to expand the ongoing ARMOR2 Ph2 clinical trial of galeterone in patients with CRPC and prepare for registration studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ARMOR2 Ph2 Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">The second study in Tokai’s ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program.<wbr> </div><div style="margin-bottom: 10px;">ARMOR2 is designed to assess the efficacy and safety of a new oral formulation of galeterone in distinct populations of CRPC patients, including both metastatic and non-metastatic treatment-naïve and those who have progressed while taking Zytiga® (abiraterone acetate) or Xtandi® (enzalutamide).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The primary endpoints of the study are reduction in prostate-specific antigen (PSA) levels, and safety.<wbr> </LI>
<LI>The secondary endpoints include tumor responses by RECIST.<wbr> Patients who respond to therapy will have the opportunity to continue treatment in an extension arm.<wbr></LI>
</UL> </div><div><EM>Source: Tokai</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8947">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-16T09:15:25+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Mirna is First to Advance MicroRNA into the Clinic for Cancer [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8944</link>
<description>Mirna is First to Advance MicroRNA into the Clinic for Cancer [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8944</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8944">Mirna is First to Advance MicroRNA into the Clinic for Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8944">Oncology8944</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2013 | 16:01</font><br><br><div style="margin-bottom: 10px;">Comment: Mirna’s pipeline consists of 8 lead candidates, all of which are directed toward oncology.<wbr> The company has initiated a Ph1 of MRX34 in patients with liver cancer.<wbr> The Ph1 study will follow a standard oncology study design, and is expected to enroll up to 48 patients in total.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ph1 Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01829971">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01829971</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MRX34 Preclinical Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">The preclinical profile of MRX34 across a range of tumors strongly suggests that miRNA-based therapeutics may represent a potent, new class of anticancer drugs working through a mechanism that affects multiple oncogenic pathways simultaneously.<wbr> </div><div><EM>Source: Mirna</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8944">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-15T16:01:15+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Algeta Reports 1Q:13 Results and US Approval of Radium-233 for CRPC [dis:Prostate, comp:BayerSchering, :PharmaWorld:mkt:NorthAmerica, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8943</link>
<description>Algeta Reports 1Q:13 Results and US Approval of Radium-233 for CRPC [dis:Prostate, comp:BayerSchering, :PharmaWorld:mkt:NorthAmerica, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8943</comments><category>dis:Prostate</category><category>comp:BayerSchering</category><category>mkt:NorthAmerica</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8943</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8943">Algeta Reports 1Q:13 Results and US Approval of Radium-233 for CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8943">Oncology8943</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2013 | 15:44</font><br><br><div style="margin-bottom: 10px;">Comment: Xofigo is the first alpha particle-emitting radioactive therapeutic agent approved by the FDA.<wbr> The commercial production of the drug is underway, with first doses expected to be ready for patient treatment within a few weeks.<wbr> Management also reported good progress with the development of its TTC pipeline, and looks forward to the results of further PC evaluations to advance candidates into clinical in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Xofigo Indication</FONT></STRONG> </div><div style="margin-bottom: 10px;">Patient with CRPC, symptomatic bone metastases and no visceral metastatic disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Xofigo Status in EU</FONT></STRONG> <a name="Oncology9184c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Bayer has received a positive opinion from the EMA CHMP recommending radium Ra 223 dichloride (radium-223) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.<wbr> </div><div style="margin-bottom: 10px;">According to Algeta CEO: " .<wbr>.<wbr>.<wbr> <FONT size="2">This recommendation, soon after Xofigo&rsquo;s US approval and launch, again highlights the need for a new therapeutic option that has been shown to significantly improve survival in prostate cancer patients whose disease has spread to the bones.<wbr> We are committed to working with Bayer to ensure patients and physicians in Europe gain access to radium-223 as soon as possible".<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2">Partnership: </FONT>Algeta is eligible for royalties and milestones based on Bayer&rsquo;s sales of Xofigo outside the US, and Algeta US, LLC is co-promoting Xofigo with Bayer in the US.<wbr> </div><div><FONT size="2">Source: Algeta</FONT> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9184" class="commentpermalink">Oncology9184</a> / <span class="date">20 September 2013</span> /
<span class="time">14:29:13 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;">Bayer submitted a MAA to the EMA in Dec 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Xofigo Partnership with Bayer</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=5609" class="defaultlink">Oncology5609: Bayer Pay Euro 560M to Co-Dev.<wbr> Alpharadin for Bone Metastases in Symptomatic HRPC Patients</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Evolving CRPC 5-Year Treatment Landscape</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">US Launch</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Alpharadin - Deliverables and Catalysts in Next 12 Months</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Continued Momentum in TTC Platform</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Items of Interest</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8943attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(78,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(66,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(68,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(79,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(77,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(79,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(63,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8943">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-15T15:44:20+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/1/ScreenCapture1.jpg" length="80746" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/2/ScreenCapture2.jpg" length="68399" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/3/ScreenCapture3.jpg" length="70540" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/4/ScreenCapture4.jpg" length="81747" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/5/ScreenCapture5.jpg" length="79235" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/6/ScreenCapture6.jpg" length="81758" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8943/7/ScreenCapture7.jpg" length="65337" type="image/jpeg"/></item><item>
<title>Update on Lexicon's Pipeline and 1Q:13 Results [:Endocrinology:dis:Diabetes, sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10449</link>
<description>Update on Lexicon's Pipeline and 1Q:13 Results [:Endocrinology:dis:Diabetes, sub:Finance]</description><category>dis:Diabetes</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10449</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10449">Update on Lexicon's Pipeline and 1Q:13 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10449">PharmaWorld10449</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2013 | 15:19</font><br><br><div style="margin-bottom: 10px;">Comment: Management reported that its objectives remains 1/<wbr> to commercialize LX1032 (for carcinoid syndrome) by themselves, and 2/<wbr> to move LX4211 (type 2 diabetes) into Ph3 with a partner this year (the type 1 diabetes indication would have 'important implications' for the partnership and commercial opportunities).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Timing of Key Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Ph2/<wbr>LX1033 (IBS-D) </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>-&gt; Top line results: 3Q:13</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">- Ph3/<wbr>Telotristat (carcinoid syndrome) </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>-&gt; The company is on track to complete enrollment in 2014 </P>
<P>-&gt; Top line results: 3Q:13</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">-  Ph2 LX4211 for Renal Impairment </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>-&gt; Results expected in 2H:13</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Results - Key Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Revenues</STRONG>:  Lexicon’s revenues for the three months ended March 31, 2013 increased 20 percent to $0.<wbr>4 million from $0.<wbr>3 million for the corresponding period in 2012 </div><div><STRONG>R&amp;D Expenses</STRONG>:  Research and development expenses for the three months ended March 31, 2013 decreased 12 percent to $20.<wbr>3 million from $23.<wbr>0 million for the corresponding period in 2012.<wbr> </div><!-- Comment details --><a name="pharmaworld10449attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10449/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(83,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10449">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-15T15:19:58+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10449/1/ScreenCapture1.jpg" length="85112" type="image/jpeg"/></item><item>
<title>Key Messages from Exelixis Presentation at BoA Merrill Lynch [dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8941</link>
<description>Key Messages from Exelixis Presentation at BoA Merrill Lynch [dis:Prostate, news]</description><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8941</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8941">Key Messages from Exelixis Presentation at BoA Merrill Lynch</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8941">Oncology8941</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2013 | 11:53</font><br><br><div style="margin-bottom: 10px;">Comment: On top of the recently approved indication of COMETRIQ (cabozantinib) for Medullary Thyroid Cancer, the company is progressing with the increase of the cabozantinib franchise in HCC (Ph3 to be initiated 3Q:13), RCC, NSCLC, Breast, Melanoma and Ovarian in addition of prostate cancer.<wbr> Management indicated it expects top-line data in 2014 for COMET-1 and COMET-2.<wbr> Additional details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">COMET-1 and COMET-2</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cabozantinib Franchise</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cabozantinib Development Program</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cabozantinib - ASCO 2013 Presentations</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Key Priorities in 2013 </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8941attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(74,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(62,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(48,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8941">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-15T11:53:18+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/1/ScreenCapture1.jpg" length="54416" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/2/ScreenCapture2.jpg" length="76241" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/3/ScreenCapture3.jpg" length="54174" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/4/ScreenCapture4.jpg" length="64203" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8941/5/ScreenCapture5.jpg" length="49595" type="image/jpeg"/></item><item>
<title>Low-Cost Rotavirus Vaccine to Reach the Indian Market [dis:Diarrhoea, news, :PharmaWorld:mkt:India, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1885</link>
<description>Low-Cost Rotavirus Vaccine to Reach the Indian Market [dis:Diarrhoea, news, :PharmaWorld:mkt:India, :PharmaWorld:mkt:Intercontinental]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1885</comments><category>dis:Diarrhoea</category><category>news</category><category>mkt:India</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1885</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1885">Low-Cost Rotavirus Vaccine to Reach the Indian Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIndia"><font color="#e95e0b">:PharmaWorld:mkt:India</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1885">GastroEnterology1885</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2013 | 10:31</font><br><br><div style="margin-bottom: 10px;">Comment: Bharat Biotech has announced positive results from a Ph3 clinical trial of a ROTAVAC®, a rotavirus vaccine developed and manufactured in India.<wbr> The company has announced a price of US$ 1.<wbr>00/<wbr>dose for the vaccine, and will soon file for registration in India.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ROTAVAC® Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">- A<FONT color="#222222"> live attenuated 116E rotavirus monovalent vaccine,</FONT> originated from an attenuated strain of rotavirus that was isolated from an Indian child at the All India Institute of Medical Sciences in New Delhi in 1985-86.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">- Developed in collaboration with the India's Department of Biotechnology, NIH's National Institute of Allergy and Infectious Diseases (NIAID), the U.<wbr>S.<wbr> Centers for Disease Control and Prevention, Stanford University School of Medicine, the Bill &amp; Melinda Gates Foundation and </FONT></FONT></SPAN><FONT face="Verdana" size="2">Program for Appropriate Technology in Health (PATH)</FONT><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">.<wbr> </FONT></FONT></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Ph3 Clinical Study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><U>Design</U></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- Randomized, double-blind, placebo-controlled</FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- Recruitment: 6,799 infants in India (aged six to seven weeks at the time of enrolment)</FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- Locations: 3 sites—the Centre for Health Research and Development, Society for Applied Studies (SAS) in New Delhi; Shirdi Sai Baba Rural Hospital, KEM Hospital Research Centre in Vadu, Pune; and Christian Medical College (CMC) in Vellore.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- Coordination: </FONT></FONT><FONT size="3"><FONT size="2">The Clinical Operations Management Unit headed by Dr Nita Bhandari at SAS oversaw the day-to-day coordination and logistical complexities of this multi-site study and played a pivotal role in the conduct of this trial.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- PIs: </FONT></FONT><FONT size="3"><FONT size="2">Dr Temsunaro Rongsen-Chandola at SAS, Dr Ashish Bavdekar at KEM, and Dr Gagandeep Kang at CMC</FONT> </FONT> </div><div style="margin-bottom: 10px;"><STRONG><U>Findings</U></STRONG> </div><div style="margin-bottom: 10px;">The India-developed rotavirus vaccine ROTAVAC® is efficacious in preventing severe rotavirus diarrhoea in low-resource settings in India.<wbr> </div><div style="margin-bottom: 10px;">ROTAVAC® significantly reduced severe rotavirus diarrhoea by <STRONG>56%</STRONG> during the first year of life, with protection continuing into the second year of life.<wbr> </div><div style="margin-bottom: 10px;">Moreover, the vaccine also showed impact against severe diarrhoea of any cause </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><U>Profile</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1885/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><U>Products /<wbr> Vaccines</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1885/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1885/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><U>Pipeline</U></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1885/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2284c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Prime Minister Narendra Modi on 9 March 2015 launched Rotavac, the</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> third such vaccine, besides GSK's Rotarix and Merck&rsquo;s RotaTeq against rotavirus.<wbr> Rotavac will cost a mere 1$ (vs 75$ for RotaTeq and over 106$ for Rotarix).<wbr></SPAN> </div><div><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">In India, diarrhoea caused by rotavirus kills nearly 80 thousand children under the age of 5 years and lead to 10 lakh hospitalizations every year.<wbr> India accounts for 22% of the global deaths that occurs due to diarrhoea-causing rotavirus.<wbr></SPAN></SPAN> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2284" class="commentpermalink">GastroEnterology2284</a> / <span class="date">11 March 2015</span> /
<span class="time">19:30:25 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130831&edate=20130501&rec=1885">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-15T10:31:17+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan to Start New Ped Trials of BOTOX® for UI Due to NDO [comp:Allergan, prod:Botox, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7009</link>
<description>Allergan to Start New Ped Trials of BOTOX® for UI Due to NDO [comp:Allergan, prod:Botox, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial, Alert]</description><category>comp:Allergan</category><category>prod:Botox</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7009</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7009">Allergan to Start New Ped Trials of BOTOX® for UI Due to NDO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7009">Neurology7009</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 May 2013 | 18:44</font><br><br><div style="margin-bottom: 10px;">Comment: <EM>Clinicaltrials.<wbr>gov</EM> is listing a new Ph3 study which will assess the safety and efficacy of BOTOX® in approx.<wbr> 132 patients (between the ages of 8 to 17 years).<wbr> Another new Ph3 trial will start in September 2013 to assess long-term safety and efficacy of the drug in approx.<wbr> 100 patients (between the ages of 8 to 19 years).<wbr> Both PE will evaluate change from baseline in daily average frequency of daytime UI episodes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01852045?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=04%2F14%2F2013&amp;rank=94"><STRONG><FONT size="3">NCT01852045</FONT></STRONG></A> </div><div style="margin-bottom: 10px;"><UL><LI>Start date: June 2013</LI>
<LI>Completion dates: Nov 2016 /<wbr> Aug 2017</LI>
<LI>Location: USA</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details <A href="http://clinicaltrials.gov/ct2/show/NCT01852058?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=04%2F14%2F2013&amp;rank=114">NCT01852058</A></FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Start date: Sept 2013</LI>
<LI>Completion dates: Oct 2018</LI>
<LI>Location: USA</LI>
</UL> </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7009">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-14T18:44:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Scottish Medicines Consortium - Approval for Betmiga and Non-Recommendation for Zytiga [mkt:UK, :Oncology:comp:Astellas, :Oncology:comp:JnJ, sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10447</link>
<description>Scottish Medicines Consortium - Approval for Betmiga and Non-Recommendation for Zytiga [mkt:UK, :Oncology:comp:Astellas, :Oncology:comp:JnJ, sub:Pricing]</description><category>mkt:UK</category><category>comp:Astellas</category><category>comp:JnJ</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10447</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10447">Scottish Medicines Consortium - Approval for Betmiga and Non-Recommendation for Zytiga</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10447">PharmaWorld10447</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 May 2013 | 18:05</font><br><br><div style="margin-bottom: 10px;">Comment: The Scottish Medicines Consortium (SMC), United Kingdom's regional health technology assessment agency for Scotland, had issued approval for Betmiga (mirabegron) for OAB, and non-recommendation for Zytiga (abiraterone) for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Approval Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><a name="pharmaworld10447attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(16,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(14,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(152,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10447">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-14T18:05:16+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/1/ScreenCapture1.jpg" length="17055" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/2/ScreenCapture2.jpg" length="15260" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10447/3/ScreenCapture3.jpg" length="156238" type="image/jpeg"/></item><item>
<title>New Takeda Device with Safety Needle for Enantone [comp:Takeda, :PharmaWorld:sub:Devices, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8936</link>
<description>New Takeda Device with Safety Needle for Enantone [comp:Takeda, :PharmaWorld:sub:Devices, headline]</description><category>comp:Takeda</category><category>sub:Devices</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8936</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8936">New Takeda Device with Safety Needle for Enantone</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8936">Oncology8936</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 May 2013 | 17:16</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Claudia Schymczyk (Marketing) please find attached the Takeda folder that Ipsen Germany got from Austria.<wbr> The message is mentioning that the new safety needle is necessary because of <EM>decree of the Federal Ministry of labor, social protection and protection of employee before injury from sharp or sharp medical instruments,</EM> which is part of an EU directive from 1st of June 2010 - now transposed into national law on 11.<wbr> of May 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Details and Comments of the Franchise</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Takeda device looks like the same needle (Magellan™ Safety Needles) we had for Decapeptyl/<wbr>Pamorelin (here in Germany we had it from 2007 untill end of 2011).<wbr> </div><div style="margin-bottom: 10px;">Takeda has also launched Prostap with the same device in UK (Thanks to Sally Hodgson for this information).<wbr> </div><div style="margin-bottom: 10px;">As you know the decision was made to go worldwide to a 20 G needle without safety for 1-month, 3-month and 6-month formulations as 20G needles didn't exist with safety needle at that time.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Objective of the EU Council Directive 2010/<wbr>32</FONT></STRONG> </div><div style="margin-bottom: 10px;">- "to achieve the safest possible working environment by preserving injuries to workers caused by all medical sharps (including needle-sticks) and protecting workers at risk in the hospital and healthcare sector".<wbr> According the Legal the current EU legislation does not create any legal obligation for Pharma Companies, but only for hospitals/<wbr> healthcare sector.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8936/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8936attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8936/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8936/3/2013%2d05%5fTakeda%5fSafety%5fNeedle%5b1%5d.pdf">2013-05_Takeda_Safety_Needle[1].pdf</a>&nbsp;&nbsp;(764,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8936">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-14T17:16:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8936/1/ScreenCapture1.jpg" length="69092" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8936/3/2013%2d05%5fTakeda%5fSafety%5fNeedle%5b1%5d.pdf" length="782481" type="application/pdf"/></item><item>
<title>Merck Reports Solide and Profitable Start in 2013 [comp:MerckSerono, class:GrowthHormone, prod:Saizen]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7346</link>
<description>Merck Reports Solide and Profitable Start in 2013 [comp:MerckSerono, class:GrowthHormone, prod:Saizen]</description><category>comp:MerckSerono</category><category>class:GrowthHormone</category><category>prod:Saizen</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7346</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7346">Merck Reports Solide and Profitable Start in 2013</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aMerckSerono"><font color="#e95e0b">:Endocrinology:comp:MerckSerono</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=prod%3aSaizen"><font color="#e95e0b">:Endocrinology:prod:Saizen</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7346">Endocrinology7346</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 May 2013 | 16:41</font><br><br><div style="margin-bottom: 10px;">Comment: Merck wants to achieve 2014 goals for sales and earnings already in 2013.<wbr> Sales for the first quarter of 2013 were up 4% to € 2.<wbr>761 million (Q1 2012: € 2,645 million).<wbr> All four geographic regions contributed to the organic sales growth of Merck Serono.<wbr> Europe accounted for the highest proportion (or 43%), of the division's sales (Q1 2012: 44%).<wbr> Of note, sales of Saizen decreased 8% to € 54 million.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/2/ScreenCapture2.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales by Product</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/4/ScreenCapture4.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7346attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(113,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(63,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(114,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(47,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7346">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-14T16:41:02+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/1/ScreenCapture1.jpg" length="39465" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/2/ScreenCapture2.jpg" length="115940" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/3/ScreenCapture3.jpg" length="65453" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/4/ScreenCapture4.jpg" length="117630" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7346/5/ScreenCapture5.jpg" length="48300" type="image/jpeg"/></item><item>
<title>re: Chiasma Reported to Have Fired One-Third of Workforce</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7345</link>
<description>re: Chiasma Reported to Have Fired One-Third of Workforce</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7345</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7345">re: Chiasma Reported to Have Fired One-Third of Workforce</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7345">Endocrinology7345</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/657">gug93330</a> | 14 May 2013 | 15:40</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Chiasma Reported to Have Fired One-Third of Workforce</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Citing unnamed sources, Globes has reported that as a consequence of the deal signed with Roche, Chiasma cannot move forward on projects at early development stages.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7343">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7343" class="commentpermalink">Endocrinology7343</a> / <span class="date">13 May 2013</span> /
<span class="time">12:58:04 o'clock CEST</span>
</font></div><div>Interesting to see that worldwide, "other indications" represent 20% of SSA market sales - amounting 300M&euro;.<wbr> </div><!-- Comment details --><font size="-1">gug93330 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7345" class="commentpermalink">Endocrinology7345</a> / <span class="date">14 May 2013</span> /
<span class="time">15:40:17 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7345">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7343">View thread  Endocrinology7343: Chiasma Reported to Have Fired One-Third of Workforce</a>]]></content:encoded><dc:date>2013-05-14T15:40:17+02:00</dc:date><dc:creator>gug93330</dc:creator></item><item>
<title>Astellas Reshapes Research Framework [comp:Astellas, :PharmaWorld:func:RnD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8931</link>
<description>Astellas Reshapes Research Framework [comp:Astellas, :PharmaWorld:func:RnD, news]</description><category>comp:Astellas</category><category>func:RnD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8931</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8931">Astellas Reshapes Research Framework</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8931">Oncology8931</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 May 2013 | 10:18</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas aims to achieve four objectives and several specific initiatives to switch to a framework that can 'resiliently' respond to the changing environment.<wbr> In a separate article you will find the company's FY12 results and strategy (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8930" class="defaultlink">Oncology8930: Key Messages from Astellas FY012 Results</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Four Objectives</FONT></STRONG> </div><div style="margin-bottom: 10px;">- use more external resources and capabilities </div><div style="margin-bottom: 10px;">- initiatives to be undertaken in new TAs and innovative technologies (incl <U>regenerative medicine</U> and vaccines) </div><div style="margin-bottom: 10px;">- accelerate the dev of PC pipeline </div><div style="margin-bottom: 10px;">- ensure sufficient investment in late-stage clinical pipeline </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Specific Initiatives</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Futur Astellas Research</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Specific Initiatives for 2013</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8931attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(127,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(72,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(118,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(78,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(100,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8931">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-14T10:18:31+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/1/ScreenCapture1.jpg" length="92245" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/2/ScreenCapture2.jpg" length="130624" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/3/ScreenCapture3.jpg" length="74642" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/4/ScreenCapture4.jpg" length="121491" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/5/ScreenCapture5.jpg" length="80276" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8931/6/ScreenCapture6.jpg" length="103318" type="image/jpeg"/></item><item>
<title>Key Messages from Astellas FY012 Results [comp:Astellas, headline, dis:Prostate, dis:Gynea, :PharmaWorld:mkt:Intercontinental, prod:Eligard]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8930</link>
<description>Key Messages from Astellas FY012 Results [comp:Astellas, headline, dis:Prostate, dis:Gynea, :PharmaWorld:mkt:Intercontinental, prod:Eligard]</description><category>comp:Astellas</category><category>headline</category><category>dis:Prostate</category><category>dis:Gynea</category><category>mkt:Intercontinental</category><category>prod:Eligard</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8930</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8930">Key Messages from Astellas FY012 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aEligard"><font color="#e95e0b">:Oncology:prod:Eligard</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8930">Oncology8930</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 May 2013 | 09:55</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside plans to reshape its research framework (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8931" class="defaultlink">Oncology8931: Astellas Reshapes Research Framework</a>), Astellas reported financial results for FY012.<wbr> Sales increased to 1,005.<wbr>6bn yen (major growth drivers include Vesicare, Mirabegron XTANDI).<wbr> Americas, EU and Asia remain key countries for the company.<wbr> Several slides were dedicated to Enzalutamide such as an update of the development programs, and future development in earlier prostate cancer (Ph3 planning to start this year).<wbr> Key presentations of the Uro and Onco Franchises are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Enzalutamide</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development in Earlier PCa Patients</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Forecasts for FY2013</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales by Region</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Overactive Bladder Franchise in Urology</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Oncology Franchise</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline Status</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Oncology</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/10/ScreenCapture10.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8930attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(93,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(87,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(85,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(82,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(100,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(70,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(155,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(127,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(113,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(88,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8930">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-14T09:55:03+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/1/ScreenCapture1.jpg" length="86277" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/2/ScreenCapture2.jpg" length="104055" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/3/ScreenCapture3.jpg" length="95646" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/4/ScreenCapture4.jpg" length="89372" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/5/ScreenCapture5.jpg" length="87357" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/6/ScreenCapture6.jpg" length="84640" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/7/ScreenCapture7.jpg" length="102465" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/8/ScreenCapture8.jpg" length="72593" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/9/ScreenCapture9.jpg" length="159240" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/10/ScreenCapture10.jpg" length="130379" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/11/ScreenCapture11.jpg" length="116386" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8930/12/ScreenCapture12.jpg" length="90446" type="image/jpeg"/></item><item>
<title>Actavis in Early Talks to Buy Warner Chilcott for &gt;$4.5bn [:GastroEnterology:dis:IBS, :GastroEnterology:dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10443</link>
<description>Actavis in Early Talks to Buy Warner Chilcott for &gt;$4.5bn [:GastroEnterology:dis:IBS, :GastroEnterology:dis:IBD]</description><category>dis:IBS</category><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10443</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10443">Actavis in Early Talks to Buy Warner Chilcott for >$4.<wbr>5bn</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20130831&edate=20130501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10443">PharmaWorld10443</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 May 2013 | 15:22</font><br><br><div style="margin-bottom: 10px;">Comment: Warner Chilcott total revenue in the quarter ended March 31, 2013 was $593 million (a decrease of $92 million, or 13%, compared to the quarter ended March 31, 2012).<wbr> The company's ASACOL is the leading treatment for ulcerative colitis in the U.<wbr>S.<wbr> market for orally administered 5-aminosalicylic acid products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Warner Chilcott 1Q:13 Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://ir.wcrx.com/releasedetail.cfm?ReleaseID=763847">http:/<wbr>/<wbr>ir.<wbr>wcrx.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=763847</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Actavis</FONT></STRONG> </div><div style="margin-bottom: 10px;">- To let Actavis sell Warner Chilcott’s products abroad.<wbr> Actavis is expanding in European and emerging markets, and had 18 percent of its sales outside the U.<wbr>S.<wbr> last year, while 90 percent of Warner Chilcott’s sales were in the U.<wbr>S.<wbr> or Canada.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- To get a new therapeutic area -- dermatology -- and women’s health market.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- To add branded women’s health, gastroenterology (<FONT size="3"><FONT size="2">with ASACOL/<wbr>DELZICOL (ulcerative colitis) which remains its highest value franchise)</FONT></FONT>, urology and dermatology, primarily in North America, to Actavis’ off-patent lower margin high volume generic drug portfolio</FONT><FONT size="2">.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Warner Chilcott Products</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 6px"><B>Women's Health</B></DIV> </div><div style="margin-bottom: 10px;"><DIV class="text">ACTONEL<SUP>®</SUP> is the leading branded product in the U.<wbr>S.<wbr> non-injectable osteoporosis market for the prevention and treatment of osteoporosis in women.<wbr><BR></DIV> </div><div style="margin-bottom: 10px;"><DIV class="text">LOESTRIN<SUP>®</SUP> 24 Fe was the first oral contraceptive featuring 24 days of active therapy compared with the traditional 21-day dosing regimen.<wbr> The Company's oral contraceptive portfolio also includes FEMCON<SUP>®</SUP> Fe, OVCON<SUP>®</SUP> 35 and OVCON<SUP>®</SUP> 50 and ESTROSTEP<SUP>®</SUP> Fe.<wbr> <BR></DIV> </div><div style="margin-bottom: 10px;"><DIV class="text">ESTRACE<SUP>®</SUP> Cream is a leading topical product for the treatment of urogenital symptoms of menopause.<wbr><BR></DIV> </div><div style="margin-bottom: 10px;"><DIV class="text">FEMHRT<SUP>®</SUP> is a systemic therapy for the treatment of menopausal symptoms.<wbr><BR></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 6px"><B>Dermatology</B></DIV> </div><div style="margin-bottom: 10px;"><DIV class="text">DORYX<SUP>®</SUP> 150 mg, a tetracycline-class oral antibiotic, is indicated for the adjunctive treatment of severe acne.<wbr> DORYX is one of the leading branded oral tetracyclines in the U.<wbr>S.<wbr> market</DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 6px"><B>Urology</B></DIV> </div><div><DIV class="text">ENABLEX<SUP>®</SUP> is prescribed to adults to treat the symptoms of overactive bladder.<wbr></DIV> </div><!-- Comment details --><a name="pharmaworld10443attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10443/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(98,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10443/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(42,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10443">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-13T15:22:05+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10443/1/ScreenCapture1.jpg" length="101055" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10443/2/ScreenCapture2.jpg" length="43357" type="image/jpeg"/></item><item>
<title>Chiasma Reported to Have Fired One-Third of Workforce [comp:Roche, dis:Acromegaly, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7343</link>
<description>Chiasma Reported to Have Fired One-Third of Workforce [comp:Roche, dis:Acromegaly, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7343</comments><category>comp:Roche</category><category>dis:Acromegaly</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7343</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7343">Chiasma Reported to Have Fired One-Third of Workforce</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7343">Endocrinology7343</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 May 2013 | 12:58</font><br><br><div style="margin-bottom: 10px;">Comment: Citing unnamed sources, Globes has reported that as a consequence of the deal signed with Roche, Chiasma cannot move forward on projects at early development stages.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Feedback in Traction</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7265" class="defaultlink">Endocrinology7265: Roche Acquires Rights To Octreolin in $595m Deal</a>.<wbr> </div><div style="margin-bottom: 10px;">CEO Roni Mamluk predicted that clinical study with Octreolin (for acromegaly) would be completed in 2014, and if successful the drug could be launched in early 2015.<wbr> </div><div style="margin-bottom: 10px;"><EM>Source: First Word Pharma</EM> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7343/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7345c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Interesting to see that worldwide, "other indications" represent 20% of SSA market sales - amounting 300M&euro;.<wbr> </div><font size="-1">gug93330 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7345" class="commentpermalink">Endocrinology7345</a> / <span class="date">14 May 2013</span> /
<span class="time">15:40:17 o'clock CEST</span>
</font></div><a name="endocrinology7343attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7343/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7343/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(74,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7343">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-13T12:58:04+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7343/1/ScreenCapture1.jpg" length="32881" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7343/2/ScreenCapture2.jpg" length="76477" type="image/jpeg"/></item><item>
<title>Key Highlights from Medivation’s Q12013 Financial Results [dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8927</link>
<description>Key Highlights from Medivation’s Q12013 Financial Results [dis:Prostate, headline]</description><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8927</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8927">Key Highlights from Medivation’s Q12013 Financial Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8927">Oncology8927</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 May 2013 | 13:55</font><br><br><div style="margin-bottom: 10px;">Comment: Xtandi is going from strength to strength and final EU decision for post chemo approval should come by mid- July 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Highlights from Medivation’s Q1 2013 Earnings Call are found below</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Net sales of XTANDI® (enzalutamide) capsules for the quarter were $75.<wbr>4 million, an increase of $18.<wbr>0 million over the prior quarter </div><div style="margin-bottom: 10px;">- From its US launch until the end of the first quarter, prescriptions for more than 19,000 XTANDI bottles have been written by more than 2,800 individual prescribers and more than 400 institutional accounts </div><div style="margin-bottom: 10px;">o More than 98% of both Medicare and commercial plans now covering XTANDI </div><div style="margin-bottom: 10px;">o From a prescriber perspective, XTANDI has over 90% aided awareness among oncologists and urologists and leads in share of voice for oncologists </div><div style="margin-bottom: 10px;">- Medivation expect to hear a final decision from the European Commission shortly regarding their post chemo filing in the EU </div><div style="margin-bottom: 10px;">o EU final decision should come by mid-July2013 </div><div style="margin-bottom: 10px;">o XTANDI marketing applications are also under review in Switzerland, South Korea, Canada and Brazil for the treatment of post-chemotherapy mCRPC patients </div><div style="margin-bottom: 10px;">o Astellas expect to file in Japan by end 2013/<wbr>early 2014 </div><div style="margin-bottom: 10px;">- Key trials (STRIVE &amp; TERRAIN) are progressing steadily - Both trials are evaluating enzalutamide's effects on PFS when compared head-to-head versus bicalutamide </div><div style="margin-bottom: 10px;">o TERRAIN is enrolling approximately 370 men with metastatic disease primarily in Europe (run by Asteallas) </div><div style="margin-bottom: 10px;">o STRIVE is enrolling approximately 400 men with either metastatic or non-metastatic disease primarily in the U.<wbr>S (run by Medivation) </div><div style="margin-bottom: 10px;">- Still no firm date for data release on PREVAIL </div><div style="margin-bottom: 10px;">o At the beginning of April, Medivation exceeded the protocol-specified number of radiographic PFS events required for the final analysis of the study and they plan to conduct an interim overall survival analysis this year </div><div style="margin-bottom: 10px;">- With regards to the new trial announced in the M0 setting, Medivation intend to have this up and running with patients onborded this year </div><div style="margin-bottom: 10px;">o “We do intend to dose this year.<wbr> As you know, it’s a Phase 3 trial; it’s large and there are a lot of logistics to get the study up and going from an operational standpoint.<wbr> We’re making great progress on that, and Medivation will be operationalizing this study.<wbr> So we are very confident that we’ll be getting it up in a timely fashion” - Lynn Seely </div><div style="margin-bottom: 10px;">ASCO data release: </div><div style="margin-bottom: 10px;">o “We have three abstracts that are going to be presented at ASCO.<wbr> We have more data from the oral – the hormone-naïve monotherapy study that Matt Smith will be presenting.<wbr> We have some data on men with visceral metastases from the AFFIRM trial and then we have a presentation on docetaxel enzalutamide combination study…” - Lynn Seely </div><div><EM>Source: Medivation</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8927">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-10T13:55:23+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NPS Reports on U.S Launch and EU Strategy for Gattex (SBS) [:PharmaWorld:mkt:NorthAmerica, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7340</link>
<description>NPS Reports on U.S Launch and EU Strategy for Gattex (SBS) [:PharmaWorld:mkt:NorthAmerica, news]</description><category>mkt:NorthAmerica</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7340</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7340">NPS Reports on U.<wbr>S Launch and EU Strategy for Gattex (SBS)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7340">Endocrinology7340</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 May 2013 | 12:33</font><br><br><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">Comment: From the mid-Feb launch to May 3rd, physicians wrote 160 Rx for Gattex (an 88 Rx increase since a mid-March update).<wbr> US sales totaled $654 thousand for 1Q:13.<wbr> Although Japan represents a "big opportunity" management reported they will launch in EU first.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="3"><STRONG>Drug Status in EU and US</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">Gattex<SUP>®</SUP> (U.<wbr>S.<wbr>)/<wbr>Revestive<SUP>® </SUP>(EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="3"><STRONG>EU Strategy for Revestive</STRONG></FONT> </div><div style="margin-bottom: 10px;"><P align="left"><FONT face="Verdana" size="2">Management outlined that:</FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT face="Verdana" size="2">" .<wbr>.<wbr>.<wbr> Just to give you an idea, even though we had only one third of our clinical sites in Europe, we were able to recruit two thirds of our patients from Europe.<wbr> And the main reason, frankly, is, number one, the fact that you have very sophisticated key opinion leaders in Europe that know the space extremely well.<wbr> S</FONT><FONT face="Verdana" size="2">econd, also to your point, the treatment of short bowel syndrome is much more concentrated around these centers of excellence in Europe.<wbr> So if you take a country like <U>France</U>, for example, even though they have 50 million people, you have probably less than 10 centers of excellence that actually attract most of the short bowel syndrome patients.<wbr> F</FONT><FONT face="Verdana" size="2">rom a commercial perspective, once we go beyond the hurdle of pricing and reimbursement, it will require a relatively small -- actually a very small field organization to reach these key opinion leaders and start generating revenues</FONT><FONT face="Verdana" size="2">.<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT face="Verdana"><FONT size="2">" .<wbr>.<wbr>.<wbr> <SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT color="#000000"><FONT face="Verdana">you have a total</FONT> <FONT face="Verdana">of 30 countries, and it is not unusual to have a significant price differential between these countries.<wbr> And this is part of the process of the prioritization</FONT>, <FONT face="Verdana">where we are trying to hit first these countries where it will be the easiest to get a solid reimbursement.<wbr> And it will be used as a reference for the</FONT> <FONT face="Verdana">other countries.<wbr> So also, I think that on the August call, we will be able to give you a little bit more color on the progress of our European reimbursement process".<wbr></FONT></FONT></SPAN></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="3"><STRONG>Regulatory Status for Pediatric Indication</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">- NPS recently met the FDA to review the strategy for the drug in pediatric short bowel syndrome (SBS).<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">- NPS plans to meet with the EMA to discuss a global strategy for the drug, and is initiating the development of a core value dossier.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="3"><STRONG>Teduglutide Programs</STRONG></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="3"><STRONG>Recent Information</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">In March 2013, NPS reacquired the rights to teduglutide outside the United States, Canada, Mexico and Israel from Takeda.<wbr></FONT> </div><div><FONT face="Verdana" size="2"><EM>Source: NPS Pharm</EM></FONT> </div><!-- Comment details --><a name="endocrinology7340attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(8,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(6,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7340">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-10T12:33:36+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/1/ScreenCapture1.jpg" length="24078" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/2/ScreenCapture2.jpg" length="8559" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7340/3/ScreenCapture3.jpg" length="7112" type="image/jpeg"/></item><item>
<title>Accelerated Approval Pathway Potential for Sarepta's DMD Drug [dis:MuscularDystrophy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7007</link>
<description>Accelerated Approval Pathway Potential for Sarepta's DMD Drug [dis:MuscularDystrophy]</description><category>dis:MuscularDystrophy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7007</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7007">Accelerated Approval Pathway Potential for Sarepta's DMD Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMuscularDystrophy"><font color="#e95e0b">:Neurology:dis:MuscularDystrophy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7007">Neurology7007</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 May 2013 | 11:24</font><br><br><div style="margin-bottom: 10px;">Comment: Sarepta reported chances looked good the FDA would consider the company's eteplirsen under an accelerated approval pathway.<wbr> It is finalizing a response to the agency's request for more data to help determine the feasibility of such a pathway, with expectations of submitting documents by the end of May.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analyst View</FONT></STRONG> </div><div style="margin-bottom: 10px;">Leerink Swann analyst pointed out that : </div><div style="margin-bottom: 10px;">- it remains unclear, however, whether the FDA would require Sarepta to complete an additional pivotal trial before accepting an eteplirsen NDA, which could make the drug second to market in exon-51 DMD in the US.<wbr> </div><div style="margin-bottom: 10px;">- individual patient data for eteplirsen demonstrated fairly consistent six-minute walk test (6MWT) response, with all 10 patients who remained ambulant and received drug at some point during weeks 36 through 74 demonstrated a less than 10% change in their scores.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Drug Manufacturing</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2">- Sarepta has decided to accelerate its large-scale eteplirsen production to meet future demand.<wbr></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Clinical Trials</FONT></STRONG> </div><div style="margin-bottom: 10px;">With the eteplirsen Phase II trial unblinded at 36 weeks and all patients were made aware they were on drug, the FDA could require Sarepta to execute a pre-approval placebo-controlled trial.<wbr> </div><div><A href="http://clinicaltrials.gov/ct2/results/displayOpt?flds=a&amp;flds=b&amp;flds=f&amp;flds=c&amp;flds=n&amp;flds=o&amp;submit_fld_opt=on&amp;term=eteplirsen&amp;show_flds=Y">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>results/<wbr>displayOpt?flds=a&amp;flds=b&amp;flds=f&amp;flds=c&amp;flds=n&amp;flds=o&amp;submit_fld_opt=on&amp;term=eteplirsen&amp;show_flds=Y</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7007">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-10T11:24:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Messages from Dendreon 1Q:13 Results [dis:Prostate, class:Vaccines]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8926</link>
<description>Key Messages from Dendreon 1Q:13 Results [dis:Prostate, class:Vaccines]</description><category>dis:Prostate</category><category>class:Vaccines</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8926</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8926">Key Messages from Dendreon 1Q:13 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8926">Oncology8926</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2013 | 19:02</font><br><br><div style="margin-bottom: 10px;">Comment: The company reported Provenge revenue was <MONEY>$67.<wbr>6 million</MONEY> compared to <MONEY>$82.<wbr>0 million</MONEY> for the quarter ended <CHRON>March 31, 2012</CHRON>, down 17.<wbr>6% year over year.<wbr> Management outlined it is actively evaluating partnering strategies for European expansion.<wbr> Analysts at Barclays forecast EU approval of the vaccine delayed from mid-2013 to 2H13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analysts Point of View</FONT></STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> We are incrementally more concerned about the European approval given that the questions from the European authorities involved both manufacturing and the clinical data.<wbr> In our opinion, this casts greater doubt on the approval prospect of Provenge in Europe, especially in the context of the high price tag of the regimen".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Upcoming Provenge Data</FONT></STRONG> </div><div style="margin-bottom: 10px;">PROVENGE and ADT sequencing study &gt; presented initial data at ASCO-GU and expect to present additional data in 2013.<wbr> </div><div style="margin-bottom: 10px;">PROVENGE and Zytiga<SUP>®</SUP> (abiraterone) sequencing study &gt; presented initial data at ASCO-GU and expect to present additional data in 2013.<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px">Ph2 trial for sequencing PROVENGE with Xtandi<SUP>®</SUP> (enzalutamide) &gt;expect to begin enrolling patients in 4Q:13.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Points</FONT></STRONG> </div><div style="margin-bottom: 10px;">Continued new physician interest in PROVENGE<SUP>®</SUP> (sipuleucel-T): </div><div style="margin-bottom: 10px;"><UL><LI style="MARGIN-BOTTOM: 10px">Added 33 net new accounts in the first quarter, bringing total number of accounts that have infused to 835 </LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px">Demonstrated positive early indicators in effectiveness of direct-to-consumer advertising: </P> </div><div style="margin-bottom: 10px;"><UL><LI style="MARGIN-BOTTOM: 10px">Addresses significant need for patient education and awareness </LI>
<LI style="MARGIN-BOTTOM: 10px">First national TV commercial aired <CHRON>March 7</CHRON> </LI>
<LI style="MARGIN-BOTTOM: 10px">Patients contacting <ORG value="NASDAQ-NMS:DNDN">Dendreon</ORG> directly for more information, resulting in a significant increase in call center and relationship marketing activity </LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px">Continued improvement in reimbursement landscape for physicians: </P> </div><div style="margin-bottom: 10px;"><UL><LI style="MARGIN-BOTTOM: 10px">Reported average time to payment remains less than 30 days for physicians </LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px">Continued progress with strategic restructuring: </P> </div><div style="margin-bottom: 10px;"><UL><LI style="MARGIN-BOTTOM: 10px">The Company believes it can reduce cost of goods sold (COGS) to below 50% of net product revenue in the third quarter 2013 at its current forecast levels</LI>
</UL> </div><div><P style="MARGIN-BOTTOM: 10px"><EM>Source: Dendreon; Barclays</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8926">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-09T19:02:06+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Takeda Presents Mid-Range Growth Strategy and FY2012 Results [comp:Takeda, prod:Orteronel, dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8924</link>
<description>Takeda Presents Mid-Range Growth Strategy and FY2012 Results [comp:Takeda, prod:Orteronel, dis:Prostate, news]</description><category>comp:Takeda</category><category>prod:Orteronel</category><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8924</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8924">Takeda Presents Mid-Range Growth Strategy and FY2012 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=prod%3aOrteronel"><font color="#e95e0b">:Oncology:prod:Orteronel</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8924">Oncology8924</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2013 | 18:20</font><br><br><div style="margin-bottom: 10px;">Comment: On May 9th, management highlighted innovation, diversity and globalization being the three principles of its mid-range growth strategy.<wbr> Of note, FY2012 sales of leuprorelin decreased to 116.<wbr>5 billion yen (-3.<wbr>5% vs previous year).<wbr> Approval of Orteronel is expected in 2014 (US), 2015 (JP; EU), and of leuprorelin 6M in 2015 (JP).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">FY2012 Achievements</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Mid-Range Growth Strategy by Zone</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>- in the US</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>- in Europe</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Approval Schedule of Key Pipelines by Zone</STRONG></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Budget in FY2013</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">TAK-700 (orteronel) Position</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/6/ScreenCapture6.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Acquisitions in 2012</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8924attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(122,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(132,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(129,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(23,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(29,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8924">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-09T18:20:32+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/1/ScreenCapture1.jpg" length="41170" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/2/ScreenCapture2.jpg" length="125152" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/3/ScreenCapture3.jpg" length="135425" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/4/ScreenCapture4.jpg" length="51719" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/5/ScreenCapture5.jpg" length="132409" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/6/ScreenCapture6.jpg" length="24031" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8924/7/ScreenCapture7.jpg" length="30114" type="image/jpeg"/></item><item>
<title>Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7339</link>
<description>Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7339</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7339">Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7339">Endocrinology7339</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 09 May 2013 | 16:06</font><br><br><div style="margin-bottom: 10px;">Comment:  ALRN-5281 Phase 1 data could support once-weekly dosing, potentially providing a convenience over currently available GH and GHRH injections </div><div style="margin-bottom: 10px;">Aileron Therapeutics announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting GHRH agonist for treating orphan endocrine disorders, including adult growth hormone deficiency and human immunodeficiency virus lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/<wbr>endocrine diseases.<wbr> </div><div style="margin-bottom: 10px;">The initial Phase 1 trial evaluated the safety and tolerability of single ascending doses of ALRN-5281 administered by subcutaneous injection in healthy adult subjects: </div><div><UL type="disc"><LI>32 patients</LI>
<LI>no serious adverse events, dose-limiting safety findings, or tolerability issues leading to withdrawal during the study</LI>
<LI>data supports once-weekly dosing</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7339">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-09T16:06:12+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>Teva Believes to be Better Suited Than Competitors to Serve the Chinese Market [mkt:China, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10441</link>
<description>Teva Believes to be Better Suited Than Competitors to Serve the Chinese Market [mkt:China, mkt:Intercontinental]</description><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10441</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10441">Teva Believes to be Better Suited Than Competitors to Serve the Chinese Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10441">PharmaWorld10441</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 May 2013 | 16:33</font><br><br><div style="margin-bottom: 10px;">Comment: In a telephone interview, Teva CEO reported generic drugs, OTC and respiratory treatments represent the three growth drivers for the company.<wbr> </div><div style="margin-bottom: 10px;">He added: </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> Our portfolio more closely matches the needs of that nation than nearly any other company in the world".<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> The need for cheap generic drugs in the nation with the world's largest population - many from poor, rural areas - certainly plays into Teva's strengths as the No.<wbr> 1 maker of generics.<wbr> And Teva's specialty medicines, with a focus in part on respiratory treatments, could also become critical to a nation battling illness from industrial air pollution".<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10441">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-07T16:33:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Sativex Reimbursed for Spasticity due to MS in Italy [dis:Spasticity, :PharmaWorld:mkt:Italy, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7006</link>
<description>Sativex Reimbursed for Spasticity due to MS in Italy [dis:Spasticity, :PharmaWorld:mkt:Italy, :PharmaWorld:mkt:Europe]</description><category>dis:Spasticity</category><category>mkt:Italy</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7006</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7006">Sativex Reimbursed for Spasticity due to MS in Italy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aItaly"><font color="#e95e0b">:PharmaWorld:mkt:Italy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7006">Neurology7006</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 May 2013 | 16:14</font><br><br><div style="margin-bottom: 10px;">Comment: Sativex has been granted approval for reimbursement in Italy to relieve symptoms in adult patients suffering from moderate-to-severe spasticity due to multiple sclerosis who have not had an adequate response to other anti-spasticity medication and who have shown a clinically significant improvement of symptoms associated with spasticity during an initial trial period of therapy.<wbr> </div><div style="margin-bottom: 10px;">The decision was published on the Italian official gazette on 30 April.<wbr> The drug has been assigned classification H status which indicates drugs that are only reimbursed within hospitals or equivalent structures.<wbr> </div><div style="margin-bottom: 10px;">The maximum price approved in the provision is EUR440.<wbr>00 (ex-manufacturer) and EUR726.<wbr>18 (retail).<wbr> The contract between the manufacturer and the Italian agency is valid for 24 months and, according to the conditions negotiated by the parties, is subject to a cost-sharing agreement.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7006">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-07T16:14:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Russia 2012 Pharma Market Grew 11.6% From Last Year According to Remedium.ru [mkt:Intercontinental, mkt:Russia, func:Sales]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10440</link>
<description>Russia 2012 Pharma Market Grew 11.6% From Last Year According to Remedium.ru [mkt:Intercontinental, mkt:Russia, func:Sales]</description><category>mkt:Intercontinental</category><category>mkt:Russia</category><category>func:Sales</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10440</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10440">Russia 2012 Pharma Market Grew 11.<wbr>6% From Last Year According to Remedium.<wbr>ru</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=func%3aSales"><font color="#e95e0b">:PharmaWorld:func:Sales</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10440">PharmaWorld10440</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/14">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD</a> | 07 May 2013 | 10:36</font><br><br><div style="margin-bottom: 10px;">Comment : in 2012 Russia's DLO market increases 3% in value terms  while Commercial segment grew by 14.<wbr>7%.<wbr> </div><div style="margin-bottom: 10px;">As reported by Remedium.<wbr>ru : </div><div style="margin-bottom: 10px;"><UL><LI><U>Russia DLO market</U>, the GVT reimbursement programme, has reported a 3% year-on-year increase in 2012, in value to RUB79,950 billion (<STRONG>USD2.<wbr>52 billion</STRONG>).<wbr> In USD terms the value however declined 3% y/<wbr>y.<wbr>The volume of this segment of the market remained almost flat (0.<wbr>3% y/<wbr>y increase).<wbr> The price per unit of package had decreased to USD27.<wbr>61 from USD28.<wbr>5 in 2012.<wbr> The share of the top 10 companies (including , J&amp;J, Novartis &amp;  Sanofi) amounted to 63% on this segment.<wbr>
</LI>
<LI>The <U>Commercial segment</U> on its side, grew by 14.<wbr>7% y/<wbr>y  in value terms to RUB536.<wbr>6 billion (<STRONG>USD17.<wbr>8 bn)</STRONG>.<wbr>
</LI>
<LI><SPAN style="line-height: 1.5em;">In terms of </SPAN><U style="line-height: 1.5em;">Hospital segment</U><SPAN style="line-height: 1.5em;">, the value of the market increased 11% y/<wbr>y to RUB157.<wbr>2 billion (</SPAN><STRONG style="line-height: 1.5em;">USD 5.<wbr>21 bn)</STRONG><SPAN style="line-height: 1.5em;"> but declined by 2% y/<wbr>y in volume terms.<wbr></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;">
In 2012 the Russian market was valued USD 25.<wbr>5bn growing 11,6% from USD 22.<wbr>8bn  and is split into DLO (11%) /<wbr> Commercial Segment (69%) and Hospital Segment (20%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background:</STRONG> The DLO, which includes two lists the Essential Drugs List and the 7 Nosologies (priority therapeutic areas), is the national reimbursement programme, the beneficiaries of which are entitled to 100% reimbursement.<wbr> The final price level for the DLO drugs to be supplied by a manufacturer is determined during auctions held by the GVT and Region authorities (regional tendering programmes).<wbr> </div><div>Source : Remedium.<wbr>ru and DMS Group </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10440">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-07T10:36:36+02:00</dc:date><dc:creator>len82156</dc:creator></item><item>
<title>Key Messages from Prostate Cancer Survey [headline, dis:Prostate, comp:Astellas, comp:JnJ, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8923</link>
<description>Key Messages from Prostate Cancer Survey [headline, dis:Prostate, comp:Astellas, comp:JnJ, :PharmaWorld:mkt:NorthAmerica]</description><category>headline</category><category>dis:Prostate</category><category>comp:Astellas</category><category>comp:JnJ</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8923</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8923">Key Messages from Prostate Cancer Survey</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8923">Oncology8923</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2013 | 19:33</font><br><br><div style="margin-bottom: 10px;">Comment: MEDACorp conducted a survey of 50 US urologists and oncologists (25 in each specialty) with a majority of them practicing in the community setting.<wbr> The survey suggests significant use of Xtandi in the pre-chemo setting already and a near-term sales trajectory that appears to be ahead of expectations.<wbr> For Provenge, the survey suggests declining use since the end of 2012.<wbr> Companies highlighted are Dendreon, J&amp;J, and Medivation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Respondents</FONT></STRONG> </div><div style="margin-bottom: 10px;">In order to get a respondent cohort that is experienced in treating CRPC, physicians had to treat at least 30 metastatic castration-resistant prostate cancer patients personally over the past 12 months.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8923/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The survey respondents are composed of 14 physicians (28%) from the academic medical centers, 6 physicians (12%) from community hospitals, 1 physician (2%) from a VA hospital, 27 physicians (54%) from private practice and 2 physicians (4%) from a clinic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Timelines</FONT></STRONG> </div><div style="margin-bottom: 10px;">The survey was fielded and followed up from April 5 to April 29, 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">- A little over half of current Xtandi patients had previously received Zytiga, although this differed significantly between oncologists and urologists </div><div style="margin-bottom: 10px;">- Survey finds a substantial increase of Zytiga and Xtandi of 41% and 80%, respectively, from Dec.<wbr> 2012 to March 2013 </div><div style="margin-bottom: 10px;">- Majority of survey respondents consider the efficacy and safety/<wbr> tolerability profiles of Zytiga and Xtandi to be similar in the postchemo setting </div><div><STRONG><FONT size="3">Full Report available on demand to Brigitte Deschamps</FONT></STRONG> </div><!-- Comment details --><a name="oncology8923attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8923/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8923">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-06T19:33:34+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8923/1/ScreenCapture1.jpg" length="79028" type="image/jpeg"/></item><item>
<title>European Regulator to Begin Reorganisation in August [sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10438</link>
<description>European Regulator to Begin Reorganisation in August [sub:Regulatory]</description><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10438</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10438">European Regulator to Begin Reorganisation in August</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10438">PharmaWorld10438</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/13">fab42334</a> | 06 May 2013 | 19:30</font><br><br><div style="margin-bottom: 10px;">Comment : The European Medicines Agency (EMA) on Friday announced it will begin to introduce a new organisational structure from August onwards.<wbr> The new structure will take 18 months to implement to ensure continuity of operations.<wbr> </div><div style="margin-bottom: 10px;">Details of the structure will be published in the coming months, but the EMA said high-level changes will involve replacing two units dealing with medicines for human use.<wbr><BR>They will be replaced by four units, supporting the R&amp;D phase, medicines evaluation and lifecycle management, procedure management and business data and inspections and pharmacovigilance.<wbr> </div><div style="margin-bottom: 10px;">Current entities responsible for veterinary medicines, ICT and administration will remain, although their names may change.<wbr> </div><div style="margin-bottom: 10px;">Staff members, chairs of the scientific committees and heads of national medicines agencies have been involved in the rethink of the structure, according to the statement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG> </div><div style="margin-bottom: 10px;">The EMA said the changes will reflect the fact that it increasingly acts as a knowledge and data hub, sharing information with different stakeholders.<wbr><BR>The agency originally announced the change to the structure earlier this year.<wbr> EMA executive director Guido Rasi said the changes would improve the efficiency and effectiveness of the organisation.<wbr> </div><div>Source : APM International, May 3.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10438">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-06T19:30:29+02:00</dc:date><dc:creator>fab42334</dc:creator></item><item>
<title>Novartis Names Head of M&amp;A and Licensing [sub:People, :Endocrinology:news, :Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10436</link>
<description>Novartis Names Head of M&amp;A and Licensing [sub:People, :Endocrinology:news, :Endocrinology:comp:Novartis]</description><category>sub:People</category><category>news</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10436</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10436">Novartis Names Head of M&A and Licensing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10436">PharmaWorld10436</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2013 | 12:08</font><br><br><div style="margin-bottom: 10px;">Comment: Anthony Rosenberg is promoted head of M&amp;A and Licensing from Head of BD &amp; Licensing.<wbr> </div><div style="margin-bottom: 10px;">He will be replaced by Corinne Savill, who is head of Pricing &amp; Market Access at Novartis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">A Rosenberg's Short Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;">Mr.<wbr> Rosenberg is Head of Business Development and Licensing of Novartis Pharma AG and a member of the Pharma Executive Committee.<wbr> </div><div style="margin-bottom: 10px;">He joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning.<wbr> In 1994 he moved to Basel, initially as international product manager (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care.<wbr> In 2000 he became Global Head of the Transplant and Immunology Business Unit and began his current role in 2005.<wbr> He has overseen several major in-licensing transactions in the respiratory, infectious disease, CNS areas.<wbr> </div><div>Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.<wbr>Sc (Physiology) University of London </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10436">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-06T12:08:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Ambrx Initiates Collaboration with BMS for Next-Generation Antibody Drug Conjugates [news, comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8921</link>
<description>Ambrx Initiates Collaboration with BMS for Next-Generation Antibody Drug Conjugates [news, comp:Astellas]</description><category>news</category><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8921</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8921">Ambrx Initiates Collaboration with BMS for Next-Generation Antibody Drug Conjugates</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8921">Oncology8921</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2013 | 12:02</font><br><br><div style="margin-bottom: 10px;">Comment: The collaboration covers the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product resulting from the collaboration.<wbr> </div><div style="margin-bottom: 10px;">BMS will receive WW rights to develop and commercialize products resulting from the collaboration, and Ambrx is eligible to receive royalties on net sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Deals</FONT></STRONG> </div><div style="margin-bottom: 10px;">With <STRONG>BMS</STRONG> &gt; The deal is also the second between Ambrx and BMS.<wbr> In 2011, Ambrx granted BMS exclusive, worldwide rights to develop and commercialize preclinical biologics programs in Type II diabetes and heart failure.<wbr> </div><div style="margin-bottom: 10px;">- With <STRONG>Astellas</STRONG> &gt; See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8884" class="defaultlink">Oncology8884: Astellas and Ambrx Have Signed Oncology Deal Worth >$300M</a>.<wbr> </div><div><EM>Source: Ambrx</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130831&edate=20130501&rec=8921">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-06T12:02:12+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Versartis Published Positive Study Results of LA hGH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7336</link>
<description>Versartis Published Positive Study Results of LA hGH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7336</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7336">Versartis Published Positive Study Results of LA hGH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7336">Endocrinology7336</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/13">fab42334</a> | 06 May 2013 | 11:09</font><br><br><div style="margin-bottom: 10px;">Comment : Versartis pulished positive results from its first double-blind, placebo-controlled, single ascending dose study of VRS-317 in growth hormone deficient adults.<wbr> VRS-317 is expected to provide up to once-monthly dosing when at present, the approved growth hormone treatments require daily injections.<wbr><BR> </div><div style="margin-bottom: 10px;">VRS-317 is a long-acting form of recombinant human growth hormone (rhGH) utilizing the proprietary Amunix half-life extension technology (XTEN).<wbr> The multi-center study of VRS-317 was conducted in 50 adults with growth hormone deficiency (GHD).<wbr> </div><div style="margin-bottom: 10px;">Versartis is now investigating the safety and efficacy of VRS-317 in a Phase 1b/<wbr>2a clinical trial in pre-pubertal children with GHD.<wbr> The Versartis Trial In Children to Assess Long-Acting Growth Hormone (VERTICAL) study is being conducted in approximately 30 clinical sites in the United States.<wbr> </div><div style="margin-bottom: 10px;"><EM>Source : ahead of print article on April 12, 2013 in the Journal of Clinical Endocrinology &amp; Metabolism (JCEM) [doi:10.<wbr>1210/<wbr>jc.<wbr>2013-1437]</EM> </div><div><a href="http://jcem.endojournals.org/content/early/2013/04/11/jc.2013-1437.full.pdf+html?sid=bcbbe57a-f134-4a09-9d86-e67202c50f00" class="defaultlink">http://jcem.endojournals.org/content/early/2013/04/11/jc.2013-1437.full.pdf+html?sid=bcbbe57a-f134-4a09-9d86-e67202c50f00</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7336">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-06T11:09:14+02:00</dc:date><dc:creator>fab42334</dc:creator></item><item>
<title>Acorda Reports 1Q:13 and Pipeline Progress [dis:Palsy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7001</link>
<description>Acorda Reports 1Q:13 and Pipeline Progress [dis:Palsy]</description><category>dis:Palsy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7001</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7001">Acorda Reports 1Q:13 and Pipeline Progress</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7001">Neurology7001</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 May 2013 | 19:30</font><br><br><div style="margin-bottom: 10px;">Comment: AMPYRA net sales were $62.<wbr>3M (down from 4Q:12 of $72.<wbr>7M).<wbr> Management reported it plans to continue the POC trial in post-stroke deficits.<wbr> First participant was enrolled in the first Ph1 trial of rHIgM22, a remyelinating antibody for MS.<wbr> The company is preparing to initiate a Phase 2 trial of AC105 for neural protection in acute spinal cord injury.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7001/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">AMPYRA post-stroke data</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7001/2/ScreenCapture2.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;">Management answered that " .<wbr>.<wbr>.<wbr> So, we will meet with FDA when we have finished our analyses and have a plan that we want to propose to them, and obviously we're working on that as quickly as possible.<wbr> This is a very high priority program, needless to say, for us.<wbr> With respect to what we're thinking about, again, I don't want to speculate on that until we've actually put a plan together, gotten in front of the FDA and then have something to say about it.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">AMPYRA Cerebral Palsy (CP)</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to Management " .<wbr>.<wbr>.<wbr> The efficacy results of the cerebral palsy study suggested potential treatment activity on measures of walking and hand strength, but further analysis is needed to determine if they are sufficiently robust to warrant moving forward with development in this indication.<wbr> Similar to the post-stroke deficit study, the safety data from this study were consistent with our experience in MS".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analyst Forecasts</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7001/3/ScreenCapture3.jpg?user-agent=rss"> </div><div>c </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=7001">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-03T19:30:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>EMA Hopes To Clarify Biosimilar Reference [mkt:Europe, sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10435</link>
<description>EMA Hopes To Clarify Biosimilar Reference [mkt:Europe, sub:Regulatory]</description><category>mkt:Europe</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10435</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10435">EMA Hopes To Clarify Biosimilar Reference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10435">PharmaWorld10435</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 03 May 2013 | 17:15</font><br><br><div style="margin-bottom: 10px;">Comment: EMA has published a draft guidance on biosimilars that use a reference product approved outside the EU </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The guidance states that sponsors who use a reference product approved outside the EU must provide data from analytical studies showing an "acceptable bridge" between the biosimilar, the non-EU reference product and the EU-approved originator reference product.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The guidance also outlines general principles for developing biosimilars in the EU.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">This document will eventually replace the 2005 guidance and comments are due on October 31</SPAN><SUP style="line-height: 1.5em;">st</SUP><SPAN style="line-height: 1.5em;"> 2013.<wbr>   At this stage, it is still not a &lsquo;black and white&rsquo; documents as there are some questions around what the EMA will consider "similarity" or what constitutes a "significant difference" between a biosimilar and reference product.<wbr></SPAN> </div><div><SPAN style="line-height: 1.5em;">Please see link for more info - </SPAN><A href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf" style="line-height: 1.5em;" target="_blank">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>docs/<wbr>en_GB/<wbr>document_library/<wbr>Scientific_guideline/<wbr>2013/<wbr>05/<wbr>WC500142978.<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10435">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-03T17:15:43+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Lexicon on Track with Ph3 Development Programme of LX1032 in Carcinoid Syndrome [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7331</link>
<description>Lexicon on Track with Ph3 Development Programme of LX1032 in Carcinoid Syndrome [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7331</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7331">Lexicon on Track with Ph3 Development Programme of LX1032 in Carcinoid Syndrome</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7331">Endocrinology7331</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 May 2013 | 15:39</font><br><br><div style="margin-bottom: 10px;">Comment: Lexicon presented at the Needham 12th Annual Healthcare Conference in New York yesterday, focusing mainly on the ph3 lead programmes including their two diabetes compounds as well as LX1032 in Carcinoid Syndrome (CS).<wbr> </div><div style="margin-bottom: 10px;">The slide below provides the status of their pipeline.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA">Outlining the current and future CS market, stating that the majority of players are SSA’s and injectables whereas LX1032 is oral and a TPH inhibitor.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>
<SPAN lang="EN-GB" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA">NOTE: Pasireotide has been omitted from this slide due to NVS apparently no longer pursuing approval for CS.<wbr> </SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">He then went on to discuss the EU Ph2 12 wk open label results which were presented at ENETS, a reminder of the data are found below: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Greater than 40% reduction in bowel movements (primary endpoint which was achieved and have also seen a sustained effect)</LI>
<LI>70% decrease in 5-HIAA</LI>
<LI>36.<wbr>6% reduction in flushing episodes</LI>
<LI>18.<wbr>4% reduction in pain</LI>
</UL> </div><div style="margin-bottom: 10px;">Finishing up with an overview of the hP3 trial details.<wbr> Trial is ramping up, on track and they are on boarding the sites currently.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7331attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130831&edate=20130501&rec=7331">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-02T15:39:11+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/1/ScreenCapture1.jpg" length="65032" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/2/ScreenCapture2.jpg" length="104264" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7331/3/ScreenCapture3.jpg" length="51772" type="image/jpeg"/></item><item>
<title>Valeant Reports Solid 1Q:13 Despite Integration of Medicis [sub:Finance, :Neurology:comp:Medicis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10432</link>
<description>Valeant Reports Solid 1Q:13 Despite Integration of Medicis [sub:Finance, :Neurology:comp:Medicis]</description><category>sub:Finance</category><category>comp:Medicis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10432</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10432">Valeant Reports Solid 1Q:13 Despite Integration of Medicis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aMedicis"><font color="#e95e0b">:Neurology:comp:Medicis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10432">PharmaWorld10432</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 May 2013 | 15:24</font><br><br><div style="margin-bottom: 10px;">Comment: Product sales and revenues increased by 38% and 35% respectively versus 1Q:2012.<wbr> Key slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">1Q:13 Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management reported that " .<wbr>.<wbr>.<wbr> Emerging Markets segment performed extremely well in the first quarter and product sales increased 26% driven by outstanding growth in <LOCATION value="LC/pl;LB/eeur">Poland</LOCATION>, <LOCATION value="LC/ru;LB/eeur">Russia</LOCATION>, <LOCATION value="LC/br;LB/sam">Brazil</LOCATION>, <LOCATION value="LR/asp">South East Asia</LOCATION> and South Africa".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key US Brand Performance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Valeant's U.<wbr>S.<wbr> Promoted product sales increased 91% to <MONEY>$479M</MONEY> led by strong growth in key brands such as Acanya, CeraVe, Arestin, Dysport, Restylane, Perlane and AcneFree.<wbr> </div><div style="margin-bottom: 10px;"><IMG height="365" name="C:\Users\brd97880\Documents\Traction Instant Publisher\Autosaved\5-2-2013[4]\ScreenCapture3.jpg" src="file:///C:/Users/brd97880/Documents/Traction%20Instant%20Publisher/Autosaved/5-2-2013[4]/ScreenCapture3.jpg" width="507"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Medicis Deal Upsides</FONT></STRONG><IMG height="296" name="C:\Users\brd97880\Documents\Traction Instant Publisher\Autosaved\5-2-2013[4]\ScreenCapture4.jpg" src="file:///C:/Users/brd97880/Documents/Traction%20Instant%20Publisher/Autosaved/5-2-2013[4]/ScreenCapture4.jpg" width="627"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Guidance for 2013</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10432attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(27 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(30,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10432">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-02T15:24:35+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/1/ScreenCapture1.jpg" length="48736" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/2/ScreenCapture2.jpg" length="27649" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10432/3/ScreenCapture3.jpg" length="30777" type="image/jpeg"/></item><item>
<title>Key Messages from Sanofi's 1Q:13 Results [sub:Finance, :Oncology:comp:SanofiAventis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10430</link>
<description>Key Messages from Sanofi's 1Q:13 Results [sub:Finance, :Oncology:comp:SanofiAventis]</description><category>sub:Finance</category><category>comp:SanofiAventis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10430</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10430">Key Messages from Sanofi's 1Q:13 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20130831&edate=20130501&cat=comp%3aSanofiAventis"><font color="#e95e0b">:Oncology:comp:SanofiAventis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10430">PharmaWorld10430</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 May 2013 | 14:40</font><br><br><div style="margin-bottom: 10px;">Comment: Sales were €8.<wbr>1bn failing by 5%.<wbr> Generic versions of the blockbusters Plavix and Avapro have impacted results (€553M in lost sales).<wbr> Genzyme, Diabetes and Vaccines divisions performed well.<wbr> Excluding the life cycle management programs, Sanofi has got 14 NMEs in development in oncology (8 in Ph1; 4 in Ph2; 2 in Ph3 and O in the registration phase).<wbr> The company expects to resume growth in 2H:13.<wbr>Sanofi expects to resume growth in 2H:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth Platforms</FONT></STRONG> </div><div style="margin-bottom: 10px;">+8,6% in the first quarter - reached 71% of sales </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Net Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales of Leading Products</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">AUBAGIO</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Composition of the Executive Committee</FONT></STRONG> </div><div style="margin-bottom: 10px;">As of July 1st, 2013 </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Expected R&amp;D Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">GUIDANCE</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/6/ScreenCapture6.jpg?user-agent=rss"> </div><div>Full slides available <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130831&edate=20130501&rs=/link%20PharmaWorld10431%408" class="defaultlink">@8</a> </div><!-- Comment details --><a name="pharmaworld10430attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(70,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(54,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(71,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(86 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(44,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/8/Sanofi%5f2013%2d05%2d02%5fQ1Results2013%5fslides.pdf">Sanofi_2013-05-02_Q1Results2013_slides.pdf</a>&nbsp;&nbsp;(982,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130831&edate=20130501&rec=10430">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-02T14:40:45+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/1/ScreenCapture1.jpg" length="67581" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/2/ScreenCapture2.jpg" length="72223" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/3/ScreenCapture3.jpg" length="55900" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/4/ScreenCapture4.jpg" length="73144" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/5/ScreenCapture5.jpg" length="88055" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/6/ScreenCapture6.jpg" length="45298" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/7/ScreenCapture7.jpg" length="104828" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10430/8/Sanofi%5f2013%2d05%2d02%5fQ1Results2013%5fslides.pdf" length="1006288" type="application/pdf"/></item><item>
<title>New Registration and New Packaging for Botox Therapeutic [comp:Allergan, prod:Botox, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Italy, :PharmaWorld:mkt:Europe, :PharmaWorld:mkt:Intercontinental, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6991</link>
<description>New Registration and New Packaging for Botox Therapeutic [comp:Allergan, prod:Botox, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Italy, :PharmaWorld:mkt:Europe, :PharmaWorld:mkt:Intercontinental, news]</description><category>comp:Allergan</category><category>prod:Botox</category><category>mkt:Australia</category><category>mkt:Italy</category><category>mkt:Europe</category><category>mkt:Intercontinental</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6991</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6991">New Registration and New Packaging for Botox Therapeutic</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=mkt%3aItaly"><font color="#e95e0b">:PharmaWorld:mkt:Italy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6991">Neurology6991</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 May 2013 | 11:05</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to our colleagues P.<wbr> Caglioni (PM) and M.<wbr> de Abadal (MD), we have learnt that Botox 200 will be sold in Italy with a new packaging (1-2-3 or 6 vials), and that the reimbursement authority in Australia has granted listing for Botox 100 for urinary incontinence due to NDO in patients with MS, SCI or adult spina bifia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Information</FONT></STRONG> </div><div style="margin-bottom: 10px;">- In Italy, Allergan has asked the 100% reimbursement for the pack (1 vial), but the MOH has assigned any reimbursement (class C), probably because any agreement was reached on the price among Allergan and AIFA.<wbr> As for Hexvix, if the pharmacist decide to by 200U Botox the amount has to be charged on Hospital budget and not reimbursed by MHO.<wbr> </div><div style="margin-bottom: 10px;">In Australia, no information about the price yet.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6991/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6991">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-02T11:05:25+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Management Discuss 1Q:13 Performance [comp:Allergan, :PharmaWorld:sub:Finance, dis:iOAB, dis:nOAB, dis:Migraine, dis:Spasticity, prod:Botox, prod:Xeomin, sub:Aesthetics, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6989</link>
<description>Allergan Management Discuss 1Q:13 Performance [comp:Allergan, :PharmaWorld:sub:Finance, dis:iOAB, dis:nOAB, dis:Migraine, dis:Spasticity, prod:Botox, prod:Xeomin, sub:Aesthetics, Alert]</description><category>comp:Allergan</category><category>sub:Finance</category><category>dis:iOAB</category><category>dis:nOAB</category><category>dis:Migraine</category><category>dis:Spasticity</category><category>prod:Botox</category><category>prod:Xeomin</category><category>sub:Aesthetics</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6989</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6989">Allergan Management Discuss 1Q:13 Performance</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20130831&edate=20130501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20130831&edate=20130501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6989">Neurology6989</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 May 2013 | 09:32</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan sales grew vs the first quarter of 2012 by 9.<wbr>0% (lc)) and by 8.<wbr>4% (in US dollars).<wbr> D.<wbr> Pyott reported 'very strong growth in the US' of Botox therapeutic, thanks to the uptake in chronic migraine, to the uro indications (in Q1, the neurogenic bladder indication was launched in the UK and idiopathic in Germany), and also sound growth in the traditional movement disorder areas'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">BOTOX Performance for 1Q:13</FONT></STRONG> </div><div style="margin-bottom: 10px;">Migraine indication was reported as being 'a big driver', and urology as second driver for growth.<wbr> </div><div style="margin-bottom: 10px;">Sales in Q1 grew year-over-year 15.<wbr>4% (lc) and 14.<wbr>8% in dollars, with double-digit growth in both the therapeutic and aesthetic franchises.<wbr> "Regarding the global market in Q4, the last period for which we have data available, we estimate that growth was 14%, with Allergan outperforming the market at 16%.<wbr> Accordingly, BOTOX market share moved up to 78% from 76% in Q4 of 2011".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Urology Side</STRONG> </div><div style="margin-bottom: 10px;">"we’re obviously at an earlier stage of adoption and also training for the newest <U>idiopathic</U> overactive bladder indication where we received approval from FDA in January.<wbr> Since approval of <U>neurogenic</U> overactive bladder, we have now trained over 2,400 unique urologists in a target universe of 5,500 urologists and urologist gynecologists.<wbr> Insurance coverage of neurogenic is excellent at 100% of Medicare lives and at 88% of commercial lives".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Aesthetic Side</STRONG> </div><div style="margin-bottom: 10px;">In the US, based on survey data, Allergan believe that the neuromodulator market is growing high single digits and that BOTOX share was at 82% in March, an increase of 5 share points versus a year earlier given that this was before the injunction issued against Merz.<wbr> </div><div style="margin-bottom: 10px;">Xeomin share in March was estimated at 5% and Dysport share dropped to 13% from 16% in March of 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Facial Aesthetic</STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> Facial aesthetics enjoyed extremely robust growth of 32.<wbr>9% (lc) and almost the same in dollars at 32.<wbr>6%, with very strong increases in all operating regions of the world.<wbr> Whilst market growth is strong, a few factors flatter the year-over-year ex-factory increases.<wbr> U.<wbr>S.<wbr> ex-factory sales were affected by the buy-in against the 3% JUVÉDERM price increase posted on March 16, the sell-in of our Proven Results rebate promotion in combination with BOTOX, as well as the low quarter in 2012, which was a period between two of the then-promotions called Duet Dividends.<wbr> Hence, you should expect moderate year-over-year growth in Q2 of this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Allergan's Estimates</FONT></STRONG> </div><div style="margin-bottom: 10px;">(<EM>Sources: IMS as well as Allergan’s internal estimates</EM>).<wbr> </div><div style="margin-bottom: 10px;">The top ten markets for neuromodulators are roughly $1.<wbr>9 billion, growing at a rate of roughly 15% and BOTOX has approximately an 85% market share.<wbr> </div><div style="margin-bottom: 10px;">The worldwide market for neuromodulators is roughly $2.<wbr>5 billion, growing at a rate of roughly 13% and BOTOX has approximately a 77% market share.<wbr> </div><div style="margin-bottom: 10px;">The worldwide market for dermal facial fillers is greater than $1 billion, growing at a rate of roughly 6% and Allergan has approximately a 37% market share.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Update</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>DARPin "</STRONG>Allergan has completed the initial analyses for the second stage of the randomized controlled Phase II trial comparing two doses of the anti-VEGF DARPin and ranibizumab, i.<wbr>e.<wbr> Lucentis.<wbr> The data suggests some product differentiation between the DARPin and Lucentis, but do not support directly moving to Phase III.<wbr> Instead we plan to perform additional Phase II work to more completely access safety and efficacy and to guide the Phase III study design.<wbr> This will likely delay eventual approval by approximately one to two years compared to starting a Phase III program by the end of 2013.<wbr> As previously communicated, data from this Phase II trial will be presented at the American Academy of Ophthalmology Retina Subspecialty Day in November".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>bimatoprost scalp hair growth</STRONG> " .<wbr>.<wbr>.<wbr> the results of the Phase II trial in male and female hair loss indicated that the formulation was well tolerated but did not provide sufficient efficacy to proceed directly to Phase III.<wbr> As a consequence, we are extending the Phase II program to include trials with an approximately 10-fold higher concentration of bimatoprost in the current formulation and also in a novel formulation.<wbr> These trials will start enrolling male patients with androgenic alopecia in the third quarter of 2013".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Highlights of Key Points During Q&amp;A Session</STRONG> (five corporate participants from Allergan side) </div><div>Questionned on the aesthetic business, Management answered that '.<wbr>.<wbr>.<wbr> If I look at the neuromodulator market, I think we’re in a very sound position.<wbr> As I stated in the US, we estimate that market growth is upper single digits.<wbr> Then in terms of market share, a very good position.<wbr> Xeomin is coming up slower than it did in the past.<wbr> I think Dysport is dipping a little bit on the other side.<wbr> So obviously where there’s two competitors versus one, one would normally expect some share loss, but so far quite moderate'.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130831&edate=20130501&rec=6989">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2013-05-02T09:32:20+02:00</dc:date><dc:creator>brd97880</dc:creator></item></channel>
</rss>